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Neurodegenerative  diseases  are  fatal  disorders  in  which  disease  pathogenesis  results  in  the 
progressive degeneration of the central and/or the peripheral nervous systems. These diseases 
currently affect ~2% of the population but are expected to increase in prevalence as average life 
expectancy increases. The majority of these diseases have a complex genetic basis. The work 
presented in this thesis aimed to investigate the genetic basis of two neurodegenerative diseases, 
amyotrophic  lateral  sclerosis  (ALS)  and  the  human  prion  diseases  kuru  and  sporadic 
Creutzfeldt-Jakob disease (sCJD), using novel complex genetic approaches.
ALS is a fatal neurodegenerative disease in which motor neurons are seen to degenerate. It is a 
complex disease with ~10% of individuals having a family history and the remaining 90% of 
non-familial  cases  having  some  genetic  component.  The  gene  DYNCIHI  is  involved  in 
retrograde  axonal  transport  and  is  a  good  candidate  for  ALS.  In  this  thesis  the  genetic 
architecture of DYNCIHI  was elucidated  and a  mutation  screen  of exons  8,  13  and  14  was 
undertaken  in  familial  forms  of ALS  and  other  motor  neuron  diseases.  No  mutations  were 
found. A linkage disequilibrium (LD) based association study was conducted using two tagging 
single  nucleotide  polymorphisms  (tSNPs)  which  were  identified  as  sufficient  to  represent 
genetic variation across DYNCIHI.  These tSNPs were tested for an association with sporadic 
ALS (SALS) in 261 cases and 225 matched controls but no association was identified.
Kuru is a devastating epidemic prion disease which affected a highly geographically restricted 
area of the Papua New Guinea highlands, predominantly affected adult women and children. Its 
incidence has steadily declined since the cessation of its route of transmission, endocannibalism, 
in the late  1950’s.  Kuru imposed strong balancing selection on codon  129 of the prion gene 
(PRNP).  Analysis of kuru-exposed and unexposed populations  showed significant  deviations 
from Hardy-Weinberg equilibrium (HWE) consistent with the known protective effect of codon 
129 heterozygosity. Signatures of selection were investigated in the surviving populations, such 
as deviations from HWE and an increasing cline in codon  129 valine allele frequency,  which 
covaried  with  disease  exposure.  A  novel  PRNP G127V  polymorphism  was  detected  which, 
while  common  in  the  area  of highest  kuru  incidence,  was  absent  from  kuru  patients  and 
unexposed  population  groups.  Genealogical  analysis  revealed  that  the  heterozygous  PRNP 
G127V genotype confers strong prion disease resistance, which has been selected by the kuru 
epidemic.
Finally, PRNP copy number was investigated as a possible genetic mechanism for susceptibility 
to kuru and sCJD. No conclusive copy number changes were identified.
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181  Introduction
1.1  Neurodegenerative diseases
Neurodegenerative diseases  are a range  of fatal  disorders  in  which  the  disease  pathogenesis 
results  in the  progressive degeneration  of the  central  and/or the  peripheral  nervous  systems. 
These  diseases,  which  include  Parkinson’s  disease  (PD),  Alzheimer’s  disease  (AD), 
frontotemporal  dementia  (FTD),  amyotrophic  lateral  sclerosis  (ALS)  and  prion  diseases, 
currently  affect  approximately  2%  of the  population  in  the  developed  world  (Hardy  et  al., 
2006a) and show a propensity to occur with increasing age. As average life expectancy in the 
developed and developing world continues to increase, so too will the worldwide prevalence of 
neurodegenerative diseases (Kondo,  1996):  conservative models of population growth predict 
that by 2025, over 1   billion people will be aged greater than 60 years old. This shift will have 
profound  implications  on  public  health  and  therefore  our  ability  to  dissect  the  aetiology  of 
neurodegenerative disease must  match this challenge.  Understanding the genetic aetiology of 
neurodegenerative diseases will improve disease diagnosis, assist genetic counselling in familial 
cases,  inform on an individual’s susceptibility to disease, provide targets for therapeutics and 
inform future public health policy. Until recently, our ability to identify the genetic determinants 
of  neurodegenerative  disease  has  been  restricted  to  rare  Mendelian  forms.  These  gene 
discoveries have illuminated only a small  fraction of the causes of more common, apparently 
sporadic,  complex  forms  of  disease.  However,  recent  developments  in  novel  and  rapidly 
advancing  study designs,  experimental  and  analysis  techniques  have  begun  to  shed  light  on 
complex neurodegenerative diseases.
1.1.1  Common features of neurodegenerative diseases
In  the  last  decade,  several  converging  lines  of  investigation  have  revealed  common 
epidemiological  patterns,  disease  aetiologies  and  pathogenic  mechanisms,  underlying 
neurodegenerative diseases. These shared features suggest that mutual genetic mechanisms may 
also exist amongst these diseases which may be illuminated using similar techniques. Common 
features  include  the  abnormal  function  of the  following:  protein  aggregation  and  deposition 
(Skovronsky  et  al.,  2006;  Taylor  et  al.,  2002),  mitochondrial  or  oxidative  phosphorylation 
activity  (Manfredi  et  al.,  2000;  Schon  et  al.,  2003),  axonal  transport  (Roy  et  al.,  2005), 
endosomal  and  endocytic  function  (Bronfman  et  al.,  2007;  Nixon,  2005)  and  the  ubiquitin- 
proteosome system (Ciechanover et al., 2003; Petrucelli et al., 2004; Ross et al., 2004).
In addition many neurodegenerative diseases share common features of genetic epidemiology 
such as the existence of both familial and sporadic or idiopathic forms of disease. At the same 
time, familial forms are often rare and sporadic forms of neurodegenerative diseases are often 
common.  The  rare  exception  to  this  observation  are  the  triplet  repeat  disorders  such  as
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familial, or apparently sporadic but due to cryptic familial inheritance, non-patemity (Davis et 
al.,  1994) or de novo repeat expansions (Bozza et al.,  1995; Davis et al.,  1994; Durr et al.,  1995; 
Futamura et al,  1998; Mandich et al.,  1996;  Myers et al,  1993).  In addition, common to all 
neurodegenerative diseases is the familial aggregation of disease, which may imply a genetic 
component to even sporadic disease.
1.1.2  Related genetic mechanisms
Beyond the clinical, epidemiological and pathological  features of neurodegenerative diseases, 
different neurodegenerative disorders may also share a common genetic aetiology:  the genetic 
determinant of one neurodegenerative disease may be a causal or risk factor in another disease. 
A  commonly  cited  example  is  s4  allele  of the  alipoprotein  E  gene  (APOE),  which  is  a 
susceptibility factor for several diseases including: age of onset and dementia in PD (Feldman et 
al,  2006; Huang et al,  2006; Li et al,  2002; Li et al,  2004; Parsian et al,  2002; Tang et al, 
2002a), age of onset in ALS (Li et al,  2004) and age of onset in FTD (Boccardi et al,  2004; 
Borroni et al, 2005). In addition, the gene charged multivesicular body protein 2B (CHMP2B), 
which has been shown to be causative for FTD in both a Danish family and an isolated FTD 
individual (Skibinski et al, 2005) has also been identified in two cases of ALS (Parkinson et al, 
2006). Examples such as these support the view that neurodegenerative diseases, such as FTD 
and ALS, may have common genetic aetiologies. In addition familial clustering of diseases such 
as ALS  and Creutzfeldt-Jacob disease (CJD) with other neurodegenerative diseases (Majoor- 
Krakauer et al,  1994; van Duijn et al,  1998) is indicative of a common cause to these diseases 
which can identify risk factors (Riemenschneider et al., 2004).
1.2  Gene identification in Mendelian forms of neurodegenerative diseases
To date,  the overwhelming majority of genes causal  for human  disease have been  identified 
through  linkage  analysis.  These  analyses  have  commonly  required  large  pedigrees  which 
display clear Mendelian inheritance of a phenotype.  Essentially, linkage analysis relies on the 
co-segregation  of  a  disease  causing  allele  and  adjacent  DNA  markers  with  the  disease 
phenotype,  within  a  family.  Chromosomal  segments  that  do not  influence  disease  segregate 
randomly.  A  DNA  segment  that  carries  the  disease-causing  mutation  will be  shared  among 
affected family members more often than would be predicted by chance and a likelihood score 
(log-of-odds ratio;  LOD) is applied (LOD>3.6 is generally considered the criterion indicating 
linkage between a genome segment and disease).
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Figure 1.1  Allelic variants showing Mendelian inheritance discovered from 1988 to 2003
Graph depicting the number of pathogenic mutations causing monogenic disorders, recorded in OMIM 
over 15 years (Modified from Antonarakis et al., 2006).
As  Figure  1.1  illustrates,  the  number  of single  genes  responsible  for  Mendelian  disorders, 
identified  and  catalogued  in  the  Online  Mendelian  Inheritance  in  Man  (OMIM)  database 
increased rapidly between 1988 and 2001. The key to success of linkage analysis has been the 
near-complete penetrance of simple traits; affected individuals are easily identified and always 
possess  a genetic  mutation,  which  in turn  has  permitted the collection  of the  large  families 
required for linkage analysis. However, despite the advances linkage studies have provided in 
our understanding of the genetic basis of human disease, familial diseases continue to represent 
the minority of cases in almost all forms of disease. In fact, the majority of human diseases do 
not demonstrate the characteristics of simple monogenic Mendelian forms and until recently, the 
accepted dogma has regarded these non-Mendelian forms of disease as sporadic with possibly 
no genetic component. However, there is a large body of evidence that non-Mendelian diseases 
have a genetic component and are complex, i.e. are influenced by multiple genes, which interact 
with each other and with the environment.
1.3  The genetic component of non-Mendelian diseases
Diseases that do not demonstrate Mendelian inheritance may still possess a genetic component.
1.3.1  Familial genetics inform susceptibility loci in sporadic disease
Rare  monogenic  familial  forms  of  several  neurodegenerative  diseases  have  informed  our 
understanding of the genetic aetiology of sporadic disease. Causative genes identified in familial 
studies of AD,  PD,  ALS,  FTD and  CJD  for example,  have  been  found  to  be  mutated  in  a 
minority of non-Mendelian cases,  indicating that at least some sporadic cases have a genetic 
component (Table 1.1).
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AO
PD
ALS
FTD
APP
SNCA
PRKN
SOD1
DCTN1
CHMP2B
Dominant  (Tanzi et al., 1987;
inheritance  Goldgaber et al., 1987)
Dominant
inheritance
Recessive
inheritance
Dominant
inheritance
Dominant
inheritance
Dominant
inheritance
(Polymeropoulos et al., 
1996)
(Kitada etal..  1998)
(Rosen etal.,  1993)
(Puls et al.. 2003) 
(Skibinski et at. 2005)
Increases risk
Promoter di­
nucleotide 
repeat
associated with 
increased risk 
19% sporadic 
cases
2-7% sporadic 
cases
3 cases to date
1  possible case 
to date
(Brouwers etal., 2006; 
Guyant-Marecha! et 
al.. 2007)
(Tan et al., 2000; Tan 
et al., 2003)
(Lucking et al., 2001)
(Andersen etal.,
1997; Jackson etal., 
1997)
(Munch et al.. 2004; 
Munch et al.. 2005)
(Skibinski et at, 2005)
Table 1.1  Mendelian genes identified with mutations in non-Mendelian diseases
Examples of genes from four Mendelian forms of neurodegenerative diseases that have been implicated in 
complex forms of the same disease. Maximum of two loci are shown for Alzheimer's disease (AD), 
Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). 
References are not exhaustive.
1.3.2  Familial clustering of disease
The recurrence of an apparently sporadic  disease  in a  family more  frequently than could be 
predicted  by  population  prevalence  also  provides  evidence  of a  genetic  component  to  non- 
Mendelian  disease.  This  familial  clustering  of  disease,  can  be  measured  by  the  relative 
recurrence risk (Ar) - the risk to relative R of an affected proband compared with the population 
risk. Familial clustering can be interpreted in several ways: disease can be due to shared genetic 
susceptibility, shared environmental exposure(s), or both. However, familial clustering may be 
due to other factors such as incomplete penetrance, as has been shown in ALS (Robberecht et 
al.,  1996), or due to the transmission of environmental factors, such as viruses, within families 
which can mimic or confound true genetic susceptibilities (Szmuness et al.,  1973).
Another  measure  of the  contribution  of inherited  factors  to  disease  risk  is  heritability  (h2). 
Estimated  from  family  or  twin  studies,  heritability  signifies  the  fraction  of the  population 
variation that can be explained by genetic factors working together in an additive fashion. For 
diseases  such  as  late onset  Alzheimer’s  disease,  heritability may be between  58% and 79% 
(Gatz et al., 2006).
Twin studies are of particular importance in the estimation of heritability in complex diseases 
(reviewed  in  MacGregor et al.,  2000)  as  they  exploit  the  unique  degree  of genetic  sharing 
among the two types of twin pair: (i) monozygotic twins, who share a common set of genes, and 
(ii) dizygotic twins, who share on average ~50% of their genes. In addition, the use of twins can 
control for non-genetic factors, as they share aspects of their early and later environment and 
these  features allow  the population-level  variation of traits and diseases to be separated into 
genetic,  shared environmental and random environmental components.  Conversely,  for twins
22reared in different environments such as in adoption studies, variances due to environment and 
gene-environment interactions can also be assessed.
1.4  Complex diseases
Our understanding of complex diseases (also known as complex traits)  is founded within the 
fascinating history of genetics and genetic  ideas.  In the interest of brevity, the full history of 
modem genetics and complex diseases is not discussed here (but an excellent account can be 
found in Strachan et al.,  1999). However, to understand what complex diseases are and why the 
underlying genes have been difficult to elucidate, a brief review of complex genetics is required.
Historically,  there  have  been  two  traditions  within  human  genetics.  The  first  followed  the 
principles of heredity established by Gregor Mendel  who  identified  that  physical  traits  were 
inherited  discretely.  Under  this  tradition  all  traits  are  considered  dichotomous  (such  as 
polydactyly - either you have an extra fmger or you don’t) - the off-spring of a set of parents 
inherit characteristics from one parent or the other and not a blend of the two. This premise also 
formed the basis of a saltation (or non-gradual) theory of evolution, in which sudden phenotypic 
changes are seen from one generation to the next. The second tradition was based on the study 
of variation, such as that carried out by Francis Galton in the late 19th century who observed that 
human characteristics, such as weight, height and reaction time were quantitative, continuously 
variable characters. These continuous traits could not be reconciled using Mendelian genetics 
and did not explain gradual genetic variation (i.e. gradual evolution) seen in many organisms 
described in the theory of modem synthesis.
In  1918,  both  traditions  were  aligned  by  the  mathematician  and  geneticist  Ronald  Aylmer 
Fisher. Fisher proposed that continuous traits are in fact governed by a number of loci, which 
are inherited in a Mendelian fashion, and that alleles at each locus contribute quantitatively to 
the overall  phenotype.  Any variable character that depends on the  additive action of a  large 
number of individually small  independent  causes  will  be distributed  in  a  normal  (Gaussian) 
distribution in the population, and under this polygenic theory of inheritance, as the number of 
quantitative trait loci (QTL) increase, the distribution looks increasingly like a Gaussian curve.
However,  Fisher’s  polygenic  theory  of  inheritance  could  not  account  for  dichotomous 
characteristics  which are not  inherited  within  families.  This  problem  was  solved  in  1981  by 
Douglas  Scott  Falconer who  extended  the polygenic  theory  to  discontinuous  non-Mendelian 
characters  by postulating  that  (i)  an  underlying polygenic  liability to  disease  exists  within  a 
population and it is this which is continuously distributed and not phenotype and (ii) diseases 
manifest when the cumulative diseases susceptibility burden exceeds a threshold of liability. By 
inference,  individuals  whose  genetic  liability  does  not  exceed  the  threshold  value  do  not 
develop disease (Figure 1.2).
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Figure 1.2  The threshold liability model
The model shows the distribution for liability to disease within a population. Individuals to the right of the 
threshold develop disease whereas those to the left are healthy.
For  example,  this  can  be  illustrated  by  the  developmental  abnormality,  cleft  lip  and  palate. 
Every  embryo  has  a  certain  susceptibility  to  cleft  lip  and  palate  which  follows  a  Gaussian 
distribution  in the population.  During early development  the embryonic palatal  shelves must 
become  horizontal  and  fuse  together  within  a  specific  developmental  window  of time.  The 
speed at which the plates meet and fuse is unimportant, as long as they meet before a critical 
developmental stage. If they fuse at or before the critical point then a normal palate forms, and 
if they do not fuse then a cleft palate results and thus, there is a natural threshold imposed on a 
continuous trait which is transformed into a dichotomous phenotype.
Single gene
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Figure 1.3  The spectrum of human disease
Few characters are purely Mendelian, purely polygenic or purely environmental. Most depend on some 
mix of major and minor genetic determinants, together with environmental influences. The mix of factors 
determining any given character could be represented by a point located somewhere within the triangle. 
(From Strachan et al.,  1999)
The  threshold  liability model  also accounts  for  familial  clustering  in  non-Mendelian disease 
because liability genes will be more common amongst relatives and therefore all members of the 
family will be closer to the liability threshold. Not all family members will develop disease as 
several loci and environmental factors will contribute to phenotype. The challenge for human 
genetics now is to identify those genes that increase liability to develop disease (susceptibility 
genes) and those that modify, enhance or reduce a phenotype (modifier genes). In Mendelian 
diseases,  the  action  of  these  susceptibility  and  modifier  loci  may  manifest  as  reduced
24penetrance, meaning that the disease has a reduced likelihood of occurring in individuals who 
carry the risk genotype. Susceptibility to human disease can therefore be considered a spectrum 
of genetic and environmental risk, which together can explain Mendelian disease, quantitative 
traits and complex diseases (Figure 1.3).
1.5  Gene identification strategies in complex  diseases
1.5.1  Linkage analysis based approaches
Traditional linkage based approaches have worked well for Mendelian disorders (Antonarakis et 
al.,  2006)  and  have  been  carried  out  successfully  on  a  few  complex  diseases  such  as 
schizophrenia (Stefansson et al.,  2002) and type  1   diabetes (Nistico et al.,  1996). However, for 
most complex, polygenic traits, linkage analyses of extended pedigrees, siblings or parent and 
child trios, have achieved only limited success: Altmuller and colleagues found that in a review 
of  101  genome-wide  linkage  studies  in  31  complex  human  diseases,  over  two-thirds  of the 
studies  showed  no  significance  (Altmuller  et al.,  2001).  Where  genes  have  been  discovered 
using linkage analysis they usually explain only a small fraction of the overall heritability of the 
disease.  For example,  variants known to affect the risk of inflammatory bowel disease (IBD) 
together explain a sibling risk of approximately two-fold, compared with a total excess risk of 
30-fold  (Daly  et  al.,  2004),  which  indicates  that  there  are  additional  genes  in  IBD  to  be 
discovered.  The lack of success can be attributed to several reasons:  (i) linkage is an indirect 
statistical test, relying on distortions of Mendelian inheritance ratios to infer the nearby location 
of a disease-causing mutation. When the genetic effect is very large (as in Mendelian disorders), 
this indirect signal is sufficient. For QTLs with only a small magnitude of effect, the power of 
linkage may be inadequate, (ii) Large sample sizes can compensate for low magnitude of effect, 
however assembling  large  families,  each  containing  multiple  affected  individuals,  is  difficult 
particularly when the disease is rare, has an advanced age of onset and high mortality (as is the 
case for many neurodegenerative diseases), (iii) In addition, genetic  factors such as pleiotropy 
(one gene which yields multiple phenotypes) and epistasis (the non-additive effect of multiple 
genes) provide extra complications.
1.5.2  Association studies
In their simplest  form, association studies compare the  frequency of alleles or genotypes of a 
particular  variant  between  disease  cases  and  controls.  This  may  be  done  directly,  where  a 
candidate  variant,  often putatively  functional,  is tested  for enrichment  or depletion  in disease 
cases compared to normal controls. For example, resequencing the entirety of a candidate gene 
in patients and controls, and testing variants such as single nucleotide polymorphisms (SNPs) in 
cases  and  controls  is a  direct  test  of association  as  every nucleotide  is  tested  for a potential 
association with disease.  Direct tests are hypothesis-based,  with genes and candidate variants
25selected for further study either by virtue their location in a region of linkage, or on the basis of 
other evidence that they might affect disease risk (Carlson et al., 2004a).
In  contrast,  indirect  studies  test  markers  (commonly  SNPs)  for disease association under the 
assumption that the marker itself is not causal but that it may be linked by allelic association or 
linkage disequilibrium (LD) to the true causal variant. Therefore, if a risk polymorphism exists 
it will either be genotyped directly or be in strong LD with one of the genotyped markers. The 
benefit of such indirect association studies, also called LD mapping, are that they do not require 
prior determination of which marker might be functionally important.
1.5.2.1  Linkage disequilibrium
Linkage disequilibrium (LD) has become an important consideration in most association studies 
for complex  diseases.  LD  describes  the  non-random  correlation  between  alleles  at  a  pair  of 
genetic  markers (commonly SNPs).  In contrast  to  linkage,  which describes the association of 
loci on a chromosome with limited recombination between them,  LD describes a situation in 
which some combinations of alleles occur more or less frequently in a population than would be 
expected if they were segregating randomly (i.e.  in disequilibrium).  Whereas  linkage analysis 
relies on informative recombination events within a pedigree,  LD utilises informative meioses 
of an  extended  pedigree  of the  complete  human  population.  As  a  result,  the  interval  shared 
through identity by decent within a population is much smaller than that shared by linkage in a 
pedigree, which can aid in the fine mapping of disease loci.
The measure D has been widely used to quantify LD. Consider two adjacent loci — A and B, 
with two alleles (A,a and B,b) at each  locus — the observed  frequency of the haplotype that 
consists of alleles A and B is represented by PA B . Assuming independent assortment of alleles at 
the two loci, the expected haplotype frequency is PA  x PB  (where PA  is the frequency of allele A 
and PB  is the frequency of allele B). From Equation  1.1  it is clear that the primary determinant 
of LD is recombination which, in addition to recurrent mutation and evolution, serves to errode 
LD.
Equation 1.1  D = PA B  - (PA  x PB )
The utility of LD in association studies relies on the fact there is redundancy in the information 
gained  from typing multiple SNPs  in  LD:  for two  SNPs  in perfect  LD,  only one  SNP would 
need to be typed to inform on the genotype of the other. This method of selecting a minimal set 
of markers  to  represent  the  underlying  genetic  variation  is  known  as  tagging.  Additionally, 
SNPs may also be in LD with unknown SNPs that are not genotyped. If the unknown SNP is a 
causal variant for disease susceptibility, the known genotyped SNP could be used as a proxy to 
test for an indirect association with disease. The known SNP therefore is a tagging SNP (tSNP) 
for unknown genetic variation.
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Although the LD measure D provides a useful explanation as to the extent of LD between two 
loci,  the  measures  D ’  and r  are  more  commonly  used  in  association  studies  (Devlin  et  al., 
1995).  D’  varies  between 0  and  1,  is  calculated by  normalising D by  its  maximum  possible 
value,  Dmax.  D ’  = 1   only  if two  SNPs  have  not  been  separated  by  recombination.  r~  is  more 
commonly used in the context of association studies and LD mapping and can be calculated by 
normalising D' by the product of all four allele frequencies, r  is simply the squared correlation 
coefficient  between  the  two  loci.  Perfect  LD  (r'=l)  indicates  that  markers  have  not  been 
separated by recombination and have the same allele frequencies. An attractive property of r  is 
that  it directly relates to sample size and power.  For a study to detect an association between 
disease and a marker locus, the sample size must be increased by roughly 7r‘  (where n is the 
number  of  samples  in  the  study)  to  have  the  same  power  as  actually  genotyping  the 
susceptibility locus itself (Kruglyak, 1999; Pritchard et al., 2001).
1.5.2.2  Linkage disequilibrium patterns in the human genome
The pattern of LD throughout the human genome has been extensively studied and has been of 
particular importance in association studies as  it  impacts on both the efficiency and power of 
these studies. There are several salient features of LD in the human genome. The first is that LD 
is inversely correlated with distance. This aspect of LD is intuitive as recombination rates are 
generally  higher between  markers  at  increasing  distances  and  therefore,  as  LD  is  eroded  by 
recombination,  LD  decay  is  seen  over  distance  (Hartl  et  al.,  2007).  However,  LD  has  been 
shown  to  be  highly  variable,  extending  between  a  few  to  several  hundred  kilobases  (kb) 
(Dawson et al., 2002; Kruglyak,  1999).
Secondly,  whereas  LD  was  thought  to  decay  uniformly  over  distance,  several  authors  have 
provided evidence to that  islands of high  LD  exist,  separated by highly recombining regions 
(Daly et al., 2001; Rioux et al., 2001). These haplotype blocks of LD, punctuated by hotspots of 
recombination  have  been  witnessed  in  multiple  studies  (Gabriel  et  al.,  2002;  International 
HapMap Consortium, 2003; Jeffreys et al.,  2001) however more recent studies have suggested 
that  LD  at  finer-resolution  is  more  variable  than  previously  thought  (Ke  et  al.,  2004).  This 
atomistic picture of LD has been crucial in the design and efficiency of association studies (see 
below).
Thirdly, LD is heterogeneous amongst populations.  Early studies by both Reich and colleagues 
and Gabriel and colleagues identified that population samples from Africa have markedly less 
LD than Europeans and Asians (Gabriel et al.,  2002; Reich et al.,  2001a).  In contrast, younger 
or isolated populations have been shown to have the highest LD, suggesting that within different
27populations LD is a reflection of that population’s history (i.e. demographic processes influence 
LD patterns) (Bonnen et al.,  2002; Dunning et al.,  2000; Kidd et al.,  2000). This elevated LD 
can assist in the mapping of disease genes, as less haplotype diversity is seen and studies require 
fewer makers. In addition, the genetic architecture in population isolates can also be utilised as 
groups  that  have  undergone  a  population  bottleneck  tend  to  have  a  distinct  set  of common 
disease  alleles  and  tend  to  share  more  environmental  features  than  outbred  populations 
(Peltonen et al.,  2000).  Taken together, these studies have informed the design of association 
studies. By identification of the underlying LD structure across a candidate gene or even across 
the  genome,  a  small  number  of SNPs  could  be  used  to  define  a  large  proportion  of genetic 
diversity and be tested for association with disease.
1.5.2.3  Tagging SNPs
The efficacy of using a subset of SNPs to define the majority of variation was first demonstrated 
by Johnson and colleagues, who found that up to 6 SNPs could define the majority of haplotype 
diversity in a selection of gene (Johnson et al.,  2001). In all,  122 SNPs, spanning 9 genes were 
reduced to just 34 haplotype tagging SNPs (htSNPs). More recently, tagging strategies moved 
towards maximising pairwise r  as this measure is more informative with respect to association 
studies (Carlson et al.,  2004b).  Further efficacy has been gained by the observation that tSNP 
haplotypes (Figure  1.4) in turn show redundancy (Goldstein et al,  2003a; Weale et al.,  2003). 
In a study by Weale and colleagues, investigating the sodium channel gene SCNIA,  implicated 
in epilepsy, this aggressive tagging technique provided a  110-fold saving in genotyping effort. 
In summary, based on the pattern of LD within a genomic region of interest, a minimal set of 
tSNPs can be chosen to tag known and unknown variation, providing association studies with 
efficiencies of both cost and effort.
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Figure 1.4  Aggressive tagging of variation linked to six loci
Six SNP loci are shown with their corresponding alleles. A. Loci 1, 3 and 4 tag SNPs 2, 5 and 6 
respectively with a minimum correlation coefficient ^>0.85. B. Redundancy of tSNP haplotypes allows the 
AG haplotype (red) at tSNPs 1  and 3 to predict the A allele at locus 6.
1.5.3  Association study design
The design of association studies and the technology available to conduct them has changed 
dramatically since the work presented in this thesis was undertaken. These changes and their 
effect on study design are examined  in later chapters.  However, there are some  fundamental 
elements of association study design that are discussed below and in addition, advances in the 
resources available for future studies are discussed.
1.5.3.1  Study power and sample size
The power of an association study is the statistical probability that the study will detect a true 
association if one is present. There are several factors that affect study power including sample 
size,  the  prevalence  and  magnitude  of effect  of the  risk  factor,  and  the  strength  of linkage 
disequilibrium  between  the  marker  and  causal  variant.  Sample  size  is  probably  the  most 
common influential factor in association studies, especially in those of rare neurodegenerative 
diseases where achieving large cohorts would be difficult.
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Figure 1.5  Association study sample size predictions
The sample size required for 80% power to detect an association of various genotype relative risks (GRR) 
with susceptibility alleles of increasing frequency. Dashed line using linkage methodology and solid line 
using association methodology. (From Risch, 2000).
The effect on samples size due to magnitude of effect (genotype relative risk; GRR) and allele 
frequency  can  be  witnessed  through  modelling  studies.  As  Figure  1.5  illustrates  association 
studies can have greater power over linkage when GRR<2 and large sample sizes are required 
when GRR is small.
1.5.3.2  Sample selection
There are several design considerations related to sample choice and ascertainment that can lead 
to either spurious association or reduced study power. Population stratification is an important 
consideration for association studies as allele and haplotype frequencies can differ considerably 
between populations, resulting in both false positives and negatives associations. This bias can 
be  a  potential  problem  if,  for example,  disease  prevalence  varies  between  populations  (i.e. 
between ethnic groups) as this may result in the over-representation of a subgroup in the case 
cohort and the more frequent polymorphism in that subgroup will tend to be more associated 
with disease despite not influencing it (Ardlie et al.,  2002; Cardon et al.,  2003). Stratification 
may be overcome by modifying the study design to include family based controls, as is seen in 
the transmission disequilibrium test (Spielman et al.,  1993); typing multiple unlinked genomic 
control  loci to detect stratification and correct  for inflation in the test  statistic (Devlin et al., 
1999; Devlin et al., 2004); or by simply ensuring that cases and control cohorts are matched for 
ethnicity and environmental covariates (which for most studies can be easily achieved).
Power  to  detect  association  may  be  reduced  by  inadequate  selection  of case  and  control 
samples. The inadequate selection of case samples may be due to phenotypic heterogeneity or 
clinical misdiagnosis. The latter may be reduced by ensuring that all cases are diagnosed based 
on  a  set  of universally  adopted  diagnostic  criteria,  such  as  the  El  Escorial  criteria  in  ALS
30(Brooks,  1994),  and  the  latter  may  be  eliminated  by  considering  intermediate  phenotypes 
(Gottesman et al.,  2003). Intermediate disease phenotypes are likely to have fewer extraneous 
environmental influences compared to those at the endpoint of disease. To overcome phenotypic 
heterogeneity they are required to be more predictive of disease or disease progression, than 
disease  end-points,  which are often  used  as  clinical  phenotype.  For example,  in  age-related 
macular  degeneration  (AMD),  a  complex  neurodegenerative  disease  affecting  the  retinal 
pigment  epithelium,  intermediate  phenotypes  such  as  photoreceptor  segment  turnover  and 
macular pigment levels have been identified (Chamberlain et al., 2006).
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Figure 1.6  Case-control selection using the threshold liability model
Individuals with liability to disease greater than the threshold value will develop disease and be assigned to 
the case cohort. Control individuals are absent of disease but may either have an extremely low liability to 
disease (A) or be approaching the threshold value (B).
There are also several issues with the selection of control samples for case-control association 
studies  of complex  diseases.  The  first  can  be  illustrated  using  the  liability threshold  model 
(Figure  1.6). Generally, the selection of a control cohort is conducted by selecting individuals 
absent for disease phenotype. However, in complex diseases, where disease may only manifest 
once the threshold of liability is reached, any individual under the threshold may be selected as 
a  control.  If a  proportion  of the  control  cohort  is  comprised  of individuals just  below  the 
threshold  level  of liability,  this  may  reduce  the  power of an  association  study to  detect  an 
association. By choosing controls from the left-hand tail of the distribution (i.e. hyper controls), 
who  have  a  lower  population  risk  of disease,  this  power  to  detect  an  association  may  be 
increased.  In most studies where the defined phenotype is the presence/absence of disease or 
disease end-point,  it will  impossible to place the control cohort on this distribution,  however 
quantitative intermediate phenotypes (Gottesman et al., 2003) or other indicators of disease risk 
that vary normally could be used.
1.5.3.3  Candidate gene and whole genome approaches
To  date,  the  majority  of case-control  association  studies  for  complex  diseases  have  been 
undertaken  on  candidate  genes.  This  has  largely  reflected  the  limited  availability  of 
polymorphism data and the high cost of genotyping for polymorphism ascertainment, making 
genome-wide  methodologies  in complex diseases unfeasible  for most researchers.  Candidate
31genes  have  largely  been  ascertained  in  a  number  of  ways:  through  known  causation  in 
Mendelian  forms  of disease,  which  are  predicted  to  predispose  to  complex  forms;  through 
regions of linkage  from sib-pair studies;  through biological plausibility based on phenotypes; 
model organism mutants, such as mouse models of human disease, or the action of a gene in a 
pathway  relevant  to  disease  pathogenesis.  Critically,  these  methods  have  relied  on  prior 
assumptions. In contrast, genome-wide studies can be undertaken with no prior assumptions as 
to the location or function of a pathogenic variant;  However, these methods, which test up to
500,000  SNPs in one experiment and are therefore likely to detect  false positives, also bear a 
heavy multiple testing penalty.
l.S.3.4  Allelic architecture of complex disease
For most complex diseases the underlying genetic variation remains unknown. The number of 
relevant disease variants that exist is unknown as are their frequencies in the population: genetic 
variation  could  be  rare  (alleles  with  frequencies  <1%  in  the  population),  as  is  true  for most 
single-gene  disorders,  it  could  be  more  common  (frequencies  >1%  in  the  population).  The 
frequency spectrum of the alleles  for complex diseases  is  important  to consider,  because the 
allele  frequencies  of variants  that  predispose  to  disease  and  the  strength  of their phenotypic 
effects directly relate to the statistical power of genetic association studies, and therefore their 
likelihood of success.
These  underlying  allele  frequencies  are  largely unknown  because  the  causal  variants  remain 
largely unknown, however theoretical and empirical studies suggest that for complex diseases, 
some of the causal genetic variants may be common (Chakravarti,  1999;  Lander et al.,  1994; 
Reich et al.,  2001b). The common disease/common variant (CDCV) hypothesis proposes, that 
common  diseases  are  a  result  of common  variants  (Reich  et al.,  2001b).  Under this  model, 
disease susceptibility is suggested to result  from the joint action of several common variants, 
and  unrelated affected  individuals  share  a  significant proportion  of disease alleles.  There  are 
several  arguments  to  support  this  theory:  (i)  common  diseases  are  generally  not  as 
evolutionarily  disadvantageous  as  single-gene  disorders,  which  often  cause  early  death  or 
markedly decreased  reproductive capability;  (ii)  variants  that  cause  single-gene disorders  are 
highly penetrant, whereas multiple variants are required to cause common diseases and thus, the 
impact of selective pressure is diluted  for the variants  for complex traits;  (iii) the majority of 
monogenic diseases are rare, whereas most polygenic diseases are common- population genetic 
arguments predict that for common diseases, some of the causal genetic variation should have a 
high  frequency  in  the  population,  due  to  the  demographic  history  of the  human  population 
(Reich  et  al.,  2001b);  and  (iv)  empirical  evidence  has  suggested  that  common  variants  do 
contribute to the risk of common diseases (Lohmueller et al., 2003).
32However,  evidence  from  monogenic  disorders  suggests  that  the  responsible  variants  are 
generally rare, so could the variants that cause common disease not also be predominantly rare? 
The  alternative  to  CDCV  is  the  disease  heterogeneity  hypothesis  (or  multiple  rare-variant 
hypothesis),  in  which  disease  susceptibility  is  due  to  distinct  genetic  variants  in  different 
individuals and disease-susceptibility alleles have low population frequencies <1% (Smith et al., 
2002). This allelic heterogeneity is a potential problem for association studies, unlike the CDCV 
hypothesis which supports the mapping of loci through association (Pritchard et al.,  2002), and 
may be a more pervasive phenomenon in common disease (Pritchard, 2001).  So, what are the 
prospects  for  neurodegenerative  diseases?  Successes  in  mapping  the  susceptibility APOE e4 
locus associated with increased risk to Alzheimer disease (Corder et al.,  1993) has been possible 
due to high allele frequencies, ranging  from 5%-41% in various populations (Fullerton et al., 
2000) and large effect size.  However,  identification of risk factors with smaller effect sizes at 
lower  frequencies  will  require  much  larger  samples  and  possibly  more  sensitive  analytic 
techniques.
As  discussed  later,  allelic  heterogeneity  and  the  CDCV  hypothesis  may  be  a  surmountable 
problems for complex loci mapping and even some successes have been seen. For example, the 
gene  NOD2  has  been  successfully  associated  with  Crohn’s  disease  despite  the  presence  of 
moderate allelic  heterogeneity (Hugot et al.,  2001) as has  CAPN10,  a susceptibility locus  for 
type  2  diabetes  (Horikawa  et  al.,  2000).  In  addition  populations  with  a  greater  degree  of 
common variation such as isolated populations can be used to identify rare variants in outbred 
populations. For example, the Finnish population descends from two waves of immigration, 200 
years ago from the southern Indo-Europeans and 4000 years ago from eastern Uralic speakers. 
The  population  expanded  from  -50,000  in  the  12th   century  to  the  present  day  -5,000,000. 
Relative homogeneity of culture and lifestyle has also been noted. Approximately 30 recessive 
diseases are enriched in Finland, whilst rare diseases found elsewhere in the world are absent. 
Both allelic and non-allelic heterogeneity are reduced which serve to increase association study 
power.  Thus  isolated  populations  share  some  of the  advantages  of inbred  mouse  lines  and 
provide greater power in association studies to detect rare alleles (Lee et al., 2001b).
1.5.3.5  Evolving resources for association studies in complex diseases
The association  study data presented  in  this thesis  serve as  a  reminder of the  infancy of our 
knowledge of human genetic variation and ability to map complex traits. In the years since this 
work  began,  several  aspects  of study design,  theory and the  tools  available to conduct  these 
studies  have  matured.  These  advances  are  discussed  in  detail  later  and  contrasted  with  our 
understanding at the outset of this work.  Possibly the most significant difference however has 
been  the  availability  of genomic  variation  and  LD  data,  and  advances  in  SNP  genotyping 
technology.
33An important consideration in association study design has been the construction of LD maps. 
Due to costs and  feasibility issues,  LD maps have historically been determined for candidate 
genes, as SNPs have had to be located, genotyped and LD assessed. From the year 2000, the 
volume of freely available SNP information in the database dbSNP has increased (Figure  1.7). 
dbSNP database now contains over 9.7 million SNPs (as of September 2006) obviating much of 
the need to ascertain SNPs in a candidate region.
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Figure 1.7  SNP submissions to dbSNP from over 5 years from 2000
Graph shows cumulative number of non-redundant SNPs, each mapping to a single location in the 
genome (solid line), the number of SNPs validated by genotyping (dotted line) and double-hit status 
(dashed line). Years are divided into quarters (Q1-Q4). (From The International HapMap Consortium,
2005)
Part of the exponential increase in SNP submissions since 2002 has been due to the launch of 
The International Haplotype Map project (HapMap) (International HapMap Consortium, 2003). 
This international collaboration undertook an extensive SNP discovery effort in 3 populations of 
African,  Asian,  and  European ancestry to construct a dense  5kb  SNP map and ascertain the 
underlying pattern of LD and therefore haplotype structure. This project has contributed vastly 
to our understanding of human genetic variation (The International HapMap Consortium, 2005) 
and  has  provided  a  resource  for  researchers  choosing  to  undertake  association  studies.  The 
availability of HapMap data (www.hapmap.org/) has obviated the need for investigators to have 
to ascertain SNPs and construct LD maps, saving considerable time and money. In addition, the 
advent of new  genotyping technologies over the past  seven  years has seen genotyping costs 
reduced  from  $0.50  per  genotype  to  $0,001  per  genotype,  which  has  had  an  effect  on  the 
number of SNPs and the number of samples that can be screened - ultimately increasing study 
power
1.6  Evolutionary analyses
The  search  for new  methods to  identify genes involved  in complex  diseases has  led  several 
authors to propose the use of natural selection to identify disease susceptibility loci (Jorde et al., 
2001;  Nielsen,  2001).  The  rationale  behind  this  approach  is  two  fold:  (i)  The  previous
34identification of genes implicated in both Mendelian and complex diseases and other complex 
phenotypes, show patterns of genetic variation characteristic of selection (referred to from here 
as signatures of selection), see Table 1.2 —  over 90 different loci have been proposed as possible 
targets for selection to date (Sabeti et al., 2006). (ii) Genetic variants that may have been under 
evolutionary selection are by definition functional and thus maybe more likely to contribute to 
disease susceptibility today.
Disease or phenotype Gene Mode of selection Reference
Malaria resistance
G6PD
TNFSF
Positive (Sabeti et al., 2002)
Heart disease risk MMP3 Positive (Rockman et al . 2004)
Speech FOXP2 Positive (Enard et al., 2002; Zhang et al.. 2002)
Lactase deficiency
Autosomal dominant 
spinocerebella ataxia
Putative viral resistance
Sickle cell/malaria 
resistance
LCT
SCA2
CCR5
HBB
Positive
Positive
Positive & balancing 
Positive & balancing
(Tishkoff et al, 2007)
(Yu etal., 2005)
(Bamshad et al., 2002; Wooding et al, 
2005)
(Wood et al., 2005)
Immune recognition 
Kuru
Trichromatic colour
HLA
PRNP
OPN1LW
Balancing
Balancing
Purifying
(Meyer et al, 2006) 
(Mead et al., 2003) 
(Verrelli et al., 2004)
Table 1.2  Reports of selection in the human lineage
Ten examples of genes with selection in the human lineage since the divergence of humans and 
chimpanzees. References given represent recent studies only and are not exhaustive. (Modified from 
Sabeti et al., 2006).
1.6.1  Genetic variation is shaped by several forces
The  genetic  variation of human populations today,  which  may  lead to disease susceptibility, 
comprises  a  composite  of  ancestral  influences  including  mutation,  natural  selection  and 
population history, also known as demography (i.e. migration, expansion, isolation etc).
1.6.2  Measuring genetic variation and disease mapping by natural selection
Our increased understanding of human genetic variation, largely due to the sequencing of the 
human  genome  and  the  completion  of the  HapMap  project  sequencing  has  augmented  our 
ability to detect neutral variation and deviations from neutrality. The neutral theory of molecular 
evolution (Kimura,  1968), is perhaps the best place to begin this discussion as it is has been 
integral  to  recent  studies of natural  selection.  The  neutral  theory posits  that  the  majority  of 
polymorphisms that arise through random mutation have no appreciable effect on fitness (i.e. 
are neutral) and that these polymorphisms vary randomly in frequency over time (genetic drift) 
and are eliminated or fixed  in populations as a consequence of the stochastic effects genetic 
drift.  Specifically, the neutral theory can be used to make explicit and quantitative predictions 
about the amount, structure, and patterns of sequence variation expected under neutrality, and 
serves  as  a  null  hypothesis  by  which  to  evaluate  the  evidence  for  or  against  selection  in 
empirical data.
35The  pattern  of  neutral  variation  in  the  human  genome  can  be  summarised  using  the  site 
frequency  spectrum  which  represents  the  distribution  of  derived*  allele  frequencies  in  a 
population  (see  Figure  1.8C).  Data  from  the  Encyclopaedia  Of DNA  Elements  (ENCODE)* 
regions  of the  HapMap project  have  illustrated  the  exponential  decay  in  SNPs  of increasing 
frequency, which illustrates that the human genome is composed of a majority of young alleles. 
The  importance  of this  spectrum  to  population  genetics  is  that  several  tests  of selection  are 
based on deviations from this expected allele frequency distribution including Tajimas’s D, Fu 
and  Li’s  D  and  Fu  and  Li’s  F.  In  addition,  there  are  several  selection  statistics  that  are 
independent  of  the  site  frequency  spectrum  but  which  rely  instead  on  comparisons  of 
polymorphisms within and/or between species such as Macdonald-Kreitman, Hudson-Kreitman- 
Aguade (HKA) test and dN /ds tests. A comprehensive description of these tests and their relative 
merits is beyond the scope of this thesis but several excellent reviews can be found (Bamshad et 
al., 2003; Biswas et al., 2006; Kreitman, 2000; Sabeti et al., 2006).
1.6.2.1  Natural selection
Natural  selection  occurs  when  a  new  mutation  results  in  differential  reproductive  success 
(fitness). In humans, it has been estimated that ~4 new amino-acid-altering mutations arise per 
diploid  genome  per  generation  (Eyre-Walker  et  al.,  1999);  these  mutations  can  be  broadly 
categorized as positive (i.e. enhances fitness), negative (i.e. reduces fitness) and balancing (i.e. 
enhances  fitness  only  in  heterozygous  state).  Accordingly,  each  form  of  selection  can 
characteristically  increase,  decrease  or  have  an  intermediate  effect  on  the  mutant  allele 
frequency,  under  positive,  negative  and  balancing  pressure  respectively,  and  produce  a 
characteristic signature of selection in the surrounding neutral variation.
Negative selection is the most pervasive form of selection as most mutations that cause protein 
coding changes are deleterious. These mutations are selected against and are likely to be lost. As 
this type of selection conserves amino acid sequence it is often called purifying selection. In the 
presence of strong purifying selection, nucleotide diversity at tightly linked sites is also reduced 
(Charlesworth  et  al.,  1993),  although  this  background  selection  is  also  dependent  on  local 
mutation and recombination rates.
Positive  selection  occurs  when  a  new  mutation enhances  the  fitness  and  is  likely to  become 
fixed within a population.  The time taken  for the new mutation to  fixate is dependent on the 
mode of action of the new mutation:  a dominant allele  fixates  faster than a recessive one.  In 
addition,  the type and the magnitude of the selective pressure  influence time to fixation.  If a
*  New mutations create a polymorphic site - therefore derived alleles are younger than ancestral alleles 
f ENCODE represents ten 500kb regions that have been fully resequenced in 48 unrelated samples to 
identify all variation sampled within the region
36mutation increases in frequency, tightly linked neutral variation can be dragged along as well. 
This  genetic  hitchhiking  can  eliminate  variation  not  linked  to  the  advantageous  mutation, 
resulting in a selective sweep.
Balancing selection occurs when the heterozygous phenotype has a greater fitness than either 
homozygote.  The  effect  of balancing  selection  is  to  maintain  both  alleles  at  equilibrium 
frequency. There are few examples of balancing selection in human populations. Probably the 
most well known is sickle cell anaemia, in which the sickle cell mutation in the HBB gene offers 
resistance  to  malaria  in  the  heterozygous  state  but  causes  severe  and  fatal  anaemia  in  the 
homozygous state. The G6PD gene, which can cause haemolytic disease, has also been shown 
to  have  undergone  balancing  selection  possibly  as  it  is  associated  with  protection  against 
malaria in the heterozygous state. In addition, the Major Histocompatibility Complex (MHC) on 
chromosome 6 has been shown to have been under balancing selection which has been proposed 
to help  maintain a wider repertoire  for non-self-peptide  recognition  in an immune  response. 
Most recently, the prion gene (PRNP), known to be associated with risk of human prion disease, 
has been shown to have undergone balancing selection worldwide. All three forms of selection 
have distinct effects on genetic variation surrounding a mutation.
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Figure 1.8  The effects of selection on the distribution of genetic variation
(a) The genealogies of three genes with 20 polymorphic sites that are typical of loci under positive 
selection (top), balancing selection (middle) and no selection (bottom) are shown. Each circle represents 
a mutation, and the colour shows the final frequency of each mutation.
(b) Each haplotype contains mutations that have accumulated on each lineage in the gene genealogy, 
assuming no recombination, (c) The site frequency spectrum of each gene. Positive selection (top) can 
result in a lower level of sequence diversity (n), an excess of low-frequency variants (red) and, 
consequently, a negative value of Tajima's D. Balancing selection (middle) can result in a higher level of 
sequence diversity (n), an excess of intermediate-frequency variants (purple) and, consequently, a positive 
value of Tajima’s D. The diversity estimate and site frequency spectrum of a neutral locus (bottom) can be 
used for comparison. (From Bamshad et al., 2003)
371.6.2.2  Testing for signatures of selection
Sabeti and colleagues have recently published a proposal of five  signatures of selection,  into 
which all specific tests can be categorised (Sabeti et al, 2006), as summarised below:
(i) High proportion  of  function-altering mutations:  genetic variants that  alter protein  function 
are usually deleterious and are thus less likely to become common or reach fixation (i.e.  100% 
frequency)  than  are mutations that  have  no  functional effect on the protein (i.e.  synonymous 
change).  Positive selection over a prolonged period, however, can increase the fixation rate of 
beneficial  function-altering  mutations  and  such  changes  can  be  measured  by  comparison  of 
DNA sequence between species. The increase can be detected by comparing the rate of non- 
synonymous  changes  with  the  rate  of  synonymous  or  other  presumed  neutral  changes,  by 
comparison  with  the  rate  in  other  lineages,  or  by  comparison  with  intraspecies  diversity. 
Statistical tests commonly used to detect this signature include the Ka/Ks, dN /ds and MKA tests.
(ii)  Reduction  in  genetic  diversity:  As  an  allele  increases  in  population  frequency,  genetic 
hitchhiking alters the typical pattern of genetic variation in the region - leading to a selective 
sweep.  In  a  complete  selective  sweep,  the  selected  allele  rises  to  fixation,  bringing  with  it 
closely  linked  variants;  eliminating diversity in the  immediate vicinity and decreasing  it  in a 
larger  region.  Although  new  mutations  eventually  restore  diversity,  these  appear  slowly 
(because mutation is rare) and are initially at low  frequency.  Positive selection thus creates a 
signature  consisting  of a  region  of low  overall  diversity,  with  an  excess  of rare  alleles.  The 
opposite is true (but has been observed less frequently) for balancing selection, such as that of 
the prion gene PRNP - an excess of high frequency is seen. Statistical tests commonly used to 
detect this signal include Tajima's D, the HKA test, and Fu and Li's D*.
(iii) High-frequency derived alleles:  Derived alleles arise by new mutation and typically have 
lower allele  frequencies  than ancestral  alleles.  In a  selective  sweep,  however,  derived alleles 
linked  to  the  beneficial  allele can  hitchhike  to  high  frequency.  As  a  result  of an  incomplete 
sweep or recombination,  many of these derived alleles will  not  reach complete  fixation,  thus 
positive  selection  creates  a  signature  of a  region  containing  many  high-frequency  derived 
alleles. For example, the  10-kb region around the Duffy red cell antigen (FY) has an excess of 
high-frequency derived alleles in Africans and is therefore, thought to be the result of selection 
for  malaria  resistance  (Escalante  et  al.,  2005;  Hamblin  et  al.,  2002).  A  commonly  used 
statistical test to detect this signal is Fay and Wu’s H.
(iv) Differences between populations: When geographically separate populations are subject to 
distinct environmental or cultural pressures, positive selection may change the frequency of an 
allele  in  one  population  but  not  in  another.  Large  differences  between  populations  in  the 
selected  allele  frequency  or  in  surrounding  variation  can  therefore  signal  a  locus  that  has
38undergone  positive  selection.  For  example,  the  region  surrounding  the  lactase  (LCT)  locus 
demonstrates large population differentiation between Europeans and non-Europeans, reflecting 
strong  selection  for the  lactase  persistence  allele  in  Europeans  (Bersaglieri  et al.,  2004).  A 
commonly used statistic for population differentiation includes FSt-
(v)  Long haplotypes: Under positive selection, a selected allele may rise in prevalence rapidly 
enough  that  recombination  cannot  substantially  erode  LD  with  hitchhiking  alleles  on  the 
ancestral chromosome. In these circumstances alleles have both high frequency (typical of old 
alleles) and long-range LD with other alleles (typical of young alleles). Thus, selective sweeps 
can produce a distinctive signature that would not be expected under neutral genetic drift. Long- 
range LD manifests as a long haplotype that has not been broken down by recombination. For 
example,  the  lactase persistence  allele at  the LCT locus  lies  on a  haplotype  that  is  common 
(~77%) in Europeans but that extends undisrupted for more than 1   megabase (Mb) (Bersaglieri 
et al.,  2004), much farther than is typical for an allele of that frequency. This signature can be 
detected with the long-range haplotype (LRH) test.
1.6.23  Confounding factors -  demography and ascertainment
Robust  inferences  of natural  selection  from  DNA  sequence data are difficult  because  of the 
confounding  effects  of  population  demographic  history,  such  as  population  bottlenecks, 
expansions  and  subdivisions,  and  ascertainment  bias within the  study design.  Ascertainment 
bias results from the fact that low frequency SNPs can go undetected if the genotyping sample 
size is too small. As the probability that a SNP is identified in a limited sample is a function of 
the allele  frequency,  rare  SNPs are more  likely to  go  undiscovered compared with common 
SNPs.  As  a  consequence  the  site  frequency  spectrum  obtained  will  be  different  from  that 
obtained under complete sampling (e.g. by resequencing the entire study sample). As a result, 
statistical attributes that rely on the site frequency spectrum - including Tajima's D, FS j, and LD 
- will be affected.
Confounding due to population demography can mimic signatures of selection.  For example, 
both  positive  selection  and  increases  in  population  size  lead  to  an  excess  of low-frequency 
alleles in a population relative to that expected under a neutral model.  In addition population 
subdivision  can  lead  to  spurious  departures  from  Hardy-Weinberg  equilibrium  (discussed 
below).  Whilst  population  demography  affects  genetic  variation  across  the  entire  genome, 
selection  is much  more  likely to act  in a defined region only.  Therefore,  a true  signature of 
selection can be distinguished from population demography by examining unlinked loci or by 
determining  an  empirical  genome-wide  distribution  for test  statistics  used.  As  genome-wide 
genotyping  has  become  more  feasible,  a  greater  number  of authors  have  attempted  to  use
39genome-wide scans for tests of selection (Akey et al., 2002; Carlson et al., 2005; Kelley et al., 
2006; Nielsen et al., 2005).
1.6.3  Hardy-Weinberg equilibrium
Hardy-Weinberg  equilibrium  (HWE;  otherwise  known  as  Hardy-Weinberg  law  or principle) 
describes a mathematical model which has been routinely applied to population genetics and 
more recently, as a tool to identify disease loci. Independently discovered in 1908 by Wilhelm 
Weinberg, a German physician, and Godfrey Harold Hardy, a British mathematician, the Hardy- 
Weinberg  principle  states  the  frequencies  of alleles  in  a  population  will  remain  the  same 
regardless  of  the  starting  frequencies  and  that  equilibrium  genotypic  frequencies  will  be 
established after one generation of random mating (i.e.  genotype frequencies will be constant 
from generation to the next).  HWE is  found when the measured genotype  frequencies match 
those predicted by allele frequencies using
Equation 1.4  p2  + 2pq + q  = 1   (genotype frequency AA= p2, Aa=2pq, aa=qr2)
The  principle  is  based  on  assumptions  of random  mating,  large  population  size,  equal  sex 
distribution  and  the  absence  of migration,  mutation  and  selection.  Expected  and  observed 
genotype frequencies can be tested for significance using a X 2   test and departures from HWE 
can  imply that one of the assumptions  listed above  is incorrect.  Departures from HWE have 
therefore been used as a quality control measure for large-scale genotyping and as a method for 
localising disease genes and loci under selection (Feder et al.,  1996; Lee, 2003; Nielsen et al., 
1998).
1.7  Amyotrophic lateral sclerosis
1.7.1  Clinical and pathological features of ALS
Amyotrophic  lateral  sclerosis (ALS),  first described by the French physician and neurologist 
Jean-Martin Charcot in 1869, is characterised by the progressive degeneration of motor neurons 
from  the  motor cortex  and corticospinal  tract.  Disease  onset usually occurs  focally  in  either 
limb, presenting as muscle weakness, or with bulbar/corticobulbar ALS, generally presenting as 
affected speech or swallowing.  As the disease advances,  symptoms of progressive weakness, 
atrophy, paralysis, spasticity and emotional lability are seen. Death usually occurs 2 to 5 years 
after disease onset and is commonly due to respiratory failure as a consequence of denervation 
of the respiratory muscles and diaphragm.
Pathologically, ALS  is characterised by the loss of upper motor neurons in the motor cortex, 
degeneration of the corticospinal tract and loss of lower motor neurons in the brain stem and 
spinal cord.  The  selective degeneration of motor neurons only,  generally spares the patient’s 
sensory  and  cognitive  functions.  Motor  neurons  involved  in  ocular,  sphincter  and  urethral
40function are spared and these signs are often used to exclude other diagnoses. Histopathology of 
surviving lower motor neurons shows ubiquinated inclusions and marked axonal swelling.
In the absence of a diagnostic test, the clinical diagnosis of ALS is primarily one of exclusion. 
The early symptoms of ALS are often indistinguishable from similar disorders that affect motor 
neurons, and these are often confused for ALS.  In the United Kingdom (UK), these disorders 
are termed motor neuron diseases (MNDs) - a blanket term referring to a whole spectrum of 
diseases which differentially affect the upper and lower motor neurons or both. In the United 
States, the term ALS is commonly used interchangeably with MND, where it is also known as 
Lou Gehrig’s* disease, after the baseball player.
ALS is currently classified based on a set of diagnostic criteria set out by the World Federation 
of Neurology;  the  El  Escorial  Criteria  (Brooks,  1994),  and  its  recent  revision,  Airlie  House 
Criteria (Miller et al.,  1999).  Clinical diagnosis  of ALS  using these criteria,  is based on the 
presence of upper and lower motor neuron impairment, the detection of symptom progression 
over a limited period of time, and the exclusion of other conditions that may mimic ALS.
1.7.2  Epidemiology
ALS  is  currently  the  third  most  common  neurodegenerative  disease  after  Alzheimer’s  and 
Parkinson’s disease and is largely a disease of midlife (although rare juvenile onset forms are 
the exception) with an average age of onset between the 5th and 6th decade of life. A slight sex 
bias exists with males more likely to be affected than females in a ration of 1.3:1-1.6:1 (Nelson, 
1995). Estimates of the lifetime risk currently vary between  1   per 800-2000 (Cleveland et al., 
2001; Shaw, 2005) and the annual incidence of ALS is ~ 1-2 per 100,000 which increases with 
age. Disease prevalence is ~2-4 per 100,000, which is kept low due to the rapid disease course. 
ALS  incidence is uniform throughout the world with the exception of several high  incidence 
foci,  such  as  those  in  the  Western  Pacific  (the  Kii  peninsular  of Japan  and  Guam  in  the 
Marianas), where a variant of ALS seen with Parkinsonism and dementia has been observed at 
an increased frequency (Arnold et al.,  1953; Kimura, 1961). Although the vast majority of ALS 
cases are sporadic (known as sporadic ALS; SALS) with no apparent familial recurrence of the 
disease, ~10% of all ALS cases and ALS- related syndromes are inherited (known as familial 
ALS; FALS).
1.7.3  The Mendelian genetic basis of ALS
As with many other diseases, the greatest advance in our understanding of the genetics of ALS 
has come from familial forms of the disease, which show clear Mendelian inheritance. Given
*  Lou ‘The Iron Horse” Gehrig is still regarded today as one of the greatest baseball players of all time,
Of his many records, Lou Gehrig played in the most number of consecutive games over 15 years from 
1925 to 1939 -  a streak which ended when he developed ALS and subsequently died two years later.
41that  until  recently,  gene  identification  strategies  have  largely relied on observing Mendelian 
inheritance, within large families with highly penetrant mutations, it is not surprising that these 
genetic loci are the most robustly replicated genetic causes of ALS to date. However, FALS 
accounts for only a small proportion of all ALS cases and to date at least 12 genetic loci have 
been identified (Table 1.3).
The first ALS-associated gene to be identified was copper-zinc superoxide dismutase 1 (SOD1), 
on chromosome 21q22.1 (Rosen et al., 1993) which accounts for the greatest number (-20%) of 
familial ALS cases. To date, over  100 disease causing point mutations in SOD1, spanning all 
five exons, have been identified (Andersen et al.,  2003) (see www.alsod.iop.kcl.ac.uk/als). the 
vast majority of which are heterozygous missense mutations (insertions and deletions are rarely 
seen). Almost all mutations are dominantly inherited with the exception of recessive inheritance 
such as the D90A mutation (Andersen et al.,  1995).
42ALS disease type Onset Inheritance Gene Locus References
Mendelian genes
ALS1 Adult AD, AR (D90A) SOD1 21q22.1 (Al Chalabi et al., 1998; Rosen et al., 1993)
ALS2 Juvenile AR Alsin 2q33 (Hadano et al., 2001; Yang et al., 2001)
ALS4 Juvenile AD SETX 9q34 (Blair et al., 2000; Chen et al., 2004)
ALS8 Adult AD VAPB 20q13.33 (Nishimura et al., 2004b; Nishimura et al., 2004a)
Progressive LMN disease Adult AD DCTNV 2p13 (Munch et al., 2004; Munch et al., 2005; Puls et al., 2003)
ALS with dementia, Parkinsonism Adult AD MAPT 17q21 (Clark et al., 1998; Hutton et al., 1998; Siddique et al., 1995)
Mendelian loci
ALS3 Adult AD ? 18q21 (Hand eta!., 2002)
ALS5 Juvenile AR ? 15q15.1-q21.1 (Hentati eta!., 1998)
ALS6 Adult AD ? 16q12 (Abalkhail et al., 2003; Ruddy et al., 2003; Sapp et al., 2003)
ALS7 Adult AD ? 20ptel-p13 (Sapp et al., 2003)
ALS-FTD Adult AD ? 9q21-22 (Hosier et al., 2000)
Adult AD ? 9p13.2-21.3 (Morita et al., 2006; Vance et al., 2006)
Adult AD ? 17q (Wilhelmsen et al., 2004)
ALS X Adult AD ? Xp11-q12 (Siddique etal., 1998a)
Mitochondrial genes and misc.
ALS-M Maternal; Cox1 mtDNA Single case (Siddique et al., 1998a)
ALS-M Maternal IARS2 mtDNA Single case (Borthwick et al., 2006)
ALS-M Maternal CC01 mtDNA Single case (Comi et al., 1998)
AD NFH Single case (Al Chalabi et al., 1999)
Table 1.3  Familial ALS genes and loci
Autosomal dominant (AD);amyotrophic lateral sclerosis (ALS); autosomal recessive (AR); alsin (ALS2 ); cyclooxygenase 1  (COX1); frontotemporal dementia (FTD); mitochondrial 
isoleucine tRNA synthetase (IARS2); mitochondrial DNA (mtDNA); senataxin (SETX); superoxide dismutase 1  (SOD1); vesicle-associated membrane protein-associated protein B 
(VAPB); and unknown gene (?)
u>The  pathogenesis  of SOD1  mutations  is  unclear.  The  normal  153-amino  acid  SOD1  protein 
functions  as a copper and zinc containing homodimer,  which detoxifies  superoxide  (produced 
during  oxidative  phosphorylation  by  mitochondria)  to  oxygen  and  hydrogen  peroxide,  thus 
preventing oxidative damage.  SOD1  is ubiquitously expressed and predominantly located in the 
cell cytoplasm.  Most SOD1  mutations affect correct subunit folding and dimerisation, although 
the  resulting  effect  on  SOD1  activity  varies  (e.g.  G93A  mutations  have  almost  no  effect  on 
activity whilse H46R mutations inactivate SOD1).  No clear correlation has yet been identified 
between mutant SOD1 activity, including copper affinity, protein half-life and ability to scavenge 
superoxide,  and disease onset or duration.  Patients with  SOD1  mutations have  normal  protein 
levels suggesting that pathogenesis is not due to haploinsufficiency, however, SOD1 may exert a 
dominant negative effect or toxic gain of function.
Clinically, SOD1  FALS is indistinguishable from SALS although onset is ~10 years earlier and 
there  is  90%  penetrance  by  age  70.  The  mean  age  of onset  is  consistently  46  to  47  years 
regardless of the underlying  SOD1  mutation.  Mean duration is 3-6 years, however,  exceptions 
such as the aggressive A4V mutation which has a short disease duration of 1.4 years (Cudkowicz 
et al.,  1997) and G37R or G41D which have  longer survival prognoses (Orrell et al.,  1997b). 
Initially, SOD1  FALS cases present with predominantly lower motor neuron signs. Bulbar onset 
is unusual and is usually associated with a later-onset cases.
There are few common pathological features of SOD 1-mediated ALS such as corticospinal and 
anterior horn cell loss but generally pathology varies with different mutations.  SOD 1-mediated 
FALS clinical phenotype including age of onset, severity and survival all vary and the wide range 
of mutations in  SOD1  cannot account  for this variability.  In addition clinical variation can be 
observed  in  members  of the  same  family  (Andersen  et  al.,  1995),  suggesting  that  additional 
environmental or genetic factors may modify phenotype. That some SOD1  FALS mutations may 
appear more complex than previously thought is illustrated by the incomplete penetrance of the 
D90A mutation (discussed below) which is recessive on some genetic backgrounds and dominant 
on others (Al Chalabi et al.,  1998).
1.7.4  The complex genetic basis of ALS
The biggest challenge  for ALS  research  is currently dissecting the  aetiology of sporadic ALS 
which  accounts  for  ~90%  of  all  ALS  cases.  As  Simpson  and  Al-Chalabi  have  noted,  the 
assumption  that  sporadic  disease  implies  a  disease  with  no  genetic  cause  is  no  longer  valid
44(Simpson et al., 2006). Indeed, clinical, epidemiological and genetic studies of SALS cases have 
all revealed a genetic component.
1.7.4.1  A genetic component to sporadic ALS
Perhaps  the  simplest  example  of a  genetic  component  to  SALS  is  the  discovery  of  SOD1 
mutations in 2 to 7% of SALS cases (Andersen et al,  1995; Jackson et al,  1997; Jones et al, 
1994a;  Jones  et al.,  1994b),  indicating  that  at  least  some  sporadic  cases  of ALS  are  genetic, 
although  it  is unclear how many are de novo  mutations.  Several  lines of evidence implicate a 
genetic component to SALS:
Heritability  A UK twin study, investigating concordance between mono- and dizygotic twins, 
has  provided additional  support  for a  genetic  component  to  SALS.  The  authors  demonstrated 
heritability of ALS risk to be between 38 and 85% - essentially that between 38% and 85% of 
variation in ALS is attributable to inherited (i.e. genetic) factors (Graham et al,  1997). In addition 
estimated  sibling  relative  risk  (As),  under  a  set  of assumptions  regarding  family  history  and 
inheritance patterns, is between 20 and 50 (i.e. the sibling of an affected individual is 20 to 50 
times more likely to develop disease) (Simpson et al, 2006).
Ethnic differences  It is widely recognized that there is variation within and between human 
populations  with  respect  to  their  susceptibility  to  many  diseases  (Burchard  et  al,  2003). 
Investigation  of  variation  in  ALS  incidence  by  ethnicity  has  been  a  source  of  much 
epidemiological research and controversy. In these studies, ethnicity can be regarded as a proxy 
to describe population genetic variation or variation in genetic background. Epidemiological data 
from  worldwide  populations  analysing  rates  of ALS  incidence  and  prevalence,  migration  and 
mortality  have  shown  that  the  rates  are  consistently  lower  in  African,  Asian  and  Hispanic 
ethnicities that in Caucasians see for example (Dean et al,  1993; Elian et al,  1993; Noonan et al., 
2005).  However these  studies  often  suffer  from  ascertainment  and reporting bias.  Cronin  and 
colleagues  have  recently  reviewed  61  published  articles  examining  ethnic  variation  in  the 
incidence of ALS and based on standardised measures of incidence, they concluded that African, 
Asian  and  Hispanic  ethnicities  did  show  a  lower  overall  incidence  of  ALS  compared  to 
Caucasians  (Cronin et al.,  2007).  It  is entirely plausible that  these  differences  may be due  to 
differential environmental exposures too.
45Genetic background has been postulated to influence several familial forms of ALS. For example, 
the D90A mutation of SOD1  is responsible for a recessively inherited form of ALS  in families 
from the Tome Valley,  in Sweden and Finland (Andersen et al,  1995;  Andersen et al.,  1996; 
Andersen et al.,  1997).  In addition,  families from southern Sweden, UK,  France and Belgium, 
heterozygous for the D90A mutation have also been reported with a more aggressive and variable 
ALS phenotype, and a few individuals with no family history of ALS have also been described 
(Andersen  et  al.,  1995;  Robberecht  et  al.,  1996,  Jackson  et  al.,  1997;  Khoris  et  al.,  1997). 
Remarkably, all families carrying the D90A mutation have been shown to have descended from a 
single ancient  founder ~895  generations ago,  with the recessive allele becoming established  in 
Tome Valley during the settlement and isolation of the area ~63 generations ago (Al Chalabi et 
al,  1998; Parton et al, 2002). Importantly, a region of up to 265kb around SOD I is shared by the 
recessive  Tome  Valley  kindreds  which  is  postulated  to  contain  a  tightly  linked  c/s-acting 
protective factor, such that two copies of D90A are required for ALS to develop. No such linked 
protective factor has yet been identified.
In addition the failure of replication of ALS association studies conducted in different worldwide 
populations may be due to differences in genetic background, they may also be due to different 
environmental factors, e.g. VEGF (Van Vught et al., 2005).
1.7.5  Susceptibility genes in sporadic ALS
Based on the liability threshold model, susceptibility to ALS can be considered to be a spectrum 
of genetic and environmental risk: (i) at one end of the spectrum are the well studied single genes, 
with  large  effect  size,  that  cause  fully  penetrant,  autosomal  dominant  FALS  and  (ii)  at  the 
opposite end are the multiple genes of small  effect that  may interact  with the environment to 
cause  apparently  SALS.  Until  recently,  linkage  studies  have  only been  able  to  illuminate  the 
genes of large effect responsible for one side of the liability spectrum but have lacked power in 
elucidating  those  genes  of  small  effect.  Genes  of  small  effect  have,  until  recently,  been 
investigated  in  ALS  using  candidate  gene  association  studies,  often  informed  by  those  genes 
identified  from  linkage  studies.  However,  the  availability  of cheaper  genotyping  and  denser 
marker sets is changing how these susceptibility genes will be discovered. Table 1.2 summarises 
the  candidate  genes  which  have  been  investigated  in  ALS  as  modifiers  of risk or phenotype. 
Rather than list every single one of these  in the text,  I will  discuss some of the most  studied.
46Gene  Description  Rsason for investigation
ALAD
ALS2
ANG
APEX
APOE
AR
CCS
CNTF
CYP2D6
DCTN1
DYNC1H1
EAAT2
HexA
HFE
UF
LOX
MAO-B
MAPT
d-Aminolevulinic Acid 
Dehydratase
Alsin
Angiogenin
Apurinic endonuclease 
Apolipoprotein E
Androgen receptor
Copper chaperone for 
superoxide dismutase
Ciliary neurotrophic factor
Cytochrome p450, 
subfamily IID, polypeptide 
6
Dynactin
Dynein heavy chain
Excitatory amino acid 
transporter 2
Hexosaminidase A
Haemochromatosis
Leukaemia inhibitory 
factor
Lysyl oxidase
Monoamine oxidase B
Microtubule-associated 
protein tau
Lead exposure associated with ALS ALAD is involved 
in haem synthesis in erythrocytes
Causes autosomal recessive juvenile ALS (ALS2).
ANG is functionally similar to VEGF
Defective DNA repair hypothesis of ALS etiology
Implicated in several other neurodegenerative 
disorders
Causes Kennedy spinal and bulbar muscular atrophy. 
Gene responsible for copper insertion into SOD1
Mice lacking CNTF develop mild, progressive motor 
neuron loss
Hypothesized poor metabolism of xenobiotics as risk 
factor
Disruption of dynein/dynactin complex produces 
motor neuron disease phenotype in mice 
Mutations in Dnchl result in progressive motor 
neuron degeneration in heterozygous mice, 
homozygotes also have Lewy-like inclusion bodies,
Excitotoxicity hypothesized to result in motor neuron 
degeneration
HexA deficiency causes accumulation of ganglioside 
GM2 leads to neurodegeneration causing wide 
spectrum of neurological diseases 
Oxidative stress is hypothesized to be implicated in 
neurodegeneration and misregulation of iron induces 
oxidative stress. Also, abnormal iron levels found in 
spinal cords of ALS patients 
LIF is same cytokine family as CNTF, involved in 
motor neuron survival
LOX is a copper containing enzyme and copper-
induced cytotoxicity is a hypothetical mechanism of
motor neuron degeneration
MAO-B generates free radicals and these are
implicated in neuronal damage
MAPT involved in other neurodegenerative diseases
Guam variant of ALS has containing tau aggregates
Significance References
No association 
No association
Association found in Scottish and 
Irish populations
May have small role but not major 
factor
Not associated with susceptibility. 
May be associated with age of 
onset, presentation and survival
No association 
No association
Contradictory results
One reported association, not 
replicable
One reported association, not yet 
replicated
No association
No association
Occasionally causes rare ALS-like 
syndrome
(Kamel et al., 2002; Kamel et al., 2003)
(Hadano et al., 2001; Hand et al., 2003; Hentati et al., 
1994; Hosier et al., 1998; Yang et al., 2001)
(Greenway et al., 2004; Hayward et al.,  1999) 
(Hayward et al.,  1999)
(Al Chalabi et al., 1996; Drory et al., 2001; Moulard et 
al.,  1996; Mui et al.,  1995; Siddique et al.,  1998b)
(Garofalo et al.,  1993)
(Silahtaroglu et al., 2002)
(Al Chalabi eta!., 2003; DeChiara eta!.,  1995; Giess et 
al., 2002; Masu et al., 1993; Orrell et al., 1995; 
Takahashi et al.,  1994)
(Nicholl et al.,  1999; Siddons etal.,  1996)
(Munch et al., 2005)
(Ahmad-Annuar et al., 2003; Hafezparast et al., 2003; 
Munch et al., 2004; Shah et al., 2006)
(Aoki et al.,  1998; Flowers et al., 2001; Honig et al., 
2000; Jackson et al.,  1999, Lin et al.,  1998; Meyer et 
al.,  1998; Meyer et al.,  1999)
(Drory et al., 2003)
Contradictory results (Wang et at, 2004; Yen et al., 2004)
One reported association, not yet 
replicated
No association
Association with age at onset, not 
yet replicated
Association reported but p-values 
were weak
(Giess et at, 2000; Meyer et at,  1995) 
(Chioza etal., 2001)
(Orru etal., 1999)
(Kowalska et at, 2003; Poorkaj et at, 2001)Gene Description Reason for Investigation Significance References
MHO Mitochondrial DNA 
deletions
Accumulation of mitochondrial DNA mutations 
associated with aging development of degenerative 
diseases. In ALS, abnormal mitochondria are often 
found in spinal motor neurons
Associations reported, but all 
studies very small
(Dhaliwal et al., 2000; Gajewski et al., 2003; Mawrin et 
al., 2003; Swerdlow et al.,  1998; Wiedemann et al., 
2002) (Mawrin et al., 2004; Ro et al., 2003)
NAIP Neuronal apoptosis NAIP involved in related disease, spinal muscular No association. Mutations in NAIP (Jackson et al.,  1996; Kunst et al., 2000; Orrell et al.,
inhibitory protein atrophy now considered specific for SMA 1997a; Parboosingh et al.,  1999)
ND2 Subunit 2 of mitochondrial 
NADH dehydrogenase Expression of ND2 found in Alzheimer's brains No association (Lin etal., 1992)
NEFH Neurofilament, heavy 
chain Neurofilament accumulation is a hallmark of ALS
Significant association, tail domain 
deletions present in 1% ALS 
patients, not in controls. Findings
(Al Chalabi et al., 1999; Julien et al.,  1995; Meyer et 
al., 1995; Rooke etal.,  1996; Tomkins etal.,  1998; 
Vechio etal,  1996) have re  plicated in several studies
PRPH Peripherin Transgenic mice over-expressing peripherin develop 
motor neuron degeneration
Few mutations found, not a 
common cause of ALS (Gros-Louis et al, 2004; Leung et al., 2004)
PSEN1 Presenilin-1 PSEN1  involved in apoptosis, a postulated 
mechanism for neuronal death 
Poliovirus attacks motor neurons selectively,
Weak association found, small 
study, not replicated 
Association with lower motor
(Panas et al., 2000)
PVR Poliovirus receptor enteroviral nucleic acids found in spinal cord of ALS 
patients
neuron disease found in one small 
study, not yet replicated
(Saunderson et al., 2004)
SETX Senataxin Mutations in SETX cause autosomal dominant 
juvenile ALS (ALS4)
New familial gene, not yet tested 
in sporadics
(Chen et al., 2004)
SMN1/2 Survival of motor neuron 
1/2
Deletions and mutations of SMN genes cause spinal 
muscular atrophy
SMN genotypes which reduce 
SMN protein levels associated 
with sporadic ALS 
One case reported of young
(Corcia et al., 2002b; Corcia et al, 2002a; Veldink et 
al, 2001; Veldink etal., 2005)
Spastin
and
paraplegin
Hereditary spastic 
paraparesis
Mutations in spastin and paraplegin are the most 
common causes of hereditary spastic paraparesis
Persyn is a member of the synuclein family, y-
onset, slowly progressive upper 
and lower motor neuron syndrome 
with spastin mutation. No 
association with paraplegin
(McDermott et al, 2003; Meyer et al., 2005)
SNCG Persyn synuclein. Mutations in a-synuclein found in 
Parkinson's disease
No association (Flowers et al,  1999)
SOD1 Cu/Zn superoxide 
dismutase 1 Mutations in SOD1 account for 20% of familial ALS. 2-7% sporadic cases
(Andersen et al., 1997; Johnston et al., 2006; Jones et 
al.,  1994b; Rosen etal., 1993; Siddique etal.,  1991)
SOD2 Manganese superoxide 
dismutase
SOD2 is a related protein of SOD1, found in 
mitochondria No association (Tomkins et al., 2001)
VAPB
Vesicle-associated 
membrane protein- 
associated protein B
Mutations in VAPB cause an autosomal dominant, 
slowly progressive ALS (ALS8)
New familial gene, not yet tested 
in sporadics (Nishimura et al., 2004b)
VDR Vitamin D receptor Lead exposure associated with ALS. Vitamin D can 
affect lead absorption and distribution Not significant (Kamel et al., 2002; Kamel et al., 2003)
VEGF Vascular endothelial 
growth factor Susceptibility Association in some populations (Lambrechts et al, 2003; Oosthuyse et al, 2001; Terry 
et al., 2004; Van Vught et a/., 2005)
Table 1.4  ALS susceptibility loci
(Modified from Simpson et al., 2006)
oo1.7.6  DYNC1H1 as a candidate susceptibility locus
The cytoplasmic 1 dynein heavy chain I (DYNC1H1) has been implicated as a potential causative 
gene  for  motor  neuron  degeneration  and  possibly  for  ALS.  The  first  evidence  implicating 
DYNC1H1  as  a  locus  for  investigation  in  ALS  came  from  mouse  models  of motor  neuron 
degeneration  generated  by  mutagenesis  screen.  The  heterozygous  ‘Legs  at  odd angles’  (Loa) 
mouse  and  allelic  ‘Cramping  / ’  (Cral)  mouse  both  displayed  progressive  locomotor  defects. 
Although  this  did  not  affect  lifespan,  homozygous  mice  died  within  24  hours  of  birth 
(Hafezparast et al., 2003). Histopathology, of the Loa mice showed significant anterior horn cell 
loss  and  deposition  of ubiquitin,  SOD1  and  neurofilament  in  the  remaining  cells  which  also 
contained Lewy-like bodies.
1.7.6.1  The cytoplasmic dyneins and dynactin
The dyneins are large multi-subunit protein complexes that undertake a wide range of roles within 
the cell. They are microtubule minus-end-directed molecular motors that can be divided into two 
classes based on function: axonemal and cytoplasmic dyneins (reviewed in Gibbons, 1995; Vallee 
et  al.,  2004).  Axonemal  dyneins  are  responsible  for  the  movement  of cilia  and  flagella  and 
cytoplasmic dyneins are involved in a range of microtubule-associated functions within the cell. 
Two  cytoplasmic  dynein  complexes  with  distinct  cellular  functions  exist,  termed  cytoplasmic 
dynein  1   and cytoplasmic dynein 2. Cytoplasmic dynein 2 is involved in intraflagellar transport 
(IFT),  a  process  required  for  the  assembly  of  cilia  and  flagella  (reviewed  in  Cole,  2003). 
Cytoplasmic  dynein  1   is  the  more  abundant  complex  and  is  involved  in  a  greater  number  of 
functions such as diverse as spindle-pole organization and nuclear migration during mitosis and 
the  positioning  and  functioning  of  cellular  organelles  and  compartments,  including  the 
endoplasmic reticulum (ER), Golgi apparatus and the nucleus. In addition cytoplasmic dynein  1  
also  provides  the  minus-end-directed  transport  of  vesicles  along  microtubules,  including 
endosomes and lysosomes, and retrograde axonal transport in neurons.
The  cytoplasmic  dynein  1   complex  also  interacts  with  other proteins  such  as  LIS1,  which  is 
thought to modulate the enzymatic activity of DYNC1H1  (Mesngon et al.,  2006), and a second 
multimer, dynactin, which is itself comprised of at least seven different proteins including p22, 
p50 and pi50 and possesses three functional domains: microtubule-binding, dynein-binding, and 
cargo binding (reviewed in Schroer, 2004). These domains allow dynactin to function both as an 
adaptor, associating the dynein motor with different cargoes (Holleran et al.,  1998; Karki et al.,
491998; Karki et al.,  1999), and as an enhancer of dynein motor processivity is enhanced two- to 
four-fold over the distance travelled by a single dynein molecule alone (Culver-Hanlon et al., 
2006; King et al, 2000).
1.7.6.2  Cytoplasmic dynein 1 heavy chain subunit and function in neurons
The  cytoplasmic  dynein  1   complex  comprises  several  subunits:  two  large  heavy  chain 
polypeptides  (~530  kDa  each)  which  homodimerise  to  form  the  core  of  the  complex  and 
associated intermediate (-74 kDa), light intermediate (-33-59 kDa), and light chain polypeptides 
(-10-14 kDa) (see Figure 4.1). In the interest of brevity and as this thesis is largely focused on the 
dynein heavy chain, only the heavy chain will be discussed however several excellent reviews 
exist for the interested reader (see for example Pfister et al., 2005b).
The  cytoplasmic  dynein-dynactin  complex  performs  multiple  cellular  roles  and  are  essential 
protein  complexes  in  higher  eukaryotes;  both  fly  and  mouse  knockouts  are  lethal  in 
embryogenesis  (Gepner  et  al.,  1996;  Harada  et  al.,  1998).  Within  post-mitotic  neurons 
cytoplasmic  dynein  is  responsible  for several  essential  functions  including  maintaining  ER  to 
Golgi  traffic,  vesicle  transport,  mRNA  localisation  and  retrograde  axonal  transport.  In  motor 
neurons in particular, which possess axons that can exceed lm in length and which form multiple 
synapses  with  other  neurons  and  muscle  cells,  correct  and  efficient  retrograde  transport  is 
essential. Cytoplasmic dynein utilises the axonal cytoskeleton within motor neurons to transport 
cargo such as organelles and structural and signalling proteins and neurotrophic factors from the 
axon termini to the perikaryon. Indeed, defects in the machinery that drives retrograde transport 
may inhibit neurotrophic factor signalling, and therefore lead to neuronal degeneration (Holzbaur, 
2004). In support of this hypothesis, inhibition of retrograde transport in postnatal motor neurons 
by  over-expression  of a  dynactin  subunit  results  in  motor  neuron  loss  and  muscle  atrophy 
(LaMonte et al, 2002).
1.7.6.3  Cytoplasmic dynein and human motor neuron degeneration
The cytoplasmic  dynein-dynactin  complex  has  been  implicated  in  several  instances  of human 
motor  neuron  degeneration.  Puls  and  colleagues  identified  a  G59S  mutation  in  the  pl50G /M < v / 
subunit of dynactin (DCTN1) in a family with a slowly progressive autosomal dominant form of 
motor neuron disease (Puls et al., 2003; Puls et al, 2005). Affected individuals with this mutation 
developed  symptoms  in  early  adulthood  including:  vocal  fold  paralysis  causing  breathing 
difficulty;  progressive  facial  weakness,  and weakness and atrophy in distal-limb muscles.  The
50G59S mutation resides in a highly conserved domain that interacts directly with microtubules and 
the  microtubule  plus  end  protein  EB1  (Ligon  et  al.,  2005)  leading  to  decreased  microtubule 
binding and enhanced dynein and dynactin aggregation (Levy et al., 2006), thus contributing to 
the degeneration of motor neurons.
Mutations in DCTN1 have also been identified in three FALS cases and one SALS case in a study 
of 250 ALS patients and  150 unrelated controls (Munch et al.,  2004).  In this study Munch and 
colleagues investigated all DCTNJ exons and identified a T1249I change in the SALS case and a 
M571T change in one of the FALS cases. The two remaining FALS cases were related, from the 
same  kindred  and  possessed  an  autosomal  dominant  R785W  mutation.  Interestingly,  two 
unaffected  individuals  from the  same  kindred also possessed the  R785W  mutation,  suggesting 
that this mutation may display incomplete penetrance or that this mutation may not be responsible 
for  disease  and  it  is  instead  an  unknown  autosomal  recessive  gene  defect  or  that  DCTN1 
represents a genetic risk factor, rather than a causative factor for ALS.
511.8  Human prion diseases
Prion  diseases  are  a  group  of human  and  animal  neurodegenerative  conditions  that  have  in 
common a key role for the prion protein in their pathogenesis. The archetypal prion disease, sheep 
scrapie,  was  first reported in the  18th century (McGowan,  1922) (the name is derived from the 
scratching of fence posts by diseased, ataxic animals), and since then several additional animal 
and human prion diseases have been identified. There are three aetiological categories of human 
prion  disease:  inherited,  acquired  (transmitted  between  humans  or  animals)  and  sporadic. 
Inherited  prion  diseases  include  Gerstmann-Straussler-Scheinker  (GSS)  disease,  fatal  familial 
insomnia  (FFI) and  familial  Creutzfeldt-Jakob disease (fCJD);  acquired prion diseases  include 
iatrogenic CJD, variant CJD (vCJD) and kuru; and sporadic disease is sporadic CJD (sCJD).
1.8.1  Aetiology of prion diseases
A  key  feature  of  the  prion  diseases  is  their  transmissibility  amongst  and  between  species 
(Chandler.L,  1961; Cuille et al.,  1936; Gajdusek et al.,  1967). The discovery of the aetiology of 
prion diseases is a fascinating story (Collinge, 2005) and is based largely on the observations of 
disease  transmissibility  and  the  search  for,  and  identification  of,  the  transmissible  species.  A 
single protein, the prion protein (PrP), seen to copurify with infectivity has led to the development 
of a  ‘protein-only’  hypothesis  of prion  disease.  Under this  hypothesis,  the  infectious  agent  of 
prion diseases is comprised of abnormal isoforms of PrP and these disease associated isoforms act 
as templates to promote the conversion of normal  cellular PrP (PrPc)  to the pathological  state 
PrP* (Prusiner, 1982).
1.8.1.1  PrP and PRNP
The normal  prion protein  is a  large protein  33-35  kDa whose sequence  is highly conserved in 
most mammals (Wopfner et al.,  1999). PrPc is widely expressed in most adult tissues (Manson et 
al.,  1992) however highest expression levels are seen in the central nervous system. The precise 
cellular function of PrPc  is still not known, however, as a glycosyl phosphatidyl inositol-anchored 
cell-surface glycoprotein,  it has been speculated that PrPc may have a role  in cell adhesion or 
signalling processes.
Human and mouse genetics have made major contributions to prion disease research. Following 
the identification of PrP as the transmissible agent, partial sequencing of the protein allowed for 
the prediction of coding nucleotides and eventually to the cloning of the cognate human (PRNP) 
the and mouse (Prnp) prion protein genes on chromosomes 20 and 2 respectively (Chesebro et
52al.,  1985; Oesch et al.,  1985; Robakis et al.,  1986). Strong supportive evidence for the central role 
of PrP in prion disease has been provided by (i) the linkage of scrapie incubation time loci in the 
mouse to Prnp (Carlson et al.,  1986) and (ii) the identification of mutations in PRNP linked to the 
inherited human prion diseases fCJD (Owen et al.,  1989) and GSS (Hsiao et al.,  1989).
The human PRNP gene on chromosome 20 comprises two exons (Puckett et al.,  1991) and spans 
~16kb. The open reading frame (ORF) of 759 nucleotides is entirely contained within the larger 
second  exon.  In  the  mouse,  Prnp  is  located  in  the  syntenic  region  of  chromosome  2  and 
comprises three exons (with an additional short second exon compared to PRNP), with the ORF 
located in exon 3. The ORFs of mammalian prion genes are well conserved, generally exhibiting 
~90% similarity.  Several regions of human PrP are relevant to disease. The N-terminal domain 
(codons  51-91)  encodes  a  5-mer  repeat  region  consisting  of a  nonapeptide  followed  by  four 
identical  octapeptides.  Alterations  in  the  number  of repeats  are  found  as  polymorphisms  and 
pathogenic mutations, but no point mutations or common SNPs have been found in this region. 
The C-terminal domain of PrP contains known point mutations, causing inherited prion disease 
,and a common coding polymorphism at codon  129 of PRNP (A385G) between methionine and 
valine has a critical role in susceptibility and modification of prion disease (discussed later).
1.8.2  Inherited prion diseases
Approximately  15% of all human prion diseases are inherited as autosomal dominant disorders 
and all can be accounted for by mutation of PRNP, of which over 30 different mutations have 
been described to date (Mead, 2006). Three types of pathogenic PRNP mutation exist in inherited 
prion  disease:  (i)  point  mutations  leading  to  an  amino-acid  substitution  or  leading  to  (ii)  a 
premature  stop  codon  and  (iii)  insertion  of additional  octapeptide  repeats  (OPR1).  With  the 
exception of some OPRI cases and C-terminal point mutations, all mutations are fully penetrant.
Inherited prion disease is generally associated with an earlier age of onset and longer duration of 
illness than sporadic  forms.  However, the phenotype is highly variable ranging from prolonged 
slowly  progressive  dementia  over  20  years  to  an  aggressive  disease  indistinguishable  from 
sporadic  CJD.  The  spectrum  of inherited  prion  diseases  has  been  historically encapsulated  by 
three clinical categories: GSS, FFI and fCJD, with features including slow progression of ataxia 
followed by later onset dementia in GSS; refractory insomnia, hallucinations, dysautonomia and 
motor signs in FFI; and rapidly progressive dementia, with myoclonus in fCJD. The phenotypic 
variability of inherited prion diseases  is clearly  illustrated by a  large  British  6-OPRI  mutation
53family, where affected individuals show a range of pathological phenotypes from CJD to a slowly 
progressive dementia without characteristic neuropathology (Collinge et al.,  1992). Due to this 
clinical variability,  it has been difficult to estimate the incidence of inherited prion disease and 
PRNP mutation is usually sought as confirmation of disease.
1.8.3  Sporadic prion disease
Over 85% of human prion disease cases worldwide are sporadic.  In the UK, approximately 50 
cases of sporadic  CJD are seen annually (which equates to ~1  per million of the population), 
however this may be underestimated as autopsy studies have shown that 40% of all pathological 
cases of CJD go clinically undiagnosed (Bruton et al.,  1995). Disease incidence is approximately 
equal  worldwide  between  the  sexes  and  with  an  apparently  random  distribution.  Age  is  a 
dominant risk factor for sCJD. The incidence of sCJD in younger adults aged <40 years is low, 
but  above this age  incidence  increases and  is  seen  to  peak  in the  sixth decade.  At  older ages 
however,  incidence appears to decline (Will  et al.,  1998).  There  are  several  lines of evidence 
which indicate that the epidemiology of sCJD is inconsistent with a single major environmental 
influence, such as animal to human transmission. For example, cases of sCJD are well recognised 
in countries that have never reported sheep scrapie (Masters et al.,  1979).
In  general, CJD  is characterised by the rapid onset of neurological degeneration.  This initially 
presents  as  dementia,  followed  by  the  development  of movement  disorders  such  as  tremor, 
spasticity and rigidity. A common feature in almost all people with CJD is myoclonus, and most 
also display abnormal electroencephalogram recordings. Once symptoms are detected, the disease 
course  is extremely aggressive (especially when compared to other neurodegenerative diseases 
such as Alzheimer’s and Parkinson’s), with average disease duration of 7.6 months, and the vast 
majority of patients (70%) die within 6 months (Collinge, 2001). At disease end stage, patients 
sink into akinetic mutism, with death usually occurring due to systemic or pulmonary infection. 
In terms of neuropathology, CJD displays extensive spongiform degeneration and neuronal loss, 
coupled with gliosis and deposits of the prion protein within the brain.
1.8.4  Acquired CJD
The  most  recent  human  prion  disease to  have  been  identified  emerged in  1996  following  an
epidemic  of  the  bovine  prion  disease,  bovine  spongiform  encephalopathy  (BSE),  and  was
recognised as a novel clinico-pathological variant of CJD (Will et al.,  1998). To date there have 
been  161  deaths  from definite or probable vCJD (Department  of Health CJD statistics,  2 July
542007;  www.cid.cd.ac.uk/figures.htm).  Several  lines  of  evidence,  including  geographical  and 
temporal coincidence and molecular studies, support a causative link between vCJD and exposure 
to BSE-infected bovine tissue (Bruce et al,  1997; Collinge et al.,  1996; Hill et al,  1997).
vCJD exhibits marked differences in disease profile to those associated with classical CJD or the 
other human prion diseases. The age at onset ranges from 16 to 51  years (mean 29 years), and the 
clinical course is unusually prolonged (9-35  months, median  14 months) (Collinge, 2001). The 
initial symptoms are behavioural, with disorders of movement such as ataxia occurring weeks to 
months  later.  Dementia  and  myoclonus  (usually  the  initial  symptoms  in  classical  CJD)  occur 
towards the later stages of the disease. The neuropathology of vCJD is also in marked contrast to 
most other human prion diseases, with spongiform degeneration concentrated in the basal ganglia 
and  thalamus,  and  the  presence  of so  called  florid plaques,  similar to  other transmitted prion 
diseases including kuru and scrapie.
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Figure 1.9  BSE and vCJD cases in the UK
Cases are based on monthly totals. Data from www.cid.ed.ac.uk/fiQures.htm
Following  the  BSE  epidemic,  there  has  been  widespread  concern  over  an  associated  vCJD 
epidemic.  Estimates  based  on  current  vCJD  figures  (see  Figure  1.9)  suggest  that  the  total 
epidemic may be small (Ghani et al, 2003). However, dietary exposure of the UK population to 
BSE prions is known to have been widespread and the precise disease incubation period of vCJD 
is  not  yet  known.  Estimates  of incubation  period  based  on  evidence  from  the  acquired  prion 
disease epidemic kuru, where incubation times in excess of 50 years have been recorded in the 
absence  of a  species  barrier,  suggest  that  additional  vCJD  cases  may  be  seen  in  the  future 
(Collinge  et al,  2006).  Additionally,  as  evidence  from  mouse  studies  have  shown  (discussed 
later) disease incubation may be under the control of multiple genetic loci and the vCJD patients
55identified could represent a distinct genetic subpopulation possessing short incubation alleles to 
BSE prions, with the susceptibility PRNP genotype. Therefore, a human BSE epidemic may be 
multiphasic,  and recent  estimates of the  size  of the  vCJD  epidemic  based on uniform  genetic 
susceptibility could  be  substantial  underestimations  (Collinge  et al.,  2006).  Until  such  human 
modifier loci are identified and their gene frequencies in the population can be measured the size 
of a potential epidemic will be difficult to model.
1.8.5  Kuru
Kuru  first  came  to  the  attention  of  Western  medicine  in  1957,  after  it  reached  epidemic 
proportions  in  a  defined  population  of Eastern  Highlands  of Papua  New  Guinea  (PNG),  and 
provides our  largest experience of an acquired  prion  disease  for epidemiological  study.  At  its 
peak,  kuru  was  responsible  for  200  deaths  per  year  and  the  disease  predominantly  affected 
women (it was the main cause of female mortality) and children of both sexes, with only 2% of 
cases in adult men (Collinge et al., 2006)
Kuru mainly affected the people of the Fore linguistic group and also their neighbours with whom 
they intermarried and was transmitted through endocannibalism, as these communities practised 
the  ritual  consumption  of dead  relatives  as  a  mark  of  respect  and  mourning.  The  original 
acquisition of the disease is thought to have been by means of the consumption of a single person 
with sporadic prion disease, with subsequent propagation by cannibalism to epidemic proportions 
(Attenborough et al.,  1992).  The  first recorded cases of kuru were reported to the north of the 
Fore between  1920 and  1925. The disease spread southwards though the Fore where, based on 
living accounts (recorded by M. Alpers and J. Whitfield pers. comm.), cannibalism was common 
although practices varied. Different body parts were consumed by specific participants - the brain 
and other high prion titre organs were consumed by women and children.  However, boys older 
than 6-8 years participated little in mortuary feasting as they ceased residing with their mothers 
and instead lived with male members of the group. Men rarely participated in mortuary feasts as 
traditionally this  was considered emasculating and was considered to weaken a male’s power. 
This  is  likely  to  explain  the  differential  age  and  sex  incidence.  During  the  peak  of the  kuru 
epidemic,  Papua New Guinea and the Eastern  Highlands came under Australian administrative 
control  and  cannibalism  was  effectively prohibited.  With  the  abrupt  cessation of cannibalism, 
children bom after the late  1950s have been free of kuru,  indicating that maternal transmission 
was unlikely to have occurred.
561.8.5.1  Clinical and pathological characteristics
Clinically,  kuru  presents  initially as  progressive  ataxia  (kuru  is  the  Fore  word  for shaking or 
trembling) until the patient is incapacitated, and cognitive impairment is also a feature. Towards 
the final stages of the disease, dementia is common and incontinence is frequently present. Death 
usually occurs within 3 years, often through starvation, infection or through falling into cooking 
fires.  At  autopsy,  the  neuropathological  hallmarks  have  many  similarities  to  those  of CJD, 
including spongiform degeneration, vacuolated neurons and astrocytosis.
1.8.5.2  Genetics of kuru
Since  1967  when Gajdusek,  Gibbs and Alpers demonstrated that kuru could be transmitted to 
chimpanzee - the first transmission of a human prion disease which confirmed that these human 
diseases belonged within the same category as the animal prion disease- kuru has continued to 
illuminate our understanding of prion disease (Gajdusek et al.,  1967). As with other human prion 
diseases, the major genetic determinant of kuru susceptibility is PRNP. As discussed in detail in 
Chapter 6, heterozygosity at codon 129 is a major susceptibility factor for kuru incubation time. 
Other  loci  have  also  been  investigated  for  association  with  kuru  incubation  time  but  no 
associations  have  yet  been  seen  (Collinge  et  al.,  2006).  These  include:  the PRNP haplotype, 
which has previously been associated with sCJD (Mead et al, 2001); the prion-like gene Dopple 
(PRND) to which no association to prion disease has yet been seen (Mead et al.,  2000); APOE 
and HLA-DQB7 (see below).  In addition,  Mead and colleagues have shown, based initially on 
work with kuru exposed PNG samples, that the prion gene has undergone significant balancing 
selection  both  within  PNG  and  possibly  even  worldwide  (Mead  et  al.,  2003)  -  this  is  also 
discussed further in Chapter 6.
1.8.6  Evidence for human genetic susceptibility to prion disease
1.8.6.1  Information from animal studies - inbred mouse lines
Inbred mouse lines are an established model  for prion disease genetics and have been useful  in 
determining the genetic contribution to disease such as incubation time*.  Following inoculation 
with  a  particular prion  strain,  mean  incubation  times  can  vary  from  100  to  over  500  days  in 
different inbred mouse lines. There are many factors that can influence incubation time including 
prion  strain  type,  level  of host  PrPc,  dose  of infectious  material  and  route  of administration
*  In experimental transmissions to mice this is measured in days from the time of prion inoculation to the 
onset of clinical signs.
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peripheral or oral routes). When experimental conditions are kept constant, incubation times are 
highly  reproducible  with  small  standard  deviations.  Between  mouse  lines  however,  incubation 
times  can  vary  substantially:  incubation  times  in  SM/J  and  MAI/Pas  mice,  inoculated  with 
Chandler/RML mouse adapted scrapie, vary from  133±1  to 360±11  days respectively (Lloyd et 
al., 2004). The major determinant of incubation time is the inbred mouse line used which implies 
a strong genetic effect.
Inbred mouse lines can be separated into two characteristic incubation groups:  short incubation 
time (100-200 days) and long incubation time (>255 days). Over a period of a decade from 1988, 
several authors used classical genetic studies to link the genetic determinant of prion incubation 
time  in  different  mouse  strains  to  loci  on  chromosome  2 tightly  linked to PRNP,  which were 
eventually  shown  to  be  PRNP alleles  (for review  see  Lloyd et al.,  2005).  In  all,  three PRNP 
alleles have been identified which differ at amino acid 108 and 189 of the protein product: PRNF* 
(108-Leu,  189-Thr)  and  PRNF*  (108-Phe,  189-Val)  are  the  short  and  long  incubation  alleles 
respectively (Westaway et al.,  1987) and PRNF* (108-Phe, 189-Thr) is an intermediate incubation 
time allele (255±12 days)  found only in MAI/Pas mice (Lloyd et al.,  2004).  However, within a 
given PRNP genotype a range of incubation times are still seen (Table  1.5) suggesting that many 
genes, other than PRNP, also have a role in determining prion disease incubation time.
Strain Incubation time (days) + SEM
a allele mice
NZW/OlaHsd 108 ± 1 (n=38)
SJL/OlaHsd 122 ± 1 (n=37)
FVB/NHsd 131 ±1 (n=33)
SM/J 133 ± 1 (n=47)
SWR/OlaHsd 135 ± 1 (n=36)
RIIIS/J 135± 1 (n=34)
C57BL6/JOiaHsd 143 ± 1 (n=42)
b allele mice
JU/FaCt 313 l  3 (n=24)
VM/Dk 300 ±3
l/Ln 255 ± 14
c allele mice
MAI/Pas 360 ±11 (n=20)
C57 MAI-PRNP 255 ±12 (n=9)
Table 1.5  Incubation times following intracerebral inoculation
Mice inoculated with Chandler/RML mouse adapted scrapie (Modified from Lloyd et al., 2005)
The  first  non-PRNP susceptibility  locus was  identified using congenic  mice by Kingsbury and 
colleagues in  1983 (Kingsbury et al.,  1983) within the MHC on chromosome 17. The MHC was
58specifically targeted because the lymphoid system is known to have a role in the peripheral early 
replication of prions. The locus was designated prion incubation determinant-1 (Pid-1).
Incubation time is a continuous or quantitative trait which can be used as a measurable phenotype 
in linkage studies. Several whole-genome linkage studies of F2-intercrossest and backcrossesj to 
map prion disease QTLs have been conducted. Of the five studies conducted to date, over 20 loci 
have  been  mapped  on  eight  mouse  chromosomes  (Lloyd  et  al.,  2001;  Lloyd  et  al.,  2002; 
Manolakou et al.,  2001; Moreno et al.,  2003; Stephenson et al.,  2000). In the largest such study 
by  Lloyd  and  colleagues,  an  FI  intercross  between  CAST/Ei  and  NZW/OlaHSd  mice  was 
challenged with RML prion strain. Consistent with the segregation of multiple prion incubation 
genes, the resulting F2 generation showed a larger standard deviation in incubation time than the 
FI  generation (26 days and 7 days, respectively). Three highly significant regions were mapped 
to chromosomes 2 (including PRNP),  11  and 12, with suggestive linkage on chromosomes 6 and 
7. It is difficult to directly compare data from all five QTL studies, especially as they all involve 
different experimental conditions, however some loci are represented in more than one study such 
as the loci on chromosome  11  which are seen in two studies (Lloyd et al.,  2001;  Stephenson et 
al.,  2000). Loci on chromosome 2 have also been identified in more than one study, which used 
identical CAST x NZW F2 intercrosses but innoculated with different prion strains (Lloyd et al., 
2001;  Lloyd et al.,  2002). These two regions show considerable overlap and may represent the 
same underlying genes. The incubation times seen in the F2 mice were opposite to those observed 
in the parental lines, suggesting that a PRNP independent locus on chromosome 2 (or other loci) 
exists.  Such  discordance  between  incubation  times  and  PRNP  genotypes  has  been  noted 
previously by Carlson and colleagues’  whose work investigating Prni (a locus tightly linked to 
PRNP and which was at the time thought to be the major determinant of prion incubation time) 
identified  a  long  incubation  mouse  with  a  short  incubation  time  PRNP allele  (Carlson  et al., 
1986). Carlson speculated that this mouse was a rare recombinant between Prni and PRNP, which 
could not be verified as the animal died before it could be progeny tested. Together these results 
raise the possibility that a susceptibility locus tightly linked but separate from PRNP may exist.
In  summary,  studies of inbred  mouse  lines have  identified PRNP as the  major determinant of 
prion incubation time.  Other genes are also involved and although QTL studies have identified
+  Two heterozygous mice from the first filial generation (FI) are mated to produce offspring with genotypes 
in Mendelian ratios
*  A heterozygous mouse is mated with a homozygous mouse of a parental line
59several large regions of linkage, including a QTL linked to PRNP but independent of its coding 
sequence. The quantitative trait nucleotide (QTN) responsible has yet to be characterised.
1.8.6.2  HLA
The  human  leukocyte  antigen  (HLA)  locus  has  been  investigated  as  a  susceptibility  locus  in 
several neurodegenerative diseases including idiopathic Parkinson’s disease (Lampe et al., 2003) 
and Alzheimer’s (Lehmann et al., 2006; Zareparsi et al.,  2002). In mouse, the HLA locus Pid-1 
has been associated with prion disease incubation time (Kingsbury et al.,  1983). In human prion 
disease, the HLA allele HLA-DQ7, has been shown to be associated with resistance to vCJD but 
not  sCJD by Jackson and colleagues (Jackson et al.,  2001).  In  their study,  Jackson et al.  had 
access to a  small  sample  set,  analysing just  50  vCJD  and 26  sporadic  CJD cases.  Subsequent 
studies  by  other  investigators  failed  to  reproduce  this  association  but  were  also  limited  by 
available sample size (Laplanche et al., 2003; Pepys et al., 2003). The HLA-DQ7 allele has been 
shown to vary significantly in different worldwide populations (Galvani et al.,  2005) may have 
confounded these previous studies.
Despite the lack of replication, the potential association of HLA-DQ7 with vCJD is informative 
with  respect  to  the  distinct  mechanism  of pathogenesis  compared  to  sporadic  CJD.  In  vCJD 
peripheral prion replication, which occurs in the lymphoreticular system and is where the product 
of the HLA locus is likely to act, may be the greatest determinant of susceptibility (i.e. incubation 
time, progression etc.).
1.8.6.3  PRNP codon 129 polymorphism
A common polymorphism at codon 129 of the PRNP, encoding either a methionine or valine, is a 
strong  susceptibility  factor  for  all  three  aetiological  categories  of  human  prion  disease. 
Methionine  homozygotes  comprise  37%  of the  UK  population  whereas  valine  homozygotes 
comprise  12%  (Owen  et  al.,  1989).  In  sCJD,  patients  are  largely  methionine  or  valine 
homozygotes (Laplanche et al.,  1994; Palmer et al.,  1991; Windl et al.,  1996; Windl et al.,  1999), 
however an excess of methionine homozygotes over valine has been seen in sCJD (Salvatore et 
al.,  1994).  In  addition,  codon  129  genotype  has  also  been  shown  to  correlate  directly  with 
phenotype. Windl and colleagues found that 90.5% of patients diagnosed with definite CJD were 
methionine  homozygous  compared  to  1.9%  valine  homozygous.  In  addition  an  atypical  sCJD 
cohort comprised 41.4% methionine and 14.8% valine homozygotes.
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homozygosity at codon 129 (Collinge et al.,  1991). In familial 6-OPRI cases, the age of onset for 
methionine homozygotes is approximately a decade earlier than that for heterozygotes (Poulter et 
al.,  1992). Incubation time in kuru is shortened for homozygotes of either allele (Cervenakova et 
al.,  1998) and all  cases of variant CJD to date  have been  methionine  homozygotes (Collinge, 
2005).
The only non-codon  129 PRNP susceptibility allele identified to date has been a rare lysine to 
glutamine  polymorphism  at  condon  219  (E219K)  in  Japan  (Shibuya  et  al.,  1998).  In  this 
population, where both the codon  129 and 219 polymorphisms are rare, all sCJD patients have 
been  found to be homozygous  for either allele  at  codon  129  but  lack the  219  polymorphism, 
suggesting a protective effect.
1.8.6.4  PRNP regulatory elements, PRNP expression and prion disease
PRNP mediated disease susceptibility is likely to extend beyond the coding sequence of the gene 
and  also  involve  proximal  c/s-acting  regulatory  elements  including  the  PRNP  promoter  and 
upstream enhancers but also long range elements such as locus control regions. The evidence for 
prion disease susceptibility influenced by variation in PRNP regulatory regions and thus affecting 
expression, is reviewed in Chapter 7.
611.9  Aims of this thesis
The aims of this thesis are to apply the techniques and analyses available to investigate complex 
diseases,  towards  identifying  susceptibility  loci  for  two  neurodegenerative  diseases,  ALS  and 
prion disease. More specifically, this thesis aims:
•  to characterise the genomic arrangement of DYNCIH1, a candidate gene for human ALS 
supported by multiple lines of evidence
•  to  conduct  a  mutational  screen  of  human  DYNC1H1  exons,  homologous  to  those 
harbouring mutations in two mouse models of progressive neurodegeneration similar to 
ALS,  in  an  attempt  to  determine  if this  gene  explains  cases  of FALS  or other motor 
neuron diseases
•  to  conduct  a  candidate  gene  association  study  of  DYNC1H1  with  sporadic  ALS, 
ascertaining SNPs for investigation, determining the LD and haplotype structure to define 
a  minimum  set of tSNPs which would allow  an economic  and effective means to test 
known and unknown genetic variation in the gene for an association with disease
•  to clarify the nomenclature and genetic relationships of the cytoplasmic dynein subunits, 
to assist future studies and help devise a standardised nomenclature system. Investigating 
the genetic relationships of the subunit  families  in humans and mouse will also ensure 
that all homologous members of the cytoplasmic dyneins have been identified.
•  to  undertake  a  comprehensive  analysis  of  kuru  and  Papua  New  Guinea  codon  129 
polymorphism data.
•  to  identify  signatures  of selection  imposed  by  the  kuru  epidemic,  experienced  by  the 
people  of the  Eastern  Highlands  of PNG,  at  codon  129  of PRNP  as  a  paradigm  for 
additional  candidate  gene  or  whole  genome  studies.  These  candidate  genes  may  be 
identified  from  mice  models  of prion  incubation  time  or  cell-based  studies  of prion 
incubation.
•  to develop a PNG sample set that will facilitate future investigations of candidate genes 
for signatures of selection.
•  to assess the feasibility of conducting genome-wide genotyping on archived kuru DNA 
samples and identify optimal analysis parameters
•  to assess if copy number variation of PRNP is a pathogenic or protective mechanism in 
both sporadic CJD and kuru.
622  Materials and methods
2.1 Materials
2.1.1  General chemicals and reagents
lOx TBE
Absolute ethanol (100%)
Agarose (electrophoresis grade)
Biotinylated anti-streptavidin antibody 
Bromophenol blue 
Denhardt’s solution (50x)
Dimethyl sulphoxide (DMSO) 
dNTPs
EDTA (0.5M, pH 8.0)
Ethanol (96-100%)
Ethidium bromide 
Glycerol
H2O (molecular biology grade)
Herring sperm DNA 
Human Cot-1 DNA 
Hyperladder (I, IV and V)
MES hydrate SigmaUltra 
MES sodium salt 
MGB probes 
Primers
Sodium acetate (NaAce)
Sodium dodecyl sulphate (SDS)
SSPE (20x)
Streptavidin, R-phycoerythrin conjugate (SAPE)
TE buffer, reduced EDTA (lOmM Tris HC1, 0.1 mM 
EDTA, pH 8.0)
TMACL (5M)
Tween-20 (10%)
Life Technologies
Sigma-Aldrich
Invitrogen
Vector Laboratories
Sigma-Aldrich
Sigma-Aldrich
Sigma-Aldrich
Promega
Ambion
BDH Chemicals 
Sigma
Sigma-Aldrich
Cambrex
Promega
Invitrogen
Bioline
Sigma-Aldrich
Sigma-Aldrich
Applied Biosystems
Sigma-Genosys
Sigma-Aldrich
Sigma-Aldrich
Cambrex
Invitrogen
TEKnova
Sigma-Aldrich
Pierce
632.1.2  Prepared solutions
Loading Buffer Sodium Dodecyl Sulphate (SDS), 10%
0.5ml 1M Tris-HCl pH7.6 lOOg SDS per 1ml autoclaved water
25ml glycerol Stored at room temperature
0.5ml 10% SDS
0.05g bromophenol blue
Made up to 50ml with ddLLO
Stored at room temperature
2.1.3  Commercial kits
Affymetrix DNA Amplification Clean-Up Kit Affymetrix
Affymetrix GeneChip 500K Assay Affymetrix
Better Buffer Microzone
BigDye Terminator Ready Reaction kit Applied Biosystems
Clontech TITANIUM Taq buffer Clontech
Clontech TITANIUM Taq DNA polymerase Clontech
DYEnamic ET Dye Terminator kit Amersham Pharmacia Biotech
G-C Melt Clontech
GeneScan 2500 TAMRA Red Applied Biosystems
HotStartTaq DNA Polymerase Qiagen
MegaBACE ET400-R Size Standard Amersham Pharmacia Biotech
MegaBACE Loading Solution Amersham Pharmacia Biotech
MegaBACE Long Read Matrix Amersham Pharmacia Biotech
MegaBACE LPA Buffer Amersham Pharmacia Biotech
MegaMix Blue Microzone
MicroClean PCR purification kit Microzone
QLAamp 96 DNA Blood Mini kit Qiagen
QIAamp DNA Blood Mini kit Qiagen
QuantiTect Probe PCR Master Mix Qiagen
642.1.4  Restriction enzymes and ligases
Enzyme*  Buffer/conditions Company
DNasel New England Biolabs (NEB)
Hinfl  2 New England Biolabs (NEB)
Nspl  2 + BSA New England Biolabs (NEB)
PvuII  2 New England Biolabs (NEB)
T4 DNA Ligase  T4 DNA Ligase Buffer New England Biolabs (NEB)
2.1.5  Equipment
8 Strip PCR tubes and caps, thin-walled Scientific Specialities Inc
96-well PCR plates ABgene
ABI Prism 377 DNA Sequencer Applied Biosystems
Allegra 25R centrifuge for 96-well plates Beckman Coulter
Aluminium adhesive PCR foil roll ABgene
DNA Engine Tetrad PTT-225 Peltier Thermal Cycler MJ Research
Electrophoresis power packs Amersham Pharmacia Biotech
Electrophoresis tanks (Horizon 11.14) Life Technologies
Eppendorf 5415R Microcentrifuge Eppendorf
Eppendorf Comfort Thermomixer 1.5ml Fisher Scientific
GeneChip Hybridization Fluidics Station 450 Affymetrix
GeneChip Hybridization Oven 640 Affymetrix
GeneChip Scanner 3000 7G Affymetrix
Gilson pipettes Anachem
Grant JB5 waterbath Wolf Laboratories
MegaBACE 1000 DNA Analysis System Amersham Pharmacia Biotech
MicroAmp Fast Optical 96-well Reaction Plates Applied Biosystems
Micro  Amp Optical 96-well Reaction Plates Applied Biosystems
MicroAmp Optical Adhesive Film Applied Biosystems
Microtubes, hyrdophobic 0.65ml Scientific Specialities Inc
PCR seal film ABgene
Pipette tips Anachem
QIAvac 96 vacuum manifold Qiagen
Raven incubator CTE Scientific
Sigma 6K 15 plate rotor 2 x 96-well plate Qiagen
*  updated nomenclature used, see (Roberts et al., 2003).
65Sigma 6K 15 refrigerated centrifuge 
Ultrospec 2000 UV visible spectrophotometer 
Vacuum pump
Sigma Laborzentrifugen GmbH 
Pharmacia Biotech 
KNF Neuberger
2.1.6  Photography
Gel Doc EQ UV-transilluminator  Bio-Rad Laboratories
Thermal paper for Mitsubishi video printer  Bio-Rad Laboratories
2.1.7  Software
Bioinformatic- 
Harvester 
BLAST 
ClustalW 
Ensembl Fugu 
Genome Browser 
Entrez 
GDAS 
HapMap 
HGNC 
MGI
MultiPipmaker 
NCBI 
NEBcutter 
Nspl library files
PHASE
PHYLIP
PL-EM
PLINK
Power Calculator 
Primer Express v2.0 
Primer3 
PubMed 
RepeatMasker 
Sequence Analyzer
and websites
http://harvester.embl.de/
http://www.ncbi.nlm.nih.eov/BLAST (Altschul et al.,  1990) 
http://www.ebi.ac.uk/clustalw (Thompson et al.,  1994)
http://www.ensembl.ore/Fueu  rubripes
http://www.ncbi.nlm.nih.eov/Entrez/index.html 
GeneChip DNA Analysis Software (Affymetrix) 
www.hapmap.org
http://www.eene.ucl.ac.uk/nomenclature/
http://www.informatics.iax.ore/
http://pipmaker.bx.psu.edu/cgi-bin/multipipmaker
http://www.ncbi.nlm.nih.eov
http://tools.neb.com/NEBcutter2/index.php
GeneChip Human Mapping 500K Set library files (Affymetrix)
http://www.stat.washineton.edu/stephens/software.html (Stephens et al.
2003)
http://evolution.es.washineton.edu/phvlip.html 
http://www.people.fas.harvard.edu/~iunliu/plem (Qin et al., 2002) 
http://pneu.meh.harvard.edu/~purcell/plink/ 
http://pngu.meh.harvard.edu/~purcell/gpc/ (Purcell et al., 2003) 
Applied Biosystems
http://frodo.wi.mit.edu/cgi-bin/primer3/primer3  www.cgi 
http://www.ncbi.nlm.nih.gov/entrez/querv.fcei?db= PubMed 
http://www.repeatmasker.org/cgi-bin/WEBRepeatMasker 
Molecular Dynamics (Wu and King, 2003)
66SNPHAP http://archimedes.wcll.ox.ac.uk/pisc/snphap-simple.html (Clayton, 2004) 
http://popgen.biol.ucl.ac.uk/software.html (Goldstein et al, 2003b; Weale et 
al, 2003)
http://us.expasv.org/tools/dna.html
http://genome.ucsc.edu
http://www.firstmarket.com/cutter/cut2.html
TagIT
Translate
UCSC
WebCutter
2.2  Samples
2.2.1  Healthy population DNA samples
DNA  samples  from  healthy  individuals  were obtained  from the  following sources:  33  European 
trios were obtained from the Centre d'Etude du Polymorphisme Humain (CEPH) and 48 unrelated 
Japanese  and  49  unrelated  West  African  (Cameroonian)  individuals,  were  obtained  from  the 
laboratory of Professor David B. Goldstein, Institute for Genome Sciences and Policy, Centre for 
Population Genomics and Pharmacogenetics, Duke University, North Carolina, USA. DNA samples 
were  collected  by  the  Goldstein  laboratory  with  signed  consent  or  were  anonymous  legacy 
collections provided by collaborators from other academic institutions.
480 UK White Caucasian control samples (plates HRC-1  to 5), were obtained from the European 
Collection of Cell Cultures (ECACC). A further 90 UK Caucasian control samples used for whole 
genome SNP genotyping were collected by Dr. Simon Mead, MRC Prion Unit, London, UK from 
the West  End Blood Donor Centre, do Dr Jean Harrison,  London, UK.  North American control 
samples comprising of both unaffected spouses from Caucasian familial ALS pedigrees and other 
Caucasian individuals were collected with signed consent by Professor Robert H. Brown Jr., Day 
Neuromuscular  Research  Laboratory,  Massachusetts  General  Hospital,  Massachusetts,  USA  or 
provided  to  R.H.  Brown  by  collaborators  from  other  North  American  academic  and  clinical 
institutions.
Chimpanzee  DNA was extracted  from blood provided by the  Institute of Zoology,  London Zoo, 
Regents Park.
2.2.2  Patient/case DNA samples
Sporadic  ALS  DNA  samples  were  obtained  from  patients  seen  by  Professor  R.H.  Brown  at 
Massachusetts  General  Hospital  or  provided,  to  R.H.  Brown  by  collaborators  from  various 
academic and clinical  institutions across North America.  All  sporadic ALS patient samples were 
obtained with informed consent. Patients were diagnosed by El Escorial criteria and had not been
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average age at diagnosis of 46 years (range 24 to 79 years). 34% of patients were diagnosed with 
early onset in the lower extremities, 35% with upper onset, 30% with bulbar onset and site of onset 
in the remaining 2% was unknown.
Motor neuron disease samples screened for DYNC1H1 mutations were index cases from pedigrees 
with familial history of disease. ALS samples were collected by Professors Pamela Shaw, Sheffield 
University,  Sheffield,  UK  and  Karen  Morrison,  Department  of  Neurology,  University  of 
Birmingham,  Birmingham,  UK  and  Dr  Richard  Orrell,  Department  of  Clinical  Neuroscience, 
University College London, London, UK. All ALS samples were Caucasian adults with definite or 
probable ALS, without detectable SODl  mutation.  Spinal muscular atrophy (SMA) samples were 
adult and juvenile onset cases without SMN deletions provided by Professor Morrison.  All  SMA 
cases  were  Caucasian,  except  2  Indian  and  1   Arab  case  (K.  Morrison pers.  comm.).  Hereditary 
Spastic Paraplegia (HSP) samples were British Caucasian index cases from 32 different families (20 
recessive inheritance families and 12 dominant inheritance families).
Sporadic  CJD  samples  were  obtained  from  patients  seen  at  the  Institute  of Neurology,  Queen 
Square,  London,  UK,  with  signed  consent.  Prion  disease  was  confirmed  post-mortem  by  the 
histological identification of spongiform change, astrocytosis, neuronal loss and proteinase-resistant 
PrP50 deposition in the brain. Of prion disease cases, sporadic CJD is a diagnosis of exclusion and 
diagnosis was made  in the absence of histopathological  and  PrP50  strain-type  features of variant 
CJD, the absence of mutation of the PRNP open reading frame seen in inherited prion disease and 
the absence of obvious exposure to infectious human prion material.
2.2.3  Papua New Guinea Samples
Papua New Guinean samples were obtained as frozen DNA and/or blood archives from the MRC 
Prion Unit, London, UK, or from the Papua New Guinea Institute of Medical Research (PNGIMR), 
Goroka,  PNG.  All studies were approved by the Papua New Guinea Medical Research Advisory 
Committee and by the local UK research ethics committees. The  full participation  in the project 
from the communities, which was critical with respect to the ethics and operation of the study, was 
established and maintained through discussions of the joint MRC-PNGIMR field team with village 
leaders, communities, families, and individuals. Field studies followed the principles and practice of 
the Papua New Guinea Institute of Medical Research.
682.3  Methods
2.3.1  DNA isolation from chimpanzee blood
DNA was extracted from whole blood using QIAamp DNA Blood Mini Kit (Qiagen) following its 
associated  protocol.  The  basis  of the  procedure  is  salt  deproteinisation  and  is  summarised  as 
follows: 200/d whole blood was added to 20/d QLAGEN Protease in a 1.5ml microcentrifuge tube - 
all  centrifugation  steps  were  carried  out  in  a  microcentrifuge  (Eppendorf).  The tube  was  gently 
agitated to ensure the proper mixing of the blood and enzyme. 200/d Buffer AL was added and the 
sample pulse-vortexed for 15 seconds to ensure efficient lysis of all cells. The protease and buffer 
mixture is required to lyse cells in the sample and degrade all proteins,  including those bound to 
DNA. The buffer has a high salt content and optimum pH to precipitate protein out of solution and 
away from the DNA. The mixture was incubated in a waterbath at 56°C  for  10 minutes and tube 
centrifuged  briefly  to  remove  liquid  condensed  on  the  lid.  200/d  ethanol  (96-100%)  (BDH 
Chemicals) was added and the sample was again pulse-vortexed  for  15  seconds and centrifuged 
briefly.
The sample was transferred into a QIAamp Spin Column placed in a 2ml collection tube, sealed and 
centrifuged at 6000 relative centrifugal force* (ref), for  1   minute. The silica gel membrane within 
the spin column absorbs DNA but does not retain protein or other contaminants within the lysate. 
The addition of ethanol to the lysate optimises  DNA binding to the membrane. The  filtrate was 
discarded and the QIAamp Spin Column was placed in a clean 2ml collection tube and 500/d Buffer 
AW1  was  added.  Buffers AW1  and AW2  are  both ethanol  based  wash  buffers  used to  remove 
residual contaminants without affecting DNA binding to the spin column membrane. The QIAamp 
Spin Column was again centrifuged at 6000 ref for 1   minute and the collection tube containing the 
filtrate was again discarded. The QIAamp Spin Column was placed in a clean 2ml centrifuge tube 
and 500/d Buffer AW2  was added. The column was centrifuged at 20,000 ref for 3  minutes and 
then placed in a clean  1.5ml  microcentrifuge tube and the collection tube containing filtrate was 
discarded. 200/d Buffer AE was added to the column to elute the DNA. The column was incubated 
at room temperature for 5 minutes and then centrifuged at 6000 ref for  1   minute and the primary 
eluate containing the DNA was collected and stored at -20°C. The QIAamp Spin Column was again 
placed in a clean 1.5ml centrifuge tube for a second elution to increase the total DNA yield. Again, 
200/d Buffer AE was added, incubated at room temperature for 5 minutes and centrifuged at 6000 
ref for 1  minute. The second elute was also stored at -20°C.
*  ref to rpm conversion: ref = 1.12 x r x (rpm/1000)2, where r is rotor radius and rpm revolutions per 
minute.
692.3.2 DNA isolation from human blood
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Figure 2.1  Overview of the QIAamp 96 DNA Blood Mini kit procedure
Adapted from the QIAamp DNA Blood Mini Kit protocol (Qiagen)
DNA was extracted from whole blood using QIAamp 96 DNA Blood Mini Kit (Qiagen) following 
its associated protocol. The kit is identical to the QIAamp DNA Blood Mini Kit but spin columns 
are  in  a  96-well  plate  format  for  increased  throughput  and  a  modified  protocol  summarised  as 
follows:  20/d QIAGEN Protease was aliquoted to each well of a 96-round-well block (Figure 2.1) 
and 200/d whole blood was then added. 200pl Buffer AL was added to each sample and the wells 
were sealed using caps for blocks and tubes. Care was taken not to wet the well-rims at this stage to 
prevent caps from loosening in later steps. The sample was then mixed thoroughly by holding the 
round-well block with both hands and shaking up and down vigorously for 15 seconds. The block 
was centrifuged briefly at 2200 ref (all centrifugation steps were carried out using the Sigma 6K 15 
refrigerated centrifuge  set  at 40°C,  unless otherwise stated) and then incubated at 70°C  in  a dry 
incubator for 10 minutes. A large heat-resistant weight was placed on top of the block to prevent the 
caps  from  popping off during the  incubation and the contents evaporating.  After  incubation,  the 
round-well  block  was  briefly centrifuged  again  at  2200  ref.  200pl  ethanol  (96-100%)  was  then 
added to each well of the block and the wells sealed with new caps for blocks and tubes. The block 
was again vigorously mixed by shaking for 15 seconds, and briefly centrifuged at 2200 ref.
A QIAamp 96 plate was placed on top of an S-Block (Figure 2.1) and both were marked for later 
identification. The contents of the round-well block (620pl per well) was added to the QIAamp 96 
plate.  Care  was  taken  not  to  wet  the  rims  of  the  wells  to  avoid  aerosol  formation  during
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the S-Block into the centrifuge rotor bucket and centrifuged at 5796 ref for 4 minutes.
The S-block was emptied of lysate and 500pl Buffer AW1  added to each well of the QIAamp 96 
plate.  The  plate  was  sealed  with  a  new  AirPore  Tape  sheet  and  centrifuged  at  5796  ref for  2 
minutes.  Again the S-Block was emptied and 500pl Buffer AW2 was added to each well  of the 
QIAamp  96 plate.  The plate and  S-Block  were  centrifuged  at  5796  ref for  15  minutes,  without 
AirPore Tape (which was omitted to allow the heat generated during centrifugation to evaporate 
residual ethanol from Buffer AW2 in the sample).
To elute the DNA a QIAamp 96 plate was placed on top of a rack of elution MicroTubes (Figure 
2.1) and 200pl Buffer AE was added using a multichannel pipette. The plate was sealed with a new 
AirPore tape sheet and  incubated for 5  minutes at room temperature.  The plate and MicroTubes 
rack were then centrifuged at 5796 ref for 4 minutes. A further 200/d Buffer AE was added and the 
plate centrifuged at 5796 ref for another 4 minutes to obtain an extra 20% yield.
23.3  Determination of DNA concentration and purity
DNA concentration and purity was determined using spectrophotometric analysis, where necessary. 
An appropriate dilution of DNA was prepared and absorption readings were taken at 260nm and 
280nm,  using  either  a  Ultrospec  2000  Ultra  Violet  (UV)  visible  spectrophotometer  (Pharmacia 
Biotech)  or  a  NanoDrop  1000  spectrophotometric  analyser  (NanoDrop  Technologies).  The 
following equations were used:
DNA purity =  A26o/A28o (an ideal A260/A28o ratio was between 1.8 to 2.0)
DNA concentration (/ig//d) =  A260 x dilution factor x 50/ig/ml
2.3.4  Primer design
Primers  were  designed  for  Polymerase  Chain  Reaction  (PCR)  amplification,  genotyping  and 
sequencing  reactions.  Genomic  sequence  for  the  region  of interest  was  obtained  from  National 
Center  for  Biotechnology  Information  (NCBI)  (www.ncbi.nlm.nih.gov).  Amplicon  sequence  and 
flanking  primer  binding  sequence  was  examined  for  DNA  repeats  using  RepeatMasker 
(www.repeatmasker.org/cgi-bin/WEBRepeatMasker) and potential primer sequences were designed 
to avoid annealing to repetitive DNA. Primers for PCR and sequencing were designed using Primer 
3  software  (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3  www.cgi)  or  designed  by  eye.  All 
primers were made by Sigma-Genosys.
712.3.4.1  Real-time PCR primers and probe design
Real-time primers and probes were designed using Primer Express v2.0 (Applied Biosystems) and 
all  real-time  probes  were  designed  as  Minor  Groove  Binder (MGB)*  Primers  and  probes  were 
designed based on the following principles:
•  The template strand was selected to increase the cysteine (C) content of the probe rather 
than the guanine (G) content.
•  Primers were designed to be as close to the probe as possible with an overall amplicon 
length of ~50-150bp.
•  Minimum probe length was 13 nucleotides.
•  Probe/primer G-C content was maintained at a 30-80% range.
•  Probes with a guanine nucleotide on the 5' end were avoided.
•  Primers  were  limited  to  no  more  than  two  G  and  C  residues  within  the  last  five 
nucleotides at 3’ end.
•  Probes/primers containing runs of an identical nucleotides were avoided (especially four 
or more guanine’s)
•  Probe melting temperatures (Tm ) were between 65-67 °C.
•  Primer Tm’s were between 58-60 °C.
Primers were made by Sigma-Genosys and probes by Applied Biosystems.  Probes were divided 
into 100/d aliquots upon receipt and care was taken to avoid excessive freeze-thawing and exposure 
to  ultra  violet  (UV)  light  -  which  promotes  aberrant  cleavage  of the  end-labelled  fluorescent 
reporter dyes.
2.3.5  Polymerase chain reaction
All  PCRs  were  carried  out  using  the  following  protocol  in  0.65ml  microtubes  (Scientific 
Specialities Inc), 8 well PCR strips (Scientific Specialities Inc) or 96-well plates, unless otherwise 
stated: A PCR master mix was prepared containing 1  x PCR Buffer (supplied with HotStarTaq kit), 
200/tM dNTPs,  1//M  forward primer,  1/tM reverse primer, 0.2U//d HotStarTaq DNA Polymerase 
(Qiagen) and distilled water, made up to a final reaction volume of 20/ri. The master mix was then 
divided  into  18/d  aliquots  using  a  Gilson  Distriman  repeater-pipette  and  1/d  DNA  (~100ng//d 
concentration) was added to each tube/well with one well assigned as a non-template, water control.
Thermal  cycling  conditions  on  the  DNA  Engine Tetrad Thermal  Cycler (MJ  Research)  were  as 
follows: HotStarTaq polymerase activation at 95°C for 1   min and then 35 cycles of: DNA template
*  MGB probes use non-fluorescent quenchers, which allow a more precise measurement of reporter dye 
compared to conventional probes, They also bind the DNA minor groove, increasing their melting 
temperature (T„,) and allowing the use of shorter probes, with better allele discrimination properties.
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table 3.1)  for 30 seconds, extension 72°C  for  1   minute,  and a final extension step at 72°C  for 5 
minutes.  After  amplification,  4/d  PCR  product  was  mixed  with  4/d  loading  buffer  and 
electrophoresed on a 2% agarose gel; 2 grammes (g) agarose (Invitrogen) dissolved in  100ml  lx 
TBE (Life Technologies), containing 0.1/tg/ml  ethidium bromide (Sigma) and visualised by UV- 
transillumination. All agarose gels were 2% unless otherwise stated. 4/d of the appropriately sized 
DNA ladder of was used to estimate the specificity of PCR amplicons.
PCRs  for genotyping  microsatellites,  a54000*,  a 108990*,  D20S889,  D20S482  and  D20S97  were 
carried out in 15/d reactions containing 13.7/d MegaMix Blue (Microzone), 0.15/d forward primer 
(50pm//d), 0.15/d reverse primer (50pm//d) and  1/d template DNA (~50ng//d). Cycling conditions 
on the Tetrad thermal cycler were polymerase activation step of 95°C  for 3  minutes and then 34 
cycles of: DNA template denaturation at 95°C for 30 seconds, primer annealing at 55°C (or relevant 
temperature) for 40 seconds, 72°C extension step for 45 seconds, and a final extension step of 72°C 
for 5 minutes and  15°C for 2 minutes. PCR products were electrophoresed as described above but 
without addition of loading buffer.
2.3.6  Purification of PCR amplicons for sequencing
PCR products were purified using m/croCLEAN (Microzone), to remove reaction buffers, enzymes, 
primer  dimers  and  unincorporated  primers  and  dNTPs,  following  the  manufacturer’s  protocol. 
Briefly, an equal volume of m/croCLEAN was added to a 96-well plate containing PCR products 
and  incubated at  room  temperature  for 5  minutes.  The plate  was centrifuged at  3000  ref for 40 
minutes and then inverted onto absorbent paper and pulsed at  100 ref to discard the supernatant. 
The purified DNA pellet was then resuspended in 20/tl sterile distilled water.
2.3.7  Sequencing of purified templates
Automated fluorescent sequencing was carried out with the BigDye Terminator Ready Reaction Kit 
(Applied Biosystems), DYEnamic ET Dye Terminator Kit (Amersham Pharmacia) and  1/tM PCR 
primers.  For  the  BigDye  Terminator  Ready  Reaction  Kit,  a  sequencing  master-mix  was  made 
containing  (per  reaction)  l/il  BigDye  terminators,  5/tl  BetterBuffer  (Microzone),  0.5/tl 
forward/reverse primer (1/tM), and 7/tl sterile distilled water. A Gilson Distriman repeater-pipette 
was used to aliquot  13.5/tl BigDye master-mix into wells of a skirted 96-well plate, to which 1.5/tl 
purified PCR products were added,  for a total reaction volume of 15/tl.  Cycling conditions were 
96°C for 30 seconds, followed by 30 cycles of 50°C for 15 seconds and 60°C for 3 minutes and a 
final hold step of 15°C for 5 minutes.
*  From (Mead, 2002)
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terminators, 6/d BetterBuffer and 4/d forward/reverse primer (1/iM).  12/d ET terminators master- 
mix was aliquoted into wells of a skirted 96-well plate, to which 8/d purified PCR products were 
added,  for  a  total  reaction  volume  of 20/d.  Cycling  conditions  were  25  cycles  of 95°C  for  20 
seconds, 50°C for 15 seconds and 60°C for 1  minute, with a final hold step of 10°C for 10 minutes.
2.3.8  Post-reaction clean-up with ethanol/salt precipitation
Sequencing products were precipitated to remove reaction buffers and unincorporated terminators 
to  avoid  tall  early peaks,  often termed “terminator blobs”.  55/d  100%  absolute ethanol  (Sigma- 
Aldrich) and  1/d 3M sodium acetate (Sigma-Aldrich) was added to 20/d reaction and the mixture 
was chilled on ice for 15 minutes. The plate was centrifuged at 3000 ref for 45 minutes to pellet the 
DNA and the supernatant discarded by inverting onto absorbent tissue paper and pulse-centrifuging 
at  100  ref for  1   minute.  150/d  70%  ethanol  was  added  to  wash  the  pellets  and  the  plate  was 
centrifuged at 3000 ref for  10 minutes. Again, the plate was inverted onto absorbent tissue paper, 
pulse-centrifuged at 100 ref for 1  minute to remove the supernatant and the pellet was allowed to air 
dry for 10 minutes.
2.3.9  DNA sequencing on the MegaBACE 1000 DNA Analysis System
The  automated  MegaBACE  1000  DNA  Analysis  System  (Amersham  Pharmacia)  was  used  to 
sequence  DNA.  The  MegaBACE  uses  capillary  array  electrophoresis  to  perform  fragment  size 
separation of fluorescently labelled DNA samples with a confocal  optical  system to collect data. 
The  manufacturer’s guidelines and protocols  were  followed unless otherwise stated.  Precipitated 
DNA with fluorescently labelled terminators, was resuspended in 10/d MegaBACE Loading Buffer 
(Amersham Pharmacia), vortexed thoroughly to ensure the complete solublization of the DNA and 
then pulse-centrifuged to return the liquid to the bottom of the 96-plate wells.
MegaBACE Long Read  Sequencing Matrix (Amersham Pharmacia) was used to pressure-fill the 
capillary  array  with  sieving  matrix  to  separate  DNA  fragments  of  varying  sizes.  Sequencing 
products were electrokinetically injected into the capillary array by a potential difference of 3kV for 
40 seconds and electrophoresis was carried out in  lx LPA Buffer (Amersham Pharmacia) at 9kV 
for  100  minutes.  Laser  excitation  of  the  fluorescently  labelled  samples  yielded  data  as  an 
electropherogram for each capillary/sample which were analyzed in forward and reverse directions 
using the Sequence Analyser v3.0 package (Molecular Dynamics), and inspected by eye.
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SNPs  within  DYNC1H1  were  tested  for  alteration  of restriction  enzyme  recognition  site  using 
WebCutter  (http://www.firstmarket.com/cutter/cut2.htmn  and  NEBcutter
(http://tools.neb.com/NEBcutter2/index.php).  For  SNPs  that  modified  restriction  enzyme 
recognition sites, PCR primers were designed to amplify a region of approximately 500bp around 
the polymorphism. PCR was performed as previously described in a 20/d reaction volume of which 
4/d was electrophoresed on 2% agarose gel to check quality.
Restriction digestion was performed in 0.65ml  microtubes  in a total  20/d  reaction volume, using 
16/d un-purified PCR product and a 4/d restriction master-mix based on  1  /d buffer recommended 
by manufacturer and  1-10 units of restriction enzyme per well. The amount of restriction enzyme 
required per SNP was estimated by initially performing a restriction digest on a subset of samples 
with only 1  unit of enzyme per sample. If this led to partial digestion of the amplicon after 3 hours, 
the experiment was repeated by adding additional enzyme until complete digestion was achieved. 
Digested amplicons were electrophoresed on 2% agarose and visualised as described previously.
The efficacy of SNP  genotyping by restriction digest  was  tested by assaying a panel  25  CEPH 
samples, with a priori genotypes distinguished by DNA sequencing, in a blind test randomised by a 
second operator.  Genotyping results  from the blind test  were then matched to sequence  verified 
genotypes by the second operator and an efficacy score as a percentage was calculated.
2.3.11  Microsatellite genotyping
PCRs for microsatellites D20S482, D20S97, D20S889 and 108991  were initially multiplexed (each 
forward primer was tagged  with  6-FAM,  HEX,  TET,  6-FAM  fluorophores  respectively;  Sigma- 
Genosys) for the same DNA sample by mixing PCR products in the ratio 1:2:2:6 respectively, in a 
separate 96-well plate. Multiplexed PCRs comprised a total volume of 22/d and were made up to a 
total volume of 90/d with dd.H20. 45/d aliquots were stored at -20°C and the remaining 45/d were 
carried forward for clean-up. D20S97-HEX forward primer was eventually replaced by D20S97-6- 
FAM  due  to  a  low  signal  affected by  spectral  overlap*  with  microsatellite  108991  which  had  a 
similar sized PCR product.  PCR clean-up was carried using ethanol/salt precipitation as describe 
above  for post-sequencing reactions, with the following amendments:  45/d of ethanol was mixed 
with 1/d NaAce and aliquoted into 45/d multiplexed PCR sample. Pellets were resuspended in 10/d 
dd.H20.
*  spectral overlap refers to the emission spectrum of one fluorophore overlapping with that of another, The 
excitation of one fluorophore therefore causes an erroneous recording of both fluorophores.
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solution of 5.6/d MegaBACE Loading Solution, 0.4/d MegaBACE ET400-R size standard and 2/d 
dd.H20  was aliquoted into a new 96-well plate and 2/d resuspended PCR product added. The plate 
was vortexed briefly at medium speed and centrifuged briefly at 3000 ref. The MegaBACE  1000 
DNA Analysis System was set up following the manufacturer’s guidelines and as described above. 
Multiplexed  PCR products were electrokinetically injected into the capillary array by a potential 
difference of 3kV for 60 seconds and electrophoresis was carried out in 1   x LPA Buffer at 9kV for 
70 minutes. Results were analysed using the Genetic Profiler vl.5 package (Molecular Dynamics).
2.3.12  Affymetrix GeneChip 250k NspI Assay
Whole-genome  SNP  genotyping was  achieved using the  NspI  array of an  Affymetrix  GeneChip 
500k kit. The manufacturer’s protocol for the Affymetrix GeneChip 250k NspI assay was followed 
and is summarised in Figure 2.2. A designated pre- and post- PCR clean area was defined for the 
following  steps,  to  avoid  cross-contamination  of pre-PCR  steps  with  PCR  amplicons.  Genomic 
DNA samples were diluted to a 50ng//d working dilution with reduced EDTA TE buffer (0.1 mM 
EDTA) (TEKnova).
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Figure 2.2  An overview of the Affymetrix GeneChip 250k NspI protocol
2.3.12.1  NspI digestion
The DNA Engine Tetrad thermal cycler was preheated to 37°C in preparation for genomic  DNA 
digestion. A genomic DNA digestion master mix was prepared on ice with lx NE Buffer 2 (NEB), 
lx BSA (NEB) and 0.5 Units NspI (NEB), made up to a total volume of 14.75/d per sample, with 
molecular biology grade H20  (Cambrex). 5/d genomic DNA (50ng//d) was added to each well of a 
96-well plate with a Gilson Distriman repeater-pipette and 14.75/d of the digestion master mix was 
added to each sample. The plate was then covered with a plate seal (Applied Biosystems), vortexed
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placed on the thermal cycler on the following program: 37°C for 120 minutes, 65°C for 20 minutes 
and then held at 4°C. The digested DNA plate was stored in a -20°C freezer until required.
2.3.12.2  NspI adaptor ligation
The Tetrad thermal  cycler was heated to  16°C  in preparation  for NspI adaptor ligation.  A DNA 
ligation  master mix  of total  volume  5.25/d  per  sample,  was prepared  on  ice containing  1.5mM 
Affymetrix  NspI  adaptor (50mM),  lx  T4  DNA  ligase  buffer (NEB),  T4  DNA  ligase  (400U//d) 
(NEB). 5.25/d ligation master mix was aliquoted into each digested DNA sample. The 96-well plate 
was covered with a new plate seal, vortexed at medium speed for 2 seconds and then centrifuged at 
716 ref for 1   minute. The plate was run in the thermal cycler at 16°C for 180 minutes, 70°C for 20 
minutes and then held at 4°C.  The adaptor ligated samples were  stored in a -20°C  freezer until 
required.
2.3.12.3  Adaptor-ligated fragment PCR and clean-up
The PCR master mix was prepared on ice to a final total volume of 270/d per sample, where each 
sample was amplified in triplicate in a volume of 90/d. For each 270/d triplicate reaction,  118.5/d 
molecular biology grade H20  was added with lx Clontech TITANIUM Taq PCR buffer (Clontech), 
1M  G-C  Melt  (Clontech),  350/iM  each  dNTP,  4.5/iM  PCR  Primer  002  (Affymetrix)  and  lx 
Clontech TITANIUM Taq DNA Polymerase (Clontech). The 25/d NspI adaptor-ligated DNA was 
diluted  1   in 4 by adding 75/d molecular biology grade H20  and  10/d was aliquoted to a 96-well 
plate in triplicate. 90/d PCR master mix was aliquoted to each adaptor-ligated DNA sample using a 
Gilson Distriman repeater-pipette. The plate was then covered with an adhesive plate seal, vortexed 
at medium speed for 2 seconds and then centrifuged at 716 ref for  1   minute. The plate was then 
placed on a thermal cycler under the following conditions: 94°C for 3 minutes, 30 cycles of 94°C 
for 30 seconds, 60°C for 30 seconds and 68°C for 15 seconds, 68°C for 7 minutes and finally held 
at 4°C.
PCR clean-up was carried out using a Clean-Up Plate (Affymetrix) placed on a QLAvac 96 vacuum 
manifold (Qiagen) and attached to a vacuum pump (K.NF Neuberger). 8/d 0.1M EDTA (Ambion) 
was added using a Gilson Distriman repeater-pipette to each PCR and the plate covered with a plate 
seal,  vortexed at medium speed for 2 seconds and centrifuged at 716 ref for  1   minute. The three 
PCRs for each sample were consolidated into a single well of the Clean-Up Plate and ~600mbar 
vacuum applied until the wells were completely dry.  The PCR products were washed by adding 
50/d of molecular biology grade H20  and dried by applying a ~600mbar vacuum. Two additional 
washes were applied. The Clean-Up Plate was removed from the vacuum manifold and any excess
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Affymetrix Clean-Up Kit) was added to each well and the plate covered with a PCR plate seal. The 
Clean-Up Plate was agitated at a moderate speed on a plate shaker (the plate was secured by strong 
adhesive tape to an Eppendorf Thermomixer usually used for mixing  1.5ml Eppendorf tubes), for 
10  minutes  at  room  temperature,  to  recover  the  PCR  product.  Recovered  PCR  products  were 
pipetted to a new 96-well plate and yield quantified using spectrophotometric analysis of a 50-fold 
diluted sample. Approximately 90/ig of purified DNA was transferred to a new 96-well plate and 
the total volume of each sample brought up to 45/d with RB Buffer (supplied with GeneChip kit).
2.3.12.4  Fragmentation
For the  fragmentation  step,  the  thermal  cycler  was  pre-heated  to  37°C.  5/d  lOx  Fragmentation 
Buffer was added to each sample on ice. The Fragmentation Reagent was diluted to 0.05U//d in a 
total volume of 120/d (12/d Fragmentation Buffer and the remainder molecular biology grade H20  
up to 120/d), on ice. 5/d of diluted Fragmentation Reagent was added to the sample plate containing 
Fragmentation Buffer. A plate seal was used to cover the plate and it was vortexed at medium speed 
for 2 seconds and then centrifuged briefly at 716 ref at 4°C. The fragmentation plate was placed 
immediately in the pre-heated thermal cycler and the following cycling conditions were applied: 
37°C  for 35 minutes, 95°C for  15 minutes and finally the plate held at 4°C. 4pl fragmented PCR 
product  was  mixed  with  4pi  loading  buffer  and  run  on  4%  agarose  gel  (made  as  described 
previously) at 120V for 45 minutes.
2.3.12.5  Labelling and target hybridisation
A labelling master mix was prepared on ice containing  lx Terminal deoxynucleotidyl Transferase 
(TdT)  Buffer,  0.857mM  GeneChip  DNA  Labelling  Reagent,  1.5U/pi  TdT,  at  a  total  volume  of 
19.5/d per sample, and vortexed at medium speed for 2 seconds.  19.5/d of the labelling master-mix 
was aliquoted into the fragmentation plate containing 50.5/d of product from the fragmentation step. 
The plate was vortexed at medium speed for 2 seconds and then centrifuged at 716 ref for 1  minute. 
The plate was then cycled at 37°C for 4 hours, 95°C for 15 minutes and held at 4°C indefinitely. 
The plate was again centrifuged briefly at 1500 ref.
All procedures carried out from this point forward were undertaken at the Institute of Child Health 
Gene-Array  Centre,  Institute  of Child  Health  (ICH),  London,  UK,  using  solutions  specified  in 
Affymetrix protocol, prepared by staff at the centre (consult the Affymetrix manual for details on 
making up these solutions). A hybridisation cocktail master mix was prepared to a total volume of 
190ul  containing  0.056M  2-(N-Morpholino)  ethanesulfonic  acid  (MES)  (1.25M),  5%  dimethyl 
sulphoxide (DMSO) (100%), 2.5x Denhardt’s Solution (50x), 5.77mM EDTA (0.5M), 0.115mg/ul
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(1 mg/ml), 0.0155% Tween-20 (3%) and 2.69M TMACL (5M).
Each  70/zl  labelled  DNA  sample was  transferred  from  the plate to a  1.5ml  Eppendorf tube  and 
190/d of hybridization cocktail master mix aliquoted into the same tube. The 260/d mixture was 
heated at 99°C in a pre-heated heat block (a stationary Eppendorf Thermomixer was used) for  10 
minutes to denature the DNA and cooled on ice  for a maximum of 10 seconds. The tubes were 
centrifuged at 400 ref in a microcentrifuge and placed at 49°C for a minute. The solution was mixed 
by pipetting to  ensure  any precipitate  was  properly dissolved and then  200/d  injected  into  each 
GeneChip  array.  Arrays  were  hybridised  in  Affymetrix  Hybridisation Oven  640  at  49°C  for  16 
hours at 60 rpm.
2.3.12.6  Washing, staining and scanning
The Fluidics Station 450 was set-up according to manufacturer’s guidelines to run the GeneChip 
arrays.  Buffers Wash A (non-stringent wash buffer), Wash B (stringent was buffer),  Stain Buffer 
and lx Array Holding Buffer were prepared by staff at the ICH Gene-Array Centre according to the 
Affymetrix  protocol.  Each array was  filled with 250/d  Array Holding Buffer.  For each  Fluidics 
module, 495/d Stain Buffer was mixed with 5/d Streptavidin Phycoerythrin (SAPE) (1 mg/ml) in an 
Eppendorf tube  and placed  in  sample  holder  1;  495/d  Stain  Buffer mixed  with  5/d  biotinylated 
antibody (0.5mg/ml) was placed in sample holder 2 and 800/d Array Holding Buffer was placed in 
sample  holder  3.  The  Fluidics  wash/stain/scan  protocol  was  run  as  described  in the  Affymetrix 
protocol.  Briefly,  the  protocol  involved  two  post  hybridisation  washes  of the  arrays,  with  non- 
stringent Wash Buffer A and stringent Wash Buffer B to remove excess labelling and hybridisation 
reagents. The arrays were then stained with SAPE solution. SAPE contains streptavidin molecules, 
which bind with high affinity to biotin and therefore will bind biotinylated DNA hybridised to the 
array, conjugated to the fluorophore phycoerythrin. A post-stain wash with Wash Buffer A removed 
excess  SAPE and a second  staining with the biotinylated anti-streptavidin antibody,  followed by 
SAPE  solution,  was  used  to  amplify  the  fluorescent  signal.  A  final  wash  with  Wash  Buffer  A 
removed  any unbound  SAPE  and the arrays  were then  filled and held  in Array Holding  Buffer. 
Arrays were scanned on a GeneChip Scanner 3000 7G (Affymetrix) and the data stored for analysis 
using GeneChip DNA Analysis Software (Affymetrix).
2.3.12.7  Array data analysis
GeneChip  array  intensities  were converted  into  genotype  calls  and  call  rates  assessed  using  the 
Affymetrix  GeneChip  DNA  Analysis  Software  (GDAS)  at  various  rank  score  thresholds  (see 
Chapter 6).  Concordance/discordance data  for replicate or pseudo-replicate chips were generated
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Affymetrix Genotyping Analysis Software (GTYPE) into Haploview.
2.3.13  Quantitative real-time PCR
Allele  discrimination  reactions  for  SNP  genotyping  were  performed  as  follows.  Initially  15/d 
volume reactions were used. A quantitative real-time PCR (qPCR) master-mix was prepared on ice 
consisting  of  8/d  QuantiTect  Probe  PCR  Master  Mix  (2x)  (Qiagen),  0.3/d  forward  primer 
(50pmol//d), 0.3/d reverse primer (50pmol//d), 0.65/d SNP probe allele A (5pmol//d), 0.65/d SNP 
probe allele B (5pmol//d) and 4.1/d dd.H20.  14/d qPCR master-mix was aliquoted using a Gilson 
Distriman repeater-pipette into a MicroAmp Optical 96-well Reaction Plate on ice and 1/d genomic 
DNA  (~50ng//d)  added.  Work  by  colleagues  within  the  MRC  Prion  Unit  had  suggested  that 
efficient allelic discrimination could be achieved with total reaction volumes of 5/d and therefore in 
the latter part of my work the following small-volume qPCR master-mix was used, on ice:  2.5/d 
QuantiTect Probe PCR Master Mix (2x), 0.09/d forward primer (50pmol//d), 0.09/d reverse primer 
(50pmol//d), 0.2/d SNP probe allele A (5pmol//d), 0.2/d SNP probe allele B (5pmol//d) and 0.92/d 
dd.H20. 4/d the qPCR master-mix was aliquoted into a MicroAmp Optical 96-well Reaction Plate 
on ice and 1  /d genomic DNA (~50ng//d) added.
Plates were sealed using MicroAmp Optical Adhesive Seals with particular attention paid to sealing 
around the edges of the plate to prevent evaporation. Plates were then vortexed briefly at medium 
speed for 2 seconds and pulse centrifuged at 3000 ref.  Plates were run on an ABI 7000 Sequence 
Detection  System  (Applied  Biosystems),  following  the  manufacturers  protocol.  A  rubber 
evaporation mat  supplied with the machine was used to prevent evaporation.  Cycling conditions 
were: 95°C for 10 minutes, 40 cycles of 94°C for 15 seconds and 60°c for 1  minute.
Copy number assays were conducted in a similar manner to allelic discrimination assays but run in 
triplicate in 25/d reaction volumes, unless otherwise stated. The major differences in protocol are as 
follows:  A qPCR master-mix was prepared containing  12.5/d QuantiTect Probe PCR Master Mix 
(2x),  1/d  SNP PRNP probe (5pmol//d),  1/d  SNP (SActin probe allele B  (5pmol//d), 0.45/d PRNP 
forward primer (50pmol//d), 0.45/d PRNP reverse primer, 0.1 /d QActin forward primer (50pmol//d), 
0.1 /d frActin reverse primer (50pmol//d), and 7.4/d dd.H20. The master-mix was aliquoted into a 
MicroAmp Optical 96-well Reaction Plate or a MicroAmp Fast Optical 96-well Reaction Plate as 
previously  described,  and  run  following  manufacturers  guidelines  on  an  ABI  7000  Sequence 
Detection System or ABI 7500 Sequence Detection System, respectively. Data was analysed using 
ABI Sequence Detection Software vl.3.1 (Applied Biosystems).
802.3.14  Linkage disequilibrium analysis and “tagging” SNP selection
Linkage  disequilibrium  between  SNPs  was  calculated  and  visualised  using  the  freely  available 
program,  TagIT  (Goldstein  et  al.,  2003a;  Weale  et  al.,  2003) 
(http://popgen.biol.ucl.ac.uk/software.html). Methods outlined in the associated User’s Guide were 
followed  and  the  supplied  matrix  converter  was  used  to  convert  SNP  genotypes  into  a  binary 
matrix. Briefly, SNP genotypes were imported into the TagIT matrix converter and modified using 
the convention  l=major allele and 2=minor allele for each locus in the CEPH population and 0 for 
missing genotypes.  All  subsequent  allele  assignments  in  additional  populations were  identical  to 
those  in  the CEPH  to ensure that  each  allele  was  represented  by the  same  binary number  in all 
populations. For trio data, TagIT was used to identify deviations from Mendelian inheritance using 
the “checkM(M)” command, as a safeguard against genotyping errors. Genotypes at each locus were 
checked  for deviations  from HWE which, although may often be caused by gene mutation,  gene 
migration, genetic drift, non-random mating or natural selection (Hosking et al., 2004), may also be 
caused by sampling or genotyping errors. Non-significant ^  values (y2  >3.841, p>0.05) indicated 
consistency with HWE.
Haplotypes  were  inferred directly  for trio  data  using  the “EMtrio”  function,  with  EM  algorithm 
parameters  as  default:  haplotypes  returned  with  an  estimated  minimum  frequency  (“limit” 
parameter) of 0.5% and with a frequency difference of less than 10*6 for any haplotype between one 
EM iteration and the next. Haplotypes were cropped to those with an estimated frequency  >1% and 
the remaining haplotype  frequencies  were summed to  one.  Linkage disequilibrium  patterns  were 
detected and presented using the TagIT graphical output for D ’ and r*. The Fisher’s Exact test P- 
values  for  2x2  tables  was  invoked  using  the  “EMpairP’  command  specific  for  EM  estimated 
haplotypes  and  visualised  in  a  graphical  format  to  statistically  correlate  non-random  association 
between SNPs.
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Figure 2.3  The principle of haplotype tagging
SNPs A.B.C and D are tSNPs for a genomic region. As shown none of the tSNPs has a pairwise r2 against 
SNP X, however SNP X is perfectly predicted by the haplotype r2 criterion or coefficient of determination. 
(Modified from Goldstein et al., 2003a).
81A minimal  set of SNPs,  or “tagging”  SNPs (tSNPs),  sufficient to represent a  level total  genetic 
diversity in a gene region was identified using the following TagIT routine: Criterion 5 was used to 
assess the performance of tSNP sets as this criterion was recommended by the authors as the best to 
use to identify tSNP sets to be used in future association studies (see TagIT User’s Guide). TagIT 
uses a direct approach to identify a set of tSNPs which maintain high r2 values directly with other 
(Goldstein et al, 2003a) SNPs or a set of haplotypes that do so, however selecting tSNPs based on 
their  pairwise  r2  values  with  the  tagged  SNPs  (Carlson  et  al.,  2003)  has  well-documented 
limitations in that to achieve high r2  values, the frequencies of the variants must be matched. Using 
haplotype r’, or the coefficient of determination resolved by a linear regression of tSNP haplotypes 
which predict the state of tagged SNPs, can overcome the limitation of pairwise analysis (Figure 
2.3). This method also has shortcomings and has reportedly failed to represent SNPs even though 
the coefficient of determination with tSNPs (or the haplotypes they define) was 1   (Goldstein et al., 
2003a).  A  minimum  r2  threshold  was  chosen  at  the  0.85  level,  allowing  any  tSNP  chosen  to 
represent 85% of the detected and undetected variation.
Using crit=5 and an r2 threshold of 0.85, the “best” set size H SNPs was determined so that the set 
H+1   did not greatly increase the performance of the “best” against excluded loci, as described in 
(Goldstein et al, 2003a). Briefly, the performance of a set of tSNPs against excluded loci can assess 
how well the set represent as yet undetected SNPs. If K is the total number of SNPs identified in the 
region of interest, H the tSNPs identified from K and A the set of all common SNPs in the region, 
the issue is how well H represents A. The “excludes” function in TagIT invoked a sub-sampling 
procedure to determine this: SNPs are sequentially dropped out from the set K (to give K’) and the 
performance of tSNPs derived from K’ is tested for ability to predict the state of each dropped SNP 
in  turn.  For  large  data  sets,  the  “excludes”  function  was  too  computationally expensive  and  so 
alternatively, the “forward2Bx” function was used. tSNP sets were also evaluated for performance 
against known loci without excluding loci.
2.3.15  Haplotype inference
For unrelated individuals, haplotypes were identified in a phase unknown manner using either: (i) 
Partition  Ligation-Expectation  Maximisation  (PLEM)  (Qin  et  al,  2002)
(www.people.fas.harvard.edu/~iunliu/plem/) run using parameters top=0, parsize=2 (Japanese data 
only) and  1   (West African Data only), buffei=n (population size) and number of rounds=20 and 
input data  file prepared according to published documentation,  (ii) SNPHAP (Clayton,  2004) via 
the  online  GENEPISE  interface  at  the  Archimedes/Wellcome  Trust  server
82(http://archimedcs.well.ox.ac.uk/pise/snphap-simple.html).  with input data file prepared according 
to published documentation.
PHASE  (version  2.1)  (Stephens  et  al.,  2003)  (www.stat.Washington.edu/stephens/software.html) 
was used with the following command line parameters: -n, -fl, -S (random seed) and default values 
for  number of iterations  (100),  thinning  interval  (1)  and  bum-in*  (100).  The  random  seed  was 
required  to  initiate  the  random  number  generator  and  was  changed  for  each  subsequent  run. 
Adhering to the author’s recommendation, each data set was run a minimum of five times to ensure 
that results were consistent. For obtaining more reliable recombination data the xlOO flag was also 
added, which multiplied the number of iterations, thinning intervals and burn-ins by 100 fold.
Comparison  of haplotype  inference  simulations  using  PL-EM,  PHASE  and  SNPHAP  has  been 
shown to demonstrate a good concordance (Adkins, 2004) although PL-EM performs slightly better 
under certain circumstances (Goldstein, pers. comm.). Unless otherwise stated, haplotype inference 
was achieved using PL-EM  data and using  SNPHAP and PHASE to assign allelic  states to loci 
unspecified by PL-EM.
2.3.16  Human and mouse cytoplasmic dyneins nomenclature, map positions and 
sequences
Cytoplasmic  dynein  nomenclature  was  collated  using  literature  searches  of the Human  Genome 
Nomenclature  Committee  (HGNC)  database  (www.gene.ucl.ac.uk/nomenclatureA.  the  National 
Library  of  Medicine  database,  PubMed  (www.ncbi.nlm.nih.gov/entrez/querv.fcgi?db=PubMed): 
searching the Mouse Genome Informatics (MGI) database (www.informatics.iax.org/). the single­
query interface Locus-Link available at NCBI (www.ncbi.nlm.nih.gov/) and all aliases recorded in 
sequence submissions to the GenBank and Entrez sequence databases (Wheeler et al., 2003).
Human and mouse chromosomal locations were obtained from the literature and from the MGI and 
LocusLink databases. Nucleotide and protein sequences (prefix NM_ and NP_ respectively) were 
NCBI  Reference  Sequence (RefSeq)  and  UniProt/Swiss-Prot accession numbers (Wheeler et al., 
2003)  drawn  from  the  primary  sequence  database  GenBank  using  the  Entrez  query  interface 
(www.ncbi.nlm.nih.gov/Entrez/index.html).
2.3.17  Human/mouse homology searches
Homology searches of human and mouse genes for paralogy and orthology were conducted using 
Position Specific Iterative BLAST (Altschul et al.,  1997) at NCBI (www.ncbi.nlm.nih.gov/BLAST.
*  A bum-in is the portion of the Markov Chain algorithm (implemented in the PHASE software) that is 
discarded before a stationary distribution is reached.
83The PSI-BLAST program identifies families of related proteins using an iterative BLAST procedure 
(Altschul et al.,  1997). In an initial search, a position specific scoring matrix (PSSM) is constructed 
from  a  multiple sequence alignment  of the  highest  scoring hits.  Subsequent  iterations  using  the 
PSSM  are  performed  in  a  new  BLAST  query  to  refine  the  profile  and  find  additional  related 
sequences.  Nucleotide and protein sequences of known genes were used through  PSI-BLAST to 
query  the  human  and  mouse  non-redundant  (nr)  sequence  databases  at  GenBank,  using  default 
parameters  and  the  BLOSUM-62  substitution  matrix,  the  most  effective  substitution  matrix  to 
identify new  members of a protein  family (Henikoff et al.,  1993).  Where protein  isoforms were 
present,  the  longest  sequence  was  used  to  search  the  databases.  Homology  searches  to  identify 
conserved  non-coding  sequences  were  conducted  using  MultiPipmaker 
(http://pipmaker.bx.psu.edu/cgi-bin/multipipmaker) (Schwartz et al., 2000).
2.3.18  Phylogenetic analyses of the cytoplasmic dynein genes
Homologous sequences were identified by searching the GenBank non-redundant protein database, 
with  the  human  protein  using  PSI-BLAST  with  default  parameters  and  the  BLOSUM-62 
substitution matrix.  Searches of pufferfish sequence  Takifugu rubripes were performed using the 
BLAST  (TBLASTN)  feature  at  the  Ensembl  Fugu  Genome  Browser  (version  release  2.0; 
www.ensembl.org/Fugu  rubripes).  searching  with  human  protein  sequence  against  a  translated 
nucleotide database.
Protein sequences were aligned for comparison across their full-lengths using the multiple sequence 
alignment program CLUSTALW (Thompson et al.,  1994) (www.ebi.ac.uk/clustalw/) applying the 
GONNET250 matrix as default, allowing 250 accepted point mutations per 100 amino acids using 
scoring tables based on the PAM250 matrix (Gonnet et al.,  1992).
Two  different  phylogenetic  methods  were  used  to  analyse  the  dynein  gene  family  alignments. 
Maximum-likelihood trees  were  inferred under the Jones,  Taylor,  and Thornton  (JTT)  empirical 
model of amino-acid substitution using PHYML (Version 2.4.3;(Guindon et al., 2003)), as was non- 
parametric bootstrapping* using 100 resampled alignments for each gene family. Bayesian analyses 
were performed using MrBayes (Version 3.0) (Ronquist et al.,  2003), using the default  Bayesian 
priors on tree topologies and branch lengths. Two different sets of analyses were performed for each 
gene family, the first allowing the Markov-chain Monte-Carlo algorithm to move between the  11 
different  amino-acid  substitution  models  available  in  MrBayes,  and  another  specifying  the  JTT
*  Bootstrapping is a method for testing the reliability of a dataset. It involves the creation of pseudoreplicate 
datasets by resampling of the original. The frequency with which a given branch is found is recorded as the 
bootstrap proportion and can be used as a measure of the reliability of branches in the optimal tree.
84model.  The  first  analysis  allowed  the  chain  to  take  into  account  uncertainty  in  the  substitution 
process. For all analyses performed, the posterior probability of the JTT model was at least 99%, 
confirming that this model best describes the evolution of the dynein sequences. Only results from 
the fixed-JTT model analyses were used.
For each analysis, three chains of 1,000,000 generations each were run, sampling parameters every 
100  generations and discarding the  first  100,000  generations as  a bum-in period.  Running these 
multiple independent chains allowed visual confirmation that the chains had reached a stationary 
state by ensuring that all  three chains were moving around a region of similar likelihood.  In all 
cases, the majority rule consensus of the posterior sample of tree topologies from all three Markov 
chains was used and trees drawn using TREEVIEW (Page,  1996) with posterior clade probabilities 
and maximum-likelihood bootstrap values shown for each clade on these trees.
2.3.19  PRNP codon 127 statistical analysis
Analysis of FS j was performed with SPAGeDi. The age of the G127 polymorphism was estimated 
using the formula in (Risch et al.,  1995), as corrected by (Colombo, 2000): for a given marker, the 
age in generations (g) is estimated from g = log(delta) / log(l - theta) where, if p_D is the frequency 
of  a  specified  allele  on  V  carrying  chromosomes  and  p_D  the  frequency  on  G  carrying 
chromosomes, delta = (p_D - p_N)/ (1  - p_N).  13 micro-satellites were genotyped for this analysis: 
of these 4 were uninformative and one was excluded because of doubt over the genetic distance 
between this marker and PRNP. The median results for the remaining 8 markers was used as the 
point  estimate  of age,  and  provide  confidence  intervals  based  on  10000  bootstraps  of the  data 
(Efron, 1993).
2.3.20  Miscellaneous software
DNA sequence was translated into protein sequence in all  six reading  frames using the program 
Translate (http://us.expasv.org/tools/dna.html) at the online proteomics server, ExPASy.  Genomic 
DNA, mRNA and protein sequences were retrieved from NCBI (www.ncbi.nlm.nih.gov/). HapMap 
data was downloaded  from  www.hapmap.org.  Power calculations were calculated using Genetic 
Power Calculator at http://pngu. mgh. harvard.edu/~purcel 1/gpc/.
853  Mutation screening of DYNC1H1
3.1  Introduction
The research detailed in this chapter investigates the candidate gene DYNCIHI  for motor neuron 
disease  associated  variation.  The paucity of information available on  human DYNCIHI  and the 
recent publication of high quality human genome sequence, dictated that the initial work required 
for identifying disease associated variants was to elucidate the genomic architecture of DYNCIHI, 
using in silico methods. The localisation of DYNCIHI to chromosome 14q32.32 on human genome 
contig  AL118558  and  identification  of a  78-exon  structure  is  the  first  work  presented  in  this 
chapter, and these data informed much of the later work in this chapter and subsequent chapters. 
The 86.6kb locus of DYNCIHI would have been too costly to resequence in its entirety and so, this 
chapter concludes with a screen of candidate exons 8 and 13, homologous to those causally mutated 
in the Loa and Cral mouse models of late-onset neurodegeneration, and also intron 13 and exon 14. 
No  variants were  identified as  significantly associated with motor neuron disease  in the regions 
screened  and  so  this  chapter  closes  with  a  discussion  on  the  significance  of this  result  and 
shortcomings of this technique.
3.2  Determining the genomic structure of the DYNCIHI locus in silico
When this study was undertaken in April 2003, little or no published information was available on 
the genomic architecture of human DYNCIHI.  With emerging evidence for the importance of this 
gene as candidate for ALS and other motor neuron diseases, determining the genomic organisation 
of the gene was paramount. Following the publication of high-quality genomic sequence of human 
chromosome  14 in February 2003 (Heilig et al,  2003), it became possible to accurately determine 
the  genetic  architecture  of DYNCIHI  by  in  silico  means:  essentially,  transcribed  DYNCIHI 
sequences collated in sequence databases could be aligned back on to a genomic reference sequence 
to  identify  protein-coding  sequences  (Figure  3.1).  The  results  of this  otherwise  straightforward 
experiment  were  extremely  important,  primarily  for  formulating  a  cost-effective  strategy  for 
screening the gene for an association with disease.
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Figure 3.1  Scheme representing the reverse mapping of transcribed sequences onto 
genomic sequence
A. Transcription and intron splicing of protein coding genes. B.  In silico identification of exonic sequence using 
cDNA homology and alignment to a human genome contig.
3.2.1  Information available on the genomic organisation of DYNCIHI in 2003
The chromosomal  location of human  DYNCIHI  had  been  known  since the publication of work 
from Narayan and colleagues in 1994, who used fluorescence in situ hybridisation (FISH) to locate 
the gene to the long arm of chromosome 14 (Narayan et al.,  1994). Refinement of the chromosomal 
position to the cytogenetic band  14q32 was published in 2002 (Witherden et al., 2002), but further 
refinement  of  gene  location,  to  the  resolution  of  human  genome  assembly  contig  and  exact 
sequence, would be needed before elucidating the genomic architecture of DYNCIHI could even be 
attempted.
Cursory  information  was  available  however,  on  the  genomic  organisation  of DYNCIHI  at  two 
public sequence repositories and genome browsers, NCBI and Ensembl, but the data available were 
neither  comprehensive  nor  conclusive.  For  example,  comparing  NCBI  RefSeq*  entries  for 
DYNCIHI  coding  sequence  (Acc:  NM  001376),  between  April  2003  (GIf  29788997)  and  May 
2006 (GI 94557306) illustrates the paucity of sequence information available in 2003, as compared 
to the current state of the database: A 443% increase in coding sequence length is seen between the 
two DYNCIHI RefSeq entries, increasing the available cDNA sequence from 3210 bp to 14229 bp 
(full-length).
The  Ensembl  database  and  genome  browser  (release  16;  May  2003)  did  provide  some  useful 
information on predicted DYNCIHI  genomic organisation.  Ensembl  is a stable genome database 
with  the  capability  of annotating  known  genes  and  predicting  novel  genes  against  the  human
*  RefSeq or Reference Sequence, is a database that provides a biologically non-redundant collection of DNA, 
RNA, and protein sequences. Each RefSeq represents a single, naturally occurring molecule from a particular 
organism is a synthesis of information, not a piece of a primary research data in itself.
+  GI or Genelnfo Identifier is a unique sequence identification number for a nucleotide sequence. Every time 
a change is made to a sequence, a new version of the sequence is produced and a new GI number is assigned. 
GI numbers are not changed after changes to sequence annotation)
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87genome reference sequence (see Hubbard et al., 2002). The Ensembl gene annotation process is an 
automated  one,  based  upon  ab initio  gene  predictions  that  are  either  supported  or  modified  by 
comparison with experimental sequence evidence submitted to the database. The accuracy of these 
predictions  are  therefore  a  function  of  the  completeness  of  the  sequence  database.  Ensembl 
predicted exon/intron  structure of the  gene  was  available  (May  2003;Acc:ENSG00000100839.1, 
current Acc:ENSG00000197102) and used for analysis.
3.2.2  Fine-scale localisation of DYNCIHI to the human genome, chromosome 14 
assembly
The initial step in determining the genomic architecture of DYNCIHI was to localise the gene at the 
resolution of DNA sequence, on the Human Genome Project assembly (human genome build 33; 
April  2003).  The  genome  assembly  DNA  sequence  would  provide  a  reference  to  compare 
transcribed sequences against and allow annotation of the genomic architecture of the gene.
At  the  time,  no  full-length  human  cDNA  or  overlapping  cDNA  clones  had been  published  for 
DYNCIHI  but full-length mouse cDNA (Dynclhl  Acc:  AY004877) and human protein sequence 
(DYNCIHI Acc: NP001367) were both available to conservatively estimate the size of the human 
gene. The length of the mouse cDNA and reverse translation of the 4646 amino acid human protein 
both suggested that the size of the human gene was at  least -14 kb.  Assuming the human gene 
contained introns,  the gene size was likely to be greater than  14 kb. The mouse Dynclhl  cDNA 
sequence was aligned against the human genome using the sequence alignment tool WU-BLAST 
v2.0,  interfaced  through  Ensembl  genome  database  and  browser.  The  sequence  aligned  with  an 
average  of 92%  homology  to  human  bacterial  artificial  chromosome  (BAC)  clone  ALII8558, 
contained within the chromosome  14  ‘golden tile path’  BAC  RP11-1017G21  and  RefSeq contig 
NT  026437, and the cytogenetic location of the gene was found to be 14q32.32 (Figure 3.2).
Figure 3.2  Fine-scale localisation of DYNC1H1 on chromosome 14 (Builds 33 to 36.1)
DYNC1H1 was localised to clone AL118558, within the ‘golden’ tile path BAC RP11-1017G21, and contig 
NT_026437at the margin of 14q32.31  and 14q32.32. Adapted from www.ensembl.ora/Homo  sapiens.
883.2.3  Identifying DYNCIHI exons and introns
DYNCIHI  exons  were  identified by aligning transcribed  gene  sequences  against  human genome
contig  ALII8558  and  identifying  regions  of homology,  which  were  then  annotated  against  the
genomic reference (Figure 3.1). In the absence of available full-length human cDNA sequence, full-
length  cDNA  sequences  from  mouse  (Acc:  AY004877)  and  rat  (Acc:  D13896)  were  used.  The
mouse and rat transcribed sequences were specifically chosen as (i) both species are closely related
to humans reducing the omission of exonic sequences due to species/sequence divergence and (ii)
full-length  sequences  were available.  Sequences  were  aligned  against  AL118558  using  the  web-
based  alignment program  ‘BLAST 2  Sequences’.  In  addition,  a number of partial  human cDNA
sequences (Acc:  AB002323,  AF234785,  LOCI96863  and  U53530)  and  expressed  sequence  tags
(ESTs)  (Acc:  AI418688,  AI457261  AI478488,  AI497769,  AI652200,  AI971265,  AI991665,
AW292121,  BE673985,  BE701697,  BE701780,  BE811371,  BF062339,  BF511560,  BF511676,
BF515276, BF940018) were aligned against AL118558 (not shown).
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Figure 3.3  Exon sizes across the DYNC1H1 genomic locus
78 exons of varying sizes were identified by sequence alignment of transcribed human, mouse and rat dynein 
1  heavy chain 1  sequences, against human chromosome 14 genome clone, AL118558. Exons are shown in 
genomic order and exons 1  and 78 include the 5’ and 3’ UTR sequences respectively. Median exon size was 
165bp (broken red line).
In total, 78 putative exons were observed with an average 90% identity between the three species. 
The  largest  and  smallest  exons  were  1077bp  and  61 bp  in  length  (Figure  3.3)  and  median  exon 
length  was  165bp (mean  188bp),  which conforms well with  the mean exon  size observed  in the 
human genome of <200bp (excluding non-coding UTR sequences) (Sakharkar et al.,  2004). All 78 
exons  had near identical  alignments  between the  three species,  which provided a  high degree of 
confidence  for the result.  However, discordance between alignments were repeatedly observed at
89intron/exon  boundaries,  which  were  easily  resolved  by  inspecting  boundary  sequences  for 
conserved splice junction motifs* (Figure 3.4).
The  in silico  delineated  gene  architecture  was  compared  to  the  predicted  exon/intron  structure 
available on  Ensembl  (accessed April  2003;  search term “DNCH1”)  and all exons corresponded 
extremely well (data not shown), except exons 1  and 78
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Figure 3.4  Consensus sequences at DYNC1H1 splice junctions
Relative frequencies are shown at each base pair, extending up to 6 nucleotides 5’ and 3’ of the splice junction 
(position 0). Positions with relative frequencies of 0 represent sites where each of the four nucleotides is 
equally frequent.
3.2.4  Identifying the 5’ and 3’ UTRs of exons 1  and 78
The discordance of the first and last exons identified above and Ensmbl predictions was thought to 
be due to the accuracy of identifying the size and position of both 5’  and 3’  untranslated regions 
(UTRs). UTRs are regions which commonly encode functional elements such as transcription factor 
binding sites and cDNA stabilisation sites, and are essential for correct gene expression. Mutations 
in these regions (especially the 5’UTR) can affect gene dosage and therefore these regions may be 
important in disease process. Consequently, exons 1   and 78 were examined in detail to ensure that 
the UTRs were identified in their entirety.
Exon 1  contains the common ATG translational start site (TSS) at nucleotide 92,523 of the cDNA, 
which encodes the first amino acid - a methionine - of the DYNCIHI protein. The methionine TSS 
is  well  represented  within  a  conserved  ribosomal  binding  motif,  known  as  a  Kozak  consensus 
sequence (Figure 3.5), named after Marilyn Kozak who first described the sequence (Kozak,  1981; 
Kozak,  1984;  Kozak,  1986). The 5’  UTR of exon  1   was delimited to position 91,948 by aligning 
human EST BF511676 against the genomic sequence. The placement of the 5’ UTR was supported 
by  the  identification  of  several  common  eukaryotic  RNA  polymerase  II  elements  within  the
*  consensus sequences of up to 9 nucleotides in which AG/GT is commonly conserved at exon-intron 
boundaries and AG/G is commonly conserved at intron-exon boundaries; see (Mount, 1982).
90sequence: a conserved transcriptional start site or transcriptional initiator (Inr) element was found at 
position 91,948 and a well conserved downstream promoter element (DPE) was seen at 91,971  nt. 
In addition two promoter elements, a TATA box motif and CAAT box motif, were seen at positions 
approximately  30  nt  and  80  nt  respectively,  upstream  of the  transcription  initiation  site.  The 
software  UTRscan  identified  two  cis-acting  elements  further  upstream  of the  Inr,  including  an 
internal  ribosome  entry  site  (IRES),  both  of  which  are  involved  in  cDNA  stabilisation  and 
translational control.
The  3’  UTR  of  exon  78  was  defined  by  the  alignment  of  human  EST  AW249663  against 
AL118558. The translational stop codon (TAA) was seen at  178,392 nt and polyadenylation signal 
at 178,605 nt. The final verification of DYNCIHI genomic architecture was achieved by translating 
concatenated  exonic  sequence,  using  TRANSLATE,  into  a  polypeptide  and  comparing  against 
protein sequence available on NCBI (NP  001367). Table 3.1  gives the  final genomic  location of 
DYNCIHI exons and introns on AL118558.
5*  UTR  CAAT box  TATA box
TC  CAATG7  CGGTCT  TCGTGCCBHHTTGGTACCTGATACGTAGTC
+1  +1
ATTCA  I ^ p I J C G G A G C C  
Inr  DPE  [   TSS
Kozak signal
3' UTR  stop codon  polyadenylation signal
....CAGAGBBACTTTT.  AC  ^CACTAAGCATGAGCCGGCTCCGCCT
Figure 3.5  DYNC1H1 UTR sequences and conserved motifs
Coding sequence shown in red and UTRs highlighted in yellow. 5’ UTR extends to the transcription initiator 
(Inr; +1  position), position 91,948 on AL118558, encompassing the downstream promoter element (DPE) at 
91,971  and translational start site (TSS) at 92,523.
91Exon/intron  AL118558 poa" (bp)  Siza  Sequence
number Start End 5’ 3’
1 5' UTR 91,948 92,778 830 TT  CAAT  GAGAGAACA GCT  CCACGCT  CAAAG
intron 92,779 103.542 10764 GTGCGGGGCCGCGGA TATTATGATTTGTAG
2 exon 103,543 103,630 88 AGGACGT  CGGT  GAT  G GGTT  AAAT  CCAAT  AG
intron 103,631 107,149 3,519 GT  GAGT  AGTACAAAT TATHTTCTTI I T  AG
3 exon 107.150 107,323 174 CTT  GGCATT  CATT  AA T  GGCAAGGCAGACAG
intron 107,324 107,549 226 GT  AAAAACT  GT  GGTT GAAATCTGT I IT TAG
4 exon 107,549 107,805 256 GGAT  GGT  GAT  AAAAT CGAGAAATT  CAAAAA
intron 107,806 108,194 389 GT  AAGAGCACAGGAT ATTTTATTTTCAAAG
5 exon 108,195 108,381 187 GT  GACCAAACT  GGAT TT  GACACT GACACAG
intron 108,382 110,849 2,468 GT  AACAACT  AGAACT TCTCTGTTAATATAG
6 exon 110,850 111,121 272 GT  CT  AAAACAGGCTT GAAGAATTT  GAAAAA
intron 111,122 111,212 91 GTAAGTTTGAATATA GAAATTATATCCTAG
7 exon 111,213 111,440 228 GTTAT  GGTAGCAT  GC GT  CCT  GAGGCCAC  AG
intron 111,441 113,517 2,077 GT  AAGATTT  GCATT  C ATCTTTCTCCTTTAG
8 exon 113,518 114,594 1,077 GT  CACGGCAGTT  GCA AACTTCCAAGAAAAG
intron 114.595 115,283 689 GTATGCTCTCATGTA TATTTCTTCCTTCAG
9 exon 115,284 115,463 180 GT  GGAT  GATCT  GCT  G AAGCTT GACAT GGAG
intron 115,464 116,533 1,070 GT  AAGGGAT  AGAATT TAACGTTGTCTGTAG
10 exon 116,534 116,683 150 ATT GAAAGAATATT  G GAGCCAAAGAT  CAAA
intron 116,684 119,357 2,674 GT  GAGT  GCTT  CT  GT  G ACCTTT  CTTT  CACAG
11 exon 119,358 119,504 147 AATGTCGTTCATGAG AGT  CAGAGGTACCAG
intron 119,505 122,014 2,510 GT  AAGCCTTT  GGT  GA GCTTT  GGTT  GGCTAG
12 exon 122,015 122,155 141 GT  GGGT  GT  AC  ATTAC GAACAGTAT  GT  CAAG
intron 122,156 122,503 348 GT  AAGAAACT  CCTAA GTT  CTT  CATTT GCAG
13 exon 122,504 122,680 177 GTTT  GGCTT  C  AGTAT AT  AGATT  AT  GGC  AAG
intron 122,681 122,816 136 GT  GAGCCCT  GCT  GT  C CT  ATTT  CACCCT  CAG
14 exon 122,817 122,927 111 GT  AC  AAT  CTAAGGT  G T  CCCAGAT  CT  CAAAG
intron 122,928 123,011 84 GT  GAGGACATAGGAT CCT  CT  CT  CT  GAACAG
15 exon 123,012 123,131 120 TCCCGCCAAGAGTTG GAGAAGCAAGTTGAG
intron 123,132 124,865 1,734 GT  GAGCT  CT  GT  GC  AT III IAACT  CT  CAAAG
16 exon 124,866 125,105 240 CTCTACCGCAAT  GGC ACCAAGCCT  GTCACG
intron 125,106 127,819 2,714 GT  GAGT  CCCGCCAGG TCTGACTGCTTTCAG
17 exon 127,820 127,975 156 GGCAACCTT  CGCCCA GAAGAGCGCGT  GCAG
intron 127,976 128,116 141 GT  AT  GAACCACT  GGG TATTCTCAATCGCAG
18 exon 128,117 128,230 114 GT  GGCCTT  AGAAGAA GT  ACAGCCT  CGAAAG
intron 128,231 128,784 554 GTATATCATGAAATC TGTTTCTCTCGACAG
19 exon 128,785 128,895 111 CTTCGACAAAATTTG AAAGGTTACAT  GAAG
intron 128,896 128,975 80 GTAGGT GGCCAGTAT TT  ACTTT  CT  CCAC  AG
20 exon 128,976 129,185 210 ATAAATATGCTGGTG GAATTTI IGAAGCAG
intron 129,186 129,365 180 GCGAGT  AAT  AGGACT CT  GGTTT  GAATT  CAG
21 exon 129,366 129,512 147 AT  AAGAGAAGT  GT  GG T  CT  CCGT  ATT  ACAAG
intron 129,513 130,367 855 GT  GCT  GTT  GCT  GGGG CT  GT  CT  GCCCACCAG
22 exon 130,368 130,534 167 GI II I IGAAGAGGAT CCAGCGGTTT  CAGAG
intron 130,535 130,622 88 GTAT GGCCT  CCAGCC TAATTT  CATTT  GT  AG
23 exon 130,623 130,796 174 CAT  CAGCACT  GAGTT GT  CAT  CTTT  CCCC  AG
intron 130,797 132,348 1,552 GT  AAGAT  CCTT  GCTT TTAl I  I  I AA I II I AG
24 exon 132,349 132,514 166 GTTCTATTTTGTGGG CGGGAAGGAGAGGAG
intron 132,515 132,592 78 GTAAATTTATGTTCG TT  GT  ATTT  ATTT  CAG
25 exon 132,593 132,781 189 GTT  AT  GTTTAAAACT ATT  GAT  AAAT  ACCAG
intron 132,782 132,872 91 GTAATCTATAGTAGA TTCTGTGTCTTTCAG
26 exon 132,873 133,067 195 GCCC  AGCTT  GT  GGTT AAGCTAGAACACTT  G
intron 133,068 133,718 651 GTTAGT  CT  CACACCT ACTCTCTTTCTTCAG
27 exon 133,719 134,001 283 ATTACAGAGTT GGTT GGGGTTCCCCATTTG
intron 134,002 134,838 837 GT  AAGTT  CTT  CC  AC  A CTTTT  CTTT  AAACAG
28 exon 134,839 134,939 101 GACCT  GCT  GGAACT  G ACCTTT GATTTCCAG
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intron 134,940 136,008 1,069 GT  GAGAC  ACTTT  AT  G TCCTCT  CCTTT  CCAG
29 exon 136,009 136,168 160 GCAAT  GGGCCGGAT  C CCAACT  ACGACAAGA
intron 136,169 137,673 1,505 GT  AAGACACCT  CTT  C TCATCTCATTCTCAG
30 exon 137,674 137,917 244 CCT  CT  GCCCCCATT  A CGTCCCGTTTTT1  AA
intron 137,918 138,106 189 GT  AAGT  AGCCT  AGAA TTT  CTT  CTTTT  CT  AG
31 exon 138,107 138,290 184 ACT  AT  GCGAT  GAGCA CTCCCT  GAACAAGAG
intron 138,291 138,570 280 GTT  CGTTAC  AAACGT GCCCT  CT  CCCCGT  AG
32 exon 138.571 138,783 213 ATT  CT  GAT  ACAGAGC AT  GT GGGTT  GAAAAG
intron 138.784 139,705 922 GT  AACTT  GGATT  GTT T  GTT  GGGCCCT  GCAG
33 exon 139,706 139,944 239 GTT  CT  CCAGCT  CTAT ACACGT GCT  GAGAAA
intron 139,945 140,144 200 GTACGTCTTCTTTGA AT  CCTT  CCCAACCAG
34 exon 140,145 140,301 157 GAT  CAT  CGACAGCGT AGT  CTT  CCACCCAAT
intron 140,302 142,935 2,634 GT  AAGT  AGCCTTTT  G AT  GTTTT  CTTT  CAAG
35 exon 142,936 143,163 228 GT GAGAAT  AAT  GTTT T  CCCCCAT  GCT GCAG
intron 143,164 143,686 523 GT  ACGCCCAGGT GGG CCTT  CCACTTT  CT  AG
36 exon 143,687 143,917 231 AT  CCAAAGAGAT GCA GAGCGCT  ACATT  CAG
intron 143,918 144,179 262 GT  CAGGGGGCAT  CAG TTCCCTTTT1  AATAG
37 exon 144,180 144,320 141 CGAT  AT  CT  GGTTT  AT ATTATCGATTATGAG
intron 144,321 144,596 276 GT GAGCAT  GCAGCT  A CATCTCCGTGTGTAG
38 exon 144,597 144,830 234 GT  GT  CCAT  CAGCGGA TT  GCCT GACAT  GGAG
intron 144,831 144,918 88 GTAAAGAGGCCAGGA GT  CTT  CCCT  CCAAAG
39 exon 144,919 145,125 207 GT  GGT  GGGT  CT  CAAC T  CCTT  CAT  CAGACAG
intron 145,126 145,213 88 GTTTGTTTCTATCCA T  GT  CCCTT  CCTT  CAG
40 exon 145,214 145,335 122 AT  GGT  GGAGCACGGA GCCCCT  CT  CAC  AC  AG
intron 145,336 146,281 946 GTAAAACAGCTCGGT GCTAT  CT  GT  GCACAG
41 exon 146,282 146,447 166 GTT  CCT  GCGCCACGT T  ACACCAT GTCTCAG
intron 146.448 147,723 1,276 GT  ACGCAGAGTTT  CT TT  CT  CATT  GCCATAG
42 exon 147,724 147.887 164 GAGAGATT  CACCCAG T  CT  CTT  CCAAGAT  AG
intron 147,888 150,581 2,694 GT  AAGGGAAGCCGAG CT  GCT  CT  CCCCACAG
43 exon 150,582 150,711 130 ACT  CGT  AGAGGAT GA AACT  GGCT  GT  CAAAG
intron 150,712 154,404 3,693 GTAGCAAACT  CGCAT CCTiTTT 1  rCTATAG
44 exon 154.405 154,538 134 GATT  ACAT  CCCAGTA GCT GAGGATT GACAG
intron 154,539 155,004 466 GT  GGGCTTTTTT  GTT CTCGTAATGTTTCAG
45 exon 155,005 155,119 115 AATATT  CCGT  CAACC GT  GT  ACCAGATT  AAG
intron 155,120 155,213 94 GT  GCGT  CTGGTCGGT CCTCTGCTTCTGTAG
46 exon 155,214 155,375 162 GT  CCAT  AGG  AAGTAC CT  GGCCAAT  GGAGAG
intron 155,376 155.449 74 GT  AATTAGGT  GACGT T  GT  GCT  GTTT  CCC  AG
47 exon 155,450 155,664 215 GTGCCTGGTCTCTTT AGCACTTTT  CAAC  AG
intron 155,665 155,767 103 GT  ACGT  GGGCCTTTA GGGCCT  CTTT  CT  CAG
48 exon 155,767 155,972 205 GTGTGTGTTGAATTG CAGACT  CTT  CACCAG
intron 155,973 157,369 1,397 GT  GGGTT  CAGTTTT  G ACTATTTTCTGAAAG
49 exon 157,370 157,543 174 GCGAATGCTCGGCTA GAGACAGT  CGACCAG
intron 157,544 157,649 106 GT  GCGT  CACAGGCAC GGCTTT  GCT  CTTTAG
50 exon 157,650 157,769 120 GT  AGAAGAACT  GCGT GCT  GAAAAGAAGAAG
intron 157,770 157,992 223 GT  AT  GGT  GT  CAGGGA ATCCCTCCTTTCTAG
51 exon 157,993 158,113 121 GTT  AT  GAGCCAAGAA TT  GAGGCCCAGAAT  G
intron 158,114 160,102 1,989 GTATGTAAAGACTGT CCT GCT  GCCACT  CAG
52 exon 160,103 160,298 196 CTGTGAAGTCGATCA T  GCAGAGGAGAT  CAG
intron 160,299 160,895 597 GT GAGAAAGT  GGAAG ATTCGT  CTTTT  ACAG
53 exon 160,896 161,013 118 T  GACGCCATAAGGGA T GGGCAATT  GCACAG
intron 161,014 161,099 86 GT  GATT  AAC  AC  AGCC ATT  GGTT  CTT  CCC  AG
54 exon 161,100 161,315 216 CTT  AACT  AT  GC  AGAC GCT GT  CGAGGCAAAA
intron 161,316 161,806 491 GT  AAG  ATT  AT  CAT  C  A CGGTTTTCCTTTTAG
55 exon 161,807 162,019 213 GT  AAACCGGAGCACT CAAGCCAACAT  CCAG
intron 162,020 162,155 136 GT  GAGAAT  CACGGGG GGCCTT GCCTTT  CAG
56 exon 162,156 162,283 128 TT  CCGT  ACAGAT  ATT GAAACGATT  CAATAG
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intron 162,284 164,319 2,036 GTAT  GAGCT  CGGGTG T  GGCCT  CAT  CCT  CAG
57 exon 164,320 164,473 154 GTATCCGCTGATCAT CCCCTT  CT  GGT  CCAG
intron 164,474 166,290 1,817 GTT  GGT  GTT  GGCCTT CCGT  GT  GGAAT  GCAG
58 exon 166,291 166,437 147 GAT  GT  GGAAAGCTAC ACCCGGGAT  CCAACT
intron 166,438 166,528 91 GT  AAGGAAT  GGGACC TACCTAI  I I  IGGCAG
59 exon 166,529 166,679 151 GT  CGAGTT  CCCACCA TT  CTT  AAACTT  CAAG
intron 166,680 166,831 152 GT  AGGAT  CT  GGACCT TTTT  ATT  CATTT  AAG
60 exon 166,832 167,085 254 GGGAATTT  CAGCT  CC GAGTCCCT  CAAGCAG
intron 167.086 167,242 157 GT  GGGT  GCCTT  GGCC ACT GCTT  CCTTT  CAG
61 exon 167,243 167,377 135 ATACACTTCTTGTAC AAGGACCT  CTT  CCAG
intron 167,378 167,468 91 GT  AGAGT  GAGGT  CCT CT  GCT  CTT  GTCCCAG
62 exon 167,469 167,563 95 GT  GGCGTTT  AACCGA GAAGGGCACCGT  GGG
intron 167,564 168,066 503 GT  AAGAGCACT  C  ACG TT  GCACCCTT  CGCAG
63 exon 168,067 168,241 175 GGAGCCCACCTACGA GTT  CAGGCAGACGAG
intron 168,242 168,428 187 GT  GATT  GTT  CT  CTT  G CT  ATT  GT  CT  CC  AC  AG
64 exon 168,429 168,504 76 C  AATTT  GGC  AT  CT  GG AAGAAACACCT  GCAA
intron 168,505 169,404 900 GT  AAGCCCCACT  GT  G CT  GTACCT  GTTT  CAG
65 exon 169,405 169,565 161 CACCCATT  GGCCAGG ATT  GT  GGGCACAGAG
intron 169,566 169,843 278 GTAATGTCCTGGTAC CTT  CTTT  GTTT  GCAG
66 exon 169,844 169,955 112 GT  GAAGCCCAACACT CTT  CAATT GCAAT  CG
intron 169,956 170,058 103 GT  AAGGAT  GCTT  GAG GTTT  CCCT  GCACCAG
67 exon 170.059 170,119 61 GCT  CT  GCAGAAGGCT T  GT  AAAGT  CGGGCAG
intron 170,120 170,214 95 GT  AGGCCT  GTT  CT  CT ACTTT GT  GT  GT  GCAG
68 exon 170,215 170,338 124 GT  GGGT  GAT  GCT  GAA GAGATCAACCCCAAG
intron 170,339 170,465 127 GT  GGGT  GGTT  GAAGG GGCGCT  CT  CCCTTAG
69 exon 170.466 170,579 114 GTGCCTGTGAATCTG T CACGGAT  ATGCAAG
intron 170,580 171,705 1,126 GT  AAGTACCTT  GT  CC CACTTT  CCT  C  ACCAG
70 exon 171,706 171,876 171 T  CT  CCCAACGAGCGT GAT GACACGGCCAAG
intron 171,877 172,104 228 GCAAGT  GT  GGGCCAT CTTTT  CCT  CCCCCAG
71 exon 172,105 172,322 218 GGCAGGCAGAACAT  C GCCAGAT  GGCATCAG
intron 172,323 172,425 103 GTATGCTGCTGCCTG GCACTGGI I I I CTAG
72 exon 172,426 172,529 104 GCGAGAGGAGTTT  GT T  CCTT  ACC  ACAC  AGG
intron 172,530 175,647 3,118 GT  AGGCAACAAGGAT GGGACT  GT  GGCCCAG
73 exon 175,648 175,859 212 GT  GT  GGACAT  GAT  CA GT  GGAGAAT  AT  CAAG
intron 175,860 176,346 487 GT  AGCT  GGGAGGGT G TTT GAACGATTTT  AG
74 exon 176,347 176,500 154 GAT  CCTTT  GTT  CAGG ACGAGCTAGT GAAAG
intron 176,501 177,270 770 GT  GCGT  GAGAGGCCG GT  GCCTT  GGCT  GCAG
75 exon 177,271 177,413 143 GGAT  CTT  GCCT  CGGA GCCAAGGAGCTAAAG
intron 177,414 177,544 131 GT  GAAGGCGCT  CCT G T  GCT  GCTTT  CCACAG
76 exon 177,545 177,713 169 AAC  AT  CCACGT  GT GC GCTT  CGGAGT  CACGG
intron 177,714 177,901 188 GT  GAGT  GGAGT  CT  CA GCTT  CCGCCT  CACAG
77 exon 177,902 178,029 128 GTTT  GAAACTT  CAAG AAGAAGGCCAGT  GT  G
intron 178,030 178,265 236 GT  AAGGAGGCACT  GC CCT  CT  GCTT  CT  GCAG
78 exon 178,266 178,628 363 GT  AACCTTACCT  GT  C CTAAGCATGAGCCGG
Table 3.1  DYNC1H1 genomic organisation
78 exons of DYNC1H1 were identified. Exon/intron positions given relative to position on genome contig 
AL118558. First and last 15 nt of exon/inton sequence is shown. (From Ahmad-Annuar et al., 2003).
943.3  Mutation screening of DYNCIHI exons 8,13 and 14, and intron 13
After determining the genomic architecture of the human DYNCIHI, the next step was to screen the 
gene for variants associated with disease. Detecting mutations by resequencing the entire 86.6 kb 
genomic locus was cost-prohibitive and therefore regions of the gene had to be prioritised.
3.3.1  Prioritising regions of DYNCIHI to screen
Screening a single gene in an association study leaves two further variables that can influence the 
cost and outcome of the study: the number of samples and the number of amplicons screened. With 
the effect size of a disease associated mutation in DYNCIHI  unknown, as many samples as were 
available were required for screening. Therefore, the number of amplicons had to be minimised to 
ensure that the study did not exceed that available budget for its completion. This required careful 
prioritization of regions of the gene that were considered a priori to be of importance to disease 
pathogenesis. It was not feasible to screen all 78 exons of coding sequence for functionally relevant 
coding changes and conserved domains such as the motor domain were too large to screen in their 
entirety. The 5’ and 3’ UTR were considered for screening but the regions that were screened were 
those which carried mutations in mouse models of motor neuron disease.
Exons 8 and 13, homologous to those harbouring the mouse Loa and Cral mutations respectively, 
were to be screened as a priority.  Aligning mouse and human protein sequences AAF91078  and 
Q14204 using BLAST, indicated that the regions corresponding to mouse and human exon 8 and 13 
share  99% and  100% homology respectively.  The conservation of amino  acids between the two 
species  suggested  that  mutation  of either  human  exon  may  also  yield  a  deleterious  phenotype 
similar to that seen in the mouse.
3.3.2  Primer design and sequencing of exons 8 and 13
Primers  for  PCR  amplification  and  sequencing  were  designed  to  incorporate  coding  sequence, 
splice junctions and flanking sequence to ensure that potential mutations producing aberrant amino 
acid  sequence or splicing would be detected.  Due  to  the  small  size  of exon  13  (177  bp)  it  was 
possible  to  include  exon  14  and  the  intervening  intron  13,  within  a  single  PCR  amplicon  and 
sequencing reaction. Exons were sequenced in both forward and reverse orientation and sequences 
were checked for mutations by eye.
3.3.3  Patient samples screened for DYNCIHI mutations
DNA from the FALS, HSP and SMA patients screened in this study was collected with informed 
consent  by  Professors  Karen  Morrison  and  Pamela  Shaw  and  Dr  Richard  Orrell.  All  samples 
collected were of UK residents although for the majority of samples, ethnicity was not known. In
95order  to  eliminate  the  possibility  that  a  potential  mutation  in  the  case  samples  was  actually  a 
polymorphism  found  at  low  frequency  in  the  Caucasian  population,  100  unrelated  CEPH 
individuals were screened as controls. Prior to the screening of any samples, ethical approval for 
research was obtained from the Central Office for Research Committee Ethics, London, UK.
3.3.4  Mutation screening of exon 8
Exon 8 coding sequence, splice junctions and flanking sequence were sequenced in a panel of 170 
FALS, 31  HSP and 26  SMA patient samples, and  100 CEPH control samples. One synonymous 
A/G variant was found at the third base pair of codon 836, encoding alanine (A836) (Figure 3.6). 
The  SNP was  found in a heterozygous state in two FALS  samples and also in a  single control 
sample, with minor allele frequencies (MAF) 0.6% in cases and 0.5% in controls.
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Figure 3.6  Exon 8 A/G synonymous SNP
Top. Exon 8 genomic sequence was screened for mutations including flanking intronic sequence (grey) and 
coding sequence (blue and orange). Position of the A/G SNP is indicated and amino acid translation of the 
exonic sequence shown above each codon (red).
Lower. Electropherograms of the exon 8 wildtype forward sequence (left) and A/G transition (right) seen in 
both cases and controls. The A/G SNP was a synonymous change at codon 836, encoding an alanine residue.
Genotypes were observed to be in HWE 'in both cases and controls and a Fisher’s exact test for the 
independence of SNP frequency in cases compared to controls was not significant (Fisher’s exact; 
p=0.1) when all cases were considered together and also, when FALS samples only were tested 
against controls (Table 3.2).
96Samples Genotype Allele frequency
(%) UUUC
Fisher’s
exact
test Types Number
(N)
Chromosomes
(2N) A/A A/G GIG A G
HWfc
Cases  FALS 170 340 168 2 0 99.4 0.6 ns
HSP 31 62 31 0 0 100 0 -
SMA 26 52 26 0 0 100 0 -
p=0.10
Controls  CEPH 100 200 99 1 0 99.5 0.5 ns
Table 3.2  Summary of DYNC1H1 exon 8 mutation screen, in motor neuron disease patients 
and controls
The mutation screen was undertaken in a cohort of familial ALS (FALS), familial hereditary spastic paraplegia 
(HSP) and spinal muscular atrophy (SMA) patients, and CEPH controls. Deviations of genotype proportions 
from Hardy-Weinberg equilibrium (HWE) and Fisher’s exact test between cases and controls were not 
significant (ns).
3.3.5  Mutation screening of exons 13, 14 and intron 13
Exons  13 and  14, intervening intron  13 and flanking sequence were sequenced in  165 FALS,  32 
HSP and 26 SMA patient samples, and 93 CEPH control samples. No variants were found within 
exon  13  and  14 coding sequences but an A/G polymorphism was  seen within intron  13  at base 
122,704 of AL118558 (Figure 3.7). The SNP was identified in 8 FALS patients (MAF= 2.4%), 5 
SMA samples (9.6%), 6 HSP samples (9.4%) and 9 CEPH controls (4.8%) and all samples bearing 
the polymorphism were heterozygous. No minor allele homozygotes were seen and all genotypes 
were in Hardy-Weinberg equilibrium. Fisher’s exact tests for independence of SNP frequency were 
not significant for the entire case cohort versus controls /?=0.83 or for cohorts analysed by disease 
type (ALS p=0.20; SMAp=0.19; HSP p=0.22 (Table 3.3).
K E F G P V V I D Y G   K  
A A A   G A G   T T T   G G A   C C A   G T A   G T T   A T A   G A T   T A T   G G C   A A G g t g a g c c c t g c   .  t g t c
Q   V   G   S
TGGTTGA  ij—AGGTGTCACGGGTAGTGTAAAGCAACATTTCTGTT  T A T T T C A C C d C A G   G T A   C A A   T C T
K   V   N L K Y D   S W H K   Amino acid
AAG GTG AAC TTG AAA TAT GAC TCT TGG CAT AAG  DNA
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Figure 3.7  Intron 13 A/G SNP
Top. Exons 13 and 14 coding sequence (blue and orange) and intron 13 sequence (grey) were screened for 
mutations. Position of the A/G SNP identified is indicated and the amino acid translation of the exonic 
sequence shown above each codon (red).
Lower. Electropherograms of the intron 13 wildtype forward sequence (left) and A/G transition (right) seen in 
both cases and controls.
97Samples Genotype Allele 
frequency (%) uu/c Fisher’s
Types Number
(N)
Chromosomes
(2N) A/A A/G GIG A G
rtWfc
exact test
Cases  FALS 165 330 157 8 0 97.6 2.4 ns
HSP 32 64 26 6 0 90.6 9.4 ns
SMA 26 52 21 5 0 90.4 9.6 ns
p=0.83
Controls  CEPH 93 186 84 9 0 95.2 4.8 ns
Table 3.3  Summary of DYNC1H1 mutation screening of exons 13,14 and intron 14 in motor 
neuron disease patients and controls
The mutation screen was undertaken in a cohort of familial ALS (FALS), familial hereditary spastic paraplegia 
(HSP) and spinal muscular atrophy (SMA) patients, and CEPH controls. Deviations of genotype proportions 
from Hardy-Weinberg equilibrium (HWE) and Fisher’s exact test between cases and controls were not 
significant (ns).
3.4  Discussion
The results detailed in this chapter describe work to assess the significance of the candidate gene 
DYNCIHI as a causal or susceptibility factor for ALS and/or other motor neuron diseases. At the 
time  that  this  research  began  in  April  2003,  little  information  was  available  on  the  genomic 
organisation of DYNCIHI. The nature of research carried out in the cytoplasmic dynein community 
has historically focused on examining proteins and expressed sequences of non-human species and 
so,  there  existed  a  paucity  of sequence  information  on  the  human  cytoplasmic  dyneins.  This 
consequently impeded initiatives by genome databases  such as Ensembl to identify the genomic 
architecture  of  predicted  and  known  genes  by  automated  methods.  Elucidating  the  genomic 
structure of a candidate gene is a problem seldom faced by researchers today, with high quality in 
silico and sequence data readily available in public databases, but establishing the size and structure 
of a candidate gene to be screened for an association with disease is paramount.
Through comparative sequence techniques (comparing against mouse and rat sequences) DYNCIHI 
was localised to chromosome  14q32.32 and to the human genome assembly on contig AL118558. 
The gene was found to comprise 78 exons and span 86.6kb. The use of homology to related species 
allowed the complete gene structure to be elucidated where only a partial structure was seen at on 
browsers such as Ensembl. A similar technique called “gene builds” has since been implemented by 
Ensembl as an automated method for identifying and describing genes from 2004 (Curwen et al., 
2004).  In  addition,  the  availability  of  additional  eukaryotic  genome  sequences  and  sequence 
comparison tools, such as MultiPipmaker (Schwartz et al., 2003), have facilitated the identification 
of  functionally  conserved  sequences,  including  putative  coding  sequences  (Morgenstem  et  al., 
2002), and confirm the genomic structure predicted in this chapter was correct.
98The  final  results  in  this  chapter  detail  the  screening  of exons  8,  13  and  14  and  intron  14  of 
DYNCIHI for mutations associated with various forms of motor neuron disease. Two variants were 
identified; one in exon 8 and one within intron 13. The exon 8 variant was an A/G transition at low 
frequency (-0.5%) in both cases and controls and constituted the third base position of an alanine 
codon (A837). Due to the redundancy of the human genetic code, the SNP does not alter the amino 
acid composition of the protein - GCA and GCG both code for an alanine - and so a deleterious 
phenotype  in individuals possessing the  SNP  is  unlikely.  There was  no  significant difference  in 
allele frequency of the SNP between cases and controls, and therefore it is likely that this SNP is 
simply a neutral polymorphism.
The intron  13  SNP was identified in all  three disease types and controls,  at varying  frequencies, 
which is likely to reflect an ascertainment bias due to sample size. The SNP was an A/G transition 
which bears no obvious functional relevance as it does not occur at the splice junctions. There was 
no  significant  difference  in  allele  frequencies  between  cases  and  controls,  when  cases  were 
compared by disease type or when combined, and genotypes were seen in HWE, suggesting that 
this SNP is not associated with disease.
3.4.1  Updated SNP information
Since this screen was carried out, information on SNP content of DYNCIHI and SNP frequencies 
has become available at dbSNP. The SNPs discovered in this screen have been identified by other 
investigators and have been submitted to dbSNP in 2004, with SNP IDs: rs 17512054 and rs4900529 
for exon 8 and intron 13 respectively. Both SNPs have been validated and frequency information is 
available.  No  other SNPs have been discovered  in the regions  screened in this  study except  for 
rs 17540908, which is 9bp downstream from rs4900529. This SNP, with a MAF of 0.6%, has not yet 
been validated and so may be an artefact.
Frequency data available for rsl 7512054 gives a MAF of 1.4% which is in contrast to the 0.6% and 
0.5% we identified in cases and controls. This discrepancy is almost certainly due to differences in 
populations used as the dbSNP data are  generated using a multi-ethnic  polymorphism discovery 
resource panel of 90 samples (PDR90) and a Caucasian population was used in this screen (Collins 
et  al.,  1998).  Population  differences  accounting  for  frequency  discrepancies  seen  for  SNP 
rs4900529, for which a MAF of 4.8% was found for Caucasian controls in this screen compared to 
a MAF of 14.7% on dbSNP using PDR90.  As rs4900529 was genotyped in the HapMap project, 
population specific frequencies are available and it is clear that in European samples the MAF is 
5.8%  and  in  Asian  and  Sub-Saharan  African  samples  the  MAF  varies  from  27.5%  to  19.3%.
99Therefore the minor allele frequencies experimentally derived for both SNPs in this screen were 
similar to the frequencies known for these SNPs in Caucasian populations.
3.4.2  Implications and explanations of a negative screen
The  lack of association between  the  SNPs  in  exon  8  and  intron  13  and FALS,  HSP  and  SMA 
suggests that these specific SNPs may not be relevant to disease pathogenesis but does not preclude 
the significance of mutations in DYNC1H1 to ALS pathogenesis and other motor neuron diseases. 
There are several caveats to this screen: (i) although the FALS cohort was of a reasonable size, the 
HSP and SMA cohorts were small, with 32 and 26 individuals respectively. It is possible therefore, 
that these variants may account for a rare minority of familial SMA and HSP which would not be 
detected with such a limited sample size, (ii) all three diseases are known to demonstrate genetic 
heterogeneity and although SOD1, SMN and Spastin mutations had been ruled out  in the FALS, 
SMA and HSP cases respectively, several additional loci which are known to be mutated in familial 
forms of these disorders, had not been screened, (iii) the study only screened a discrete region of 
DYNC1H1 for association with disease. Without an understanding of the extent of LD surrounding 
these SNPs, this screen can only be considered a direct association study and therefore, regions of 
the gene not investigated may still harbour disease associated mutations. To investigate the gene in 
its entirety, the LD pattern spanning the gene was elucidated and an association study conducted.
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4.1  Introduction
Despite  screening DYNC1H1  candidate  exons  8  and  13  in  a  number  of familial  motor  neuron 
disease cases and controls, no variants associated with disease were found. This chapter extends 
those previous analyses by using a linkage disequilibrium based association study to investigate the 
entire DYNC1HI  genomic  locus in an attempt to identify an association with sporadic ALS  in a 
northern  European-derived  population.  16  SNPs  were  examined,  of which  two  (rs2251644  and 
rs941793) were found to be sufficient to tag the majority of haplotypic variation (r2 >0.85). These 
tSNPs were tested in 261 North American sporadic ALS patients and 225 matched controls but no 
association  with  the  disease  was  found.  In  addition,  the  genetic  diversity  of DYNC1H1  was 
examined in Japanese and Cameroonian populations to establish the evolutionary history for this 
gene. This chapter finishes with a brief discussion of the caveats associated with this work and how 
association studies have changed since this study was initiated.
4.1.1  Mutation screening of large genes can be problematic
As  previously described,  the  genomic  locus  of DYNC1H1  spans  over  86.6  kb  and  contains  78 
exons. Screening genes of this size for disease associated mutations can be prohibitively expensive 
and the cost of such a strategy is further multiplied for complex diseases, where mutations are likely 
to have a small effect size and require, therefore, a large sample size to have an appreciable power 
to detect a disease-associated mutation. One method for overcoming the limitations associated with 
mutation screening of large genes is to screen a limited part of the gene instead of screening for all 
possible mutants, which leads to the question:  which region of the gene should be screened? As 
previously discussed,  prior hypotheses  based  on  experimental  or bioinformatic  data  can  narrow 
down a candidate region for screening; for example, the screening of exons 8 and 13 of DYNC1H1 
was  based  upon  known  mutations  in  of the  mouse  homolog  of the  gene.  No  mutations  were 
discovered  in  this  gene  and  therefore  to  investigate  the  entire DYNC1H1  genomic  locus  for  an 
association with sporadic ALS, a linkage disequilibrium-based association study was conducted.
4.2  DYNC1H1 association study design
4.2.1  Evolving resources and methodologies in LD-based association studies 
influence study design
The  DYNC1H1  association  study  was  designed  based  on  the  understanding  of  case-control 
association studies and LD mapping available at the time the study was undertaken in 2002. The
101paucity of genetic  variation data available  for DYNC1H1  in 2002  as  compared to  today greatly 
influenced  the  study  design,  with  much  of  the  preliminary  work  directed  towards  describing 
variation  within  the  gene.  Contemporary  LD-based  association  studies  are  able  to  exploit  large 
amounts  of publicly  available  data  on  SNP  position  and  frequency,  LD  patterns,  genotypes  in 
various worldwide populations and even tagging performance -  almost none of which was available 
when this study was initiated. Today, the first stop for the majority of researchers interested in the 
genetics  of  complex  neurodegenerative  diseases  are  data  resources  such  as  The  International 
HapMap Project which,  although initiated in 2002, has come to  fruition too late to influence the 
design of this study. The majority of work presented in this chapter was designed and completed 
before changes in this field had become common place, so many of the techniques and analyses are 
redundant for today’s investigators. In later sections of this chapter, the differences in study design 
and their effect on success are discussed.
4.2.2  Three phased study design
The DYNC1H1 study design encompassed three broad phases; discovery, tagging and testing. The 
goal of the SNP discovery phase was to construct both SNP and LD maps spanning DYNCIHI at a 
density of approximately 1   SNP every lOkb. This SNP density was, at the time, shown to be highly 
effective  for identifying  regions  of elevated  LD  whilst  representing  the  true  pattern  of genomic 
variation in a region (Dawson et al., 2002; Gabriel et al., 2002; Goldstein et al., 2003a; Reich et al., 
2001a). The discovery phase was necessary due to a general deficit of available marker information 
assigned  to  SNPs  present  in  the  public  databases:  SNPs  lacked  (i)  validation  data,  essential  for 
authenticating  SNPs,  (ii)  data  on  their  physical  locations  and  (iii)  information  on  their  allele 
frequencies.  The  tagging  phase  was  used  to  identify  tSNPs  which  could  efficiently  represent 
variation across the gene. These tSNPs were then taken forward to the test phase, where they were 
assayed in case and control samples and analysed for association with disease status.
4.2.3  Estimating LD to assess tagging approach feasibility
The absence of a priori information on the pattern of LD across DYNCIHI  at  14q32.32, made it 
initially difficult to assess how powerful a tagging SNP strategy would be and the level of economy 
this approach could afford.  However,  as there  is a general relationship of inverse proportionality 
between LD and recombination distance (Huttley et al.,  1999), putative LD across DYNCIHI was 
estimated by considering recombination rates between markers flanking the gene.
102The recombination rate was estimated by comparison of genetic and physical maps for the region. 
Sequence  tagged  sites  (STSs)  flanking  DYNCIHI  were  identified  using  the  Genome  Database 
(http://www.gdb.org/gdb;  accessed November 2002) and two STS  loci, DNS  1051  and D14S293, 
were  found approximately 0.2Mb and 0.9Mb upstream and downstream, respectively.  Both  STS 
loci  had  physical  map  coordinates  on  the  NCBI  sequence  contig  Hsl4_10185  and  genetic  map 
coordinates on the G6n6thon chromosome  14 map,  which allowed a ratio (i.e. the recombination 
rate) to be calculated (Table 4.1).
D14S1051  NCBI contig Hs14_10185  5.2  Mb
G6n6thon chromosome 14  137  KosambicM
D14S293  NCBI  contig Hs14_10185  3.9  Mb
G6n6thon chromosome 14  133  KosambicM
Genetic / physical ratio  3.08  cM/Mb
Table 4.1  Marker information for sequence tagged sites flanking DYNC1H1
Physical map coordinates are given in Megabases (Mb) and genetic map coordinates given in Kosambi 
centiMorgans (cM).
The recombination rate was 3.08 cM/Mb, approximately twice the sex averaged recombination rate 
for chromosome  14  (1.36  cM/Mb)  and  almost  3  times  greater  than  genome-wide  sex  averaged 
recombination rate (1.13 cM/Mb) (Kong et al., 2002). The high recombination rate did not preclude 
however,  the  existence  of elevated  LD  at  shorter  distances  than  the  1.3Mb  physical  distance 
between the two STS markers - i.e. fine-scale LD (Reich et al., 2001a). Indeed, by considering the 
STS  marker  information  available  in  2006,  this  estimate  is  reduced  to  2.15  cM/Mb  (using 
DNS  1051 and DJ4S272 genetic positions from the Marshfield map; D14S272 is 0.17 Mb closer to 
DYNCIHI than D14S293). Without typing markers at a greater proximity to the gene and across the 
gene, it was difficult to accurately estimate the extent of LD across the region. Therefore, a SNP 
map of the region spanning the gene needed to be constructed.
4.2.4  Study power and estimating required sample size
Despite the absence of accurate LD estimates across the gene, power and sample size calculations 
were  conducted  using  the  genetic  power  calculator  of  Purcell,  Chemy  and  Sham 
(http://pngu.mgh.harvard.edu/~purcell/gpc) (Purcell et al., 2003). Calculations were performed with 
helpful advice from Professor David Goldstein and using the conventional power threshold  >80%. 
Without prior knowledge of LD across the gene, D' values between 0.8 and  1.0 were used which
*  STSs serve as landmarks on the physical map of the human genome, Each is a short DNA segment that 
occurs only once in the human genome and whose exact location and order of bases are known. Because each 
is unique, STS markers are helpful for chromosome placement of mapping and sequencing data from many 
different laboratories.
103related to samples sizes varying from 982 to 647 respectively, to achieve 80% power of detection 
(Figure 4.1).
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Figure 4.1  DYNC1H1 association study power and related sample size for varying D' values
Expected power was calculated by considering a causal variant under a multiplicative risk model, with 
genotypic relative risks of 2.0 for homozygotes and 1.41  for heterozygotes, and an allele frequency of 0.1. 
Alpha (type I error rate) was set to 0.05 and marker allele frequency was set at 0.1. Dashed grey lines indicate 
sample sizes with 80% power of detection.
4.3  Phase I - SNP discovery
4.3.1  In silico SNP ascertainment
Several  public  SNP  databases  were  used  to  identify  the  physical  locations  of  SNPs  across 
DYNCIHI,  to  construct  a  SNP  map.  The  primary  database  interrogated  was  dbSNP 
(www.ncbi.nlm.nih.gov/proiects/SNP/). a central repository for human and mouse SNP data held at 
the National Cancer for Biotechnology  Information (NCBI) as, dbSNP (Smigielski et al,  2000). 
Although by September 2000 dbSNP contained SNPs at a frequency of one SNP every 2.03kb, the 
number of SNPs  found in and around DYNCIHI  were  few and with little or no information on 
heterozygosity  or  validation  status.  A  second  database,  Human  Genome  Variation  Database 
(HGVBASE,  formerly HGBASE;  http://hgvbase.cgb.ki.se).  independent of dbSNP was also used 
(Brookes et al, 2000).
Compounding  the  paucity  of  SNP  information  was  the  absence  of  validation,  which  left  the 
possibility  that  potential  SNPs  could  be  errors  due  to  sequencing  artefacts,  the  presence  of 
paralogous sequences elsewhere in the genome or due to inaccurate laboratory assays.  Initially to 
overcome  the  problem  of verification,  overlapping  detection  of SNPs  by  multiple  independent 
databases was used to validate genuine polymorphisms. However this method proved impractical as 
only a small percentage of SNPs were seen in both databases and only 40% of final SNPs were seen 
in 3 databases. SNPs therefore had to be validated experimentally.
104Data on SNP MAF was also unavailable. The minimum acceptable SNP MAF was selected to be 
10%. Although commonly set at 5% (for later statistical chi-squared analysis to be valid), the MAF 
was set at a 10% threshold for the following reasons: (1) database SNPs with minor allele frequency 
annotation  ^10% are more likely to be genuine SNPs than artefacts, (2) to ensure that the study 
would have sufficient power to detect SNPs, even with a small discovery sample (3) to ensure that 
haplotypes later defined would be common enough to represent an ancestral state rather than more 
recent  “singletons”,  (4)  imposing  a  frequency  threshold  is  necessary  to  avoid  spuriously  high 
estimates of LD when allele frequencies are close to zero (Mateu et al., 2001). The impact of using 
a MAF >5% is discussed later in this chapter.
43.2  SNP validation and discovery
SNPs  identified  from  the  databases  were  validated  by  genotyping  in  a  discovery  sample  of 32 
chromosomes  from  16  unrelated  CEPH  individuals,  obtained  from  Dr.  Howard  M.  Cann  at  the 
Foundation Jean Dausset (Dausset et al.,  1990). Individuals from the CEPH reference families were 
chosen as their northern European ancestry is similar to that of the North American case and control 
samples which were to be tested  for association (discussed  later),  serving as a proxy for genetic 
variation  in  the  limited  North  American  samples.  Initially,  the  process  was  to  be  expedited  by 
genotyping  SNPs  which  altered  endonuclease  restriction  sites;  however these  were  found  to  be 
vanishingly rare, comprising less than 4% of the total number investigated.  SNPs were therefore, 
genotyped by automated dideoxy sequencing in both DNA strand directions. Primers were designed 
as described in Chapter 2.3.4 to maximise amplicon size, exploiting maximum sequence length to 
identify novel SNPs.
4.3.3  Minor allele frequencies
In  addition  to  validating  each  SNP,  resequencing  32  chromosomes  from  unrelated  individuals 
allowed  an  assessment  of MAF  for  each  SNP.  Invariant  loci,  or  where  SNP  MAF<10%,  were 
disregarded and instead a neighbouring SNP was chosen from the databases and validated until at 
least  one  SNP  approximately  every  10  kb  was  identified.  If no  neighbouring  SNPs  were  listed 
within the databases, SNPs were identified by resequencing sequential 500kb amplicons either side 
of the original SNP until a polymorphic site with MAF ^10% was found.
In total, 60 SNP loci were examined through resequencing approximately  16.7kb DNA:  36  SNPs 
were  found to be invariant when assayed in 32 chromosomes and a  further 8  SNPs were seen to 
have  MAF  below  the  threshold  value  (Table  4.2).  Additionally,  6  new  SNPs  were  identified
105(rs3742426*,  rs941792,  rsl0135238,  bpl83293+,  rsl 1849604  and  rsl 190618)  not  previously 
reported in any database. Anecdotally, fewer SNPs, and at lower frequencies, were seen in the 5’ 
region of the gene (between SNPs  1   and 44). Approximately  13kb of resequencing (75% of total) 
was undertaken in the region between SNPs  1   to 44, with only one novel SNP found. In contrast, 
3.7kb resequencing between SNPs 45 and 60 yielded 5 novel SNPs, suggesting possible reduced 
genetic diversity in the 5’ region of the gene compared to the 3’ region.
In total,  16 SNPs were identified with MAF ^10%, which were all unremarkable in their locations: 
8 SNPs were located within intronic sequence but not at splice junctions and 7 SNPs were outside 
the  transcribed  region.  A  single  SNP  (rsl 3749)  was  identified  within  coding  sequence  as  a 
synonymous change (Figure 4.2), located at the fully redundant third position of the 4360 threonine 
amino  acid  codon  (ACC),  and  therefore  did  not  alter  the  amino  (T4360T).  The  SNP  density, 
averaged across the gene, was approximately one SNP every 6.9kb, with the largest inter-SNP gap 
of 21 kb between rs2180510 and rs941793.
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Figure 4.2  SNP rs13749 electropherograms and the redundancy of the threonine codon
Right. A single synonymous T/C coding SNP rs13749 was identified. Left. The minor SNP allele was located 
at the fully redundant third position of the ACT threonine codon, so no corresponding coding change was seen.
*  rsl2895291 was merged into rs3742426 on dbSNP in May 2006
+  bp 183293 is not present in any database. The SNP ID is given by its position on the AL118558
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Alleles  Size (bp)  AA  AB
Frequency
1 rs2180511 27670 A/T 535 14 2 0 6.0
2 rs1678034 30289 A/C 566 14 2 0 6.3
3 rs2180513 61497 err 622 16 0 0 0
4 rsl 956297 74179 CfT 453 16 0 0 0
5 rs2474677 75613 err 360 16 0 0 0
6 rs2474678 75617 A/G 16 0 0 0
7 rs2448241 76261 err
500
16 0 0 0
8 rs2093025 76319 CfT 16 0 0 0
9 rs2474679 76323 err 16 0 0 0
10 rs1044838 76846 A/C 16 0 0 0
11 rs2281539 76858 CfT 510 16 0 0 0
12 rs2273434 76920 C/G 16 0 0 0
13 rs2273435 77049 A/G 15 1 0 3.1
14 rs2448240 77419 C/G 360 16 0 0 0
15 rs2448239 79006 A/G 520 16 0 0 0
16 rs1741151 81081 err 320 14 2 0 6.3
17 rs2403015 89054 A/G 591 16 0 0 0
18 rs1622886 89874 A/G 420 16 0 0 0
19 rs1741155 89892 A/G 12 3 1 15.6
20 rs2749911 90216 CfT
460
16 0 0 0
21 rs2720193 90225 A/G 12 4 0 12.5
22 rs2720194 90295 A/G 12 4 0 12.5
23 rs2448242 91338 A/G 440 16 0 0 0
24 rs2273438 107101 CfT 390 12 4 0 12.5
25 rs2273439 107195 CfT 380 16 0 0 0
26 rs2720218 109449 A/C 190 16 0 0 0
27 rs2749890 114824 A/G 200 12 4 0 12.5
28 rs2749894 119522 A/C 211 16 0 0 0
29 rs2720206 119787 CfT 260 16 0 0 0
30 rs2720213 126498 C/G 160 15 1 0 3.1
31 rs2251644 129341 A/G 280 12 4 0 12.5
32 rs2749896 132256 A/G
380
16 0 0 0
33 rs2749897 138855 A/G 16 0 0 0
34 rs2720197 139455 A/G 16 0 0 0
35 rs3742426* 147536 A/G 600 12 4 0 12.5
36 rs2180510 147694 A/G 12 4 0 12.5
37 rs2749899 150639 A/G 453 16 0 0 0
38 rs2749900 151540 C/G 365 16 0 0 0
39 rs2720198 151863 A/C 440 16 0 0 0
40 rs2403016 153341 err 359 16 0 0 0
41 rs2295445 157537 C/G 367 16 0 0 0
42 rs754598 160726 A/G 498 16 0 0 0
43 rs941632 163482 A/G 275 16 0 0 0
44 rs2093024 167571 A/C 530 16 0 0 0
45 rs941793 168955 CfT 260 12 4 1 17.6
46 rsl 190605 171447 C/G 420 16 0 0 0
47 rs1043455 172220 CfT 327 16 0 0 0
48 rs13749 175721 err 430 12 4 0 12.5
49 rs2273656 175929 A/C 16 0 0 0
50 rs941792* 176207 err
380
12 3 1 15.6
51 rsl 127284 176475 err 16 0 0 0
52 rs l004903 176509 A/G 12 3 1 15.6
53 rs l0135238 180364 err 530 12 4 1 17.6
54 r«1190610 180468 A/G 12 3 1 15.6
55 rs1190613 183028 err 440 12 4 1 17.6
56 bp183293*  t 183293 ATT 15 1 0 3.1
57 rs1190614 185042 A/T 570 13 3 0 9.4
58 rs11849604 185073 A/T 13 3 0 9.4
59 rs1203482 193407 err 360 16 0 0 0
60 rs l190618* 193460 C/G 12 4 1 17.6
Table 4.2  SNPs identified and validated in a discovery panel of 16 CEPH individuals
SNPs were initially identified from databases and genotyped by bi-directional resequencing in 16 unrelated 
CEPH individuals to validate their presence and determine minor allele frequency. Relative location of 
DYNC1H1 represented by the yellow box; SNPs within the yellow box are intergenic. *novel SNPs identified in 
2004, have since been added to dbSNP. t  rsl2895291  was merged into rs3742426 on dbSNP in May 2006. t  
bp183293 not present in any SNP database. SNP ID given by position on AL118558
1074.4  Genotyping validated SNPs
The  16  validated  SNPs were genotyped  in  32  mother,  father and child CEPH trios*,  to  identify 
haplotypes  and  construct  a  detailed  LD  map  across  the  region  (Figure  4.3).  Comprehensive 
genotype information was obtained by bidirectional dideoxy sequencing for all individuals using the 
same  primers/conditions  applied  to  the  discovery  panel  (full  genotyping  results  are  given  in 
Appendix  1), however, genotypes for rs3742426 and rs2180510 continually failed for the child in 
trio  6  (id: 34603).  These  SNPs  displayed  weak  PCR  products  and  their  sequencing  reactions 
continually  failed.  Both  of these  SNPs  reside  in  the  same  PCR  amplicon  and  therefore,  the 
genotyping failure may have been due to a polymorphism in the primer binding sequence which can 
reduce the affinity of a primer for the DNA template. However, as both parents were homozygous 
for  the  major allele  at  each  locus,  the  child’s  genotype  could  be  easily  inferred  and  therefore, 
genotyping this  SNP was not pursued (although this did not rule out a potential deletion  in this 
region).
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Figure 4.3  DYNC1H1 SNP map
A schematic of the DYNC1H1 genomic locus shown positioned 5’ to 3’, with dbSNP accession numbers and 
minor allele frequencies (in parentheses). Black boxes represent first and last exons.
There was good concordance between allele frequencies of the 32 chromosome validation panel and 
the full CEPH panel of 64 unrelated parents (Table 4.3), especially where MAF ^10% in the full 
panel. However, several SNPs were seen to decrease their MAF from 12.5% in the discovery panel 
to 7% in the LD panel. These SNPs were syntenic, occurring in the 5’ region of the gene whilst 
SNPs in the 3’  region of the gene maintained their MAF of approximately  18%. This may have 
been due to  a sampling anomaly whilst  randomly selecting  CEPH  individuals  for the discovery 
panel which may not have been representative of the full CEPH panel.
*  Trios were used to provide information on SNP phase and aid accurate haplotype inference
108SNP Frequency (%)
Number ID(rs) Position (bp) Alleles n»32 n=128
1 1741155 89892 A/q 15.6 13.2
2 2720193 90225 A/fl 12.5 7.0
3 2720194 90295 A/q 12.5 7.0
4 2273438 107101 T/c 12.5 7.0
5 2749890 114824 A/q 12.5 7.0
6 2251644 129341 A/q 12.5 7.0
7 3742426 147536 G/a 12.5 7.0
8 2180510 147694 G/a 12.5 7.0
9 941793 168955 A/q 17.6 17.2
10 13749 175721 T/c 12.5 14.8
11 941792 176207 G/a 15.6 16.4
12 1004903 176509 G/a 15.6 14
13 10135238 180364 T/c 17.6 18
14 1190610 180468 A/q 15.6 18
15 1190613 183028 A/q 17.6 17.2
16 1190618 193460 C/q 17.6 18
Table 4.3  SNP frequency comparison between 32 and 128 chromosome discovery panels
SNP ID refers to dbSNP identification numbers with rs- prefixs. Alleles are shown with the common allele in 
uppercase. SNP with frequencies in red changed significantly between panels.
4.4.1  Quality control - assessing genotyping accuracy
An  estimate of genotyping accuracy was  empirically determined,  to  identify assays  bias  and  to 
prevent errors affecting later association tests. This work was carried out with the help of Dr. Azlina 
Ahmad-Annuar.  SNPs  rs2251644  and rsl004903  were chosen  at  random and resequenced  in 40 
individuals, with the operator blind to all sample identifiers. A second operator coded the samples 
and when decoded,  the genotyping error rate was ~1%. This error rate demonstrated that a high 
fidelity of the genotyping assay was achieved.
4.4.2  Quality' control -  Mendelian inheritance and Hardy-Weinberg equilibrium
Genotype  data  was  prepared  for  analysis  using  the  tagging  SNP  selection  software  TaglT 
(Goldstein et al., 2003b) as described in Chapter 2.3.14. As an additional genotyping quality control 
measure and to ensure that no errors had been introduced during manual input of data, the “check 
matrix”  command  (‘checkM(M)’)  in  TaglT  was  used  to  identify  inconsistencies  in  Mendelian 
inheritance  within  trios.  A  single  case  of  non-Mendelian  transmission  was  seen  in  which  a 
heterozygous parent  (AC  genotype)  and homozygous  major parent (AA genotype)  resulted  in a 
homozygous minor child (CC genotype). Upon investigation of the original sequencing data, this
109was  found  to  be  due  to  a data  inputting error  and was  rectified.  The  data  were also  tested  for 
deviations from Hardy-Weinberg equilibrium using TaglT, a conventional practice in assessing the 
quality of genotype data.  Although there  are a  number of circumstances including mutation and 
demographic  changes  that  could  lead  to  the  perturbation  of  HWE,  deviations  from  HWE 
proportions  may also arise  from  genotyping  errors.  Non-significant  X 2   values  for all  16  loci  (X2  
<3.841,p<0.05; 1  d.f.), indicated consistency with HWE.
4.5  The haplotype structure of DYNCIHI
The  utility  of using  CEPH  trio  genotype  data  is  apparent  when  identifying  haplotypes  across 
DYNCIHI.  Although  a  number  of  frequently  occurring  haplotypes  were  visible  by  manual 
inspection  of  the  genotype  data,  TaglT  was  used  to  comprehensively  identify  transmitted 
haplotypes  from parent to child within each trio using the  ‘knownhap ’ function.  In this manner, 
TaglT  resolved  a  total  of 116  transmitted  haplotypes  from  a possible  128,  or 90% of the  total 
haplotypes possible.
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Table 4.4  The haplotype structure of DYNC1H1 in CEPH
a Haplotype designation
b Loci are arranged in the order snp1-snp16 (as in Table 4.3). A haplotype is reported if observed in resolved 
chromosomes or if EM frequency is  ^1% (1  = major allele; 2 = minor allele) 
c Frequencies and counts estimated from resolved parental chromosomes only 
d Frequencies and counts estimated by the EM algorithm for trio data
The  12 haplotypes not observed were attributable to ambiguous SNP phase in trios 9,  17 and 30; 
each  possessing  one  or  more  SNP  locus  heterozygous  in  all  three  trio  members (Figure  4.4).
Proceeding with the readily identifiable, transmitted haplotypes to discern  the pattern  of LD  across
110DYNCIHI would have omitted information from approximately 10% of the total genotyping dataset 
due to ambiguous phase, therefore the phase-ambiguous haplotypes needed to be identified.
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Figure 4.4  Phase-ambiguous SNPs in CEPH trios
In CEPH trio 9. both parents and child are heterozygous at ail loci except SNPs 11,12 and 16; SNP 4 is 
shown. In CEPH trio 17, both parents and child are heterozygous at SNP locus 16. In CEPH trio 30 both 
parents and child are heterozygous at SNP loci 13,14 and 16; SNP 13 is shown. Paternal SNP alleles are in 
black, maternal SNP alleles in red and the two possible alleles inherited by the children are shown. CEPH 
identification numbers are given above/below the pedigree symbols.
The  SNP/haplotype  ambiguity  was  resolved  by  applying  an  Expectation  Maximisation  (EM) 
algorithm  to  infer the  missing  haplotypes.  The  EM  algorithm,  first  proposed by Clark  in  1990, 
determines  resolved  haplotypes  from  individuals  with  no  haplotype  ambiguity  and  sequentially 
applies  these  to  phase-ambiguous  individuals,  to  resolve  their  haplotypes  (Clark,  1990).  The 
algorithm  uses  maximum  likelihood  estimates  of haplotype  frequencies  in  the  sample  using  an 
initial set of haplotype frequency estimates to calculate the conditional distribution for haplotype 
pairs  that  each  individual  carries  (the  Expectation  step).  The  initial  set of haplotype  frequencies 
were  restricted  to  those  phased  haplotypes  identified  from  the  CEPH  trios.  Based  on  these 
conditional distributions, haplotype  frequency estimates can be updated (Maximization- step) and 
the  algorithm  iterates  between  the  two  steps  until  the  haplotype  frequency  estimates  converge. 
Haplotypes  were  inferred  using the  EM  algorithm  implemented  within TaglT,  with  a  minimum 
frequency threshold of ^1%.
The EM analysis identified a total of 17 different haplotypes  ;>1% frequency,  15 of which were 
previously seen transmitted amongst the trios (Table 4.4). The  EM  estimated  frequencies agreed 
well  with  the  transmitted  haplotype  frequencies  and  both  data  sets  show  that  haplotype  A 
predominates,  present  at  approximately  75%  on  average.  Two  new  haplotypes  P  and  Q  were 
identified  through  the  EM  procedure,  although  these  were present  at  low  frequency (1%) and  a 
greater  number  of haplotypes  were  seen  at  3%  frequency,  which  most  likely  represent  those 
haplotypes that were previously unresolved.
IllInterestingly,  several  pairs  of haplotypes  were  seen  with  completely  mismatching  alleles  (i.e. 
nucleotides  differing  at  every  SNP  position  in  a  haplotype  pair)  which,  at  the  time  they  were 
identified,  had  not  previously  been reported  by  any other groups.  The  high  frequency  of these 
mismatching haplotype pairs: A+F, B+C and to a lesser extent J+M, seemed an odd occurrence and 
through  successive  discussions  with  colleagues  it  was  suggested  that  these  haplotypes  may 
represent a genetic signature of selection or population demography. These haplotypes have since 
been termed by Zhang and colleagues as “yin yang haplotypes” (Zhang et al.,  2003). Finally, the 
haplotype  data  provided  encouraging  anecdotal  evidence  for  linkage  disequilibrium  across  the 
region:  the A haplotype comprised approximately 75% of the total haplotype diversity, with the 
remaining 25% comprised of haplotypes at much lower frequencies many of which are variants of 
haplotype A.
4.6  Linkage disequilibrium patterns
The  empirical  assessment  of linkage  disequilibrium  across  the  gene  was  a  crucial  measure  to 
determine the magnitude of economy, if any, available in using tagging SNPs to represent variation 
across DYNCIHI and also in selecting the tSNPs.
The extent of LD across DYNCIHI was calculated by assessing the frequency of 2-locus haplotypes 
(i.e. pairwise comparisons) within the total pool of phased chromosomes and then calculating D ’  
and  t2   measures  from  these  values.  In  view  of the  haplotype  frequencies  discussed  above  and 
considering  how  the  D ’  measure  is  calculated  (D’  is  maximal  when  two  of the  four  possible 
haplotypes, in a two-locus situation for example, are absent - see D ’ derivation from Chapter  1) 
high D ' scores between the majority of pairwise SNP comparisons were predicted.
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Figure 4.5  Linkage disequilibrium  (O') betw een the 16 SN Ps spanning  DYNC1H1
112Assessing pairwise LD between the 16 SNPs across DYNC1H1 reveals two regions of elevated LD. SNP ID 
numbers arranged on the left from most 5’ (top) to the 3’ (bottom). Colour scale bar represents D' values from 
0 (white) to 1  (black).
Figure  4.5  provides  a  graphical  illustration  of pairwise  D’  between  the  16  DYNCIHI  SNPs 
calculated using TaglT and substantiated the high D' prediction. Average D’ across the gene was 
0.98 and although it is presented here as mainly a descriptive statistic, it supports the original power 
calculation made (where D'~l). D ’ also informs on recombination across the region, which appears 
to be absent except for at the 3’ most SNP.
As previously discussed, a more useful measure of LD for association studies is K.  Although r* is 
sensitive to marker allele frequencies it does provide a simple linear relationship to sample size, as 
the reciprocal of r* 2  (that is, "//) relates to the proportional increase in sample size required to obtain 
the  same  power as  testing  the  functional  variant  itself (Pritchard  et al.,  2001).  With  this  linear 
relationship in mind, a minimum working threshold of /  >0.85 was used, requiring an increase in 
sample size of M8% to have equivalent power of typing the causal SNP itself. Figure 4.6 provides a 
graphical  illustration of pairwise r2  values between the  16 DYNCIHI  SNPs.  The r2  data clearly 
show  two  defined  regions  of  elevated  LD:  the  first  region  bounded  by  SNPs  rs2720193  to 
rs3742426 and the second region by SNPs rs941793 to rsl 190613. Although the average LD across 
the gene was r*=0.61, within the two regions LD was rj2 =\ and ^=0.91 on average.
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Figure 4.6  Linkage disequilibrium (r2) between the 16 SNPs spanning DYNC1H1
Assessing pairwise LD between the 16 SNPs across DYNC1H1 reveals two regions of elevated LD. SNP ID 
numbers arranged on the left from most 5' (top) to the 3’ (bottom). Colour scale bar represents i2 values from 0 
(white) to 1  (black).
1134.7  Phase II - SNP tagging
Subsequent to identifying and phasing the CEPH DYNCIHI  haplotypes and calculating pairwise 
LD amongst the  16 SNPs, the investigation converged to identifying tagging SNPs. Tagging SNP 
selection  was  performed  using  Goldstein  and  Weale’s  TaglT  software.  Goldstein  and  Weale’s 
method uses a direct approach to identify a set of tSNPs that maintain high /  values with the other 
SNPs (thus tagging them), or that define a set of haplotypes that do so.  In general, there are two 
approaches  in  which a  reduced set  of tSNPs can be  selected to  represent  a  larger  set  of known 
SNPs. The first approach is based on capturing as much of the original haplotype diversity present 
in a set of known SNPs when condensed to a smaller set of tSNPs, as exemplified by Johnson and 
colleagues 2001 paper (Johnson et al., 2001). The second approach involves establishing a maximal 
association between the reduced tSNP set and the original set of known SNPs from which they are 
derived,  as  described  in  Chapman’s  2003  paper  (Chapman  et  al.,  2003).  Although  TaglT 
incorporates both of these approaches to  identify tSNP  sets,  the association based approach  is a 
more directly relevant approach to SNP prediction in the context of an association study (Weale et 
al., 2003), and therefore all tSNPs in this study were selected on association based performance.
The size of a tSNP set may be determined empirically or predefined.  Identifying tSNP  sets of a 
predefined size can be useful if tSNP set size is constrained by cost (for example, if a large number 
of  genes  are  being  tested  in  a  single  study);  however,  this  method  can  underpower  studies, 
especially in regions of low or variable LD. Instead, minimal tagging SNP sets can be chosen based 
on their ability to exceed a minimum performance threshold. In this circumstance the tSNP set size 
varies to provide a minimum level of association with the larger set of known SNPs from which the 
tSNP are derived.  In  selecting tSNPs to represent variation across DYNCIHI  the  latter approach 
was  used.  The  measure  used  to  evaluate  tSNP  performance  was  based  on  an  “average  locus” 
association criterion, termed by Goldstein and Weale as ‘haplotype r2\  which has been suggested to 
be  an  optimal  performance  measure  for  use  in  association  studies  (Weale  et  al.,  2003)  and  in 
estimating associations  between  SNPs  with  MAF  of 6%  or more  (Goldstein  pers.  comm.).  This 
measure reduces the performance of a tSNP set against all known SNPs, to a single value by taking 
the  weighted  average  (weighted  relative  to  the  minor  allele  frequency  at  each  locus)  of each 
individual performance measure. The minimal performance threshold used in selecting a tSNP set 
was set at ^’>0.85.
All tSNP sets of varying size H were identified for which the average locus performance criterion 
for each tSNP set was r  >0.85 against the 16 dynein SNPs (Figure 4.7).
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Figure 4.7  Average locus haplotype t* performance of all tSNP sets sizes from H= 1 to H= 5
H=1  there are 16 possible tSNP sets, H= 2 there are 120 possible tSNP sets, H=3 there are 560 possible tSNP 
sets, H=4 there are 1820 possible tSNP sets and H= 5 there are 4368 possible tSNP sets.
The  highest  performing tSNP sets  were  identified  for different tSNP  sizes.  As H increased,  the 
performance of all tSNP sets approached 1, as a greater number of variants were tagged. But which 
value of H is optimal? As Figure 4.8 illustrates, the minimum tSNP set size to achieve an average 
locus association  performance  threshold  K>0.85  is H-2.  The data  shown  in  Figure 4.8  are  the 
“best”, or highest scoring, tSNP sets taken from the average locus analysis, although more than one 
tSNP set of a given size can be “best”). There were diminishing returns in increasing H>4, with no 
appreciable increase in performance, and increasing tSNP set size beyond H=1 yields no additional 
benefit and therefore, in an average locus analysis, all haplotypes can be tagged by a minimum of 7 
tSNPs.  A two tSNP set exceeded the 0.85 threshold and also performed well  in representing the 
diversity of haplotypes available - capturing 94% of the total haplotype diversity.
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Figure 4.8  Performance of “best” tSNP sets of increasing size H chosen using two criteria
Performance measure is given as average locus haplotype diversity (blue) or average locus haplotype r2 (red).
The tSNPs that related to these optimal sets are shown in Figure 4.9. For tSNP sets H>2 there were 
multiple ‘best’ sets of equal performance. Using the TaglT ‘performU function, it was possible to 
decompose  the performance  of each best  tSNP  set,  to  show  performance  against  individual  loci 
(Figure 4.9). The optimal values were derived by combining the values for each tSNP against each 
locus and further combining the single locus scores to provide a single value for a tSNP set. The 
4 performU function displayed the combined haplotype r2 values for each locus and this manner it is 
possible to see which loci are influencing the result.
The results indicated that a solo tSNP set (SNP 5 or 9) was insufficient to capture the variation of 
the entire region - each single tSNP tags the region of elevated linkage disequilibrium it resides in. 
In concordance with the LD data and the haplotype data, the SNP tagging data confirmed that two 
“sub-regions” with different  properties exist across the gene  and that these regions could not  be 
summarised by a  single  tSNP.  A two tSNP  set  overcame this  problem  and although  a weighted 
average of the performance values was greater than 0.85, it was clear that there were four SNPs that 
could not be tagged well (SNPs  1,  10,  12 and  16). These SNPs could only be reliably tagged by 
increasing the tSNP set size to H= 3  and H=A and only if they themselves were chosen as tSNPs 
(i.e., they are tagging nothing but themselves).
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Figure 4.9  Optimal tSNP sets of size H and their performance against all loci
Left. Table gives ‘best" tSNP sets for varying set size H. SNPs 1   to 16 are rs1741155, rs2720193, rs2720194, 
rs2273438, rs2749890, rs2251644, rs3742426, rs2180510, rs941793, rs13749, rs941792, rs1004903, 
rs10135238, rsl 190610, rsl 190613 and rsl 190618 respectively. Right. Performance of “best" tSNP sets for 
each locus. All performance tested using association criterion 5. Broken grey line represents 0.85 performance 
threshold.
4.7.1  Assessing tSN Ps -  “SNP-dropping”
Of paramount  importance  in  selecting  tagging  SNPs  is  the  performance  of a chosen  tag  set to 
capture unknown variation. This was tested using the TaglT SNP-dropping routine “excludes”, to 
sequentially drop each SNP from the full SNP set, to simulate an “unknown” polymorphism, and
117assess the performance of tSNPs selected from the remaining reduced SNP set to tag the dropped 
SNP.  The SNP-dropping routine was carried out  for varying tSNP set sizes (H) and single-locus 
performance  criteria  values  were  returned  for  each  dropped  SNP  (Figure  4.10).  As  shown 
previously, more than one tSNP set was defined as equally “best” for increasing values of H and in 
these circumstances the single-locus performance criteria values returned were averaged over all 
“best” tSNP sets.
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Figure 4.10  SNP dropping performance for “best” tSNP sets of varying size
Performance relates to average single locus performance criterion 5.
Very  little  difference  was  seen  in  performance  with  increasing  H  indicating  diminishing 
performance returns (Figure 4.10). The procedure confirmed the difficulty in tagging SNP  16, and 
to a lesser extent, SNP 10 and 12. When SNP 16 was dropped, no tag set chosen from the remaining 
15  SNPs  was  able act as a proxy,  indicating that  the only method to  represent  SNP  16  and  its 
associated variation would be to include SNP 16 as a tagging SNP itself. But was it imperative that 
this SNP and its associated variation be tagged? The position of SNP 16, approximately 15kb from 
the last exon of DYNCIHI, and the absence of appreciable LD with SNP  15 (which is only 4.5kb 
from exon 78) suggested that it probably did not tag any functional variants in the 3’UTR and so, 
tagging this SNP was not a priority.
Taken  together,  these  analyses  suggested  that  a  two  tSNP  set  could  provide  the  optimal 
performance. It was unlikely that any appreciable gain would have been seen in adding extra tSNPs 
to  this  set,  apart  from  tagging  low  frequency  clades  of the  haplotype  genealogy,  however  the 
occurrence of a functional variant in a low frequency clade cannot be ruled out. Of the 14 possible 
two tSNP combinations shown in Figure 4.9, tSNPs 6 (rs2251644) and 9 (rs941793) were chosen to 
genotype in cases and controls. As all 14 tSNP sets performed equally well, the only discriminating 
criteria was the ease of genotyping - both rs2251644 and rs941793 modify restriction endonuclease 
recognition sequences and therefore these SNPs were pursued.
1184.7.2  Restriction endonuclease assays for rs2251644 and rs941793
The major allele of tSNP rs2251644 was  found to destroy an Nsil endonuclease recognition site 
within the 270bp PCR amplicon originally used for genotyping in the CEPH trios, and the minor 
allele of tSNP  rs941793  created a SacI  recognition  sequence within  its the  300bp amplicon.  To 
control  for  partial  and  complete  digestion  failures,  additional  invariant  restriction  endonuclease 
recognition sites were investigated as internal controls. These internal control endonucleases were 
chosen  on  the  basis  that  double  digestions  could  be  performed  under  identical  conditions  (at 
identical temperatures and buffers) and that the cleavage products can be easily resolved on 2.5% 
agarose  gels.  No  suitable  restriction  endonuclease  was  identified  as  an  internal  control  for 
rs2251644 cleavage, however, Nhel was found to cleave at a site  lOObp from SacI as an internal 
control for rs941793 (Figure 4.11).
All  tSNP  genotyping and restriction endonuclease cleavage optimisations were performed at the 
Cecil  B.  Day  Laboratory  for Neuromuscular  Research,  Massachusetts  General  Hospital,  Boston 
(USA) with the help of Dr.  Azlina Ahmad-Annuar.  Non-specific amplification of the rs2251644 
SNP  PCR product  was sporadically seen despite  identical  primer sequences being used to those 
used for genotyping of CEPH trios, which had previously worked well in London. Inconsistency of 
the rs2251644 PCR product may have been due to differences in the reagents and thermalcyclers 
used between the two laboratories and dictated the design of new primers for genotyping the tSNP. 
The new primers (rs2251644CBDay, shown in Appendix 2 Primer Table) provided a repeatable and 
robust PCR product, approximately 392bp in length.
Due to the absence of an internal control for tSNP rs2251644 and a change of genotyping reagents, 
protocol and location from those previously used, the restriction endonuclease assays were checked 
for genotyping fidelity. Genotypes of 96 randomly selected control individuals (from a panel later 
used in the sporadic ALS association study) for both tSNPs, were determined by double digest and 
sequencing on a Beckman Coulter Genetic Analysis system (Figure 4.11). The operator was blinded 
to  all  sample  identifiers  to  ensure  impartiality.  Genotypes  from  both  assays  were  compared  for 
consistency and  acceptable error rates of approximately  1%  were  seen  (<1%  for rs2251644  and 
1.09% for rs941793).
*  A double digest is the cleavage of a single DNA moiety by two restriction endonucleases
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Figure 4.11  Restriction digests for tSNPs rs2251644 and rs941793
Top. Table summarising tSNP restriction endonuclease properties and expected product sizes. No internal 
control was identified for rs2251644. Fragment sizes are given in base pairs after complete digestion of AA 
(major allele homozygotes), Aa (heterozygotes) and aa (minor allele homozygotes) by the respective enzymes. 
Middle. rs2251644 PCR amplicon schematic, gel electrophoresis results and sequence verification. Bottom. 
rs941793 PCR amplicon schematic, gel electrophoresis results and sequence verification.
1204.8  Phase III - Testing in sporadic ALS cases and controls
4.8.1  Association study samples
Sporadic ALS case samples were generously provided by R.H.  Brown at Massachusetts General 
Hospital or collaborators from various academic and clinical institutions across North America. All 
sporadic  ALS  patient  samples  were  obtained  with  accompanying  signed  consent.  Patients  were 
diagnosed by El Escorial criteria and had not been screened for SOD1 mutations. The patient cohort 
comprised of 134 females and 147 males with an average age at diagnosis of 46 years (range 24 to 
79  years).  34% of patients  were diagnosed with early onset  in the  lower extremities,  35% with 
upper onset,  30% with bulbar onset and site of onset in the remaining 2% was unknown.  As all 
samples were obtained retrospectively, limited phenotypic information was available.
4.8.2  Tagging SNP rs2251644 and rs941973 genoty ping in cases and controls
With the endonuclease assay functioning well, the DYNCIHI tSNPs were genotyped in 281  North 
American sporadic ALS cases and 225 age matched controls (Table 4.5).
«—  w .   j s r s a -   .a .
rs2251644
rs941793
rs10135238
rs1190610
AA 171 173.4
SALS GA 53 48.3
GG 1 3.4
AA 202 202.4
control GA 60 59.3
GG 4 4.4
AA 141 140.8
SALS GA 94 94.4
GG 16 15.8
AA 120 126.9
control GA 98 84.1
GG 7 13.9
TT 69 74.3
control TC 54 43.4
CC 1 6.3
AA 70 75.3
control GA 54 43.5
GG 1 6.3
A = 0.88  x2~ 2.15;
G = 0.12  p=0.357  x2= 1  40
A = 0.87  x2= 0.04;  ^ 0 76
G = 0.13  p= 0.850
A = 0.75  x2=0004;
G = 0.25  p= 0.100  x -  3.20
A = 0.75  x2=6.12;
G = 0.25  p= 0.01
T = 0.77  x2= 7.48;
C = 0.23  p= 0.05
A = 0.78  x2= 7.36;
G = 0.22  p= 0.05
p= 0.93
Table 4.5  G enotype frequencies of tSN Ps rs2251644 and  rs941793 in sporadic ALS c a se s 
and  m atched controls
Observed and expected tSNP genotype frequencies are shown for sporadic ALS (dark grey panels) and 
controls (light grey panels). No significant differences were seen in genotype or allele frequencies between 
cases and controls. Deviation from Hardy-Weinberg equilibrium was seen based on x2 distribution at tSNP 
rs941793 in the controls and at two additional SNP loci rsl 0135238 and rsl 190610 (cream panels).
1214.8.2.1  Association study genotyping accuracy
The genotype data was tested for deviations from Hardy-Weinberg proportions using the software 
HWSIM (http://krunch.med.vale.edu/hwsim) to assure the quality of the data and prevent errors or 
cryptic  genetic  factors  leading  to  a  spurious  association.  HWSIM  calculated  expected  genotype 
frequencies  and  performed a  Pearson j^-test  for accordance between  the observed  and expected 
genotypes. As x2-tests are a poor approximation when one or more genotype class has a value less 
than 5, HWSIM was used to implement a Monte-Carlo permutation test with  10,000 iterations for 
rs2251644 case and control data. A two-tailed test was used (obtained by counting how many times, 
across  iterations,  the original data and all  other distributions that are more deviant  from Hardy- 
Weinberg were observed) which, compared to a one-tailed test, did not require a judgement to be 
made  on  whether  greater  or  fewer  heterozygotes  are  to  be  expected.  Two-tailed  values  for 
rs2251644 and rs941793, in cases were />=0.3574 p=1.000. All other genotypes were tested using 
HWSIM based on the x2  distribution and were seen to be in HWE (i.e. ^<3.84, with  1   degree of 
freedom; d.f.) except for rs941793  in the control panel (p=0.01), which showed an excess of GA 
heterozygotes and deficit of GG homozygotes. The relevance of which is discussed further below.
4.8.2.2  Hardy-Weinberg disequilibrium in control samples
There  are  several  possible  explanations  to  account  for the  deviation of rs941793  from  HWE  in 
control  samples. The first could have been due to a poorly functioning genotyping assay.  As the 
SacI  restriction  endonuclease  assay  for  rs941793  cleaves  the  minor  (G)  allele,  it  was  initially 
thought that the deficit of GG homozygotes could be due to suboptimal or incomplete digestion of 
PCR products. However, on closer inspection of the agarose gel images of the cleavage products, 
the  internal  control  enzyme  had  cleaved  correctly.  In  addition,  due  to  the  nature  of this  assay, 
suboptimal/incomplete  digestion  of  the  PCR  products  would  have  resulted  in  a  reduction  of 
heterozygotes  rather  than  an  excess,  which  is  contrary  to  the  observed  data.  Alternatively  a 
polymorphism  within  the  rs941793  primer  binding  region,  could  have  caused  the  biased 
amplification of the major allele, although this is unlikely as both the case panel and the discovery 
CEPH  panel would be similarly affected.  In addition, no polymorphisms in the rs941793  primer 
biding regions have been identified in any SNP database to date.
As a number of 2 tSNP sets were identified as “best”, a number of additional SNPs were available 
to  replace  rs941793.  Two  such  SNPs  were  rslOl35238  and  rsl 190610,  present  on  the  same 
amplicon.  These  were  both  genotyped  in  the  control  cohort  by  sequencing  using  the  Beckman 
Coulter Sequencer - this deliberate move to use a different genotyping platform was to avoid any 
assay-related errors that may have lead to the deviation from HWE (and it allows both SNPs to be 
genotyped simultaneously). Both SNPs were found to deviate significantly (p=0.01) from the chi-
122squared  distribution,  however,  simulated  /7-values  showed  that  the  results  were  marginally 
significant Monte-Carlo p-values rsl0135238 /?=0.0495 and rsl 190610 p=0.0466. Analysis of SNP 
rs941793,  using  Monte-Carlo permutation  tests  reduces  the  significance  of deviation  to p=0.07, 
suggesting that based on the genotypes seen, the probability of obtaining equally deviant data sets 
with  a  paucity  of heterozygotes  is  highly  likely.  Taken  together,  these  SNPs  show  a  trend  to 
significance which is not entirely unexpected,  given the high LD between rs941793,  rslOl35238 
and rsl 190610 and suggests that the result may be a genuine property of the control cohort and not 
an assay-related error.
4.8.23  A sampling bias?
To identify if the HWE deviation was due to an intrinsic property of the control cohort generated 
through a sampling bias,  the details of all control  samples were reviewed with Diane McKenna- 
Yasek, coordinator of the Day Lab DNA collection. Samples from the control panel were checked 
to  identify  related  individuals,  which  could  result  in  a  skewing  of allele  frequencies  by  over­
representing  one  genotype  compared  to  another.  The  review  confirmed  that  the  majority  of the 
cohort was comprised of spousal controls, precluding relatedness between the individuals.
4.8.2.4  Hardy-Weinberg equilibrium at genes independent of DYNCIHI
Several  different  factors  can  lead  to  perturbations  of  HWE,  such  as  demographic  processes, 
selection and genotyping error. Although demographic processes, such as population admixture, can 
lead  to  deviations  in  HWE,  these  effects  are  observed  genome-wide.  Could  the  deviation  from 
HWE seen in the control samples be due to a demographic or sampling error? This question was 
answered  by  assaying  for deviations  from  HWE  at  sites  independent  of DYNCIHI.  Data  were 
available from two additional studies which used the same control panel to that used in the heavy 
chain study: 8 SNPs from a study of the cytoplasmic dynein intermediate chain 1   (DYNClIl) gene 
on chromosome  7  (Azlina Ahmad-Annuar,  pers.  comm.) and 3  SNPs  in the vascular endothelial 
growth factor (VEGF) gene on chromosome 6 (Carsten Russ, pers. comm.) were all in HWE (Table 
4.6). This suggests that the HWE perturbations seen at DYNCIHI may be a locus-specific artefact 
in the controls  rather than genome-wide effect due to demographic processes.  Genotyping errors 
may also result in significant deviations from HWE and although the majority of HWE deviations 
are due to problematic and non-specific assays, there remain a number of instances where no root 
cause for genotype error is detectable (Hosking et al., 2004).
4.8.3  A comparison of tSNP genotype frequencies between cases and controls
Despite  the  deviation  from  HWE,  genotypes  of the  two  tSNPs  were  analysed  for  significant 
differences between cases and controls, using the software. The null hypothesis was that there was
123no significant difference between the two samples and this was tested using a Fisher’s exact test of 
the tSNP genotypes and x^-test of the tSNP allele  frequencies. The tSNPs showed no significant 
differences in genotype proportions between sporadic ALS cases and age matched controls (Table 
4.5).
124tSNP ID Gene Genotype count Allele u m r n w c
Observed  Expected frequency analysis
^   IU  O.UO  A  —  A 17  2  r\ * 7-7
rs940424  DYNC1I1  AT  51  54.84  X  «  1
I  = U.oo  p—  0.59
rs2690289  DYNC1I1
AA 10 8.08
AT 51 54.84
TT 95 93.08
AA 46 50.94
AG 88 78.11
GG 25 29.94
A = 0.59  x*= 2.55;
G = 0.41  p=0.21
AA 63 58.63
AG 76 84.75
GG 35 30.63
AA  bo  ob.bo  a  —  n  cq   2  4  o c
rs3129314  DYNC1I1  AG  76  84.75  £  “  X
G = 0.42  p=0.30
rs1488513  DYNC1I1
rs1685818  DYNC1I1
AA 32 32.60
AG 80 78.79
GG 47 47.60
A = 0.48  x2= 0.04
G = 0.52  p= 0.89
GG 28 29.10
GT 83 80.80
TT 55 56.10
G = 0.42  X2 = 0 .1 3
T = 0.58  p= 0.77
AA 40 45.38
rs81018 DYNC1I1 AG 85 74.25
GG 25 30.37
AA 62 59.01
rs720780 DYNC1I1 AG 61 66.98
GG 22 19.01
GG 9 7.21
rs2299282 DYNC1I1 GT 51 54.57
TT 105 103.21
CC 13 15.02
rs6966540 DYNC1I1 CT 61 56.96
TT 52 54.02
CC 45 44.9
2578 VEGF CA 104 105.3
AA 63 61.8
GG 81 78.9
1154 VEGF GA 98 100.9
AA 33 32.2
GG 103 100.9
634 VEGF GC 90 90.7
CC 19 20.4
A = 0 .4 6  
G = 0 .5 4
X2= 3 .1 4
p= 0 .1 6
A = 0 .6 5  
G = 0 .3 5
X2= 1 .1 6  
p =  0 .4 5
G = 0.21 
T = 0 .7 9
X2= 0 .7 1  
p=  0 .5 9
C = 0 .3 7  
T = 0 .6 3
X2=  0 .6 3  
p =  0 .4 9
C = 0.46 
A = 0.54
X2= 0.0292
p= 0.86
G = 0.61 
A = 0.25
X2= 0.1380 
p=0.71
G = 0.69 
C = 0.31
X2= 0.0109; 
p=0.92
Table 4.6  DYNC1I1 and  VEGF control gen otyp es in  Hardy-W einberg equilibrium
SNPs 2578,  1154 and 634 are VEGF promoter polymorphisms
4.8.4  Comparison of tSNP haplotypes between cases and controls
As  the  tSNPs  were  originally  selected  based  on  their  individual  tagging  performance  and  as 
haplotypes, two marker haplotype frequencies were next compared between cases and controls. The 
software FASTEHPLUS (Zhao et al., 2002) was used to perform the haplotype association analysis 
based on the case control genotype data. FASTEHPLUS was used to estimate two locus haplotype 
frequencies  from  the entirety of the genotype  data  and  haplotypes  were then compared  between 
cases  and  controls.  From  the  total  dataset  of 472  individuals,  64  records  were discarded due  to 
missing data.
125tSNP haplotype Frequency (%)
X2 test
rs2251644  rs941793 C ases controls
A  A 0.75 0.74 "X- 0.32
A  G 0.13 0.12
p- 0.956
G  A 0.09 0.00
G  G 0.03 0.13
Table 4.7  DYNC1H1 tSNP haplotype frequ en cies in  sporadic ALS c a se s and  m atched 
controls
Two-marker haplotype frequencies calculated by FASTEHPLUS based on 408 unrelated 
individuals. No significant association was seen based on a x  test-
Based on comparing the two-marker haplotype  frequencies  in  sporadic  ALS  cases and matched 
controls a heterogeneity statistic is outputted based on a ^  distribution (x2= 0.32; p= 0.956). Taken 
together, the individual tSNP loci, rs225l644 and rs941793 and their two-marker haplotypes show 
no significant association with sporadic ALS (Table 4.7).
4.9  Evolutionary analysis of the DYNC1HI locus
Despite the absence of association between DYNC1H1 variants and SALS, the pattern of variation, 
more specifically the apparent reduction in diversity at the sequence level, was interesting and it 
was thought that analysis of this characteristic might hold potential clues as to the genes’ role in 
ALS. To identify differences in genetic diversity and test for selection at DYNC1H1, the  16 SNP 
loci  were  genotyped  in  additional  Japanese  and  Cameroonian  populations.  However,  since  this 
study began it has been shown that the hierarchal  sampling method commonly used to ascertain 
SNPs, and the exportation of these SNPs for investigation in other populations, can introduce bias 
to the data which can distort tests of genetic diversity and selection (Akey et al., 2003; Weiss et al,
2002).  Due  to  this  SNP  ascertainment  bias,  we  were  unable  to  exploit  many  of the  indices 
commonly used to infer selection or deviations  from neutrality.  Many of the properties of these 
three populations presented here are affected by ascertainment bias and therefore they are provided 
as descriptive.
4.9.1  SNP ascertainment bias and impact on measurements of selection
To date, the most common strategy for discovering SNPs has been by full resequencing of a small 
number of samples,  followed by targeted genotyping of these discovered SNPs in larger clinical 
samples. The initial appeal of this strategy is obvious - it makes sound economic sense - but it has 
since been shown to introduce bias which can confound subsequently population genetic analyses. 
The  problem  of  this  ascertainment  bias  has  affected  almost  every  large-scale  polymorphism 
discovery project to some extent, including The SNP Consortium and HapMap projects (Clark et
126al.,  2005) and affects the DYNC1H1  study too. Ascertainment bias results from the fact that SNP 
discovery panels are often small, so that the probability that a SNP is identified in this sample, and 
later  genotyped  in  a  larger  sample,  is  a  function  of the  allele  frequency  (the  probability  of 
witnessing a rare allele is the same as its frequency). This conditional sampling of genetic variation 
imposes a bias, in that rare variants are likely to be missed in the larger sample. This frequency- 
specific distortion in SNP discovery consequently means that the SNP frequency spectrum obtained 
from a two-tier sampling will be different from that obtained under complete sampling (for example, 
by  resequencing  the  entire  study  sample).  As  a  result, statistical  attributes  that  rely  on  the  site 
frequency spectrum will be affected.
4.9.2  DYNC1H1 chimpanzee genotyping
Before further analysis was undertaken, the ancestral allelic states of the  16 DYNCIHI  SNP loci 
were  assessed.  Knowing  the  ancestral  status  of  human  polymorphisms  can  provide  valuable 
evidence of evolutionary forces acting on the region. The 16 loci were genotyped, in 8 chimpanzees 
{Pan  troglodytes)  permitting  alleles  with  MAF>6.25%  be  identified.  DNA  was  extracted  from 
chimpanzee  blood  (provided  by  the  Institute  of Zoology,  London  Zoo,  Regents  Park,  UK)  and 
genotyping conducted by bidirectional resequencing using identical primers and cycling conditions 
as those previously used on human samples.
SNP number
1 2 3 $ 6  7 8 9  10  11  12  13  14  15  16
Chimpanzee ■n ■■KBB
Human m Hn ■■KB
Table 4.8  A ncestral chim panzee and  com m on  hum an  DYNC1H1 haplotypes
Ancestral alleles are shown in red and derived alleles in white. SNPs are indicated by position 5’ to 3’ along the 
gene
In  the  chimpanzee,  all  loci  corresponding  to  the  human  SNPs  were  either  monomorphic  or 
polymorphic  at  an  undetectable  frequency  (MAF<6.25%)  in  this  small  sample.  There  was 
concordance between the ancestral chimpanzee and the common human SNP allele at only 9 loci 
(Table 4.8). There is a direct relationship of a derived* allele with age (Kimura et al.,  1973) and it 
has been shown that (generally) for major SNP alleles with frequencies greater-than 80%, the major 
allele usually represents the ancestral allelic state (Hacia et al.,  1999). This implies there should be 
a preponderance of DYNCIHI major SNP alleles identical to the chimpanzee alleles, as they are all 
present in the CEPH at frequencies »80%  - however there is concordance between the two species
*  A derived allele is the term given to a new allele produced by mutation
127at only 9 of the  16 loci. Moreover, the ancestral chimpanzee haplotype is completely absent from 
the CEPH haplotype pool.
These relationships between allele frequencies and their age are generally true under conditions of 
neutrality. So, does this evidence suggest that neutrality may have been perturbed at this locus? An 
excess of high-frequency-derived mutations can be a signature of positive selection, or of genetic 
hitchhiking* with linked alleles driven rapidly to fixation (Smith et al,  1974). However it may be a 
pronounced  feature  of a  population  bottleneck,  so  to  discriminate  between  the  two,  additional 
populations could be useful.
4.9  3  Genetic variation of DYNCIHI in additional populations
To determine if the pattern of variation seen at the DYNCIHI locus in the European-derived CEPH 
samples was confined to northern Europe or common across populations, the  16 DYNCIHI  SNPs 
were  genotyped in 48  unrelated  individuals  from east  Asia (Japan) and 49  unrelated  individuals 
from West Africa, namely Bantu speaking Cameroonians. These samples were obtained from the 
laboratory of Professor David Goldstein, with full and appropriate consent for research. With the 
exception of SNP  16 in the Cameroonian samples (x^ 10.8717; /KO.OOl), all SNPs were in HWE. 
There was no obvious reason why SNP 16 was not in HWE.
4.9.3.1  Allele frequency comparisons
Comparison  of SNP  frequencies,  standardised  by  the  derived  CEPH  allele,  in  each  population, 
showed a clear reduction in allele frequency in the northern European-derived samples as compared 
to the other two populations (Figure 4.12).
Average gene diversity or expected allelic heterozygosity (//), which assesses the genetic diversity 
in a population and may be characteristically altered by natural selection, was calculated under the 
assumptions  of HWE  for each population,  using Nei’s  measure of heterozygosity.  Generally the 
average gene diversity was expected to be higher in the West African population than the Japanese 
or CEPH, as African populations are more diverse. Average gene diversity (H ± S.E.M) across the 
DYNCIHI  locus  was:  northern  Europeans  0.211 ±0.019,  Japanese  0.317±0.016  and  Cameroon 
0.440±0.011. A clear gradient in allelic heterozygosity was observed from the northern Europeans, 
to the Cameroonians. This result is not unexpected as African populations generally display greater 
diversity and populations which have later migrated out of Africa possess a part of that diversity.
*  Genetic hitchhiking occurs when alleles linked to a selected mutation, which is driven rapidly to fixation, are 
also dragged along to high frequency
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Figure 4.12  A comparison of DYNC1H1 SNP allele frequencies between 3 populations
Minor allele frequencies are shown, standardized by allelic state in northern European, Japanese and 
Cameroonian populations.
4.9.3.2  Genetic differentiation
Interpopulation  differences  in  gene  diversity  can  be  attributed  to  genetic  differentiation  due  to 
causes including natural  selection, population sub-division and admixture. To assess the possible 
role of selection in shaping population differentiation, Wright’s FS t is often calculated. This statistic 
allows  allelic  diversity  of sub-populations  to  be  measured  against  a  global  average  to  quantify 
genetic differentiation (varies between 0 and  1   with  1   being complete genetic differentiation).  A 
modification  of Wright’s  measure  is  Weir’s  weighted  F St.  which  is  used  here  to calculate  total 
(global)  and population  pairwise comparisons of F St  at  each  locus (Figure 4.13).  Global  F St  (±  
SEM) averaged across the entire locus is 0.25±0.04 and pairwise comparisons of northern European 
against  Japanese  is  0.04±0.05;  against  Cameroonian  is  0.37±0.056  and  Japanese  against 
Cameroonian is 0.29±0.065.
129N. European vs Japanese
Global
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Figure 4.13  Global and pairwise FSt comparisons
Weir’s FST is shown for global and population comparisons at each SNP locus. The region bounded by SNPs 
rs2720193 and rs2180510 demonstrated less differentiation than other SNPs tested.
4.9.4  Haplotype and LD comparisons between three worldwide populations
The  software  PLEM  was  used to  infer haplotypes  for the  unrelated  Cameroonian  and  Japanese 
samples. Inferring haplotypes using unrelated samples can occasionally lead to spurious results and 
therefore haplotype frequencies were verified by reseeding the EM algorithm applied within PLEM 
with varying integers and also by using a second EM based program, SNPHAP, for conformation. 
No  appreciable  differences  were  seen  in the  results  from  varied  seeds and  either program.  EM 
inference  of  Japanese  haplotypes  yields  9  haplotypes  >1%  frequency,  suggesting  a  simple 
haplotypic  structure  of DYNCIHI.  In  contrast  with  both  the  northern  European  and  Japanese 
haplotypes,  there  are  28  haplotypes  exceeding  an  estimated population  frequency  of  1%  in  the 
Cameroonian  samples.  Generally,  greater  allelic  and  haplotypic  diversity  was  seen  in  the 
Cameroonian population compared to the Japanese and European-derived, which is consistent with
130other reports (Stephens et al.,  2001).  Haplotype A, the most frequent  haplotype in the CEPH at 
74.2%, was found to be the highest frequency haplotype in all 3 populations:  with frequencies of 
67.9% and 21.4% in the Japanese and Cameroonians respectively (Table 4.9). Haplotype C is also 
common to all three populations and conversely to haplotype A which increases in frequency from 
the Cameroonian to northern European population, haplotype C is decreases in frequency.
A Ewens-Watterson test (F) was used to evaluate the observed haplotype frequency-distribution for 
goodness of fit with that expected under neutrality using the infinite alleles model of mutation (i.e. a 
model  with  no  selection,  where  all  mutations  are  selectively  neutral)  (Ewens,  1972;  Watterson, 
1978;  Watterson,  1986). For the northern European population only, F is positive and significant 
(p=0.976)  at  the  0.05  level  in  this  two-tailed  test,  implying  that  the  haplotype  distribution  is 
inconsistent with neutral conditions devoid of selection.
131Haplotypes cropped at 1%
SNP Identity
SNP location
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Hapkltype □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □
Hapiotyf 
CEPH  A
Japanese
West
African
Frequency
0 742
0 023
0 023
0 023
0016
0.679
0 026
0.026
0013
0013
0013
0.214 
0.108 
0.086 
0.076 
0.065 
0.061 
0 049 
0.037 
0.031 
0.025 
0.020 
0.015 
0.015 
0.012 
0.011 
0.011 
0.010 
0.010 
0010 
0010 
0.010 
0010 
0.010 
0.010 
0.010 
0.010 
0.010 
0.010
Table 4.9  Northern European, Japanese, Cameroonian and chimpanzee DYNC1H1 
haplotypes
Haplotypes >2% frequency shown with corresponding single letter identifiers. SNPs coded as major allele (-) 
and minor allele (+). Major SNP allele shown as uppercase.
132The general pattern of pairwise LD in the Cameroonians was similar to that seen in the northern 
Europeans, comprising two regions of elevated LD between SNPs 2 and 8, and between 10 and 15. 
However, the pairwise LD values were the lowest of all three populations, reflected by a greater rate 
of LD decay with physical distance compared to the northern Europeans and Japanese. LD in the 
Japanese was a single elevated region delimited by SNPs 1  and 16 and LD was seen to decay at the 
lowest rate over distance.
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Figure 4.14  Linkage disequilibrium decay across DYNC1H1 in 3 populations
Plotting pairwise a2 values amongst the 16 SNPs spanning DYNC1H1 in N. European, Japanese and 
Cameroonian populations against distance between each comparison illustrates three very different patterns of 
LD decay.
Pairwise haplotypic Fst between populations was also calculated and FSt comparisons were highly 
significant for both the northern Europeans and the Japanese against the Cameroonians (Fsr=0.228, 
p«0.000001  and  F^O.1375, /K<0.000001)  and just  significant  for the CEPH  versus Japanese 
(F57=0.0348,/K0.02).
133These results  showed a general reducing cline  in  average  gene diversity at DYNCIHI  from  the 
northern European to the Cameroonians.  This reduction in variation was further illustrated by an 
elevated global Fst value for all three populations combined, compared to the empirical genome- 
wide average of 0.123 (Akey et al.,  2002), largely due to the extent of differentiation between the 
northern Europeans and Japanese against the Cameroonians.
4.9.5  Natural selection at DYNCIHI?
The haplotype results show an approximate cline in frequency of haplotype A from West Africa, to 
East Asia and to northern Europe (21%, 68% and 74%). Although this may be due to population 
demography  which  can  confound  the  genetic  signals  of selection,  the  concomitant  decrease  in 
frequency of haplotype C in these populations (11%, 15% and 2%) suggests mechanisms other than 
demography  may  operate.  We  asked  if the  increase  in  frequency  of the  common  haplotypes, 
reduction in diversity and to some extent genetic differentiation, could be signals of selection at this 
locus  rather than  demographic  or  neutral  processes.  Positive  selection  for  an  allele  can  reduce 
genetic diversity, elevate LD and lower the rate of LD decay with physical distance (Bamshad et 
al.,  2003  see  for  review).  The  elevated  LD  levels  in  the  northern  Europeans  compared  to  the 
Cameroonians may be a feature of selection rather than demography, although due to confounding 
by ascertainment bias, our results are unable to conclusively differentiate between the two.
4.10  Discussion
4.10.1  DYNCIHI association study caveats
The involvement of DYNCIHI  in the pathology of sporadic ALS  remains unclear. Although this 
study has not detected an association of DYNCIHI variants with SALS, it does not preclude a role 
of the  gene  as  a  susceptibility  factor  as  there  are  several  caveats  to  the  approach  that  must  be 
acknowledged.
4.10.1.1 An under-powered study?
The numbers of case and control samples used are likely to have not been amenable to detecting 
associated variants. As described previously, under optimistic allelic association conditions where 
D -1,  a  sample  size  of 647  case  individuals  are  required  to  achieve  80%  power.  In  this  study, 
although  D ’  was  approximately  equal  to  1,  a  maximum  of only  281  cases  were  available  for 
screening, giving 51% power to detect an association (at a marker/disease allele frequency of 12%). 
This relative power of detection could be improved by supplementing this analysis with additional 
cases and controls, collected since this study was undertaken.
1344.10.1.2  Changes in study design?
Since this work began  in 2002, there have been a number advances in our understanding of the 
problems  and  pitfalls  associated  with  association  studies  and  their  design.  There  are  countless 
variables  that  can  be  potentially  altered  in  any  LD-based  association  study,  including:  SNP 
ascertainment  strategies,  densities,  minor  allele  frequencies,  haplotype  inference,  tagging  SNP 
selection  which  have  all  come  under  recent  scrutiny.  Many  of  the  changes  proposed  were 
introduced too late to influence this study but mark essential considerations for future association 
studies:
4.10.1.2.1  Two-stage SNP ascertainment
SNP discovery and validation are two issues that many contemporary association studies will not
have to face,  having access to a priori information on LD patterns and tSNPs in many different
populations from sources such as the HapMap project. SNP discovery and validation was essential
in  this  study  to  identify  the  underlying  pattern  of LD  across  DYNCIHI  and  to  select  tSNPs,
however, this may have introduced a source of potential bias that reduced the overall power of the
association study. Identifying or validating SNPs in a smaller sub-sample of individuals, although a
common  sense  approach  for  any  investigator  with  limited  resources,  biases  the  distribution  of
variants detected towards high frequency common variation. The deficit of SNPs of low frequency 
*
in this two-stage  approach to  SNP ascertainment means that the power to detect associations is 
reduced when the variants that actually cause disease are rare. Therefore, ascertainment bias may 
have eroded the power of this study to detect and tag rare variants associated with disease, when 
applied  to  a  larger  case/control  sample.  Conversely,  the  power  to  detect  associations when  the 
causal SNP is common is actually thought to be increased (Clark et al., 2005).
*  Two-stage SNP ascertainment describes the identification of SNPs in a limited sub-sample of individuals 
from which tagging SNPs are derived (stage one) and applied to test a larger sample of cases and controls 
(stage two). N.B. two-stage is not referred to here in terms of replication of a tSNP association in a larger 
sample set, as described in (Hirschhom et al, 2005).
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Figure 4.15  Site frequency spectra for empirical data with varying ascertainment bias
Site frequency spectra for the fully resequenced NIEHS gene set, for the Periegen sequencing-by-hybridization 
SNP ascertainment set, and for the set of SNPs that the International HapMap consortium genotyped, all 
contrasted to the neutral expectation. Note the marked absence of rare SNPs and oversampling of SNPs of 
intermediate frequency in the HapMap sample. (From Clark et al., 2005)
Ascertainment bias is a common issue, known to also have affected large polymorphism discovery 
projects  including the Human Genome Project and the HapMap and to date few robust methods 
exist to avoid introducing this type of bias or for correcting biased data (Clark et al., 2005).
4.10.1.2.2  What is the "right" SNP density and allele frequency?
Over the last five years, the most appropriate SNP density for association studies has been under 
considerable debate. Early studies using marker densities varying from SNP per kb to one SNP per 
15kb (Dawson et al, 2002; Jeffreys et al, 2001; Patil et al, 2001) demonstrated that the extent of 
linkage disequilibrium is inversely related to marker density. Although this holds true for fine-scale 
LD,  broader patterns of LD  remain relatively insensitive to  SNP  (Ke et al,  2004).  Gabriel and 
colleagues suggested that as a trade-off,  using a  SNP density of one common  SNP every 7.8kb 
would be sufficient to capture the majority of common haplotype variation throughout the genome 
(Gabriel  et  al,  2002).  However,  Wang  and  Todd  showed  in  2003  using  simulated  data,  that 
incomplete SNP maps of 1   SNP per 2.5kb, 5kb and lOkb ascertained approximately 75%, 50% and 
40% of the total underlying common SNP variation, respectively,  implying that only dense SNP 
maps  would  be  useful  for  indirect  association  mapping  (Wang  et  al,  2003).  Choosing  an 
appropriate  marker  density  for  an  association  study  SNP  map  relies  on  a  number  of  factors 
including SNP ascertainment criteria, SNP frequency, LD and tagging methods used (Wang et al,
2003). The HapMap has settled on map densities of 5kb (Phase I) and  lkb (Phase II) to provide 
researchers with data on fine-scale variation in LD and it is this information that will most likely
136influence future studies: modifying SNP density for an association study according to the extent of 
LD (Dunning et al, 2000; Kruglyak, 1999; Pardi et al., 2005; Reich et al., 2001a)
Almost all recent association studies utilising LD patterns and haplotype structures in the human 
genome to identify disease susceptibility loci, have focused on common SNPs with a minor allele 
frequency of 5% or greater.  The  main rationale  for this  is the  "common allele-common disease 
hypothesis"  suggesting  that  the  majority  of  common  genetic  disorders  are  caused  by  genetic 
variants common in the general population (Bueler et al.,  1993; Collins et al.,  1997; Lander,  1996). 
However, despite the limitations stipulated by the CDCV hypothesis, several authors have recently 
demonstrated that tag SNPs chosen from common (M AF >5%) variants can capture a proportion of 
rare alleles (1%<MAF<5%), dependent on the method of tag selection (using an exhaustive allelic 
transmission disequilibrium test, or EATDT, approach) (de Bakker et al.,  2005;  Lin et al.,  2004). 
An  interesting  development  of the  influence  of allele  frequencies to  the outcome  of association 
studies comes from the frequency matching of SNPs. It was recently empirically shown that using 
the r: LD measure, if SNPs of equal or near equal frequency are compared, the correlation between 
them more accurately represents the true correlation than of SNPs of unmatched frequencies (Eberle 
et al, 2006) (an intuitive result considering the derivation of the r2 equation). Although the resulting 
impact of this finding on the power of tag SNPs selected from these frequency matched variants has 
not  yet been  investigated,  this  information taken together with the EATDT data,  may mean that 
future studies will not be worried so much about minimum MAF of each SNP, but more so about 
ensuring that MAFs are approximately equal.
4.10.1.2.3  Tag SNP selection
There are myriad algorithms implemented  in software currently available to select tagging SNPs 
from genotype data (see Table 1   from (Halldorsson et al., 2004) for example and see (de Bakker et 
al, 2005; De La Vega et al., 2006; Howie et al, 2006; Liu et al., 2006)). It is beyond the scope of 
this thesis to review the relative merits of these algorithms against the TagIT method implemented 
in this study however, the TagIT routine (i.e. not the algorithm, but the way it is implemented) has 
been updated since its use in this study by Ahmadi et al. (Ahmadi et al, 2005) and can be assessed.
If an identical data analysis was undertaken today, the criterion used in the TagIT routine would be 
based on a ‘worst locus’ (TagIT criterion 11) rather than ‘average locus’ (TagIT criterion 5) which 
describes how the tSNP set of any size is described in terms of its performance against all of the 
original  SNPs  it  was  derived  from (Ahmadi  et al,  2005).  The  ‘worst  locus’  approach  returns a 
single  value based on the minimum performance of any tSNP  set,  where as the  ‘average  locus’
137approach  returns  a  weighted average  value.  In  this  respect,  the  ‘worst  locus’  approach  is  more 
conservative and provides a minimum performance for a tSNP set. Based on the original data and 
analysed  with  criterion  11,  a  minimum  of 3  tSNPs  would  be  needed  to  provide  a  minimum 
haplotype r2 performance >0.85 (data not shown), implying that some regions of the gene may not 
have  been  sufficiently  represented  in  the  original  study,  thus  reducing  power  to  detect  an 
association.
4.10.2  Case sample heterogeneity
As  previously described  in this chapter,  the  281  sporadic  ALS  samples  used  in this  study were 
obtained  retrospectively  with  little  accompanying  phenotypic  information.  There  was  some 
variation  in  the  pattern  of onset  amongst  patients,  with  approximately  a  third  of all  patients 
presenting with either (i) early onset in the lower extremities, (ii) upper onset and (iii) with bulbar 
onset.  Although  these  patients  were  screened  by  the  El  Escorial  criteria,  it  is  not  known  what 
proportion of patients were possible, probable or definite ALS and what proportion were diagnosed 
later with primary lateral sclerosis or primary muscular atrophy. These variations of ALS may have 
slightly different pathogenesis and therefore it is conceivable that different genes may be involved. 
Such phenotypic (and potentially genetic) heterogeneity can reduce the power of a candidate gene 
association study to identify a true association.  In addition, genetic heterogeneity may have been 
introduced by the unknown SOD1 status of the case samples, which may have again reduced study 
power.
4.10.3  The availability of HapMap data
With  SNP  and  HapMap  data  now  available,  the  extent  of power  lost  in  using the  study  design 
adopted here could be cursorily examined.  At the beginning of 2007,  information on 42  coding 
SNPs within DYNCIHI  was available  from dbSNP (which contrasts starkly to the single coding 
SNP discovered in this study) and 95 SNPs were identified from HapMap in the ~ 121 kb sequence 
surrounding  the  DYNCIHI  locus.  After trimming  of SNPs  with  MAF<1%,  56  SNPs  remained, 
giving  an  average  SNP  density of 1   SNP per -2.1 kb -  over three-times  the  density empirically 
determined in this study. The HapMap data was analysed using Tagger, with MAF set to 0.01, 0.05 
and 0.07,  HWE p-value cut-off at 0.001, and minimum percentage genotype at 75%. At all MAF 
thresholds, strong LD was identified.
138Figure 4.16  Linkage disequilibrium (r^) across DYNC1H1  identified using HapMap data
SNPs from 121 kb region centring on DYNC1H1 were analysed using Haploview. Only SNPs with MAF >1% 
were included in the analysis.
It is difficult to directly compare the experimentally derived data with that from the HapMap as they 
are composed of different SNP sets, obtained in different ways and analysed by different methods. 
Using the aggressive tagging approach implemented in Haploview (pairwise tagging and by 2 and 3 
SNP haplotypes), only 63% of SNPs with MAF>1% could be tagged by two tSNPs ^>0.8 (mean 
S=0.97). Both of these tSNPs (rslOl 35238 and rs2251644) were identified in the DYNCIHI study 
and one,  tSNPs (rs2251644), was used to  interrogate case and controls.  It could be extrapolated 
therefore, that the original tSNPs from the association study may have only tagged -63% of SNPs > 
1% frequency.
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5.1  Introduction
The absence of association between DYNCIHI and sporadic ALS and the propensity for ALS and 
other neurodegenerative disorders to demonstrate genetic heterogeneity provides a compelling case 
to  investigate  additional  components  of the  cytoplasmic  dynein  complex  for  association  with 
disease.  The work presented in this chapter was bom through a necessity for clarification of the 
mouse  and  human  cytoplasmic  dynein  subunit  data presented  in  the  literature  and  in databases 
including  nomenclature,  genetic  mapping positions  and  family relationships.  The chapter begins 
with a justification for why this work was considered necessary and the results of an effort to collate 
the  varied aliases historically applied to  the  subunits.  Clarifying the cytoplasmic  dynein  subunit 
mapping positions is presented next, describing an in silico methodology which also provided an 
excellent  opportunity  to  survey  both  mouse  and  human  genomes  for  novel  cytoplasmic  dynein 
paralogs. This chapter concludes with an in silico experiment to identify cytoplasmic dynein subunit 
orthologs,  a  description  of how  these  data  have  aided  the  implementation  of a  new  system  of 
nomenclature and the direction in which these results may lead a future dynein and ALS association 
study.
5.1.1  Beyond the cytoplasmic dynein heavy chain -  the need to consider pathways
Despite the evidence implicating DYNCIHI as both a causal locus and susceptibility factor for ALS 
and other motor neuron disorders,  no association with disease has  yet been  found.  As discussed 
previously,  one  potential  explanation  may  be  the  confounding  effect  of  non-allelic  genetic 
heterogeneity (mutations in different genes resulting in identical phenotypes) reducing the power to 
detect a disease-associated variant. The propensity for familial ALS cases to demonstrate genetic 
heterogeneity  and  the  precedence  of  genetic  heterogeneity  within  single  pathways  in  other 
neurodegenerative diseases (such as the APP pathway in Alzheimer’s), it is plausible that genetic 
heterogeneity  within  the  dynein  pathway  may  elicit  an  ALS  phenotype.  In  addition,  tantalising 
evidence for dynein associated non-allelic genetic heterogeneity has come from the investigation of 
the dynein-associated complex dynactin, a subunit of which is mutated in familial forms of motor 
neuron disease (Munch et al.,  2005; Puls et al.,  2003). The next line of enquiry of the role of the 
cytoplasmic dyneins in ALS and other motor neuron disorders should consider subunits additional 
to the heavy chains of the dynein complex.
1405.1.2  The cytoplasmic dynein subunits and a need for clarity
Cytoplasmic dynein is a large multi-subunit complex which, at its core, consists of a heavy chain 
homodimer bound by various intermediate, light intermediate and light chain polypeptides (Figure
5.1  A, right panel).
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Figure 5.1  The mammalian cytoplasmic dynein complexes
A. (left panel) Polypeptides of immunoaffinity purified rat brain cytoplasmic dynein. Polypeptide mass (kDa) 
and consensus family names are indicated, (right panel) Structural model of the cytoplasmic dynein complex: 
comprising a DYNC1H1  homodimer core and intermediate, light-intermediate and light chain subunits. B. 
Structural model of the cytoplasmic dynein 2 complex. DYNC2H1  is predicted to be similar to that of the 
cytoplasmic dyneins. DYNC2LI1  is the only known subunit of this complex. (Pfister et al., 2005b)
Investigation of these subunits as potential candidate loci for ALS and other motor neuron diseases 
exposed confusion associated with their nomenclature and the mapping positions of their genes in 
the  literature  and  within  databases.  Before  further study could  be  undertaken  to  investigate  the 
dynein complex as a candidate in ALS, it was necessary to clarify the number of dynein subunits, 
their names, mapping positions and other information relevant for further study.
5.1.3  Standardising nomenclature -  why agreeing a name for each gene is 
important.
The need to standardise human gene nomenclature was recognised as early as the  1970s when the 
first  guidelines  for human  gene nomenclature were presented at the  Edinburgh  Human Genome 
Meeting (Shows et al,  1979) and is based  largely on the fact that many genes share a common 
origin. The accepted dogma is that all present-day genes are likely to be derived from a ‘core’ of 
between 7,000 and 12,000 ancestral genes that existed more than 500 million years ago (Nebert et 
al.,  2003). Therefore present-day genes, which exhibit homology within and between species, can 
be  clustered  together  as  families,  and  as  such,  should  be  identified  as  being  related  by  being 
designated with a similar symbol.
141However,  in practice scientific communities working on diverse organisms have regularly named 
genes  and proteins  in an uncoordinated manner (see  for example names  such as  ‘daughterless’, 
‘groucho’ and ‘saxophone’ used by fruit-fly geneticists). These genes often have homologs in other 
species  that  may  be  given  names  based  on  a  different  nomenclature  system  specific  to  that 
community’s research. The situation becomes more complicated when you consider bias in letter 
usage which can result in different genes and proteins of different organisms, with quite different 
functions, having identical names and symbols (Nebert et al.,  2004) - or vice versa. With the ever 
expanding number of genome sequencing initiatives (409 eukaryote genomes have been sequenced, 
of which 107 are animals; www.ncbi.nlm.nih.gov/entrez/querv.fcgi?db= genomepri. as of November 
2006),  providing  vast  amounts of gene  and  sequence  data  for myriad  species,  the  only  feasible 
method to handle and utilize data is to use computers. The ability of current computer software to 
accurately  and  efficiently  cross-reference,  cross-index  and  analyse  all  of thse  data,  requires  a 
systematic and co-ordinated approach to gene nomenclature to aid in data retrieval and to minimise 
errors (Nebert et al.,  2003). Each gene therefore should have a unique core symbol which can be 
applied and amended to other members of a gene family (Wain et al., 2002).
One  well  utilised  method  for  identifying  members  of a  gene  family prior to  standardising  their 
nomenclature is to use evolutionary trees- a phylogenetic approach -which has already been used 
for over 124 families/superfamilies (Nebert et al., 2004).
5.2  Clarifying mouse and human cytoplasmic dynein subunit nomenclature, 
genomic locations and accession numbers
Research on the cytoplasmic dynein subunits has historically been undertaken in myriad organisms 
from  yeast  {Saccharomyces  cerevisiae)  to  humans  {Homo  sapiens).  The  nomenclature  of 
mammalian genes encoding these proteins has drawn on homologs  in other organisms,  which in 
turn have often been defined and named by criteria such as their molecular mass and mobility on 
sodium  dodecyl  sulphate-polyacrylamide  electrophoresis  (SDS-PAGE)  gels  (Figure  5.1 A,  left 
panel)  (Pfister et al.,  2005b).  Consequently a  number of synonyms  can be  found  for any given 
human  or  mouse  cytoplasmic  dynein  subunit.  Much  of the  early  research  into  the  cytoplasmic 
dyneins was conducted in the biflagellate green alga Chlamydomonas, on the dyneins found in the 
flagellar axoneme, and therefore some mammalian cytoplasmic dynein nomenclature derives from 
these studies. For example, mammalian members of the cytoplasmic light chain families DYNLRB 
and DYNLL have commonly been referred to as LC7 and LC8 respectively, which are the names of 
homologous Chlamydomonas axonemal dynein subunits.
142The  lack of consistency and coordination of dynein nomenclature has also  led to  the erroneous 
cross-indexing of gene names and other data on databases. Consequently, this has introduced errors 
in nomenclature, mapping position and in the sequence accession numbers into the databases, which 
are propagated onto additional databases and even into the literature (the opposite is also true; errors 
in the literature are propagated onto database entries). For example, searching NCBI LocusLink for 
human and mouse gene entries with the root symbol ‘dhc’, often prefixed to the cytoplasmic dynein 
gene names, gives  17 results which include cytoplasmic and axonemal dyneins,  several different 
enzymes and transmembrane proteins (Table 5.1).
Gene name  Organism  symbol  LocusLink*
Cytoplasmic dynein heavy chain 1 Homo sapiens DHC1 1778
Dynein heavy chain domain 1 Homo sapiens DHCD1 144132
Axonemal dynein heavy chain 12 Homo sapiens DHC3 8679
Transmembrane 7 superfamily member 2 Homo sapiens DHCR14 1717
Lamin B receptor Homo sapiens DHCR14B 3930
7-dehydrocholesterol reductase Mus musculus Dhcr7 13360
3-beta-hydroxysterol delta-24 reductase Mus musculus Dhcr24 116932
Table 5.1  NCBI LocusLink human and mouse genes containing the root symbol ‘dhc’
Search limited to records created between 1995 and 2004. *LocusLink accession number
5.2.1  Collating human and mouse cytoplasmic dynein subunit synonyms
To  identify the extent and  variety of synonyms  in use,  literature searches  were conducted using 
PubMed and the online databases MGI, NCBI (including LocusLink/Entrez Gene) and Ensembl (all 
searches  were  carried  out  between  January  and  July  2004).  For  fast  interrogation  of  online 
bioinformatics resources, the bioinformatics meta-search engine Bioinformatic-Harvester was also 
used. Table 5.2 lists aliases, map position and protein/DNA sequence accession data identified for 
each known mouse and human cytoplasmic dynein gene. More synonyms were observed in online 
databases  than  cited  in  the  literature,  which  most  likely  reflects  both  the  automated 
collection/annotation approach of database records and the lack of curation/review of these entries. 
The  origins  of each  cytoplasmic  dynein  subunit  synonym  were  traced  to  verify  their  validity 
ensuring for example, that the synonym did not simply represent a typographical error.
Many  of the  synonyms  identified  were  named  in  accordance  with  their method  of detection  - 
projects  responsible  for  originally  identifying  a  gene  or  gene  product,  or  projects  detecting 
previously identified genes or gene product. For example (from Table 5.2), the ‘MGC’ prefixes are 
from the National Institutes of Health Mammalian Gene Collection (MGC) as part of an initiative to 
identify and sequence cDNA clones containing a full-length open reading frame for human, mouse 
and  rat  (Strausberg  et  al,  2002).  ‘CGI’  prefixes  are  assigned  by  the  Comparative  Gene
143Identification study, which use the Caenorhabditis elegans (C. elegans) proteome as an alignment 
template to assist in novel human gene identification from human EST nucleotide databases (Lai et 
al.,  2000).  ‘Rik’  suffixes  are  aliases  assigned  by  the  Riken  Genomic  Sciences  Centre 
(http://genome.gsc.riken.ip).
5.2.2  The many names of cytoplasmic dynein 1 heavy chain 1
Amongst  the  cytoplasmic  dynein  subunits,  DYNCIHI  had  the  greatest  number  of  synonyms 
published in the literature and online, with 15 aliases published for the human heavy chain and 9 for 
the  mouse.  Some  alternative  cytoplasmic  dynein  gene  names  were  from  large-scale  gene  and 
transcript  identification  efforts  such  as  the  partial  DYNCIHI  clone  KJAA0325  and  its  mouse 
homolog  ‘mKIA00325’,  generated  by  the  Kazusa  cDNA  project  (Ohara  et  al,  1997).  A  small 
number of gene names were derived  from DNA markers and cDNA clones used to  identify the 
genes, for example, DYNC2LI1 was named DKFZp564A033 after the cDNA sequence and clone of 
the same name and DYNCIHI referred to as Hp22 after a marker generated from its human cDNA 
sequence, as well as the rat-derived marker Rk3-8 and a cDNA clone named HL-3.
Two  synonyms  for  mouse  and human DYNCIHI  that  were  investigated and ultimately  rejected 
were  ‘cell  division  cycle  22’  (CDC22)  and  ‘cell  division cycle  23’  (CDC23),  respectively.  The 
mouse CDC22  alias  was annotated on to  the NCBI  entry  for Dynclhl  full-length mRNA (Acc. 
NM  030238;  sequence revision history 21  December 2003) and partial mRNA (Acc.  BC004751; 
sequence revision history 16 April 2003), and was also found at the MGI database (Figure 5.2). The 
human CDC23 alias was annotated on to the NCBI entry for DYNCIHI  full-length mRNA (Acc. 
NM  001376;  sequence  revision  history  23  December  2003)  and  partial  mRNA  mRNA  (Acc. 
BC021297; sequence revision history 9 December 2003) (Figure 5.2). The validity of these aliases 
were investigated by first conducting literature searches using the search terms ‘CDC22’, ‘CDC23’ 
and  ‘cell  division  cycle’  and  identifying  any  papers  citing  these  terms  in  association  with 
cytoplasmic dynein. No citations of these terms were found or with the name ‘cytoplasmic dynein 
chain’  with the suffixes ‘22’ and ‘23’. This suggested that the error was most probably generated 
and propagated solely on the database.
144Figure 5.2  Mouse and human DYNC1H1 synonyms from the Entrez database at NBCI
Screen-shot of the NCBI sequence database entry for human DYNC1H1 mRNA sequence, accession number 
NM_001376 (A) and mouse Dync1h1 mRNA sequence, accession number NM_030238 (B). Synonyms listed 
within the entry are indicated by the red arrow and CDC22 and “cytoplasmic dynein complex" are boxed in red. 
Database accessed April 2004.
To test the validity of these synonyms and to identify if they had been assigned based on sequence 
homology to other known proteins, homology searches were conducted. Human and mouse CDC23 
and CDC22 cDNAs and protein sequences were obtained by searching GenBank using the terms 
‘CDC23’  and  ‘CDC22’.  The  GenBank  entries  for  CDC23  were  listed  as  “cell  division  cycle
protein    homologous  to Saccharomyces  cerevisiae cdc23”,  however no entries  were  seen  for
CDC22. The yeast cdc23 protein, a component of anaphase-promoting complex (APC), is essential 
for cell cycle progression through the G2/M transition and highly conserved in eukaryotic cells, was 
also included for comparison. The human and mouse dynein heavy chains were compared against 
the human and mouse cell division cycle subunits and against two different yeast cell division cycle 
subunits  using  BLAST.  The  Schizosaccharomyces  pombe  cdc22  protein,  which  shows  no 
significant  homology  to  S.  cerevisiae cdc23  was  included  as  a  possible  homolog of the  mouse 
CDC22.  Both  cDNA  and  protein  alignments  were  conducted  using  ClustalW.  No  significant 
similarity was seen between the dynein heavy chains and the cell division cycle proteins at both the 
nucleotide of protein level (data not shown).Cytoplasmic 
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Informatics. 2004) 
MGC32416 (NCBI, 20041)
Mmu9 F3 235661
2135610 NM_146229 NP_666341
DYNC1LI2
Human
LIC53/55 (Hughes et al., 
1995)
LIC-2 (Hughes etal., 1995) 
DYJ2  HUMAN*
Hsa16q22.1 1783 NM_006141 NP  006132 
043237
Dync1li2
Mouse
Dnclic2 (Mouse Genome 
Informatics. 2004)
Mmu8
(50cM)
110801 and see 
234663 
107738
XM_134573 XP_134573
Cytoplasmic 
dynein 2 light
DYNC2LI1
Human
D2LIC (Grissom et al., 2002) 
LIC3 (Mikami el al., 2002b) 
CGI-60 (Mikami el al., 2002a; 
NCBI. 2004a) 
DKFZP564A033 (NCBI. 
2004a)
Hsa2p25.1-
p24.1 51626
NM_016008 
(isoform 1) 
NM  015522 
(isoform 2)
NP_057092 
(isoform 1) 
NP_056337 
(isoform 2)
intermediate
chain
Dync21i1
Mouse
4933404011Rik (NCBI. 
2004g)
D2LIC (NCBI. 2004g) 
mD2LIC (NCBI, 2004g) 
MGC7211 (NCBI. 2004g) 
MGC40646 (NCBI. 2004g)
Mmu17E4 213575
1913996 NM_172256 NP  758460
DYNLT1
Human
TCTEL1 (Watanabe el al., 
1996)
Tctexl (King el al., 1996c; 
Lader el al., 1989)
Protein CW-1 (Mueller el al., 
2002)
DYLX  HUMAN*
Hsa6q25.3 6993 NM  006519 NP  006510 
Q15763
Cytoplasmic 
dynein Tctexl 
light chain
Dynltl
Mouse
Tctexl (King etal., 1996c) 
Tcd1 (King el al..  1996c; 
Lader el al.. 1989)
DYLX  MOUSE*
Mmu17
(4cM)
21648
98643 NM  009342 NP  033368 
P51807
DYNLT3
Human
TCTE1L (Roux el al., 1994) 
rp3 (Roux et al., 1994) 
TCTEX1-L (Roux el al., 
1994)
TCTL  HUMAN*
HsaXp21 6990 NM_006520 NP  006511 
P51808
Dynlt3
Mouse
Tctell (Mouse Genome 
Informatics. 2004) 
2310075M16Rik (Shibata el 
al., 2000)
TCTL  MOUSE*
MmuX A1.1 67117
1914367 NM_025975
NP  080251 
P56387
Cytoplasmic 
dynein light 
chain 
Roadblock
DYNLRB1
Human
MGC15113 (NCBI, 2004d) 
DNCL2A(Jiang etal., 2001) 
bithoraxoid-like protein (BLP) 
(Bowman et al., 1999; Dole 
etal., 2000)
BITH (Fracchiolla et al.,
1999)
hkm23/mLC7-1 (Tang etal., 
2002b)
RobJ1 (Nikulina el al., 2004) 
Roadblock(robiyLC7 
(Bowman etal., 1999) 
HSPC162 (Quackenbush el 
al., 2001; Zhang et al., 2000) 
DL2A  HUMAN*
Hsa20q11.2
1 83658
NM_014183 
(isoform a) 
NM_177953 
(isoform b) 
NM_177954 
(isoform c)
NP  054902 
Q9NP97 
(isoform a) 
NP_808852 
(isoform b) 
NP  808853 
(isoform c)
147Dynlrbl
Mouse
Dnc!2a (Mouse Genome 
Informatics, 2004)
Dnclc2A
km23/mLC7-1 (Tang etal., 
2002b)
2010012N15Rik (Shibata et 
at., 2000)
2010320M17Rik (Shibata et 
al., 2000)
DL2A  MOUSE*
Mmu2 H1 67068
1914318 NM_025947 NP  080223 
088567
DYNLRB2
Human
DNCL2B (Jiang et al., 2001) 
bithoraxoid-like protein (BLP) 
(Bowman ef a/., 1999; Dole 
etal., 2000)
Robl2 (Nikulina et al., 2004) 
LC74ike (Jiang et al., 2001) 
mLC7-2 (Tang et al.. 2002b) 
DL2B  HUMAN*
Hsa16q23.3 83657 NM_130897 NP  570967 
Q8TF09
Dynlrb2
Mouse
Dncl2b (Mouse Genome 
Informatics, 2004)
DL2B  MOUSE*
Mmu8 E1 75465
1922715 NM_029297
NP  083573 
Q9DAJ5 
AAH48623
Cytoplasmic
dynein light
DYNLL1
Human
DCL1 (Naisbitt et al., 2000a) 
DNLC1
DNCL1 (Cras-Meneu  ratal., 
2004)
Mr 8000 LC (King et al., 
1996b)
Mr8000 DLC (King etal., 
1995)
DLC8 (Espindola et al., 2000) 
LC8 (Pazou  ref a/., 1998) 
LC8a (Wilson et al., 2001)
PIN (Jaffrey etal., 1996) 
hdlc1 (Dick et al.,  1996b) 
Dlc-1 (Crepieuxefa/., 1997) 
DYL1  HUMAN*
Hsa12q24.3
1 8655 NM  003746 NP  003737 
Q15701
chain LC8
DynlM
Mouse
Dnclcl (Mouse Genome 
Informatics. 2004)
Mmu5 F 56455
1861457 NM_019682 NP  062656 
Q9D6F6
DYNLL2
Human
DLC2 (Naisbitt et al., 2000a) 
LC8b (Wilson et al.. 2001) 
MGC17810 (NCBI, 2004c)
Hsa17q23.2 140735 NM  080677 NP  542408
Dynll2
Mouse
Dlc2 (Mouse Genome 
Informatics, 2004)
1700064A15Rik (NCBI, 
2004b)
6720463E02Rik (NCBI. 
2004b)
Mmu11 C 68097
1915347 NM_026556 NP_080832
Table 5.2  Human and mouse cytoplasmic dynein genes and map positions
Mapping prefixes are Hsa (Homo sapiens) and Mmu (Mus musculus) followed by the chromosomal 
localisation. All databases were accessed November 2005. 
a HUGO: www.gene.ucl.ac.uk/nomenclature/ 
b  NCBI: www.ncbi.nlm.nih.Qov
c MGI: www.informatics.iax.ora/: mapping position shown in cM or cytogenetic band 
d  NCBI Entrez Gene: www.ncbi.nih.aov/entrez/auerv.fcqi?db=qene 
e SwissProt: httD://ca.exDasv.ora/sorot/
* name as given by SwissProt
5.2.3  Clarifying subunit mapping positions and identifying paralogs
Mapping positions of mouse and human cytoplasmic dynein subunits were clarified by identifying 
regions of sequence homology between the dynein subunit sequences, available from the sequence 
databases,  and  the mouse or human  genome assembly.  The elegance  of this method was  that  it 
provided an assumption-free approach to identifying cognate genetic  loci as it did not rely on a 
priori data  from the  literature or databases.  However,  published data  obtained through  PubMed
148literature searches and from the online databases MGI, NCBI (including LocusLink and OMEM) 
and  Ensembl,  was  also  used,  but  only  when  corroborated  by  the  sequence  alignment  results. 
Genome  alignments  were  conducted  using  megaBLAST,  with  default  settings  and  restricted  to 
human  and  mouse  genomes  only.  To  designate  the  alignment  of a  query  sequence  against  the 
genome as a cognate dynein subunit genetic locus, the following specified criteria had to be met:
1.  the entire query sequence must align to discrete region of the genome
2.  the alignment  must demonstrate a rational  genomic architecture - conservation of splice 
junctions, promoter sequences etc.
3.  in silico splicing and translation of the putative cognate locus results in a known protein 
product of that subunit
4.  supporting evidence from the literature, if available
The mapping results are  shown  in Table  5.2.  This approach also provided a valuable  secondary 
analysis by identifying potential unknown dynein subunit paralogs*.
The dynamic  nature of mouse and human  genome  evolution can generate paralogous  sequences 
through  mechanisms  of duplication  at  the  level  of entire  genomes,  chromosomes,  chromosomal 
segments and retrotransposition events (see for example, (Koonin, 2005;  Sankoff, 2001; Taylor et 
al.,  2004)).  Each  distinct  mechanism  of  gene  duplication  and  subsequent  functional  or  non­
functional sequence divergence generates a specific signature of evolution; from intron containing 
paralogs created by duplication to intron-less pseudogenes created by retrotransposition. However, 
as with many bioinformatics techniques, the limitation of this approach was anticipated to be the 
quality and completeness of the query sequences and the genome assembly. Therefore homology 
searches  were  also  made  against  the  nucleotide  and  protein  sequence  databases  (GenBank)  to 
identify potentially expressed and translated paralogs. Although low homology sequence was seen 
frequently, no functional  loci were identified (data not shown) except for DYNLL1.  Although the 
DYNLL1  locus appeared  functional,  no protein product was  found.  In the  interest of brevity two 
examples of this work are given here, which are representative of the full work undertaken.
5.2.3.1  Example 1: Cytoplasmic dynein light chain 1
The  cytoplasmic  dynein  light  chain  1  (DYNLLI)  gene  illustrates  many  of the  methods  used  to 
clarify  dynein  subunit  information.  DYNLLI  possessed  two  different  loci,  the  cognate  locus 
12q24.21  and  the  incorrect  locus  at  14q24  which  was  reproduced  and  propagated  on  genome 
browsers. The origin of the discrepancy most likely stemmed from the work of Dick and colleagues
*  Paralogs are genes related by duplication within a genome. Orthologs retain the same function in the course 
of evolution, whereas paralogs evolve new functions, even if these are related to the original one.
149who  took  N  and  C  terminal  sequences  of Drosophila  and  C .elegans  and  designed  primers  by 
reverse  translation  and  used  PCR  to  design  300bp  probes  and  isolated  2  cDNAs  (Dick  et  al., 
1996a). FISH probes constructed with this sequence mapped to  14q24. This error was also seen at 
the Human Genome Nomenclature Committee (HGNC) website at the Galton Laboratory,  UCL, 
London,  UK (www.gene.ucl.ac.uk/nomenclature) during a search of all  loci containing the name 
“cytoplasmic  dynein”.  The  Galton  Laboratory  gave  DYNLLl  a  14q24  locus  and  two  additional 
pseudogene  loci,  DNCL1P1  and DNCL1P2  on  chromosome  14.  In  addition  Online  Mendelian 
Inheritance  in  Man  (OMIM)  website,  used  to  collate  information  about  human  genetic  diseases 
reported  a  14q24  location but  LocusLink  (now  EntrezGene)  gave  a  12q24.23.  To  resolve  these 
differences  the  full-length  DYNLLl  cDNA  was  aligned  against  the  human  genome  using 
megaBLAST (Table 5.3).
150Genomic location Alignments (nt) % identity ORF? Protein % identity Ensembl Gene  NCBI Gene
Chromosome Hsa Contig DYNLL1 Contig Position NM_003746 (aa) NP  003737 Name Accession Accession
1 1p36.13 NT_077921 2-371 456983 - 457323 91 Yes 89 87 DYLL_HUMAN ENSG00000124854
XM_372768
XP_372768
1 1p36.11 NT_037485 307 -  550 2790937 -  2790695 93 No — —
3 3q25.3 NT005612
39-94
119-640
60870198 - 60870252 
60870268-60870791
83 No — —
4 4q23 NT_016354
23 - 546 
570 -  628
25458035 - 25457518 
25457506 - 25457440
83 No — —
7 7q21.1 NT_007933
1-66
79-370
10245012-10244953
10244947-10244659
93 No — — Hs_7_c1269 OTTHUMG00007007517
LOC392947
XM_374628
XP_374628
377 -  640 10245024-10245285 93 No — —
LOC392067
XM_373171
XP_373171
12 12q24.13 NT_009775
87 -  456 
472 -  578
4746361 -  4745993 
4745993 -  4745887
89
89 No — —
560 - 640 4745587 - 4745506 82
12q24.31
1-89 
8-226 
224 - 640
11452675-11452763
11452960-11453099
11454616-11455032
98 
100
99
Yes 89 100
14* 14q31.1 NT_026437 1-640 61633039-61632401 94 Yes 89 91 K14_NN_963_1
ENSG00000183992 
and
OTT  G00000002869
LOC246720
NG_001584
14q31.1 38 -  635 61799299-61799896 94 No — — K14_NN_968_1 OTTG00000002889
Table 5.3  DYNLL1 megaBLAST alignments against the human genome
An intact open reading frame (ORF) was seen on three chromosomes, with three potentially translated proteins 89 amino acids (aa) in length. Chromosome 12q24.31  was 
identified as the cognate genetic locus and loci on chromosome 1  and 14 as untranslated pseudogenes. Mapping prefix Hsa refers to Homo sapiens chromosomal 
location and all alignments are given by nucleotide (nt)Alignments to chromosome 12q24.31 had the highest percentage identity, spanning the entire length 
of the cDNA  sequence.  To ensure  this  megaBLAST alignment was  correct,  the DYNLLl  cDNA 
sequence was aligned against chromosome  12 contig only (Acc:  NT  009775) using BLAST2Seq 
and  the  corresponding  alignments  checked  for  the  presence  of  conserved  sequence  features 
indicative  of  an  expressed  gene.  The  sequence  alignment  was  identical  to  that  seen  using 
megaBLAST (data not shown). The entire cDNA length was represented against the chromosome 
12 contig in three distinct exonic regions and  several conserved sequence motifs,  such as  Kozak 
consensus sequence, splice junctions and polyadenylation signals were identified which supported 
this chromosomal locus (Figure 5.3). The exonic sequences were artificially spliced and translated 
using  TRANSLATE  and  resulting  protein  compared  to  DYNLLl  (Acc:  NP003737)  using 
BLAST2seq - the two sequences were identical (Figure 5.4).
Exon 1  CTCCCCCAGGAGACCGTTGCAGTCGGCCAGCCCCCTTCTCCACGgtg
    J T + 1
CCCActagGTAACCATGTGCGACCGAAAGGCCGTGATCAAAAATGCGGA 
Exon 2  CATGTCGGAAGAGATGCAACAGGACTCGGTGGAGTGCGCTACTCAGGCGC 
TGGAGAAATACAACATAGAGAAGGACATTGCGGCTCATATCAAGAAGgtgag
TCCagGAATTTGACAAG  ATTCTTCTGTTCAAATCTGGTTAAAAGCATGGA
Exon 3  CTG...................CACGTTGTTTTCTCTCAAAATCCATTCCTTTAAAAAATAAATC
TGATGCAgatgtgtatgtgtgtgaat
Figure 5.3  Schematic representation of the putative DYNLL1 locus at 12q24.31
Exonic sequence shown in blue font and intronic in grey font. Translational start codon (methionine) is shown 
in red at +1  within Kozak conserved signal (grey box). Conserved splice junctions indicated within green lines, 
TAA stop codon and polyadenylation signal highlighted in yellow.
0 34417 *
0 07 * 11*
14354
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Figure 5.4  In silico translation of artificially spliced DYNLL1 alignments
DYNLL1 alignments from various chromosomes were spliced and translated in silico and aligned to the known 
DYNLL1  protein NM_003746 using ClustalW. The alignment at chromosome 12q24.31  showed complete 
homology to DYNLL1 and all other loci showed evidence of sequence degeneration associated with 
pseudogenes.
This method of analysis was carried out for all DYNLLl  alignments shown in Table 5.3.  Several 
loci  including those on chromosomes  1,  7  and  14 were characteristic  of processed pseudogenes; 
lacking introns, encompassing a poly(T) tail and comprised of degenerate sequence (i.e. possessing
152stop codons in the ORF) (Vanin, 1985). The “processed” nature of these loci implied duplication of 
the cognate locus by retrotransposition. This hypothesis was confirmed by analysing the sequence 
context  of each  suspected  locus using  RepeatMasker  (www.repeatmasker.org/) -  all  loci  except 
chromosome  12q24.31,  were  seen to  possess  hallmark  flanking  sequences  of non-long  terminal 
repeats (LTR) Class I retrotransposable elements: chromosome  1   loci possessed short interspersed 
nuclear  elements  (SINEs)  and  chromosome  12  possessed  long  interspersed  nuclear  elements 
(LINEs). Corresponding sequences were seen in the mouse in regions syntenic to those in humans 
suggesting that duplication of the cognate locus occurred in the common ancestor of both human 
and  mouse  species.  Locus  12q24.31  was  proposed  identified  as  the  cognate  locus,  which  was 
supported by the mapping of the mouse Dynlll to a region syntenic to 12q24.31 on Mmu5.
To ensure that no potential paralogs had been missed the cDNA and protein sequences of DYNLL1 
were  used  to  search  the  sequence  databases  using  nucleotide  and  protein  BLAST.  A  match  to 
“Homo sapiens lung cancer oncogene 5” (HLC5) was found with 99% identity over 85% of the 
length of DYNLL1  cDNA. In silico translation of the antisense strand of HLC5 produced a  100% 
match to the full length DYNLL1. It is likely that the HLC5 data, which remains unpublished and is 
based on a single observation from a study of mRNA species in cancerous tissue, is incorrect and 
most likely represents a detection of DYNLLl.
5.2.3.2  Example 2: Cytoplasmic dynein 1 heavy chain I
A  search  for  sequences  paralogous  to  DYNCIH1,  using  BLAST  to  query  the  cDNA  sequence 
against the nucleotide database, did not yield significant results however a BLAST search of the 
protein  database  yielded  a  sequence  with  27%  identity  to  DYNC1H1.  The  sequence  (Acc. 
XP  085578, XM  085578) was the predicted product of a hypothetical gene, FLJ46675, located at 
chromosome  17pl3.1.  The  existence  of a  second  heavy  chain  species  DYNC2H1  was  already 
known and so this result suggested a possible third heavy chain existed. By aligning the sequences 
for DYNC1H1,  DYNC2H1,  FU46675  and  DNAH9 used as an outgroup,  it was shown that the 
sequence  was  more  likely  to  be  axonemal  (33%  identity,  51%  similarity  to  DYNC1H1)  than 
cytoplasmic (Figure 5.5).
 -----------------------------------------------------------   NP  001367 DYNC1H1
L   —  —  —  ■  —  XP_370652 DYNC2H1
-----------------------------------------------------------------------------------  XP_085578 FLJ46675
    NP_594491  DNAH9
Figure 5.5  Cladogram of the relationships between human dynein heavy chains and the 
hypothesised heavy chain FLJ46675
153Human cytoplasmic heavy chains DYNC1H1  and DYNC2H1 are more closely related to each other 
than the hypothetical protein FLJ46675. Axonemal heavy chain DNAH9 was used as an outgroup.
5.2.4  Cytoplasmic dynein subunit accession numbers
Cytoplasmic dynein subunit nucleotide and protein accession numbers were obtained from NCBI 
RefSeq.  The  majority  of sequences  were  found  through  links  from  the  central  gene-based  data 
resource LocusLink. Human DYNC2H1 sequences XM  370652 and XP  370652 were predicted by 
analysis of genomic sequence (NT  033899) using the NCBI gene prediction method GNOMON, 
supported by mRNA and EST evidence. Mouse Dynlli2 sequences XM_134573 and XP_134573 
were also predicted on genomic sequence (NT  078575) using a similar method.
5.3  Identifying cytoplasmic dynein orthologs
With the availability of sequence data from different organisms, cytoplasmic dynein orthologs were 
identified  by  searching  the  GenBank  non-redundant  protein  database,  with  the  human  dynein 
proteins  using  PSI-BLAST  with  default  parameters  and  the  BLOSUM-62  substitution  matrix. 
Searches  of  pufferfish  sequence  Takifugu  rubripes  were  performed  by  using  human  protein 
sequence  against  the  translated  Fugu  Genome  nucleotide  database  (version  release  2.0; 
www .ensembl .org/Fueu  rubripes  I.  Where  possible,  outgroup  sequences  were  identified  from 
homologs in Chlamydomonas reinhardtii as these axonemal dynein proteins have been extensively 
studied in this species and many of the subunits in higher-order species are known to be related. The 
accession  numbers  of all  protein  sequences  identified  are  given  in  the  Appendix.  Phylogenetic 
analyses were conducted using these sequences by Dr James Cotton at the Natural History Museum, 
London, UK;  using the methods outlined in Chapter 2.3.18.  For the Markov-chain approach, the 
consensus of three Markov-chain analyses was used to ensure that the algorithm had converged to a 
stationary state. For one of the cytoplasmic dynein heavy chain gene family, the three chains had 
reached  different  likelihood  values  after  1,000,000  generations,  suggesting  failure  to  converge. 
Running  another  three  independent  chains  resulted  in  five  out  of  six  chains  agreeing  on  the 
likelihood  values,  suggesting  that  only  one  chain  had  not  converged  properly.  In  all  cases,  the 
phylogeny presented is the majority rule consensus of the posterior sample of tree topologies from 
all  three  Markov  chains.  A  positive  control  in  the  identification  of homologous  sequences  to 
construct phylogenetic trees was the multiple independent detection of subunits: e.g. searching for 
human DYNC1H1 paralogs identified DYNC2H1 with an alignment score of 30%.
5.3.1  Cytoplasmic dynein heavy chain gene family (DYNC1H1, DYNC2H1)
Figure  5.6A  illustrates  the  phylogenetic  relationships  amongst  the  sequences  identified  as 
orthologous  to  DYNC1H1  and  DYNC2H1  from  various  organisms.  The  existence  of  several
154axonemal  dynein  heavy  chain  proteins  in  the  Chlamydomonas  proteome  made  identifying  an 
outgroup sequence difficult, however the outer arm heavy chain (ODA11) was arbitrarily chosen 
(all  C.  reinhardtii  heavy  chains  had  comparable  sequence  similarity  to  DYNC1H1).  A  partial 
fragment of a suggested third dynein heavy chain identified in the literature (Vaisberg et al.,  1996a) 
was included in the analysis (fragment was termed “DNAH12frag”). Only partial sequence (336aa) 
of the mouse DYNC2H1  (XP  35830) protein was available in the GenBank database. Adding this 
partial sequence to the analysis resulted in spurious clustering and therefore, an extended putative 
sequence was required. The extended sequence was obtained by aligning human and rat sequences 
XP  370652 and NP075413  respectively,  against the translated mouse genome (Build 32) using 
TBLASTN.  Incomplete  mouse  genomic  assembly  at  the  DYNC2H1  locus  yielded  a  truncated 
sequence 3455 amino acids in length, 85% the length of human DYNC2H1.
The heavy chain sequences fell into two distinct clades and the relationships within each clade were 
generally consistent with known evolutionary distances between the organisms shown*. The deep 
branching  of the  dynein  1   and  dynein  2  clades,  and  the  presence  of myriad  species  on  both 
branches,  suggests that the origin of these  two  dynein  heavy chain proteins  is ancient,  possibly 
predating the divergence of C. reinherdtii from a primordial species. The phylogeny complemented 
and  extended,  previous  phylogenetic  analyses  of the  heavy  chain  proteins  (Porter  et  al.,  1999; 
Vaisberg  et  al,  1996b).  Importantly,  the  analysis  indicated  that  the  partial  human  sequence, 
suspected  to  be  a  third  cytoplasmic  heavy  chain,  was  unlikely  to  be  a  cytoplasmic  dynein;  it 
possessed good homology to DNAH12 (Acc:AAB09729) and was termed “DNAH12frag”.
5.3.2  Cytoplasmic dynein intermediate chain gene family (DYNC1U, DYNC1I2)
Figure  5.6B  shows  the  dynein  intermediate  chain protein phylogeny.  The protein  sequence data 
demonstrated  an  evolutionary  distant  relationship  between  axonemal  and  cytoplasmic  dynein 
intermediate chains; for example, mammalian rat DYNC1I1 (NP  062107) has 48% similarity to the 
Chlamydomonas axonemal outer arm dynein intermediate chain encoded by the ODA6 locus and 
therefore  ODA6  was  used  as  an  outgroup  (Mitchell  et  al.,  1991;  Paschal  et  al.,  1992a).  The 
intermediate  chain  sequences  fell  into  two  clades,  intermediate  chain  1   and  2,  which  were 
comprised of vertebrate species only.
An alternative placement of a Takifugu sequence, as a member of the intermediate chain  1   clade 
was almost as well-supported by the data as the placement shown in Figure 5.6B (49% bootstrap
*  Relationships amongst dynein sequences of different species do not necessarily reflect the evolutionary 
relationships amongst species as a gene tree does not always reflect a species tree; see (Tajima, 1983) and 
(Pamilo et al., 1988) for further details.
155support against 51% support).  In view of this and with all non-vertebrate species falling outside 
these clades, the data suggest a recent evolutionary origin for an intermediate chain  1   and 2 gene 
split, perhaps as part of a ‘2R’ event of genome duplication (see (Wolfe, 2001) for review). The 
absence of an amphibian intermediate chain 1  protein may have been due to the paucity of Xenopus 
laevis sequences in the GenBank sequence database at the time of analysis.
5.3.3  Cytoplasmic dynein light intermediate chain family (DYNC1LI1,
DYNC1LI2, DYNC2LI1)
Figure 5.6C illustrates the phylogenetic relationships amongst the dynein light intermediate chain 
protein sequences from various organisms. The light intermediate chains separated into two deep 
clades, mirroring the dynein 1  and 2 heavy chain tree. The dynein 1  clade was further split the two 
intermediate chain components of cytoplasmic dynein  1   complexes, DYNC1LI1  and DYNC1LI2 
(Entrez GenelD: 51143 and 1783, respectively) which are more closely related to each other than to 
the cytoplasmic dynein 2 light intermediate chain,  DYNC2LI1.  DYNC2LI1  homologs were only 
identified in species possessing DYNC2H1, emphasising the distinct cellular identities and roles of 
these  separate  dynein  complexes  (Figure  5.IB).  C  .elegans  appeared  to  possess  one  light 
intermediate  chain  (dli-1)  (Entrez  GenelD:  178260)  for  cytoplasmic  dynein  (DYNC1 HI-based 
complexes), and one (xbx-1) (Entrez GenelD:  184080) for cytoplasmic dynein 2 (DYNC2H1-based 
complexes) (Schafer et al., 2003).
5.3.4  Cytoplasmic dynein light chain Tctexl-family (DYNLT1, DYNLT3)
Cytoplasmic  dynein  light  chain  Tctexl-family  is  one  of three  known  dynein  light  chain  gene 
families  that  are  components  of  cytoplasmic  dynein  1:  (1)  the  /-complex  associated  family 
(DYNLT1, DYNLT3), (2) the Roadblock family (DYNLRB1, DYNLRB2), and (3) the LC8 family 
(DYNLL1,  DYNLL2).  These  gene  families  are  named  according  to  their  original  discovery, 
through  the  effect  of  mutations  in  mouse  (t-complex  associated,  Tctexl)  and  Drosophila 
(Roadblock)  or according to the size of the protein  in  Chlamydomonas (LC8).  The dynein  light 
chain  Tctexl-family  protein  phylogeny  is  shown  in  Figure  5.8A,  and  shows  distinct  clades  for 
DYNLTl-like and DYNLT3-like sequences.
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Figure 5.6  Protein-based phytogenies of the cytoplasmic dynein heavy chain, intermediate 
chain and light intermediate chain families
Species names for heavy chain (A), intermediate chain (B) and light intermediate chain (C) phylogenies are 
given with NCBI/GenBank gene/protein names (sequence accession numbers are given in Appendix). 
Orthologous human, mouse, and rat gene names use the revised systematized consensus nomenclature 
(Pfister et al., 2005b). Named clades are indicated in the right margins. Bayesian and maximum-likelihood 
bootstrap values are shown as percentages adjacent to branch points. ‘bootstraps below 50%. ^bootstraps at 
100%. Scale-bar represents evolutionary distance (estimated numbers of amino-acid substitutions per site).
1575.3.5  Cytoplasmic dynein light chain Roadblock family (DYNLRB1, DYNLRB2)
Figure 5.8B shows the phylogenetic relationships amongst the dynein light chain Roadblock protein 
family in various organisms. The Roadblock sequences appeared well-conserved from T.  rubripes 
to  humans,  with  96%  of pairwise  sequence  comparisons  amongst  all  sequences  demonstrating 
sequence  identity  >50%  (data  not  shown).  However,  the  high  alignment  scores  may  have  been 
produced through the limited number of sequences used and the paucity of more distant species. 
The conservation of Roadblock sequences (i.e.  Roadblock domains) within the coding regions of 
genes  of mammals  and  other  species  (Bowman  et  al.,  1999;  Koonin  et  al.,  2000)  highlights  a 
necessary functional constraint.  However, these genes are not thought to be cytoplasmic dyneins; 
e.g.  MAPBPIP  (Entrez  GenelD:  28956)  in  human  and  mouse  functions  mainly  in  the 
endosome/lysosome pathway (Lunin et al., 2004).
5.3.6  Cytoplasmic dynein light chain (LC8) 1, DYNLL1
Figure  5.8C  shows  the  phylogenetic  relationships  amongst  the  dynein  light  chain  LC8  family 
protein sequences  from various  organisms.  The phylogeny shows  that the mammalian  LC8  light 
chain family falls into two distinct clades containing DYNLL1- and DYNLL2-like genes. DYNLL 
is highly conserved from algae to humans, which is illustrated by:  (i) a high degree of sequence 
similarity between distant species - 92% similarity exists between Drosophila Cdlcl  (NP525075) 
and  the  8kDa  flagellar  outer arm  dynein  light  chain  from  Chlamydomonas  (Q39580),  and  91% 
between  human  and  C.  elegans  light  chain  1  (NP  498422)  and (ii)  a  flat tree with  short  branch 
lengths  between  taxa.  In  total,  67%  of pairwise  sequence  alignments  illustrated >50%  sequence 
identity  which,  although  fewer  that  seen  for  the  Roadblock  proteins,  includes  sequences  from 
several more distant species and therefore accounts for a lower number of high identity alignments 
(Figure  5.7).  Taken  together these data  suggest  that DYNLLl  and DYNLL2 are both  likely to be 
under strong purifying selection to conserve protein function.
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Figure 5.7  Cytoplasmic dynein light chain (LC8) family protein alignments
67% of all alignments were >50% sequence identity. Protein sequences are presented in the same order as 
the tree in Figure 5.8C. Alignments were conducted using ClustalW.
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Figure 5.8  Protein-based phylogenies of the cytoplasmic dynein light chain family
Species names for Tctexl  (A), Roadblock (B) and LC8 (C) dynein light chain phylogenies are given with 
NCBI/GenBank gene/protein names (sequence accession numbers are given in Appendix). Orthologous 
human, mouse, and rat gene names use the revised systematized consensus nomenclature (Pfister et al., 
2005b). Named clades are indicated in the right margins. Bayesian and maximum-likelihood bootstrap values 
are shown as percentages adjacent to branch points, ‘bootstraps below 50%. •bootstraps at 100%. Scale-bar 
represents evolutionary distance (estimated numbers of amino-acid substitutions per site).
5.4  Discussion
In  preparing  to  undertake  a  systematic  analysis  of the  components  of the  cytoplasmic  dynein 
pathway  for  a  large  scale  association  study,  confusion  and  errors  regarding  the  nomenclature, 
mapping positions and sequence accession numbers were observed in the literature and databases.
159The  accuracy  of electronic  data  should  be  a  concern  for  all  research  communities  as  it  is  an 
increasingly common problem; it is estimated, for example, that ~15% of annotation in GenBank 
contains  errors,  many  of which  have  been  found  to  be  propagated  in  peer-reviewed  literature 
(Pennisi,  1999). The dynein community is not exceptional in this respect and as the data presented 
in this chapter catalogue, several errors were identified in cytoplasmic dynein subunit annotation. 
Where mistakes were identified in databases and other online resources, the hosting institute was 
contacted to review their data and amend it where necessary.
Table  5.2  catalogues  the  key  data  for  mouse  and  human  dynein  subunits  including  subunit 
synonyms,  mapping positions and mRNA and protein accession numbers,  which has  since been 
published as a valuable resource for the cytoplasmic dynein community (Pfister et al., 2005b). The 
investigation of novel mouse and human paralogs was a valuable secondary analysis in confirming 
the cognate genetic locus of each dynein subunit. In both species, for many of the subunits tested, 
alignments of expressed sequences were seen against various regions of the genome however, these 
regions  were  identified  as  either:  (i)  genes  and  proteins  containing  homologous  domains  to  the 
dynein  subunits  tested,  (ii)  pseudogenes  of whole  or  partially  duplicated  loci  or  (iii)  incorrect 
genome assembly. DYNLL1 possessed a large number of homologous sites which were determined 
to be pseudogenes created by duplication events.  All  loci  identified except chromosome  1,  have 
since been included on the human pseudogene database (www.pseudogenes.org). The “intronless” 
nature of the pseudogenes and the SINE and LINE  flanking repeat sequences were indicative of 
duplication by a non-LTR Class 1  transposable element, which moves by reverse transcription of an 
RNA intermediate (Silva et al, 2004). The presence of identical transposed sequences in the mouse 
provides an indication of the age of the DYNLL1  duplication -  predating the mouse and humans 
species divergence ~75 million years ago (Waterston et al., 2002).
5.4.1  Cytoplasmic dynein nomenclature
Collation  of the  myriad  names  used  to  describe  the  cytoplasmic  dynein  subunits  illustrated  the 
extent  of confusion  in  the cytoplasmic  dynein  field.  All  subunit  synonyms  were  investigated  to 
establish their accuracy and  many,  such  as  the “CDC23”  synonym  were proven to  be  incorrect 
(Chapter  5.2.2).  The  data  presented  in  this  chapter,  including  the  phylogenetic  analyses,  were 
influential in facilitating a revision of the human and mouse dynein nomenclature to a standardised 
format. Standardising nomenclature of large gene families has been undertaken for many different 
proteins; see for example (Marenholz et al., 2004; Miki et al., 2005; Rodgers et al., 2007; Wilson et 
al.,  2006) and have in common the use of phylogenetic analyses to establish inclusion/exclusion 
criteria for family members. The investigation of paralogous and orthologous cytoplasmic dynein
160sequences  allowed  a  complete  investigation  of  known  and  unknown  dynein  subunit  family 
members, which could then be named accordingly.
5.4.1.1  A new nomenclature system for the cytoplasmic dynein subunits
Revision of the mammalian cytoplasmic dynein nomenclature system was undertaken by Pfister and 
colleagues  (Pfister  et  al,  2005a)  and  was  approved  by  the  Human  Genome  Organisation 
Nomenclature  Committee  (HGNC,  2004)  and  the  International  Committee  on  Standardised 
Nomenclature  for  Mice  (Maltais  et  al,  1997).  Phylogenetic  analyses  of  the  dynein  proteins 
substantiated the existence of two distinct dynein complexes, cytoplasmic dynein 1  and cytoplasmic 
dynein  2  and  the  exclusive  occurrence  of DYNC2H1  and  its  binding  protein  DYNC2LI1.  In 
accordance with HGNC policy, Pfister and colleagues designated each unique cytoplasmic dynein 
subunit with the root “DYNC” (for dynein, cytoplasmic), followed by the specific dynein complex 
subtype  1   or 2 (e.g. cytoplasmic dynein 2 was designated DYNC2). The shared light chains were 
rooted  with  “DYN”  and  other  subunits  were  designated  with  a  letters)  for  the  size  of  the 
polypeptides:  H for the Heavy Chain,  I  for the Intermediate chain,  LI for the Light  Intermediate 
Chain, and L for Light Chain. Additional letters (T, RB and L) were used to distinguish the three 
distinct light chain families and individual members of the gene families were assigned numbers. 
The revised nomenclature has been used throughout this thesis.
5.4.2  Changing databases and future studies
As with many in silico approaches, the results of an investigation are often correlated to the quality 
and completeness of the raw data used and as such, the data presented in this chapter reflect the 
state of the sequence and genome databases at the time they were accessed. Identifying paralogous 
dynein  sequences  in the mouse and human benefited  from the availability of complete genome, 
nucleotide  and  protein  data,  however,  the  identification  of orthologous  sequences  in  newly  or 
partially  sequenced  genomes  may  have  suffered  from  incomplete  sequence  ascertainment. 
Therefore, the cytoplasmic dynein subunit phylogeny is currently accurate but with the publication 
of genome sequences from additional species, the phylogeny may be refined in the future and weak 
nodes provided with greater support.
5.4.2.1  Priority candidate genes: DYNLL family and DYNLRB family
The  cytoplasmic  dynein  light  chain  LC8  phylogenetic  tree  suggests  that  human  DYNLL1  and 
DYNLL2 may both be promising candidates for a future ALS candidate gene association study. The 
flat branch network illustrated the extent to which proteins of this family are conserved between 
distantly related  species that diverged ~1717  million years  ago  (Nei  et al,  2001).  More closely 
related species such as human, mouse, rat, pig, and cow show extraordinary sequence conservation;
161between  these  species  the  amino  acid  sequences  of both  DYNLL1  and  DYNLL2  are  identical 
(Wilson et al.,  2001). The observed DYNLL amino acid sequence homogeneity between species 
can be explained by the action of purifying selection which serves to eliminate those mutations that 
have  a  deleterious  effect  on protein  function.  Purifying  selection  is  generally  a  more  pervasive 
mechanism of selection than other forms of directional  selection (Hughes et al.,  2003;  Kimura et 
al.,  1974) and has been shown to maintains stringent interspecies sequence homogeneity in proteins 
with essential  functions,  such as H4 histones (Piontkivska et al.,  2002).  The conservation of the 
DYNLL  protein  family  raises  questions  as  to  what  essential  function  these  proteins  play  and 
whether perturbation of this function may yield a neurodegenerative phenotype. As yet, no neuronal 
phenotypes are known.
The  significance  of DYNLL  to neuronal  function  (and  conversely,  degeneration)  is  not  known. 
However,  DYNLL  is  known  to  be  an  integral  part  of brain  cytoplasmic  dynein,  although  it  is 
ubiquitously  expressed  in  all  cells  of the  body  and  large  amounts  of brain  DYNLL  are  not 
associated with the dynein complex  (King et al.,  1996a). The  functional role of these  LC8  light 
chains  is  varied:  DYNLL  is  a  substrate  of a  p21-activating  kinase  (Vadlamudi  et al.,  2004),  a 
component  of the  actin-based  motor myosin  V  (Naisbitt  et al.,  2000b)  and  a component  of the 
nNOS complex (Grissom et al., 2002). DYNLL mutants display various developmental and fertility 
phenotypes (reviewed in (Pfister et al.,  2005b) and total loss-of-function Drosophila mutants are 
embryonic lethal (Dick et al.,  1996a).
Drosophila Roadblock mutants also result in a number of phenotypes including the accumulation of 
axonal cargoes, mitotic defects, female sterility, and larval/pupal lethality (Bowman et al.,  1999). 
The  Roadblock  proteins  also  demonstrated  high  sequence  similarity  of  interspecies  pairwise 
alignments which suggests that these proteins have also been conserved. Although, more distantly 
related  species were not available  for comparison during the original  analyses (which may have 
inflated the apparent  level of protein conservation),  several new protein sequences have recently 
become  available  and  continue  to  show  high  sequence  identity:  Dictyostelium  discoideum 
hypothetical  protein  (XP  637964)  displays  62%  sequence  similarity  to  human  DYLRB1 
(NP  054902).  The  Roadblock  proteins  are  promising  candidates  for  neurodegeneration  with 
mutants  affecting  neuroblast  proliferation,  reducing  dendritic  complexity  and causing  defects  in 
axonal transport (Reuter et al., 2003).
The human DYNLL and DYNLRB genes should therefore make valuable candidates for future ALS 
and other motor neuron disease association studies.
1626  Identifying kuru susceptibility loci
6.1  Introduction
Mapping disease susceptibility loci by identifying genes affected by natural selection imposed by 
the  disease,  is  a  novel  approach  to  mapping  complex  traits.  In  this  chapter  such  evolutionary 
analyses of the prion gene (PRNP) is undertaken as a paradigm for future studies of prion disease 
candidate loci and whole-genome analyses. This chapter begins with an updated analysis of the role 
of codon 129 as both a susceptibility locus and as a protective factor for kuru, in the kuru-exposed 
linguistic groups of the Eastern Highlands of Papua New Guinea. The resulting genetic impact of 
the kuru epidemic is investigated in the surviving populations, with codon 129 genotypes analysed 
stratified by age and sex. A large sample of elderly South Fore females and slightly younger South 
Fore males show significant Hardy-Weinberg disequilibrium at codon  129, driven by an excess of 
heterozygosity, an observation consistent with their participation in mortuary feasts. Examination of 
codon  129  valine  allele  frequency  worldwide  illustrates  a  significant  West-East  reducing  cline, 
against which the PNG valine frequency contrasts starkly. An update and refinement of individual 
village exposure to kuru by establishment of an Exposure Index, allowed a more subtle analysis of 
valine  allele  frequency.  A  significant  increasing cline was  seen  from non-Highland to  Highland 
populations however no local cline within the Eastern Highlands was seen. Similarly, no increase in 
LD between microsatellites flanking PRNP is seen. This chapter concludes with a feasibility study 
on  the  whole-genome  analysis  of a  small  number  of elderly  Fore  women  and  whole  genome 
amplified kuru samples using 250,000 SNP arrays. Although the amplified kuru samples genotyped 
poorly, the remaining 7 samples from elderly Fore women are used to determine analysis criteria 
and examine cursory LD data.
6.1.1  Kuru and the evolution of human PRNP
The  evolution  of human  PRNP  is  a  contentious  topic  which  has  been  investigated  by  several 
authors.  In 2003, the work of Mead and colleagues  investigated the PRNP locus  in a number of 
worldwide populations including the people of the Eastern Highlands of Papua New Guinea who 
experienced the human prion disease epidemic of kuru (Mead et al., 2003). Mead identified that the 
prion  locus  had  undergone  kuru  imposed  balancing  selection  in  the  Fore  people  of the  Eastern 
Highlands by identifying a significant excess of heterozygotes in the surviving Fore population; a 
significant excess of human coding polymorphisms as tested by a McDonald-Kreitman test against 
both Old and New World monkeys;  a significant positive Tajima’s D for polymorphisms within 
4.7kb sequence; a bifurcating haplotype genealogy characterised by two long deep branches with 
highly divergent clades (which were associated with each codon  129 allele) and extended linkage
163disequilibrium with microsatellites flanking ~30 kb either side of PRNP with reduced diversity of 
alleles. In addition, several of these features were shared by other worldwide populations prompting 
the suggestion that the prion gene had undergone balancing selection throughout human history and 
speculation that (as one hypothesis) the selective pressure was provided by widespread cannibalistic 
practices in prehistoric humans. Several authors have challenged Mead’s proposition with regards 
to balancing selection at PRNP,  imposed by cannibalism-associated prion-like diseases during the 
evolution  of modem  humans,  citing  polymorphism  ascertainment  as  a  bias  introducing  factor 
(Brookfield, 2003; Soldevila et al., 2003; Soldevila et al., 2006).
Despite this, there is general agreement that the data presented for the Fore does illustrate the action 
of natural selection in this population and that the basis for this selection pressure is the marked 
survival  advantage  of PRNP codon  129  heterozygotes  (Cervenakova  et  al.,  1998;  Mead  et  al., 
2003).  The  strength  of balancing  selection  in  the  Fore,  within  a  single  generation,  has  been 
identified  as  the  strongest  documented  to-date  in  any  human  population  (Hedrick,  2003)  and 
surpasses  the  commonly  quoted  example  of malaria  on  the  C  and  S alleles  of /3-haemoglobin 
(Hedrick, 2004). Such great selection pressures could rapidly establish/eliminate mutations within 
the  population  and  therefore  by  examining  the  evolutionary  signatures  of selection,  kuru  may 
provide  a  unique  resource  for the  investigation  of disease  modifying  loci  in  prion  disease  and 
possibly  other  neurodegenerative  diseases.  Therefore,  the  main  aim  of this  chapter  was  not  to 
resolve the debate regarding worldwide balancing selection but to  investigate further the genetic 
signature of balancing selection on the Fore, how this can be utilised to identify other mediators of 
human prion disease and the applicability to this  method of analysis to other neurodegenerative 
diseases. Further, this chapter aims to:
to update previous assessments of the role of codon  129 in kuru susceptibility and protection, by 
analysing larger data sets.
(i)  to  identify  a  correlation  between  the  extent  of kuru  experienced  by  Eastern  Highland
linguistic groups and the pattern of genetic variation at PRNP (i.e.  identify signatures of
selection) as a precedent for performing larger candidate gene or whole-genome study
(ii)  to establish a resource to  identify novel susceptibility loci.  By identifying a correlation of
genetic  variation  at  PRNP  proportional  to  exposure  to  kuru,  a  panel  of samples  from 
different linguistic groups with differing exposure to kuru could be used to identify/support 
additional susceptibility loci
(iii)  to pilot a whole genome  hyper-case-control association study between kuru and multiple
exposure samples.
1646.2  Kuru susceptibility is mediated by PRNP codon 129 genotype
Cervenakovd and colleagues originally  illustrated  the  influence of codon  129  genotype  on  kuru 
susceptibility by examining genotype data from 92 kuru patients (Cervenakova et al.,  1998). They 
correlated homozygosity at codon  129 with an earlier age of kuru onset and shorter duration of 
illness,  compared  to  heterozygosity.  The  MRC  Prion  Unit’s  collection  of  161  kuru  samples 
provided an opportunity to re-examine the effect of codon 129 on kuru susceptibility with a larger 
sample size and for a sex-specific genotype distribution.
Kuru samples were obtained as either DNA or blood/sera from which DNA was extracted by the 
MRC Prion Unit Human Genetics Group, using QIAmp mini DNA extraction kits and following 
safety  procedures  relevant  to  handling  infectious  material.  PRNP  codon  129  genotyping  was 
performed by allelic discrimination on all  samples (described in Materials and Methods Chapter 
2.3.13) using a FAM-tagged PRNP codon  129M probe, VIC-tagged PRNP codon 129V probe and 
flanking  forward  and  reverse  primers  taqmvf2  and  taqmvr  respectively  (see  Primer  Table  in 
Appendix).  Data on age at sample collection and sex were obtained  for all samples however,  18 
samples  lacked this information and were removed from further analysis.  Deviations from HWE 
were calculated using PLINK.
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Figure 6.1  Distribution of PRNP codon 129 genotypes by age in 147 kuru cases
The proportion of kuru MV heterozygotes increases with age of onset.
Genotype  proportions  in  early  onset  kuru  cases  were  significantly  distorted  away  from  those 
estimated by HWE (Figure 6.1) with excess homozygosity (Pexact =0.0003, in patients  ^0  years 
old).  Concomitant  increase  in  heterozygosity  was  seen  with  age,  with  a  significant  excess  of 
heterozygotes in the age groups 31 to 40 years {Pexact =0.003) and 41 to 50 years {Pexact =0.006). The 
11  to 20 and 21  to 30 years age groups were both in HWE {Pexact =0.70 and 0.087 respectively), 
which represented the intersection of decreasing homozygosity and increasing heterozygosity with 
age and therefore the genotype proportions appeared normal. Comparison by Pearson X 2  test of the
165most  (<20  years old) and  least  susceptible (>30 years old) kuru  groups was  highly  significantly 
different (/*«0.001, 2 d.fi). These data illustrate the protective effect of heterozygosity at codon 
129 which results in a later age of kuru onset.
When  partitioned  and analysed  by sex  (Figure  6.2)  the  data  illustrated and  was  consistent  with 
several  epidemiological  aspects  of kuru  including:  (i)  the  extent  to  which  kuru  largely  affected 
females as compared with males and (ii) the peak kuru incidence in males occurred between  11  to 
20 years old, which supports the participation of only boys less than 8 years old at mortuary feasts 
(given a mean kuru incubation period of ~12 years).
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Figure 6.2  Sex specific distribution of PRNP codon 129 genotypes by age at collection in 
146 kuru cases
Top. Female kuru cases. Bottom. Male kuru cases.
Detailed  inspection  of the  earliest  onset  males  and  females  cases  (^ 0   years  old),  identified an 
excess of female valine homozygotes and methionine homozygotes  in males (two-tailed Fisher’s 
exact,  P=0.015).  Lee  and  colleagues  also  noted this  result  in  young  Fore  males  ^ 0   years  and 
suggested that it reflected an increased susceptibility of methionine homozygotes to kuru (Lee et al., 
2001a)  although  their  analysis  may  have  been  affected  by  small  sample  size.  Taking  this  into 
account,  the  conflicting  absence  of MM  and  VV  genotypes  in  males  and  females  most  likely 
reflects a sampling artefact.
6.3  PRNP codon 129 heterozygosity mediates protection against kuru
Expanding on the work of Mead and colleagues who examined codon 129 status in 30 elderly Fore 
women, blood was obtained from an additional 104 women (Mead, 2002). All women were aged 50
166years or over in the year 2000, had a history of multiple exposures to kuru at mortuary feasts and 
resided in a village documented to have a moderate to high level of exposure. The  134 samples 
were obtained form the South Fore (n=68), North Fore (n=36), Gimi (n=27) and Keiagana (n=3) 
and ranging in age from 50 to 82 years old, with a mean age of 60 years. On closer inspection of 
village-specific kuru exposure (explained later in this chapter), 9 individuals were found to originate 
from an unexposed village and were removed from further study.
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Figure 6.3  Observed and expected PRNP codon 129 genotype frequencies for elderly Fore 
women repeatedly exposed to kuru
Expected frequencies calculated under HWE. Significant deviation of the observed data (Pe*act=3.1  x 10-5) 
from HWE and significant heterozygote excess (P«0.000001).
The  remaining  125  samples were genotyped at codon  129 (as described  in 2.3.13). The elderly 
multiple-kuru exposure women demonstrated a highly significant deviation from Hardy-Weinberg 
equilibrium (P„aC /=3.1  x  10'5 ) with a significant excess of heterozygotes (P«0.0000001) as tested 
using the Score test* implemented in the software GENEPOP (Figure 6.3).
The  added  data  support  the  original  analyses  and  illustrate  the  remarkable  survival  advantage 
proffered by heterozygosity at codon 129 to a cohort with acute and repeated exposure to kuru. An 
interesting question raised by these data relates to the “protection” afforded to homozygotes - in a 
cohort  of  women  acutely  exposed  to  kuru  on  multiple  occasions,  how  have  women  with  a 
“susceptible” codon 129 genotype managed to survive? These data suggest the possibility of codon 
129 independent protection, which is examined later in this chapter.
*  The Score test (or U test) as implemented in GENEPOP, is an exact HWE test which specifically tests for 
excess heterozygosity as an alternate to the null hypothesis, which is that the population examined is in HWE
1676.4  Investigating PRNP for a kuru-mediated signatures of selection
6.4.1  Codon  129 genotypes in the surviving Eastern Highlands population
Codon  129  genotype  proportions  were  used  to  examine  the  scale  and  the  extent  of the  kuru 
epidemic in the surviving population of the Eastern Highlands. The reduced fitness of codon  129 
homozygotes  and  their  subsequent  removal  from  the  population  should  have  produced  a 
characteristic  signature  in  the  genotype  proportions  of the  remaining  population,  detectable  as 
deviation from HWE.
Figure  6.4  Schematic map of the Eastern Highlands of Papua New Guinea
Approximate localisation of neighbouring linguistic groups are shown. For simplicity, geographical and 
topographical features have been omitted. Linguistic groups with experience of kuru are shaded brown and 
groups unaffected by kuru are shaded green.
The extent of Hardy-Weinberg disequilibrium will be proportional to the extent of kuru experienced 
by each population examined, with the greatest deviations seen  in the North and  South Fore. To 
examine  HWE  by  kuru  exposure,  an  estimate  of exposure  level  for  each  linguistic  group  was 
obtained based on an assessment of number of kuru cases recorded since records began  in  1957 
made by the MRC-PNGIMR field team. The Eastern Highlands were divided into kuru exposed and 
unexposed areas (Figure  6.4).
A  total  of 3200  DNA  samples  representing  12  linguistic  groups  of the  Eastern  Highlands  were 
obtained, either as previously extracted DNA samples held at the MRC Prion Unit or extracted from 
whole blood. All samples were genotyped at codon  129 as described previously. For each sample 
the following data were collated and samples lacking these data were not retained for analysis: the 
individual’s sex, age at collection, year of collection and village. Approximately 2350 samples from 
the South Fore (n=1279), North Fore (n=276), Keiagana (n=220), Yagaria (n=l 14), Agarabi (n=90),
168Tairora  (n=77),  Siane  (n=74),  Awa  (n=46),  BenaBena  (n=46),  Jate  (n=43),  Morae  (n=43)  and 
Gadsup (n=42) were carried forward for further analysis.
6.4.1.1  The special case of heterozygote advantage
The availability of age at collection and date of collection data was imperative for accurate HWE 
analysis to be undertaken. These data allowed the analysis of individuals bom during the period of 
the kuru epidemic, as opposed to individuals bom after the cessation of cannibalism. To understand 
the importance of obtaining the effect of balancing selection on allele frequencies in generations 
subsequent to the removal of selective pressure should be considered:
Balancing  selection  establishes  a  unique  condition  in  which  although  Hardy-Weinberg’s  law  is 
disobeyed  (i.e.  the  assumption  of an  absence  of selection  is  violated),  the  allele  and  genotype 
frequencies in successive generations, after the selective pressure is removed, remain stable and in 
equilibrium.  Consider  the  condition  where  complete  heterozygote  advantage  is  seen  (i.e. 
homozygosity is lethal) in a single locus system with alleles A and B. Within a single generation all 
AA  and  BB  homozygotes  perish  and  only  AB  heterozygotes  remain.  Following  mating  of the 
surviving  heterozygotes  (frequencies  of both  alleles  A  and  B  are  50%  each)  all  genotypes  are 
represented at equilibrium frequency (AA and BB at 25%  frequency and AB at 50%).  With the 
removal  of  selective  pressure,  only  a  single  generation  is  required  to  return  genotypes  to 
equilibrium conditions and any signal of selection that is based on allele frequency and genotype 
proportions is lost.
Therefore, the PNG samples were analysed stratified by age and exposure to kuru, calculated based 
on epidemiological information available. The enforced cessation of cannibalism in the mid-1950s 
was used as a watershed for age calculations. The majority of PNG samples were collected between 
1997 and 2002 and individuals recorded as being >50 years old at sample collection were assumed 
to have lived during the kuru epidemic.
6.4.2  Hardy-Weinberg equilibrium in the surviving population
The  surviving  linguistic  groups of the  Eastern Highlands were tested  for deviations  from  HWE, 
stratified by age. Linguistic groups were analysed (i) as a whole, (ii) stratified by age and (iii) for 
the North and South Fore only, stratified by age and sex, as these cohorts were sufficiently large 
enough to avoid small sample sizes. Significance was tested using the exact x2  test implemented in 
PLINK (Table 6.1). Significant Hardy-Weinberg disequilibrium was seen in the South Fore for the 
whole group (Pexact =0.005) and all South Fore individuals >50 years alive during the kuru epidemic 
(Pexact =0.003). By analysing the >50 years group by sex, it was seen that females >50 years were
169driving this result (Pexact =0.0004) and no significance was seen for the corresponding male group. 
Significant deviation from HWE was also seen in South Fore males <50 years old. This group was 
further analysed by decade of birth (data not shown) and only those men bom between  1950 and 
1960, during the peak of the kuru epidemic, showed a significant deviation (Pexact =0.0287). These 
data support the epidemiological and cultural data suggesting that boys up to 8 years of age would 
have participated at feasts with their mothers.
HWE in the North Fore population and additional kuru exposed groups including Keiagana, Jate, 
Agarabi, Yagaria and Awa, was puzzling. Kuru cases have been recorded in all of these linguistic 
groups and the North Fore, in particular females >50 years old, are recorded to have experienced 
frequent kuru cases, second only to the South Fore. The absence of a significant deviation from 
HWE in these linguistic groups may relate to a sample ascertainment problem, with all linguistic 
groups sharing a paucity of individuals >50 years old.
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Linguistic Group 
(years old) N=
MM
Codon 129 
MV W
P-value
m   HW E
S.Fore 1279 248 687 344 0.005
>50 122 16 77 29 0.003
<50 1157 232 610 315 0.044
S.Fore male 426 72 240 114 0.006
>50 74 11 40 23 0.474
<50 352 61 200 91 0.007
S.Fore female 853 176 447 230 0.149
>50 48 5 37 6 0.0004
<50 805 171 410 224 0.571
N.Fore 276 52 146 78 0.331
>50 81 10 43 28 0.356
<50 195 42 103 50 0.474
N.Fore male 109 19 53 37 1.0
>50 42 5 21 16 0.749
<50 67 14 32 21 0.807
N.Fore female 167 33 93 41 0.163
>50 39 5 22 12 0.506
I
<50 128 28 71 29 0.288
X
LU Keiagana 220 42 106 72 0.784
>50 4 2 1 1 0.429
<50 216 40 105 71 0.890
Jate 43 7 26 10 0.226
>50 14 1 8 5 0.590
<50 29 6 18 5 0.278
Agarabi 90 17 37 36 0.190
>50 13 1 8 4 0.566
<50 77 16 29 32 0.061
Yagaria 114 28 56 30 0.853
>50 36 8 19 9 1.0
<50 78 20 37 21 0.655
Awa 46 5 26 15 0.351
>50 4 1 1 2 0.429
<50 42 4 25 13 0.194
BenaBena 46 11 23 12 1.0
>50 8 1 5 2 1.0
<50 38 10 18 10 0.752
Gadsup 42 4 26 12 0.101
>50 5 0 5 0 0.127
TJ <50 37 4 21 12 0.321
a X
Morae 43 10 19 14 0.540
>50 0 0 0 0 n/a
0)
c <50 43 10 19 14 0.540
3
Siane 74 18 35 21 0.646
>50 17 4 9 4 1.0
<50 57 14 26 17 0.595
Tairora 77 15 43 19 0.364
>50 16 2 8 6 1.0
<50 61 13 35 13 0.313
Table 6.1  Hardy-Weinberg analysis of the Eastern Highland linguistic groups
HWE P-value calculated using exact test -  significant deviations from HWE are in bold6.4.3  Heterozygosity at codon 129
The  Hardy-Weinberg  data  in  Table  6.1  clearly  indicates  that  deviations  from  HWE  are  due  to 
excess heterozygosity at codon 129. It has been proposed that reduced diversity at various loci can 
be used as a tool to identify genes undergoing directional selection (Hughes et al.,  2003) and so it 
was  hypothesised  that  conversely,  loci  with  greater-than-expected  diversity  may  indicate  genes 
undergoing balancing selection. To further refine the HWE data and develop a test to apply to other 
loci, heterozygosity (H) was examined at codon 129. Linguistic groups were grouped based on kuru 
exposure  levels:  1668  high  kuru  exposure  samples  (North  and  South  Fore),  333  low  exposure 
samples (Awa,  Gimi,  Jate,  Keiagana  and Yagaria)  and 487  unexposed samples (Agarabi,  Asaro, 
BenaBena, Gadsup, Gahuku, Labogai, Morae, Siane, Tairora and Yabiyufa) were analysed.
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Figure 6.5  Heterozygosity at PRNP codon 129 stratified by sex and age
Mean heterozygosity (H) shown ± 1.96 SEM
The difference between expected and the observed heterozygosity (AH) was calculated and highly 
exposed women >50 years and men <50 years both differed significantly (P0.001) from the global 
mean AH ±  1.96 SEM (Figure 6.5).  In addition, all cohorts examined for HWE were tested using 
the Score test implemented in GENEPOP. All results were negative except highly exposed women 
>50 years, /MJ.0002 and South Fore men between 40 and 50 years P=0.0049.
6.5  Variation of PRNP codon 129 valine allele frequency
The  geographical  co-variation of allele  frequencies  with  intensity of selective pressure has been 
routinely cited as a  signature of natural  selection in human populations,  see  for example lactase 
persistence alleles and the establishment of dairy farming (Harvey et al.,  1998; Swallow, 2003) and 
blood pressure regulating alleles co-varying with latitude (Young et al., 2005). Several authors have
172identified  a  geographical  cline  of  PRNP  codon  129  allele  frequency  worldwide.  Mead  and 
colleagues first reported an approximate West-East reducing cline of the codon  129 valine allele, 
towards South East Asia and Oceania, identified through analysis of several world wide populations 
(Mead et al.,  2003). The valine allele frequency of the Fore population of PNG was found to be 
strikingly increased compared to neighbouring populations. Mead postulated that, taken with other 
data, one hypothesis describing the selective pressure responsible for creating and maintaining such 
a cline was the widespread occurrence of acquired prion disease, transmitted through cannibalism in 
prehistoric  human  populations  and  that  in  stark  contrast  the  high  valine  frequency  in  the  Fore 
represented a more recent episode of selection. This result was supported by the work of Soldevila 
and colleagues and Hardy and colleagues who investigated worldwide codon 129 allele frequencies 
in populations comprising the CEPH diversity project (Hardy et al., 2006b; Soldevila et al., 2003). 
Both Soldevila’s and Hardy’s data supported a longitudinal West-East cline in valine frequency and 
identified the highest known valine allele frequencies in several Central American populations with 
suspected histories of cannibalism. In addition, although Lucotte and Mercier’s work investigating 
valine  frequency in  12  French and Western European populations  failed to  identify a significant 
longitudinal  cline,  they  did  however  identify  a  significant  correlation  of allele  frequency  with 
latitude  (North-South)  (Lucotte et al.,  2005).  Population data  from these and other international 
studies  provided  the  opportunity to  perform  a  combined  analysis  to  assess  worldwide  clines  in 
codon 129 allele frequency.
6.5.1  Variation of codon 129 valine allele frequency worldwide
Published  codon  129  genotype data  for  normal  worldwide  populations  were  collected  from  the 
literature  representing  41  countries.  Data  from  281  unexposed  Fore  individuals  was  obtained. 
Where data existed for distinct ethnic groups within a country, these were analysed separately. For 
simplicity,  the  geographical  positions  used  for  distance  calculations  were  either  (i)  the  country 
capital or (ii) the regional capital or largest regional town (for studied populations comprising of 
multiple  ethnic  groups).  For example,  several  authors  have  studied  PRNP variation  in  multiple 
Chinese  ethnic  groups  including  the  Hui  and  the  Uygur  peoples,  whose  provincial  capitals  are 
separated by almost 2000 km and whose valine allele frequencies differ markedly by almost  15% 
(Figure 6.6).
The  online  map  tool  MultiMap  (www.multimap.com.  accessed  2006)  was  used  to  identify 
latitudinal and longitudinal coordinates in decimal degrees and distances from the Prime Meridian 
(at Greenwich, UK; 51.28N, 0E respectively), calculated using the Haversine formula employed in 
a java script (www.movable-tvpe.co.uk/scripts/LatLong.html). Figure 6.7 illustrates the remarkable 
reducing cline seen in valine allele frequency worldwide. The correlation of allele frequency with
173distance from the Prime Meridian was highly significant (Correlation coefficient R=0.80, R2=0.65 
and P=4xl01 2 ). The highest published valine frequency was found in Central America (Colombia 
81% and Brazil  79%)  (Hardy et al.,  2006b)  and the lowest  frequencies were  found in  East  and 
South East Asia (Taiwan  1.5% and Japan 2%) (Mead et al.,  2003; Ohkubo et al.,  2003). In stark 
contrast  to  other  populations  at  comparable  distances  east  of the  Prime  Meridian,  the  Eastern 
Highlands  valine allele  frequency (based on the Fore population)  significantly deviated  from  its 
predicted value.
174Figure 6.6  Worldwide PRNP codon 129 valine allele frequency
See Figure 6.7 legendThese data consolidate previous studies of worldwide variation of codon 129 and illustrate the Fore 
population  of  PNG  as  an  outlier  to  this  trend.  As  other  authors  have  noted  the  two  highest 
occurrences  of  valine  allele  frequency  occur  in  the  Fore  population  of  PNG  and  in  Central 
American populations, which all have documented cases of cannibalism.
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Figure 6.7  Variation of PRNP codon  129 valine allele frequency w orldwide
Red data points: Austria (n=300) (Zimmermann et at., 1999), China (Uygurs n=223; Han n=205) (Yu et a!., 
2004), France (n=161) (Deslys et at., 1994; Laplanche et at., 1994), Germany (n=722) (Vollmert et at., 2006), 
Greece (Crete n=205) (Plaitakis et at., 2001), Greece (n=348) (Saetta et at., 2006), Holland (n=117) 
(Bratosiewicz-Wasik et at., 2007), Iceland (n=208) (Georgsson et at., 2006), Italy (n=318) (Del Bo et at., 2005), 
Japan (n=466) (Ohkubo et at., 2003), Korea (n=529) (Jeong et at., 2004), Poland (n=194) (Gacia et at., 2006), 
Slovakia (n=613) (Mitrova et at., 2005), Slovenia (n=97) (Galvani et at., 2005), Spain (n=268) (Combarros et 
at., 2000), Turkey (n=100) (Erginel-Unaltuna et at., 2001), United Kingdom (n=406) (Collinge et at., 1991), USA 
(n=86) (Brown et at., 1994), Scotland (n=150), Northern Ireland (n=150), Republic of Ireland (n=203), Finland 
(n=1957) (Nurmi et at., 2003), Mexico (Maya n=22; Pima n=25), Brazil (Surui n=21; Karitiana n=24), Colombia 
(n=11), Senegal (Mandenka n=24), Scotland (Orcadian n=16), Algeria (Mozabite n=30), Russia (n=25), Russia 
(Adygei n=17), Israel (Bedouin n=24), Central African Republic (Biaka Pygmy n=36), Cameroon (n=39)
.Yoruba (n=25), Pakistan (Balochi, n=26), Siberia (Yakut n=26), Democratic Republic of Congo (Mbuti Pygmy 
n=15), Kenya (Bantu n=20) (Hardy et at., 2006b), Sri Lanka (n=35), Taiwan (n=70), PNG/Madang (n=83), 
Bougainville (n=22), Fiji (Taveuni n=10, other Fijian n=18), Tonga (n=22), Vanuatu (Port Olry n=33; Maewo 
n=32) (Mead, 2002). Blue data point: Papua New Guinea Fore population (n=281). Linear regression to the 
mean (R2) indicated.
6.5.2  Variation of codon  129 valine allele frequency in the Eastern Highlands
As  the  results  above  show,  the  equilibrium  valine  allele  frequency  in  the  Eastern  Highlands 
contrasts  distinctly  with  the  reducing  cline  seen  worldwide  particularly  with  neighbouring 
populations,  including the costal  PNG population of Madang (valine frequency 30%).  Within the 
Eastern  Highlands of PNG,  kuru  incidence  is known  to have varied geographically amongst  the 
various linguistic groups that inhabit the region. The Fore linguistic groups comprised the epicentre 
of the kuru epidemic and the burden of kuru decreased, or was completely absent, in neighbouring 
linguistic  groups.  This  geographical  variation  of  kuru  incidence  afforded  the  opportunity  to 
investigate the variation of PRNP codon  129  allele  frequencies with kuru exposure amongst  the 
linguistic groups of the Eastern Highlands, providing further evidence of the role of PRNP as a kuru 
susceptibility  locus  and  a robust  method  for assessing other candidate  susceptibility loci.  Valine
176allele frequency was calculated for each linguistic group and compared by exposure levels which 
were  approximately  proportional  to  distance  from  the  focus  of the  epidemic  in  the  South  Fore 
region.
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Figure 6.8  PRNP co d o n   129 valine frequencies  acro ss the Eastern  H ighlands
A. Linguistic groups with high exposure to kuru are shaded dark brown (Keiagana n=220; North Fore n=276; 
South Fore n=1279 and Gimi n=25). Low exposure linguistic groups are shaded light brown (Siane n=73; 
Tairora n=77; Yagaria n=114; Awa n=46 and Jate n=43). Unexposed linguistic groups are shaded green 
(Agarabi n=90; Yabiyufa n=30; Asaro n=26; BenaBena n=46; Gadsup n=42; Gahuku n=39; Labogai n=23 and 
Morae n=43). B. Mean valine allele frequency by kuru exposure level - no significant differences seen. Error 
bars are 1.96xSEM
Unexpectedly, an equilibrium valine allele frequency was identified across the linguistic groups of 
the  Eastern  Highlands,  which  was  a  surprising  result  (Figure  6.8A).  There  were  no  significant 
differences in allele frequency between those linguistic groups known to have been acutely exposed 
to  kuru  and  those  with  low  exposure  (T-test,  P=0.16)  and  unexposed  groups  (T-test,  P=0.46) 
(Figure  6.8B).  In  addition  there  was  no  significant  difference  between  the  low  exposed  and 
unexposed groups {T-test, /M).28). This intriguing result may have been due to: (i) demography - 
the uniform high valine frequency may reflect a historical bottleneck due migration and settling of 
the region rather than disease (ii) an older and more widespread incidence of kuru in the Eastern 
Highlands  than  previously  reported  (Jerome  Whitfield,  pers.  comm.)  and  (iii)  the  absence  of 
balancing  selection  -  highly  unlikely  with  evidence  of  HWE  deviation  presented  earlier.  In 
addition, the insensitivity of these analyses to the extent of kuru exposure of individual villages, as 
opposed  to  entire  linguistic  groups,  may  explain  have  confounded  the  results.  It  is  known  that 
within linguistic groups which experienced high occurrences of kuru, there were some villages that 
remained unexposed (Jerome Whitfield pers. comm.).
1776.6  Linkage disequilibrium measures in PNG
Linkage  disequilibrium  was  also  investigated  as  a  differentiating  signature  of  kuru  imposed 
selection. Under the balancing selection model, the frequency of the valine allele increased in the 
Fore populations from an initial value (possibly that similar to the costal Madang population -30%) 
to its present equilibrium frequency. The oral evidence collected from kuru survivors suggests that 
the kuru epidemic was swift, affecting at most 3 generations of Eastern Highlanders, implying an 
equally dramatic and swift increase in valine frequency. Such a large increase in allele frequency at 
a locus can cause a “hitchhiking” effect of the surrounding genetic variation, known as a selective 
sweep. One consequence of such a selective sweep is increased LD around the functional allele.
6.6.1  LD between microsatellites flanking PRNP
Microsatellites  108 and 53*, previously identified by Dr Simon Mead 30 kb upstream and 24 kb 
downstream  respectively  of codon  129  (Mead,  2002),  were  genotyped  in  high  and  low  kuru 
exposure populations and unexposed populations as described in Chapter 2.3.5.  Haplotype phase 
was resolved by genotyping codon  129 homozygotes only. Mead previously demonstrated reduced 
microsatellite diversity and extended LD at both  108 and 53  in the Fore compared to European, 
Japanese and African populations. The additional samples and data on exposure index allowed LD 
comparisons  across  the  Eastern  Highlands  to  be  made,  controlling  for  differences  due  to 
demography of the international samples.
Microsatellites 108 and 53 and codon 129 were in significant LD (Pexaa <0.000001, tested using the 
log likelihood method implemented in Arlequin) in all three groups examined on both haplotypic 
backgrounds. Similar patterns of allelic diversity and LD were seen in both directions for high, low 
and unexposed groups on both codon  129 methionine (Figure 6.9) and valine (Figure 6.10) allelic 
backgrounds. This result implied that either kuru had no effect on LD in the Eastern Highlands, or 
that the extent of LD surrounding PRNP in the Eastern Highland populations extends further than 
the  two  microsatellites examined and therefore,  extended  LD could not  be detected.  If the  latter 
were true and kuru had affected LD surrounding PRNP, a reduction in allelic diversity would also 
be expected on the valine haplotype, which is not seen either.
*  also referred to as a 108990 and a54000 in (Mead, 2002)
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Figure 6.9  M icrosatellite diversity upstream  and dow nstream  of the PRNP codon  129M allele
Allele frequencies at microsatellites 108 (upstream) and 53 (downstream) on the PRNP codon 129M 
haplotype. Maximum number of haplotypes: high exposure n=406, low exposure n=176 and unexposed n=136. 
No significant differences were seen in allele diversity or LD when compared between groups.
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Figure  6.10  M icrosatellite  diversity  upstream   and  dow nstream   of  the  PRNP  cod on   129V 
allele
Allele frequencies at microsatellites 108 (upstream) and 53 (downstream) on the PRNP codon 129V haplotype. 
Maximum number of haplotypes: high exposure n=562, low exposure n=246 and unexposed n=162. No 
significant differences were seen in allele diversity or LD when compared between groups
179Microsatellites D20S97, D20S482 and D20S889 (~720kb, ~161kb and ~143kb upstream of codon 
129,  respectively)  flanking  PRNP  at  greater  distances  were  identified  using  the  STS  database 
UniSTS.  These  microsatellites  were  genotyped  as  previously  discussed  with  help  from  James 
Uphill,  in  samples  homozygous  at  codon  129,  to  help  phase haplotypes:  high  exposure  samples 
from the kuru region, unexposed samples bordering the kuru region and UK ECACC samples for 
comparison. Although microsatellite diversity in the PNG samples was markedly different form the 
UK samples, there was no significant difference between the kuru exposed and unexposed samples 
on both haplotypic backgrounds (Figure 6.11 and Figure 6.12).
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Figure 6.11  M icrosatellite diversity upstream   of the PRNP the codon  129M  allele
Allele frequencies at microsatellites 108, D20S97, D20S482 and D20S889 upstream of codon  129M allele. 
Maximum number of codon 129M haplotypes PNG high exposure n=44, unexposed n=228 and UK n=288. 
Allele diversity is reduced in the PNG samples compared to the UK and also in the high kuru exposed group 
compared to the unexposed. Although linkage disequilibrium is extensive in the PNG samples compared to the 
UK samples, little difference is seen between the PNG cohorts acutely exposed to kuru and those unexposed.
180108
©
©
■  268
■  270
□  274 
B  278
■  280 
■  282 
■  284
□  286
Figure 6.12  M icrosatellite diversity upstream   of the PRNP codon  129V ailele
Allele frequencies at microsatellites  108, D20S97, D20S482 and D20S889 upstream of codon 129V allele. 
Maximum number of codon 129V haplotypes PNG high exposure n=40, unexposed n=344 and UK n=60. Allele 
diversity is reduced in the PNG samples compared to the UK and also in the high kuru exposed group 
compared to the unexposed. Although linkage disequilibrium is extensive in the PNG samples compared to the 
UK samples, little difference is seen between the PNG cohorts acutely exposed to kuru and those unexposed.
6.6.2  Microsatellite Fst
Fsr  analysis  of the  above  populations  was  performed  using  Arlequin.  On  both  methionine  and 
valine haplotypic backgrounds significant differentiation was seen between the two PNG cohorts 
against the UK cohort (P « 0 .000001, data not shown). Marginal significance was seen for valine 
associated alleles between kuru high exposure and unexposed {P=0.02 ± 0.02) cohorts, indicating 
that some genetic differentiation exists between these two groups. The methionine comparison was 
not significant (P=0.06 ± 0.01).
6.7  Refining the exposure of linguistic groups -  exposure index
The continuing efforts of the MRC-PNGIMR field team collecting biological samples, clinical and 
historical data relating to the kuru epidemic permitted a refining of kuru exposure estimates to the 
level  of  individual  villages  within  linguistic  groups.  A  detailed  explanation  of  how  the  new 
exposure  index  (El)  for  each  village  was  calculated  is  provided  in  the  Materials  and  Methods. 
Briefly the El for each village community was defined as the number of recorded kuru deaths in the
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181database for a village, normalise by its estimated population in  1958 and scaled by  1000. The El 
was  calculated  for  each  individual  village  in  the  Fore,  Gimi  and  Keiagana  linguistic  groups, 
however  for  the  smaller  number  of villages,  and  deaths,  in  other  linguistic  groups  the  El  was 
calculated for each linguistic group, based on the estimated kuru-affected population. Broadly three 
levels  of kuru  exposure  were adopted:  high  exposure  (EI>200),  medium  exposure  (30<EI<200) 
consisting of villages bordering the kuru region with at least some documented cases of kuru and 
low exposure (EI<30) consisting of villages with at least one recorded case of kuru. The new index 
permitted a refining of the level of exposure and the area of exposure, which may have confounded 
previous analyses.
6.7.1  Hardy-Weinberg equilibrium analysis indexed by exposure
A proportion of the Eastern Highland samples were reanalysed using the new El (Table 6.2). As 
previously observed,  increased homozygosity at codon  129 was associated with early onset kuru 
and increased heterozygosity associated with protection from kuru.  39/56 kuru cases with age at 
onset  <20  years  were  homozygous  at  codon  129  compared  to  39/125  elderly  women  EI>30 
(PexacT 1-8 x 10'6) and 14/50 elderly women EI>200 (P=3.4 x 10'5). Hardy-Weinberg disequilibrium 
was found in elderly women with EI>30 (P=  6.6 x 10'9) and with EI>200 (/*=0.004), increasing the 
significance which was a more significant deviation than that seen before in the linguistic group 
analysis.  Loss of HWE was not  found in a stratum of slightly younger women aged 40-50, bom 
towards  the  end  of the  practice  of mortuary  feasts,  and  was  also  absent  from  elderly  men  and 
unexposed elderly women. As previously identified, a stratum of men aged 40-50, who would have 
participated in mortuary feasts as children, displayed marginal HWE deviations (/*=0.016).
6.7.2  PRNP codon 129 valine allele frequency analysis indexed by exposure
Using the new El classifications, codon 129 genotypes from 282 elderly women (>50 years old in 
2000) from villages with EI>30 in the North Fore, South Fore, Keiagana and Gimi were obtained 
(referred hereafter as the kuru region; Figure 6.14). Codon 129 data were also obtained for low 
exposure populations, comprising individuals from Gimi (n=87), Jate (n=157), Keiagana (n=221), 
Kanite (n=35) and Awa (n=46) linguistic groups. Mean valine allele frequency was not significantly 
different between the kuru region and low exposure populations (57.4% and 54.3% respectively) by 
a two-tailed x2  test (Figure 6.13).
Additional Highland populations with no recoded cases of kuru comprising of individuals from 
villages speaking Asaro (n=19), BenaBena (n=20), Gadsup (n=22), Gahuku (n=42), Labogai
182(n=47), Siane (n=29), Tairora (n=79), and Yabiyufa (n=27) were also tested against the mean allele 
counts of the kuru region data and found to be significant (two tailed X * test P=0.004; Figure 6.13).
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Figure 6.13  An  increasing cline in codon  129 valine frequency within Papua New Guinea
Codon 129 allele counts were compared between the kuru region (n=282) and: low exposure populations 
(n=546), Highland populations with no recorded kuru (n=281) and non-highland populations (n=313). 
Subpopulations are shown in grey. (From Mead et al., 2007).
Codon  129 genotypes were also obtained from more distant, non-Highland populations including: 
Vanimo/wewak (n=5), islands neighbouring PNG (n=44), Port Morseby (n=l 1), Western Highlands 
(n=4), Madang and its neighbouring inland area (n=239), and Lae (n=10) and comparison against 
the kuru region for allele count was highly significant (two tailed x2  test at PO.OOOl; Figure 6.13). 
The mean distances between the villages examined and Waisa in the South Fore were calculated as 
previously described for each analysis group.  Valine allele frequency significantly co-varied with 
distance from Waisa and exposure to kuru (correlation coefficient R=-0.99, P=0.007; Figure 6.13).
6.8  Additional PRNP susceptibility loci
During genetic screening studies of PRNP at the MRC Prion Unit by the Molecular Genetics Group, 
a novel coding change was detected in a highly conserved and structured region of PrP. The change 
at codon  127 of PRNP from glycine to valine was identified in elderly women >50 years from the 
geographically restricted region of the  Purosa Valley and neighbouring villages (Figure 6.14).  In 
this area, with the highest kuru exposure, G127V is a common variant, occurring at ~7% frequency 
and  exclusively  on  the  129  methionine  background  (based  on  a  retrospective  analysis  of Fore 
pedigrees collected prior to the discovery of the allele).
183Figure 6.14  The kuru  region divided  into three zo n es of increasing exposure
Villages in grey with at least one recorded case of kuru but exposure index (El) <30, a zone of El >30<200, a 
high exposure zone with El>200. Red points show the location of 127V individuals. (From Mead et at., 2007).
The G127V change was genotyped by dideoxy resequencing in  161  WGA kuru samples and was 
found to be completely absent. This absence was significant when  127V-129M haplotype counts 
were compared by a two-tailed exact Pearson X2  test, to 125 elderly women (>50 years old in 2000) 
from the exposed region (P=0.005; Table 6.2). Based on the codon  129 heterozygous/homozygous 
resistance/susceptibility model, homozygosity at both loci was investigated. Homozygosity at both 
codon  127  and  129  was  seen  in 37/49  of the  kuru cases  <20  years  old,  compared  to  39/125  of 
elderly  women  (<20  years  old  during  the  peak  of the  epidemic)  which  was  highly  significant 
CP=6.6xlO'9, exact X2  test, see Table 6.2). In addition, division of the kuru cohort by long (>30 years, 
onset after  1990) and short  (aged <20 at sampling) average  incubation time,  illustrated that only 
12/49 of the short incubation cohort were heterozygous at either codons 127, 129 or both, compared 
with 86/117 of elderly women (P=  6.5 x 10‘7; exact x2  test, see Table 6.2).
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184G127V  M129V
n GG GV VV MM MV W   |
All Kuru8 161 161 0 0 39 94 28
Incubation <20b years 49 49 0 0 23 12 14
Incubation >30 years 10 10 0 0 1 8 1
Women >50c 
El >30 125 119 6 0 16 86 23
Women >50d  years 
El >200 50 44 6 0 6 36 8
Women 40-50® years 150 144 6 0 30 80 40
Men >50f years 122 121 1 0 20 58 44
Men 40-509 years 83 81 2 0 14 53 16
Unexposedh women >50 years 50 50 0 0 13 28 19
Table 6.2  G enotypes of kuru patients and age-stratified healthy population controls
a all kuru vs. women >50 years, El >30 (using 127V-129M haplotype counts) P=0.005 
b  kuru incubation <20 years vs. women >50 years, El >30, P=6.6 x 10-9 
0 women >50 El >30 exact test of HWE at codon 129, P=3.1  x 10-5 
9 women >50 El >200, exact test of HWE at codon 129, P=0.004
8 women 40-50 exact test of HWE at codon 129, P=0.42 
f men >50 exact test of HWE at codon 129, P=1
9 men 40-50 exact test of HWE at codon 129, P=0.016
h  Unexposed women >50 years, exact test of HWE at codon 129 P=1.0 
(From Mead eta!., 2007).
The relative fitness of each codon 127 and 129 haplotypic combination was calculated for the entire 
exposed population of both genders aged over 40 (n=472), which was chosen to be a large sample 
representative of the genetic effect of kuru on the descendent population. The relative fitness of 
each  heterozygous  combination  (127GV-129MM,  127GG-129MV  and  127GV-129MV)  was 
assumed to be equal as there was insufficient data to calculate these separately. The relative fitness 
for 127GG-129MM was 0.64 and  127GG-129VV was 0.74, relative to a combination of the three 
heterozygous  genotypic  combinations.  More highly  kuru-exposed  subgroups  had  an even  lower 
relative  fitness  of  homozygous  genotypes:  elderly  exposed  women  (EI>30),  127GG-129MM 
relative fitness was 0.38, and 127GG-129VV was 0.48; elderly exposed women (EI>200), 127GG- 
129MM relative fitness was 0.23 and 127GG-129VV was 0.42.
6.8.1  Genealogy and codon 127
To confirm or refute the function of G127V mutation as a resistance factor, the incidence of kuru in 
the parents of the current living 127V probands, who would have lived through the kuru epidemic, 
was ascertained. This hypothesis was based on the assumption that as one of the parents would be 
expected to be a  127V carrier,  an increased or reduced history of kuru  in this generation would 
indicate whether 127V was acting as a susceptibility or resistance factor.
51  individuals carrying the  127V mutation, aged  16-78 years (mean age 35 years,  11  individuals 
aged 50 or older), were interviewed by an MRC-PNGIMR research nurse and none were found to
185be symptomatic of dementia, ataxia or other evidence of neurodegenerative disease. Genealogies 
had  been  obtained,  prior  to  the  detection  of the  variant,  from  18  probands  with  127V.  127V 
genealogies were matched to  all  127G pedigrees obtained from villages  in  the Purosa valley  in 
which  more  than  one  127V  individual  had  been  detected  to  obtain  a  control  cohort.  With  the 
exception  of Agakamatasa  and  Ilesa  with  moderate exposure,  the  village were  all  found  in  the 
region of highest kuru exposure.  The village El values were as  follows:  Purosa-Takai  (172),  Ai 
(221),  Takai  (362),  Kamira  (337),  Ketabi  (265),  Ivaki  (295),  Mugaimuti  (346),  Kalu  (200)  and 
Waisa (217). Only 1/36 parents from 127V genealogies was recorded as dying from kuru, whereas 
33/218  parents were recorded as  dying from kuru  in the  matched  127G pedigrees (P=0.04;  two 
tailed exact x2  test).
Given the apparent geographically restriction of the  127V mutation (Figure 6.14), it was suspected 
that there was a recent common ancestor of all alleles. 13 PRNP linked microsatellite markers were 
genotyped over 3  MB  {D20S181,  D20S193,  D20S473,  D20S867,  D20S889,  D20SU6,  D20S482, 
D20S97,  PRNP Codon  129, D20S895,  D20S849,  D20S873,  D20S95  and D20S194)  in  all  127V 
individuals  to  test  this  hypothesis  and  haplotypes  were  identified  using  PHASE.  25/52  127V 
chromosomes  shared  at  least  one  identical  microsatellite  allele  across  the  region  (Figure  6.15) 
consistent  with  a  127V-linked  haplotype.  The  same  haplotype  was  found  in  only  1/70  127G 
chromosomes.
The age of the  127V mutation was estimated by using the microsatellite data to find the time to 
most recent common ancestor (MCRA).  Of the  13  microsatellites 4 were uninformative and one 
was excluded because of doubt over the genetic distance between this marker and PRNP. The time 
to  MCRA  was  calculated  by  modelling  recombination-mediated  LD  decay  over  time  using  the 
formula of Risch et al. (Risch et al.,  1990), as corrected by Colombo (Colombo, 2000). Importantly, 
this calculation did not consider the likelihood of selection acting on the variant and was therefore 
likely to be a conservative calculation. The median result of the 8 remaining markers gave a point 
estimate  of the  most  recent  common  ancestor  of  127V  occurring  within  13  generations  (95% 
confidence intervals: 0 to 30 generations). Confidence intervals based on  10,000 bootstraps of the 
data (See Efron, 1993).
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Figure 6.15  Size of 127V-linked haplotype compared with the same haplotype on 127G 
alleles
13 microsatellites linked to PRNP were genotyped and 8 were then used to date the most recent common 
ancestor which are illustrated here (D20S181, D20S889, D20S116, Codon 129, D20S895, D20S849,
D20S873, D20S95 and D20S194; map locations relative to codon 129: -1494556, -720087, -613627, 419565, 
527025, 929772,  1049310,1475648). Codon 127-linked haplotypes were determined using PHASE software. 
The central dash refers to an individual haplotype,  127V-linked haplotypes are red and 127G are blue. 
Individuals are ordered by increasing size of linked haplotype. (From Mead et al., 2007).
6.8.2  Additional PRNP independent susceptibility loci
The identification of the codon  127  mutation in the South Fore women supported the hypothesis 
that  susceptibility  factors  other  than  codon  129  of PRNP  may  exist.  The  utility  of examining 
neighbouring linguistic populations as a means of supporting the role of codons 127 and 129 in kuru 
susceptibility demonstrated  the  potential  for this  sample  resource to  identify P/frVP-independent 
susceptibility loci using a genome-wide approach.  Genome-wide SNP data for example could be 
used to obtain both an empirical distribution of “neutral” variation data and also be used to conduct 
genome-wide association studies.
1876.9  Genome-wide analyses in the Fore linguistic group of Papua New Guinea
The  analyses  thus  far  have  addressed  PRNP  mediated  kuru  susceptibility  and  the  genomic 
signatures of variation  that  could be used  to  identify the participation  of a  locus.  Developing a 
resource  from  the  PNG  Eastern  Highland  population,  has  allowed  genetic  variation  at  potential 
susceptibility  loci  to  be to  be  examined  for co-variance  with  exposure.  Although  this  has  been 
shown above to work effectively at PRNP, possibly because of its large effect size, other loci may 
be susceptible to confounding due to factors such as population demography. Therefore, attention 
was turned to obtaining an empirical distribution of SNP genotypes, against which signatures of 
selection may be assessed and which could be used to conduct whole-genome association studies 
and whole-genome selection scans.
6.9.1  Study design
Although several whole-genome SNP genotyping platforms were available, the opportunity arose to 
utilise the Asymetrix GeneChip Human Mapping 500K Array Sets*. The Affymetrix 500K array 
provided the greatest  SNP density as compared to other commercial  platforms  with comparable 
genomic coverage. In total,  14 surplus NspI Affymetrix arrays were provided by Dr Simon Mead, 
each capable of genotyping approximately 250,000 SNPs each. The  14 arrays were used to pilot a 
kuru  versus elderly kuru-exposed Fore  females hyper-case-control  study and so the study design 
was considerate of this and several other factors including time, cost and sample/array availability. 
7  samples in each group were chosen for screening, permitting the analysis of common  SNPs at 
MAF> 7.1% in the population. In addition the feasibility of using whole-genome amplified (WGA) 
kuru samples (required to maintain sufficient quantities of DNA for future research) could be tested.
6.9.2  Whole-genome amplification of kuru samples
The majority of kuru samples held at the MRC Prion Unit were collected in the years immediately 
following  the peak of the epidemic,  between  1957  and  1960 by  investigators  from the National 
Institutes of Health (Maryland, USA). Many of these samples had either degraded over time, which 
affected  the  quality  of the  DNA  subsequently  isolated,  or  were  provided  as  blood  sera,  which 
typically  yields  low  concentrations  of DNA  (compared  to  erythrocytes).  To  fully  exploit  these 
limited resources Multiple Displacement WGA was performed by Geneservice Ltd (Eng Ang et al., 
2007)  on  a  subset  of samples  to  investigate  the  efficacy  of using  amplified  sample  for  genetic 
investigations.  8  kuru  samples  (PDGs  7450,  7456,  7468,  7470,  7504,  7520,  7595  and  7744), 
comprising  6  females  and  2  males  aged  from  8  years  to  40  years  old,  which were  provided as 
genomic DNA extracted from sera, underwent WGA. The DNA yield was increased by 1000 fold
*  Each Affymetrix 500k Array set comprises two 250K arrays which genotype SNPs proximal to either NspI 
or Styl restriction sites
188and  all  samples  passed  Geneservice’s  quality  control  criteria  except  for  PDG7520,  which  was 
dropped from further analysis due to allele drop-out.
6.9.3  Pre-hybridisation preparation of the PNG samples
The samples were prepared for hybridisation onto the Affymetrix chips as described  in Materials 
and  Methods  (Chapter  2.3.12).  During  pre-hybridisation,  PCRs  of the  adaptor-ligated  fragments 
were visualised on 2% TBE agarose gel as shown in Figure 6.16.  Prominent banding was seen at 
approximately  2.25kb  and  2.75kb  in  all  WGA  samples  only,  possibly  an  artefact  of the  WGA 
process such as biased amplification.
WGA kuru
Figure 6.16  PCR of 7 South Fore multiple kuru exposure samples and 7 kuru samples
The multiple exposure and kuru samples were amplified in triplicate to provide a sufficient quantity of PCR 
product. The whole-genome amplified kuru samples amplified poorly compared to the multiple exposure 
samples with prominent bands at approximately 2.75kb and 2.25kb. 'Sample PDG7595 showed an atypical 
band at 4kb. Run on 2% TBE agarose gel at 120V for 1  hour. Ladder sizes:  10kb, 8kb, 6kb, 5kb, 4kb, 3kb, 
2.5kb, 2kb,  1.5kb,  1kb and 0.5kb.
WGA sample PDG7595  showed an atypical band at approximately 4kb. To exclude poor sample 
handling as a cause of the atypical band, the sample preparation was repeated with a second WGA 
sample with an untreated control. PDG7595 again showed an atypical band in contrast to the control 
samples (data not shown) however, it was retained for downstream hybridisation to identify what 
effect (if any)  it  might  have on  the  genotyping call-rate.  The  PCR banding of PDG7595  had no 
effect on the fragmentation pattern (Figure 6.17).
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Figure 6.17  Fragmentation of ligated PCR products
Fragmentation of the ligated PCR amplicons resulted in a range of fragment sizes. The relative intensity of the 
multiple exposure samples compared to the WGA kuru samples reflects the differing amounts of starting 
material. *The fragmentation of sample PDG7595 was similar to the other WGA kuru samples. Run on 4% TBE 
agarose gel at 120V for 30 minutes. Ladder sizes:  10kb, 8kb, 6kb, 5kb, 4kb, 3kb, 2.5kb, 2kb,  1.5kb,  1kb and 
0.5kb
6.9.3.1  Assigning calls and data analysis
As much of the data presented in the following sections rely on different SNP call assignments, a 
brief overview  of how  SNP  genotypes  are  assigned  is  provided.  Each  250K  Affymetrix  array 
contains  over  6.5  million  features*,  each  consisting  of more  than  one  million  copies  of a  25nt 
oligonucleotide probe of a defined sequence which is complimentary to the sequence surrounding a 
SNP. Probes are arranged as quartets comprising perfect match and mismatches to each allele and 6 
or  10 probe quartets are used  for each SNP at various locations on the array.  SNP genotypes are 
called using an algorithm which utilises the fluorescent intensities of the 6 or 10 quartets distributed 
across the chip and the intensities of matches/mismatches within each quartet.
The  hybridised  arrays  were  scanned  using  a  GeneChip  Scanner  3000  and  data  analysis  was 
conducted  using  the  Affymetrix  GeneChip  DNA  Analysis  Software  (GDAS).  Genotypes  were 
called using the Dynamic  Model  (DM) Mapping Algorithm employed  within GDAS which also 
provided quality information  for each call,  based on the Wilcoxon’s  signed rank sum test.  Data 
were obtained at three rank/confidence score thresholds (P=0.33, 0.16 and 0.1). Increasing the rank 
score  threshold  (moving  the  dashed  line  in  Figure 6.18  towards  the  centre  of the  triangle)  can 
increase the number of genotypes called, thus reducing the number of no calls, but may also reduce 
the confidence of these additional calls. The converse is also true.
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Figure 6.18  Dynam ic M odel scatter plot for calling gen otyp es
Graphical representation of the Dynamic Model (DM) algorithm. Genotypes are called based on measured 
fluorescence intensities, converted using the DM algorithm and tested against one of four genotype models 
(AA, AB, BB and null), with the rank score of the most likely model used to give a confidence measure in each 
called genotype. High confidence calls (-0) are plotted at the vertices and scores closer to 1  are near the 
centre of the triangle. Decreasing the rank score threshold (dashed line) increases the number of no calls and 
increasing the threshold decreases the number of no calls. Adapted from (Affymetrix, 2005b).
6.9.4  Hybridisation efficiency and call rates
Subsequent to scanning, each NspI array image was visually inspected for an assessment of quality. 
All  samples  were  successfully  scanned  except  for  PDG7470  for  which  the  array  image  was 
exceptionally dark (Figure 6.19). GDAS analysis was undertaken at a default threshold (P=0.19) 
and call rates obtained. WGA array call rates ranged from 49.6% to 72.9% (mean -61%) and mean 
multiple exposure call rate was -95% (good quality DNA with proper handling should yield call 
rates  >93%  (Affymetrix,  2005b)).  With  an  atypical  array  image  and  a  low  call  rate  of 60%, 
PDG7470 was repeated for fear that post-hybridisation (staining and washing) reagents used for this 
chip only were contaminated. In addition, repeating the sample provided an opportunity to obtain a 
technical  replicate,  allowing  the  concordance  rate’  to  be  calculated  between  replicates  and  an 
assessment of assay repeatability on WGA samples.
Figure 6.19  G eneChip  NspI  hybridisation array im ages for sam ple PDG7470
Labelled DNA hybridised poorly onto the NspI array (right) which gave a low genotype call rate. Repeating the 
sample gave a better call rate and a brighter array image.
*  Concordance is calculated by identifying the fraction of SNPs which are assigned identical genotypes on a 
set of replicate arrays (two arrays hybridised with the same sample)
191The repeated PDG7470 call rate improved to 69.8%, representing a net gain of 10,719 genotypes 
(37,081  SNP  calls  gained  and  26,362  lost).  Importantly,  the  majority  of  new  calls  were 
heterozygotes, which are often under-represented by  fluorescence based detection due to bias  in 
detecting a 50% decrease in allelic signal compared to homozygotes. This result implied that the 
cause of the low call rate was staining of the hybridised DNA molecules which resulted in lower 
fluorescence compared to background.
With 10% of the total concordance between the two arrays comprising of “no calls”, the possibility 
of increasing the call rate by varying the stringency of the rank score threshold was examined. This 
would require a trade off between call rate and genotyping accuracy and therefore the relationship 
between these two variables was examined. Additional replicated NspI array genotyping data were 
obtained for 6 vCJD samples  from  Dr Mead and analysed with PDG7470. The 6 vCJD samples 
were not true technical replicates as one sample in each replicate was WGA treated however, they 
could provide data on WGA DNA performance on arrays. Analyses were conducted at thresholds 
0.5, 0.3 and 0.19 and compared to a base-line analysis at 0.1 (Figure 6.20).
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Figure 6.20  SNP gains and data reliability at various rank score thresholds
Increased call rates, relative those achieved at P=0.10, were seen for all threshold values. Mean values were 
calculated for the 6 vCJD samples. The maximum gain in SNP calls was achieved with P=0.19 with high SNP 
concordance and low discordance, after which increasing the threshold yielded diminishing returns. Error bars 
1.96xSEM
The  6  WGA  vCJD  samples  had  similar  call  rates  to  their  genomic  replicates  at  various  rank 
threshold values and comparing the genomic and WGA replicates, concordance varied directly with 
both threshold and call rate. At the most stringent threshold of P=0.1, a low mean call rate of 82.5% 
was seen with a low mean concordance rate of 72%. As the threshold stringency was decreased to
1920.19, 0.33 and 0.5, both the mean call rate and concordance increased proportionally suggesting that 
genotypes  were  stable  between  replicates  and  therefore  the  majority  of the  data  gained  were 
accurate. Some increase in discordance was seen however as stringency was reduced (not including 
genotypes which were converted into “no calls” or vice versa). The mean discordance amongst the 
6 arrays increased from 0.2% to 3.6% as stringency decreased. Taken together, these data suggest 
that for the vCJD samples, the WGA treatment had little effect on the quality of genotype data and 
that for chips with low call rates, the rank score threshold could be relaxed to obtain extra reliable 
data.
In comparison, the kuru chips performed poorly with, at P=0.5, a maximum mean call rate of 80%, 
concordance of 70% and an unacceptable high genotype discordance of 10%. At P=0.1, only 57% 
of the  SNP genotypes were called and with only 40% concordance between chips.  Whether this 
poor performance was due to the WGA of poor starting material or if it reflected the poor post­
hybridisation treatment of the first chip, was not known.
To identify the optimal threshold value for WGA treated arrays -  one that would accurately yield 
the  maximum  number  of  SNP  genotypes  with  the  minimum  amount  of discordance  between 
replicates -  the  mean  change  in  SNP call  rate  relative  to that  at  P=0.1  baseline  was  examined, 
against mean percentage change in concordance and discordance (Figure 6.20). For both vCJD and 
kuru chips the greatest increase in call rate was seen at P=0.19 with a large increase in concordance 
and a marginal increase in discordance. Relaxing the threshold further yielded diminishing returns 
in  terms  of  call  rate  and  although  concordance  increased,  so  too  did  discordance,  reducing 
confidence in the accuracy of the additional data.  As previously noted, the kuru chips performed 
poorly  and  although  there  was  a  greater  increase  in  SNP  calls,  the  discordance  rate  was  much 
greater, suggesting that the additional data gained was not accurate.
6.9.5  Genome-wide linkage disequilibrium
To determine LD patterns genome-wide, genotype data was exported from Affymetrix GeneChip 
Genotyping  Analysis  Software  (GTYPE)  into  Haploview  to  calculate  pairwise  LD  comparisons 
between  SNPs.  Unless stated, Affymetrix data was exported at a rank score threshold of P=0.33. 
Pairwise LD (D1 ) was determined for loci with 85% completeness of genotype data, MAF>15% and 
for  comparisons  <100kb.  The  MAF  cut-off of  15%  was  chosen  based  upon  genome-wide  data 
published for isolated population of Kosrae in which the allele frequency distribution of common 
alleles >15% was similar to other worldwide populations (Bonnen et al.,  2006) and was therefore 
not  affected  by  SNP  ascertainment  bias.  Mean  pairwise  LD  was  calculated  for  comparisons  of 
increasing 2.5kb distances.
1936.9.5.1  Genome-wide LD is inflated in small samples
Initially,  pairwise  LD  was  assessed  for the  7  samples  from  elderly  Fore  women  with  multiple 
exposure to kuru with genotype data acquired at three different rank score thresholds (Figure 6.21). 
Varying the threshold had little effect on the genome-wide LD profile.
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Figure 6.21  Pairw ise LD in 7 elderly m ultiple  kuru-exposed sam p les at different thresholds
Mean r2 was calculated for pairwise comparisons between markers with minor allele frequencies  ^15% that 
fell within the same 2.5kb intermarker distance bins for 7 multiple kuru-exposed Fore females. The LD profile is 
similar at all three thresholds. Error bars are 1  96xSEM.
With only 7 samples available for analysis, it was expected that the mean LD would be inflated due 
to the small sample size (Jorde, 2000). To test the extent of sample size on genome-wide LD NspI 
array genotype data on from 90 UK control samples was obtained from Dr Simon Mead. Genome- 
wide LD was calculated for all 90 samples (genotypes called at threshold P=0.33) and for random 
sub-samples of 7 individuals which were sampled without replacement 4 times (Figure 6.22).
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Figure 6.22 The effect of sam ple size on genom e-w ide pairw ise LD
Mean r2  was calculated for pairwise comparisons between markers with minor allele frequencies  ^15% that 
fell within the same 2.5kb intermarker distance bins for 90 UK samples and four sub-sampled sets of 7 UK 
individuals. Pairwise LD was found to be consistently inflated for the 7 sub-sampled cohorts compared to the 
complete data set at all distances. Error bars are 1,96xSEM.
194LD was consistently inflated for the smaller 7 UK sub-sampled cohort than the full 90 UK sample 
data set. Furthermore, long range LD was more susceptible to inflation (230% inflation for  lOOkb 
comparisons) compared to short range LD (113% inflation for 5kb comparisons).
6.9.5.2  Genome-wide LD compared between PNG and UK samples
To overcome discrepancies due to sample size, LD from 7 individuals from the UK were compared 
to the 7 kuru and 7 elderly multiple kuru-exposure Fore females (Figure 6.23). The Fore  females 
demonstrated elevated LD compared to the UK samples and the half-life of LD decay with genomic 
distance was substantially longer in the Fore women than in the UK samples (approximately  1.25- 
fold higher than the UK samples).
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Figure 6.23  Linkage disequilibrium decay over distance
Mean r2 for pairwise comparisons between markers with minor allele frequencies  >15% that fell within the 
same 2.5kb intermarker distance bins, for 7 UK samples (sub-sampled four times from 90 samples), 7 WGA 
kuru and 7 elderly multiple kuru exposure Fore women. LD was greater in the 7 elderly Fore women compared 
to the 7 UK samples and LD amongst kuru samples was starkly reduced. Error bars are 1.96xSEM.
Pairwise LD in the 7 WGA kuru samples was considerably lower than the other samples and decay 
over  distance  occurred  more  rapidly.  This  reduced  LD  reflected  the  poor  quality  of the  data 
obtained  from  the  NspI  arrays  for  the  WGA  kuru  samples.  The  reduced  LD  is  most  likely  an 
artefact  of either  (i)  spuriously  increased  heterozygosity  (which  serves  to  reduce  LD)  due  to 
genotyping inaccuracies across the 7 chips or (ii) a paucity of data to conduct a sufficient number of 
pairwise comparisons to obtain robust LD data.
6.9.5.3  Genome-wide LD between highly correlated SNPs
An  important  consideration  for  any  future  whole-genome  PNG  association  study,  using  the 
Affymetrix  500k  platform,  is  coverage.  As  the  SNPs  included  on  the  Affymetrix  array  were 
ascertained  in  reference  populations,  it  is  important  to  assess  how  well  these  SNPs  represent
195variation within the PNG population. The importance of coverage and several methods of directly 
assessing  this  statistic  are  examined  in  detail  in  the  discussion  (the  current  study  was  too 
preliminary with too few samples to be able to utilise these methods). However, an approximate 
indicator of coverage was ascertained by examining the proportion of minor SNP alleles that were 
highly correlated (K^0.8) and therefore might  serve  as proxies  for other unknown  variants  not 
directly genotyped on the array. The proportion of highly correlated pairwise comparisons (of the 
total  comparisons  made),  within  increasing  2.5kb  genomic  distance  bins,  was  inflated  in  small 
samples of 7 individuals repeatedly sub-sampled from a total of 90 UK samples (Figure 6.24).
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Figure 6.24  Inflation of highly correlated (r*>0.8) LD comparisons in small sized samples
Mean proportion of pairwise comparisons ^^0.8, between markers with minor allele frequencies  >15% that 
fell within the same 2.5kb intermarker distance bins, for 90 UK samples and four sub-sampled sets of 7 UK 
individuals. Error bars are 1.96xSEM.
Comparing across the three sample sets, Figure 6.25 illustrates the increased LD in the elderly Fore 
women as compared to the UK samples and the relative paucity of highly correlated SNPs in the 
WGA kuru samples. The lack of highly correlated SNPs in the kuru samples, taken together with 
the  lower  overall  LD,  as  compared  to  the  7  multiple-kuru  exposure  samples  is  likely  to  be 
attributable  to  poor genotyping  of these  samples  (i.e.  low  call  rates  and  a  greater discordance) 
compared to the other PNG samples.
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Figure 6.25  Decay of linkage disequilibrium of highly correlated (r*>0.8) alleles with 
distance
Mean proportion of pairwise comparisons P^Q.8, between markers with minor allele frequencies  >15% that 
fell within the same 2.5kb intermarker distance bins, for 7 UK samples (sub-sampled four times from 90 
samples), 7 WGA kuru and 7 elderly multiple kuru exposure Fore women. The proportion of comparisons r2^ 
0.8 was greater in the 7 elderty Fore women compared to the 7 UK samples and amongst kuru samples, was 
starkly reduced. Kosrae data from (Bonnen et al., 2006). Error bars are 1.96xSEM.
For comparison, linkage disequilibrium data from a study of the isolated Micronesian population of 
Kosrae is also illustrated in Figure 6.25. The Kosrae data represents 60 unrelated individuals and 
was generated using the Affymetrix  GeneChip  100K platform.  The smaller sample  size of the 7 
elderly Fore women compared to the 60 Kosrae samples implies that LD on Kosrae will likely be 
greater than that on PNG, however, the lower SNP density  100K array may inflate LD estimates 
slightly as it is known that SNP density can affect the pattern and extent of LD. As the only whole- 
genome  genotyping  study  of an  isolated  population,  the  Kosrae  data  will  make  an  interesting 
comparison for future PNG data.
Several additional analyses that would provide information on the genetic diversity and the utility of 
the PNG samples could no be run due to small sample size
6.10  Discussion
The results presented in this chapter have expanded on previous investigations of the effect of kuru 
on  the  PNG  Eastern  Highland  population and  the  effect  of PRNP codon  129  on  kuru  survival. 
Moreover,  the  work  presented  in  this  chapter comprises  the  largest  investigation  of the  genetic 
effect of kuru to date.
6.11  Codon 129 and kuru susceptibility
Analysis of 161 kuru samples and 125 elderly kuru-exposed females expanded on several published 
studies which observed  significant correlation of PRNP codon  129  status with kuru  survival but
197were limited by small sample sizes (Cervenakova et al.,  1998; Lee et al., 2001a; Mead et al., 2003). 
The work presented in this chapter corroborates the correlation of homozygosity at codon 129 with 
early kuru onset (and conversely, heterozygosity at codon  129 with late onset). In addition, these 
genetic analyses have recapitulated several known epidemiological aspects of the kuru epidemic:
•  the extent to which the epidemic was largely restricted to females, reflecting the majority 
participation of women at mortuary feasts
•  females  were  exposed  to  kuru  at  multiple  mortuary  feasts  throughout  childhood  and 
adulthood. This is reflected in both the peak age of kuru onset in females, which occurred a 
full  decade  in  life  later  than  in  males  and  the  gradual  decline  in  kuru  incidence  in 
subsequent decades which, in contrast to the males’ data, implies a sustained exposure to 
kuru through childhood and adulthood.
•  male exposure to kuru largely occurred up to the age of 6 to 8 years. This is demonstrated 
by a peak age of male kuru onset at  11  to 20 years, given that the mean kuru incubation 
time is  12 years, and a rapid decline thereafter. This observation is consistent with reports 
that young males lived with and attended mortuary feasts with their mothers.  Boys older 
than 6-8 years were taken from their mothers and brought up in the men’s house and from 
this point on, they were exposed only to the same risk as adult men, who participated little 
in feasts and did not eat brain (the most infectious organ in kuru) (Collinge et al,  2006). 
This practice explains why adult men in  1957-58 contributed only 2% to the total number 
of kuru cases. Consistent with a single peak period of male kuru exposure, the number of 
male kuru cases with onset in later decades declines rapidly
Within the surviving population from the kuru-exposed regions, highly significant deviations from 
HWE were seen in the surviving elderly population. The analysis of 125 women with multiple kuru 
exposure,  corroborated  and  expanded the  work of Lee  et al.  and Mead  et al.  demonstrating  the 
protective advantage of heterozygosity at codon 129 and increasing the significance of this finding 
from the original observations (Lee et al.,  2001a; Mead et al.,  2003). Use of the El classifications 
for elderly women from kuru exposed villages further increased the level of significance.
6.11.1  Codon 129 independent susceptibility?
The  analyses  of  both  the  kuru-affected  and  surviving  populations  pose  further  questions  of 
additional unidentified protective/susceptibility loci. The presence of MV heterozygotes in the kuru- 
affected  cohort  raises  the  possibility that  these  individuals  may possess  some  other codon  129- 
independent susceptibility locus. Similarly, the presence of women homozygous at codon 129 in the 
surviving  multiple-kuru-exposure  population  may  be  evidence  of  a  codon-129  independent
198protective  factor,  although  long  incubation  times  in  these  women  cannot  be  discounted. 
Alternatively, the presence of these genotypes in either cohort may reflect non-uniform exposure 
within villages and linguistic groups i.e. a “hotspot” or “coldspot” of consumption within a village 
of linguistic group than is represented by an average exposure statistic.
6.11.2  PRNP and kuru-mediated signatures of selection
Several signatures of selection were tested on codon 129 data from 12 different linguistic groups of 
the  Eastern  Highlands,  with  limited  success.  Investigation  of co-variation  of  Hardy-Weinberg 
disequilibrium with levels of kuru-exposure identified significant deviations from HWE in only the 
South  Fore  samples.  South  Fore women >50  years and  men aged between 40-50  years  showed 
significant departure from HWE disequilibrium. HWE was re-established in South Fore males bom 
after 1960, demonstrating both the abrupt end to the kuru epidemic and the swift return of genotype 
proportions of return to HWE subsequent to removal of the selective pressure.
HWE was seen in other exposed linguistic groups including the North Fore, which is known to have 
experienced acute exposure to kuru second only to the South Fore. This may have been due to the 
early cessation of mortuary feasting in the communities of the North Fore in the 1950’s or earlier, 
who were the first of the Fore people to lose their traditional practices in the wake of Australian 
administrative control (Collinge et al., 2006).
HWE  in  non-Fore  kuru-exposed  linguistic  groups  is  probably  due  to  the  absence  of  gender 
stratification  which  was  precluded  by  small  sample  sizes.  In  addition,  these  analyses  were 
insensitive to the differential exposure of villages within each linguistic group. Reclassification of 
the PNG samples using the new El permitted a more robust analysis:  women >50 years and men 
aged 40-50 years both remained highly significant results and no significant HWE deviations were 
seen for women between 40-50 years, men >50 years or unexposed women >50 years.
The analysis of codon 129 valine allele frequency worldwide and in PNG as a signature of selection 
provided  an  interesting  result.  The  valine  allele  frequency  demonstrated  a  significant  cline 
worldwide to which the Fore clearly contrasted.  Based on the early linguistic group analysis,  an 
equilibrium  valine  allele  frequency  was  seen  across  the  Eastern  Highlands,  regardless  of kuru 
exposure status. However, under the El classification an increasing local PNG cline was seen from 
the non-Highland populations, to Eastern Highland populations with no record of kuru and the kuru 
exposed region itself. No significant difference was seen between the low and high kuru exposure 
populations from the Eastern Highlands. This may be due to a historically higher incidence of kuru 
in the low exposure populations than was recorded since the 1950s.
199Investigating  the  extent  of LD  between  microsatellites  flanking PRNP did  not  yield  conclusive 
results associated with the extent of kuru exposure.  Kuru exposed and unexposed cohorts.  Only 
microsatellite FS j demonstrated marginal significance.
6.11.3  Additional susceptibility loci - PRNP G127V
The data presented in this chapter support the conclusion that G127V  is a highly geographically 
restricted, but locally common, polymorphism that confers resistance to kuru in the heterozygous 
state. How glycine to valine change protects against kuru remains unclear. The polymorphism may 
result  in  a  more  bulky  amino-acid  side-chain  which  impedes  beta-sheet  formation  and  protects 
against prion formation, although this remains speculation and additional work would be needed, to 
clarify the effect on PrP structure and the mechanism of protection.
The possibility that, rather than protecting against kuru, the 127V polymorphism might have instead 
triggered the epidemic cannot be completely excluded. Given that life expectancy in the kuru region 
is 42 years, it is possible that 127V is associated with a late-onset and low penetrant inherited prion 
disease  which  might  have  triggered  the  kuru  epidemic.  There  are  few  examples  of mutations 
causative of autosomal dominant neurodegenerative disease that achieve the polymorphic frequency 
observed  in  the  Purosa  Valley  (Wexler  et  al.,  2004).  A  wealth  of  data  indicates  that  prion 
transmission is generally more efficient where there is complementarity between the primary PrP 
sequence of donor and host, implying that if 127V was pathogenic it would be expected to confer 
susceptibility  to  the  corresponding  acquired  prion  disease  (Collinge,  2001).  Additionally,  the 
glycoform type of PrP50 in kuru, although restricted to a small number of autopsy samples, closely 
resembles sporadic CJD rather than point mutation inherited prion disease (Parchi, 2000). Finally, if 
127V had triggered kuru, the localization to the southeastern part of the Fore linguistic group would 
be inconsistent with oral history that the first kuru patient was observed in the Keiagana linguistic 
group located to the northwest of the Fore.
6.11.4  Future study of PNG and kuru samples
An  important  issue that  should be  investigated further to conclusively resolve the use of genetic 
variation to identify kuru susceptibility loci is the description of “neutral” genetic variation against 
which variation at PRNP or other loci may be compared. The availability of 14 Affymetrix NspI 
arrays permitted the limited analysis of genomic variation in 7 Highland samples and the feasibility 
of utilising degraded kuru DNA through WGA.
2006.11.4.1  The effect of whole-genome amplification of low quality material on whole- 
genome genotyping platforms
Recent studies at the MRC Prion Unit have proven the reliable use of WGA technologies for use on 
various genotyping arrays on high quality starting DNA. The results presented in this chapter have 
also illustrated the benefits of using WGA on good quality starting material but have shown that 
WGA on  low  concentration,  degraded kuru  DNA  is not  an effective method of increasing DNA 
quantity for AfTymetrix Nspl array analyses.
6.11.4.2  Ascertainment bias
All  SNPs on the Affymetrix GeneChip arrays were pre-selected based on technical quality in the 
three  HapMap  reference  populations  (CEPH,  Japanese/Chinese  and  Yoruban),  essentially 
representing  a  quasi-random  SNP  set  (Affymetrix,  2005a),  and  therefore  it  is  unknown  how 
representative  the  alleles  ascertained  in  these  reference  populations  are  of common  variation  in 
PNG. Although the Affymetrix SNPs are likely to be representative of the majority of human SNP 
alleles, there is a possibility that a major class of common allele on PNG may not be represented on 
these arrays.  Future work should concentrate on deep resequencing of several genomic regions in 
16 PNG samples from unexposed PNG linguistic groups. Resequencing a subset of the ten 500kb 
regions  investigated  in  the  HapMap  ENCODE  resequencing  project  (www.hapmap.org)  would 
permit  a direct  comparison  of PNG  genetic  diversity against  freely available data  from  African, 
European and  Asian  populations.  The  frequency distribution of all  alleles could be compared to 
ensure  that  the  Affymetrix  500k  arrays  also  represent  common  variation  in  PNG.  In  addition, 
resequencing a  subset of the  17  genomic  regions  studied in the Kosrae population would permit 
direct comparisons to be made with a second isolated population with available SNP data.
2017  PRNP copy number polymorphisms and prion disease susceptibility
7.1  Introduction
This chapter investigates PRNP copy number as a mediator of sporadic CJD and kuru susceptibility. 
The  chapter  begins  with  a  brief  consideration  of  the  relevance  of  copy  number  changes  to 
neurodegenerative  diseases  and  presents  the  hypotheses  that  PRNP  duplications  may  mediate 
susceptibility  to  sporadic  CJD,  whilst  deletion  may  afford  protection  against  kuru.  PRNP copy 
number was  investigated  using quantitative  real-time  PCR  in  28  sporadic  CJD  samples  and  104 
elderly  women  from  the  Fore.  A  suspected  triplication  was  identified  in  a  sCJD  sample  and 
although no copy number changes were identified in the Fore women, a known polymorphism at 
codon  127 of PRNP was observed.  This chapter ends with a brief discussion of the relevance of 
these results and the relevance of copy number polymorphisms to human prion disease.
7.1.1  Copy number polymorphisms in neurodegenerative disease
In recent years the insertion, deletion and duplication of DNA segments greater than 1   kb have been 
shown to occur frequently in the human genome (see for example (Conrad et al., 2006; Freeman et 
al., 2006; Khaja et al., 2006)). With approximately 12% of the human genome undergoing dynamic 
rearrangements,  these  copy  number  polymorphisms  (CNPs)  can  have  dramatic  phenotypic 
consequences,  altering  gene  dosage,  disrupting  coding  sequences,  or perturbing  long-range  gene 
regulation (Redon et al., 2006).
The  accumulation  and  deposition  of proteins  is  a  common  feature  of many  neurodegenerative 
diseases, and variability in the expression of an associated protein-coding gene is often related to 
the  severity  of  neurodegeneration  (i.e.  age  of  onset,  duration  of  disease  etc.).  This  dosage 
hypothesis is supported by several examples of pathogenic copy number changes which have been 
observed to give rise to neurodegenerative diseases: (i) tandem duplication of a 1.5Mb region of the 
gene PMP22 results in the dominantly inherited demyelinating neuropathy, Charcot-Marie-Tooth 
type  1A  (CMT1A)  (Lupski  et  al.,  1991),  (ii)  duplication  of the  amyloid  precursor protein  gene 
(APP) has been reported in five different families with autosomal dominant early onset Alzheimer’s 
disease (Rovelet-Lecrux et al.,  2006), (iii) duplication of the proteolipid protein gene (PLP) in the 
rare  X-linked  dysmyelination  disorder,  Pelizaeus-Merzbacher  disease  (PMD)  (Woodward  et  al., 
1998) and partial triplication of exons 2 to 4 of Parkin (PARK2). Perhaps most convincing support 
for a dosage hypothesis to neurodegenerative disease comes from the pathogenic multiplication the 
a-synuclein gene (SCNA) in autosomal dominant Parkinson’s disease. Triplications of SCNA have 
been independently identified in two unrelated kindreds with onset in the fourth decade (Farrer et
202al., 2004; Singleton et al., 2003). In addition duplication of the SCNA locus has also been shown to 
be pathogenic in several families, with a less severe clinical phenotype than triplication families and 
with onset a decade later (Chartier-Harlin et al., 2004; Ibanez et al., 2004; Nishioka et al., 2006).
7.1.2  Variability in PRNP expression and disease susceptibility
There  are  several  lines  of evidence  that  suggest  that  PRNP expression  is  correlated  to  disease 
outcome.  In  mice,  the  level  of expression  of Prnp,  regardless  of coding  sequence,  is  a  major 
determinant of incubation time. For example, transgenic mouse models with additional copies of the 
hamster  PrP  gene  demonstrate  an  inverse  correlation  between  PrP  expression  level  and  scrapie 
incubation time (Prusiner et al.,  1990). Bueler and colleagues importantly showed that /Vnp-ablated 
mice are resistant to developing disease when inoculated with mouse scrapie (Bueler et al.,  1993) 
and that  hemizygous /Vnp-ablated  mice  have a  greatly prolonged  incubation time (Bueler et al., 
1993).  Conversely,  increasing  Prnp  expression  by  increasing  Prnp  transgene  copy  number  in 
Prnpav  mice,  increases  susceptibility  to  Rocky  Mountain  Laboratory  (RML)  prion  infection 
(Fischer et al.,  1996).  PrP  levels  following  disease onset  have also been  able to  modify disease 
outcome.  Mice displaying disease  following RML prion infection are seen to reverse spongiform 
pathology and cognitive and behavioural defects following depletion of neuronal PrPc (Mallucci et 
al., 2003; Mallucci et al.. 2007).
In addition, a QTL mapping study of inbred mouse strains has identified a region of chromosome 2, 
encompassing Prnp, as one of three major QTLs that determine prion-disease incubation time after 
intracerebral  inoculation  with mouse-adapted scrapie (Lloyd et al.,  2001).  Intriguingly,  this result 
has been replicated in humans - a  lOkb prion haplotype confers risk to sporadic CJD (Mead et al., 
2001). Although it is not known if the associated haplotype results in altered expression of PRNP, it 
suggests that genetic variability in prion expression may contribute to sporadic disease risk.
Taken  together,  these  data  suggest  that  PRNP  mediated  disease  susceptibility  extends  beyond 
polymorphisms of the amino acid sequence and that PRNP expression may influence human prion 
disease outcome. The genetic elements that determine PRNP expression have been studied. Mahal 
and colleagues were the first to isolate and characterise the human PRNP promoter, identifying by 
progressive  5’  deletions  of  the  promoter  region,  several  candidate  sites  where  nucleotide 
polymorphisms may influence expression (Mahal et al., 2001). To date three SNPs in the regulatory 
region  of the  PRNP  have  been  identified,  a  C  to  G  transversion  at  position  -101,  a  G  to  C 
transversion at position +310 and T to C transition at position +385.  It has been shown that among 
sCJD patients homozygous for codon  129 methionine alleles, the numbers of who carried the rare 
promoter  SNP  alleles  was  higher  than  in  controls,  suggesting  that  the  regulatory  region
203polymorphisms  may  be  a  risk  factor  for  CJD  (McCormack  et  al.,  2002).  It  has  yet  to  be 
demonstrated if PRNP expression is mediated by copy number changes.
7.13  Copy number polymorphisms in sporadic CJD?
The  majority  of examples  involving  pathogenic  copy  number  alterations  in  neurodegenerative 
diseases  demonstrate  familial  or  pseudo-familial  inheritance.  Conversely,  the  majority  of 
neurodegenerative diseases including human prion disease occur sporadically, so can copy number 
changes  explain  sporadic disease?  Essentially,  the  first appearance of a pathogenic  copy  number 
change is a sporadic de novo event which is subsequently inherited, for example the various SCNA 
families possess duplications and triplications of different allele sizes reflecting their independent 
origins.  Reduced  penetrance  has  been  observed  for  several  diseases  that  result  from  CNPs, 
including the 22ql 1  deletion DiGeorge syndrome (Gong et al., 2001) as well as speech problems in 
patients  with  duplication  of the  Williams  syndrome  region (Gong et al.,  2001).  Therefore,  it  is 
possible that incomplete penetrance may also be seen with potential PRNP copy number cases that 
have been diagnosed as sCJD.
7.1.4  PRNP copy number hypothesis
Two discrete hypotheses relating altered PRNP copy number to disease susceptibility were tested in 
this chapter:
(i)  elderly Fore women (aged >50 years old in 2000), with acute exposure to kuru through 
attendance at multiple mortuary feasts, who were genotyped as codon 129 homozygotes, were 
actually hemizygous which afforded relative protection against kuru.
(ii)  sporadic CJD patients who were heterozygous at codon 129 and should have essentially been 
less susceptible to disease, actually had a duplication  of the PRNPi2 9m  allele
7.2  Quantitative Real Time PCR probe and  primer  design for PRNP
Selection  of PRNP  PCR  primers  and  MGB  probe  sequences  for  quantitative  PCR  (qPCR)  was 
performed as described  in  Materials and Methods 2.5.3. The probe was designed to anneal  5’  to 
codon  129  in  a  region  of PRNP  without  any  known  sequence  variation  (Figure  7.1).  Primers 
identical  to  those  used  for  codon  129  genotyping  by  allele  discrimination  were  used  and  a 
methionine allele specific PRNP probe was also used.  Ideally, the probe should have straddled an 
intron/exon boundary to amplify genomic DNA only (and not mRNA) however, by spanning codon 
129 probe specificity could be tested by comparing detection of M and V codon 129 alleles.
RNA contamination was minimised by treating DNA samples with RNAse either during extraction 
from blood or (for samples obtained as DNA)  following the  identification of RNA impurities  in
204DNA  by  spectrophotometry.  The  house-keeping  gene  beta-actin  (p-Actin',  OMIM:  102630)  was
used  as  an  endogenous  control  and  p-Actin  probe  and  primer  sequences  were  taken  from  the
literature (Suarez-Merino et al., 2005).
PRNP forward
AGGAGGTGGCACCCACAGTCAGTGG AACAAGCCGAGTAAGCCAAAAi CCAACATGAAGCAC
PRNP probe
ATGGCTGGTGCTGCAGCAGCTGGGGCAGTGGTGGGGGGCCTTGGCGGCTACATGCTGGGAA
reverse  PRNP,nm Prob#
AGGACCGTTACTATCGTGAACA GTGCCATGAGCAGGCC< [ATCATACATTTCGGCAGTGACTATG
P-Actln
TGATGGTGGGCATGGGTCAGAAGGATTCCTATGTGGGCG
p-Actin probe  ^ __   reverse
GCATCCTCACCCTGAAGTACCCC
forward
ACGAGGCCCAGAGCAAGAGAG
ATCGAGCACGGCATCGTCACCAACTGGGACGACATGGA
Figure 7.1  PRNP and p-Actin quantitative real tim e PCR  probes and  primers
Probes are indicated in yellow boxes and forward and reverse primers are in grey boxes. The methionine 
specific PRNP129M  probe is indicated by the black line. All PRNP probes were major groove binders (MGB) and 
were labelled with VIC fluorophore reporters. /?-Actin probes were MGB and labelled with FAM fluorophore 
reporters.
To determine changes in PRNP copy number in relation to P-Actin, the comparative CT*  method (2‘ 
^ x ) was used see (Livak et al., 2001). Although this method is usually used to quantify changes in 
gene expression it is also useful for quantifying genomic template changes and standardising assays 
across different experiments/plates. In brief, the difference between the threshold cycle of the PRNP 
target assay and the p-Actin endogenous reference assay (ACT) is calculated for both the test and 
calibrator samples:
Equation 7.1  ACT  =CT  (target gene) - CT  (endogenous control)
The difference between the average ACT value of a test sample and the average ACT for the
calibrator sample is calculated (AACT) and the expression fold value by:
Equation 7.2  AACT  (test sample) =ACT  (test sample) - ACT  (calibrator sample)
Equation 7.3  Expression fold value =2 '
7.3  Validating qPCR probe efficiencies
For the  AACT  calculation  to  be  valid,  the  amplification  efficiencies  of the  target  and  reference 
assays had to be approximately equal. A sensitive method for assessing if two amplicons have the 
same efficiency  is to  look at how ACT varies with template dilution.  PRNP\2 9m   and PRNP probe
* CT  or Threshold Cycle reflects the cycle number at which the fluorescence generated within a reaction 
crosses a baseline threshold of background fluorescence.
205efficiency was validated by serially diluting a DNA sample of known concentration over a 32-fold 
range (approximately 200ng//d to 6ng//zl - the working range of the majority of the samples used 
for the study). Assays were performed as described in Materials and Methods 2.6.7 and 5 replicates 
were conducted  for each dilution.  The average ACT was calculated as explained above (Equation
7.1).
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Figure 7.2  R elative efficien cies for PRNP and  PRNPU9M quantitative PCR probes
The efficiency of amplification of the PRNP (A) and PRNP129M  (B) targets and endogenous control fi-Actin by 
CT (top) and ACT (bottom). The data were fitted using least-squares linear regression analysis (N=5).
The relative efficiencies of the target and endogenous control probes, as calculated by the slope of 
the ACt against graph, were approximately equal (Figure 7.2) and compared well to the acceptable 
efficiency of <0.1  established by the manufacturer of the real-time  system  (Applied  Biosystems, 
1997).
MM  MV
Figure 7.3  A verage ACT  differences betw een PRNP cod on   129 MM and  MV CEPH sam p les
Error bars are ± 95% SEM. W  homozygote not shown. (N=11)
To ensure the assay was sensitive enough to detect a two-fold difference in template concentration, 
the methionine-specific PRNP\2 9m  probe was used to evaluate 23 CEPH samples blinded to codon
206129  genotype  (11  MM,  11  MV  and  one  VV  control  sample).  A  highly  significant  difference 
between the ACj of the MM and MV samples (T-test* /KO.OOOl) was seen and, as expected, the 
valine  homozygote controls  failed to amplify  with the PRNPnm  probe  (Figure 7.3).  This  result 
demonstrated that a two fold increase in genomic template (one cycle difference) could be detected.
7.4  Copy number variation in elderly Fore females
The  104  elderly  Fore  women  were  screened  with  both  the  PRNPl2 9m   and  PRNP copy  number 
probes. The samples were comprised of 17  MM  homozygotes, 64 MV heterozygotes and  18 VV 
homozygotes from the North Fore, South Fore and Gimi. The mean age was 59 years (ranging from 
50 to 82 years, with a median age 57 years).  In addition, 25 healthy controls from the North and 
South Fore were screened to identify deletion/duplication polymorphisms at a detectable frequency 
>2%. All samples were screened in triplicate as described in Chapter 2.7.3, with 5 identical control 
samples  included  to  standardise  across  plates  (the  control  sample  with  the  least  within-plate 
variation was used as the calibrator), and the mean 2*A A C T  ±1.96xSEM calculated (see Equation 7.2 
and Equation 7.3).
Initially, whilst waiting for reagents to arrive, 20 multiple-exposure samples were screened with the 
PRNPn9M  probe and three control samples (one MV, MM and VV). Samples were calibrated by an 
MM  homozygote control.  Methionine homozygotes generally  fell  within the 2 A A C T  range  1.04 - 
1.08  and  heterozygotes  between  2.04  -  2.14,  however  two  MM  samples  were  observed  to  not 
conform to the  heterozygote group:  sample PDG2711  (1.99 ± 0.07) and PDG9466 (1.57 ± 0.03) 
(Figure 7.4). Both of these samples were suggestive of a heterozygous methionine deletion.
On  closer inspection  it  was  recognised that  both of these  samples possessed a glycine  to  valine 
heterozygous mutation at codon  127, which had been recently found to occur in several  samples 
from the  Fore populations.  The mutation was a G-» T transversion at the  second position within 
codon 127 (GGC to GTC). As these samples had been genotyped as heterozygous at additional loci 
linked to codon 129 (data not shown), it was clear that the suspected deletion was a spurious result, 
most  likely a consequence of the  127 mutation lying directly within the PRNP^m  probe binding 
region.
*  The data from replicates was tested for conformation to a normal distribution, proving that the use of 
statistical tests based on the normal distribution was valid.
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Figure 7.4  PRNP 129M cop y num ber an alysis of 25 Fore w om en over 50 years old  repeatedly 
exp osed  to kuru
Samples calibrated by an MM homozygote. Red and blue lines give average homozygote and methionine 
heterozygote 2'A A C T values respectively with dashed lines ±1.96xSEM.
When examined with the general PRNP probe, these samples were seen to lie within the population 
range. The difference in the 2‘A A C t values of PDG2711  and PDG9466 from the MM average may 
reflect a stochastic effect of the  127 mutation spuriously affecting probe binding to the template. 
Although  this  result  was  due  to  an  oversight  in  assembling  the  sample  set,  it  also  provided  a 
precedent for the assay to detect sequence variations.
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Figure 7.5  PRNP cop y num ber analysis of Fore w om en over 50 years old  repeatedly 
exp osed  to kuru
Samples calibrated by an MM homozygote control.  104 samples were screened with 5 control samples. The 
blue line gives average 2‘a a c t   value ±1.96xSEM. Error bars are ±1.96xSEM.
The 104 multiple kuru-exposure samples were screened as described above, with 5 control samples 
to ensure data were standardised between experiments (Figure 7.5). Mean 2'A A C T  was 0.98 ± 0.02,
208with values within a normal range of 0.8 - 1.2. All samples were observed to fall within the normal 
range and close to the population mean. The 25 healthy control samples also showed no difference 
in copy number (data not shown). The general PRNP probe was not affected by the G-» T mutation 
at  codon  127  (possibly  due  to  the  position  of the  probe/template  mismatch  generated  by  the 
mutation).
7.5  Copy number variation in sporadic CJD samples
To examine copy number changes of PRNP as a pathogenic mechanism in sCJD, 28 brain- derived 
sCJD samples were screened with the PRNP copy number probe, with 4 healthy control samples 
from the UK. All samples were RNAse treated and qPCR was undertaken in triplicate as described 
above. As Figure 7.6 illustrates the majority of samples fell within the population mean of 0.95 ± 
0.05  (±SEM) however,  one  sCJD  sample (PDG2271) with  average 2*A A C T value  3.77 ± 0.3  was 
clearly distinct  from the others.  PDG2271  was taken form an anonymous patient with confirmed 
sporadic CJD who was heterozygous at codon 129. As a consequence of anonymity of the sample, 
the patient’s clinical  information was not available. The average copy number of PDG2271  was 
approximately 4,  which  suggested  that  the  patient  would  have  possessed  a  triplication  of both
PRNP alleles.
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Figure 7.6  PRNP copy number analysis of sporadic CJD samples
A total of 28 sCJD samples and 4 control samples are shown (samples 29 to32 are controls). Red line gives 
average 2'A A C T value ±1.96xSEM. Error bars are 1.96xSEM.
The DNA quality of PDG2771 was rechecked as described in Materials and Methods 2.3.3 and the 
26 0 / 2 8o ratio was found to be sub-optimal at 1.64. A standard curve was constructed using a 32-fold 
serial dilution of PDG2271 (as described above) to dilute any impurities that may have affected the 
experiment. The standard curve produced for PDG2271 was within the tolerances described 
previously (data not shown) and therefore DNA quality could be excluded.
2097.6  Discussion
This chapter describes the development of a robust assay to examine PRNP copy number as a novel 
mechanism  for disease  susceptibility  in prion  disease  and  extends  the  development  of the  PNG 
sample collection as a model to detect novel susceptibility loci. The PRNP and (i-Actin probes and 
primers  designed  for this  assay were demonstrated to  effectively discriminate two  or more  fold 
differences  in  PRNP and PRNPnm copy number,  from  genomic  DNA  varying  in concentration 
from  6ng//tl  to  200ng//xl.  This  assay  was  applied  to  test  two  hypotheses,  both  based  on  the 
observation that codon  129 status alone is insufficient to explain disease susceptibility in several 
human prion diseases.
7.6.1  Hypothesis 1 -  PRNP deletion mediates protection against kuru
The first hypothesis related to the elderly Fore women of the Eastern Highlands of PNG, who were 
repeatedly exposed to kuru at multiple mortuary feasts but failed to develop disease. Based on data 
from the previous chapter,  ~30% of elderly kuru-exposed women possessed a susceptible codon 
129 homozygous genotype and yet had not developed disease. The mechanism regulating protection 
may involve the deletion of a PRNP allele to effectively reduce PrP production to a level where the 
clinical  disease is not seen.  The assay was applied to  104 samples and 25  controls and failed to 
detect any deletions of PRNP.
Using the methionine specific assay, two samples, which had been genotyped as MM homozygotes, 
were seen to deviate from the average 2'A A C T  copy number value. These two samples were found to 
harbour  a  known  polymorphism  at  codon  127,  within  the  probe-binding  region.  The  resulting 
single-base mismatch may have affected specificity of probe binding and thus deviating CT  values. 
Indeed the sensitivity of MGB probes to mismatches has been described in the  literature,  see for 
example (Yao et al., 2006). It is intriguing however that only the binding of the methionine specific 
probe was affected by the mismatch, despite both probes spanning the same region. It is likely that 
the  type  and  relative  position  of the  mismatch  influences the  kinetics of probe binding,  such  as 
altering melting temperatures, which can explain differential results such as these (Kutyavin et al., 
2000).
The absence of PRNP deletions in the elderly Fore females was a disappointing result however, the 
limit of detection of PRNP CNPs was 0.4%,  implying that  it is unlikely that PRNP deletion is a 
common protective mechanism against kuru.
2107.6.2  Hypothesis 2 -  PRNP duplication mediates susceptibility of codon 129 
heterozygotes to sCJD
The hypothesis that those individuals heterozygous at codon 129 but who had succumbed to sCJD 
may  have  possessed  a  duplication  of a  PRNP  allele  (which  would  have  gone  undetected  by 
genotyping  codon  129  alone)  was  examined.  Of the  28  UK  sCJD  samples  tested,  one  potential 
triplication  of PRNP  was  found.  This  was  an  intriguing  result  not  least  because  the  possible 
triplication had occurred on both alleles. The triplication of both PRNP alleles as a de novo event is 
incredibly unlikely {de novo CNP of two allelic  loci  is restricted to a few circumstances such as 
polyglutamine tract expansions). As witnessed in Parkinson’s disease, triplications often result in an 
earlier age of onset and pseudo-autosomal inheritance (Lesage et al.,  2006; Lucking et al.,  2001). 
The  inheritance  of two  triplicated  loci  is  a  possible  mechanism,  although  without  population 
frequency data it can only be assumed that the probability of acquiring such a genotype through 
random mating is small, implying therefore that the patient belonged to a consanguineous pedigree. 
Unfortunately, historical anonymisation of sCJD samples restricted the availability of clinical and 
familial data which would have helped to confirm this potential result.
Due to time limitations, additional work could not be undertaken to explore this sample further. 
However, future work to ensure that the result is genuine should explore the following avenues:
•  the result should be replicated - the sample was originally extracted from autopsied brain 
material and should therefore be re-extracted to ensure that the result is replicated and not 
merely a product of inherent, undetected contamination.
•  the  assay  could  be  repeated  with  different  probes,  both  for  the  target  and  endogenous 
control, to ensure that unknown polymorphisms in the binding regions of the primers and 
probes are excluded and that the copy number of the beta actin gene does not vary.
•  a second independent technique could be used to  identify a duplication,  such as FISH or 
extended homozygosity/heterozygosity.
7.6.3  Limitations of this approach and future work
There are limitations to the approach used in this chapter to detect CNPs and demonstrate that these
are phenotypically relevant.
7.6.3.1  PRNP gene coverage
Despite the sensitivity of the copy number assay, it was limited to resolving information on relative 
copy  number  in  a  restricted  region  of  the  gene.  PRNP  spans  approximately  15kb  across 
chromosome 20 with a 12.5kb intron separating exons one and two. The assay amplified ~100bp of
211exon  two  which  therefore  omitted  information  on,  amongst  other  regions,  the  promoter.  With 
regards to dosage effects and expression levels in neurodegenerative diseases, the promoter is an 
important  region  of the  gene  to  assay  -   and  with  the  promoter  and  other  upstream  elements 
implicated  in  sCJD (Mead et al.,  2001)  hint.  Therefore  it may be necessary,  for  future  work to 
design probes/primers that span the PRNP genomic locus representing in particular, the promoter 
region.
7.6.3.2  PRNP copy number and kuru
One  attractive  hypothesis  would  be  to  investigate  potential  duplications  in  individuals  who 
succumbed  to  kuru despite being  heterozygous  at  codon  129.  Currently the  availability  of good 
quality DNA for such tests is limited although efforts are currently being pursued at the MRC Prion 
Unit to consolidate samples using whole genome amplification - although it is not known how gene 
copy numbers will be affected by these procedures.
7.6.3.3  A test for somatic mutation
The somatic mutation hypothesis is a likely mechanism to explain the majority of sCJD and the role 
of CNPs in these somatic mutations will only be elucidated by a sensitive test (such a sensitivity test 
was  planned but  limited time dictated that  the test was not conducted).  The copy number assay 
developed  here  should be tested  for detection of less than two-fold  increases  in template.  Brain 
tissue displaying somatic mosaicism is likely to comprise of subtle differences in templates and so 
the ability to detect a range of template concentrations should be investigated.
7.6.3.4  A test for other diseases associated with PRNP
The development of a copy number assay for the prion gene could also inform on the pathogenesis 
of other diseases in which the PRNP has been implicated.  Inclusion body myositis (IBM)  is one 
such disease, which was beyond the scope of this study (MIM:  147421).  IBM  is one of the most 
common inflammatory myopathies of late onset and is defined histologically by inclusions which 
are immunoreactive  for several proteins including beta amyloid  fragments.  PrP immunoreactivity 
has also been noted within  IBM  inclusions and an association between codon  129 genotype and 
IBM  has been proposed but  not replicated (Lampe et al.,  1999;  Orth et al.,  2000).  Although the 
consequence of PrP deposition within inclusions in IBM is not known, a similar dosage mechanism 
to that hypothesised here for human prion diseases may exist and therefore, such a copy number 
assay may be able to elucidate the genetic mechanism responsible.
2128  General discussion
The work presented in this thesis has attempted to apply evolving techniques and analyses used to
investigate  complex  diseases  to  two  different  neurodegenerative  diseases.  As  each  set  of 
experiments has been discussed individually, the purpose of this chapter is to review this work in 
context.
8.1  Evolving tools and techniques
A  common  thread  throughout  this  thesis  has  been  the  rapid  advance  in  our  ability  to  analyse 
complex traits. Many of the tools and techniques evolved during or after the work in this thesis was 
carried  out  and  therefore  too  late  to  impact  this  work.  However,  where  this  has  happened,  the 
implications  of these  changes  have  been  discussed.  The  effect  of large  scale  project  and  new 
resources such as the HapMap, on research carried out concomitantly is not a new phenomenon. 
Prior to the sequencing of the human genome, methods to localise Mendelian disease genes were 
extremely difficult and very expensive. For example, localising the cystic fibrosis gene cost several 
hundred million dollars because of the huge amounts of unknown DNA which needed cloning and 
careful analysis.
8.2  DYNC1H1 and ALS
Mutation screening of DYNC1H1  The  preliminary  aim  of the  work  presented  in  the  first 
results chapter was to elucidate the genomic structure of DYNC1H1, a candidate gene for ALS. The 
initial evidence implicating a role for DYNC1HI in ALS pathogenesis came from mouse models of 
neurodegeneration in which mutations were positionally cloned to the mouse homologue Dynclhl. 
More recently, mutations in FALS families have been identified in a subunit of dynactin, a binding 
partner of cytoplasmic dynein. Using in silico methods, a 78 exon genomic structure of DYNC1H1 
spanning 86.6kb was elucidated.
Subsequent  work  in  this  chapter  aimed  to  screen  DYNC1H1  exons  8,  13  and  14  for  disease- 
associated mutations in index cases from FALS, HSP and SMA families and controls. These exons 
were  homologous  to  those harbouring  mutations  in the  Loa and Cral  mouse models of disease. 
Although two SNPs were identified in exons 8 and the intervening intron between exons 13 and 14, 
neither was seen to be associated with disease. This was essentially a direct association study and 
therefore unknown variants within the gene were not tested.
DYNC1H1 association study  The second results chapter aimed to conduct an indirect association 
study, to investigate genetic variation across DYNC1H1  for an association with SALS. SNPs were
213ascertained, the underlying pattern of LD elucidated and tSNPs selected. Two tSNPs were found to 
be sufficient to tag the majority of variation across DYNC1H1 and these were genotyped in SALS 
cases and controls. No significant association was seen.
During investigation of DYNCIH1 the pattern of genetic variation - specifically, reduced diversity 
-  was  suggestive  of an  evolutionary  signal  of  selection.  Several  indicators  of  selection  were 
investigated  including  heterozygosity,  FSt,  haplotype  frequencies  and  LD  decay,  in  northern 
Europeans,  Cameroonians  and  Japanese  populations.  Although  the  results  were  suggestive  of 
selection at this locus, due to ascertainment bias, no conclusive answers could be reached.
Genetic analysis of the cytoplasmic dynein subunit families  The  aim  of  this  third  results 
chapter  was  to  conduct  a  phylogenetic  study  to  clarify  the  relationships  between  the  known 
cytoplasmic dynein subunits, clarify their mapping positions, identify novel members of the subunit 
families  and  clarify  discreprencies  in  their  nomenclature.  In  the  absence  of an  association  of 
DYNCIHI with both FALS and SALS, several additional components of the cytoplasmic dynein- 
dynactin complex were considered for further study. However, the available data on these subunits 
was  found  to  be  confusing  and  even  erroneous.  Interspecies  phylogenetic  comparisons  and  an 
exhaustive  search  for  novel  human  and  mouse  homologs  have  clarified  many  existing 
discrepancies.
8.2.1  Is there a role for DYNCIHI in ALS?
The role of DYNCIHI in ALS remains unclear. The studies conducted in this thesis have identified 
no  association  of DYNCIHI  with either FALS  or  SALS  however,  as  previously discussed,  it  is 
highly likely that these studies were underpowered due to the lack of available samples and factors 
intrinsic to the study design.
Evidence  is  accumulating  that  suggests  DYNCIHI  remains  a  good  candidate  for  ALS  and 
potentially  other  neurodegenerative  diseases  by  virtue  of  its  importance  in  retrograde  axonal 
transport. Defective axonal transport has been observed in models of ALS by several investigators 
(Jablonka et al.,  2004; Rao et al.,  2003; Williamson et al.,  1999) and defects in anterograde axonal 
transport are one of the earliest pathologies observed in SOD1  mice (Williamson et al.,  1999). The 
work of Hafezparast and colleagues directly linked Dynclhl mutations in both Loa and Cral  mice 
with inhibited retrograde axonal transport and a progressive motor neuron degeneration phenotype 
(Hafezparast  et al.,  2003).  More  recently,  compelling  data  for the  involvement  of DYNCIHI  in 
ALS pathogenesis has come from a surprising observation by Kieran and colleagues in a compound 
heterozygous  mouse  created  by  crossing  a  SOD1G93a  mouse  with  a  Loa  heterozygous  mouse 
(Kieran  et  al.,  2005).  Kieran  and  colleagues  noted  that  whilst  heterozygous  littermates  of both
214mutations displayed a normal disease phenotype with impaired axonal transport and motor neuron 
death,  the  compound  heterozygote  showed  a  28%  increase  in  lifespan  (compared  to  SOD1G 93 a 
mice),  increased motor neuron survival and rescued axonal transport deficits. The mechanism by 
which the dynein mutation induces amelioration in Z,oa/SODlG 93A  mice is still under investigation, 
however Kieran postulates that amelioration of disease in Loa/SODlG 93A  mice may result from the 
restoration of axonal homeostasis as the balance between anterograde and retrograde transport in 
double-heterozygote  motor  neurons  is  restored.  In  addition,  the  dynein  mutation  may  result  in 
abnormal  intracellular transport,  which  in turn may change the interaction of mutant  SOD1  with 
organelles such as mitochondria, thus delaying cell death.
8.2.1.1  The dynein-dynactin complex and ALS
Beyond DYNCIHI there is substantial evidence linking the cytoplasmic dynein-dynactin complex 
with  ALS  pathogenesis.  Mutations  in at  least three different  subunits  of the complex,  Dynclhl, 
dynamitin (p24) and dynactin (pi 50), have all been shown to result in motor neuron degeneration 
phenotypes (Hafezparast et al., 2003; LaMonte et al., 2002; Munch et al., 2004; Munch et al., 2005; 
Puls et al.,  2003;  Puls  et al,  2005).  In  addition,  the role of this complex as a retrograde motor 
protein makes it a good candidate in other axonal transport-mediated neurodegenerative diseases. 
For example, DYNCIHI  has been  found to colocalise with amyloid plaques in the brains of AD 
patients  and  transgenic  mouse  models  of AD  (Liao  et  al.,  2004).  In  addition,  disrupted  axonal 
transport  has  been  witnessed  in  Huntington’s  disease  in  which  the  expanded  mutant  huntingtin 
protein is thought to disrupt axonal transport by interaction with the pl50G lued subunit of dynactin 
indirectly,  via  the  huntingtin-associated  protein  HAP1  (Engelender et al.,  1997).  The  expanded 
glutamine repeats in huntingtin have been proposed to disrupt the integrity of the dynein/dynactin 
complex, thus reducing the efficiency of neurotrophic factor transport and contributing to neuronal 
death (Gauthier et al., 2004).
There is clearly some degree of genetic heterogeneity in the cytoplasmic dynein-dynactin complex 
and  its  associated  neurodegeneration  phenotype.  Clarification  of the  genetic  relationships  of the 
cytoplasmic dynein subunits was undertaken with a view to conduct a future association study in 
which  multiple  members  of the  dynein-dynactin  complex  may  be  investigated  in  a  ‘candidate 
pathway’ approach. KasperaviCiute and colleagues recently performed such a study, analysing 1277 
putative functional and tSNPs in 134 genes, including 17 members of the dynein-dynactin complex, 
in  822  British  SALS  samples and  872 controls (Kasperaviciute et al.,  2007).  19  SNPs showed a 
trend of association in the initial screen and were genotyped in a replication sample of 580 German 
sporadic ALS patients and 361  controls, after which no  strong evidence of association was seen. 
Despite  this  negative  result,  this  study  was  only  able  to  capture  common  SNPs  (>5%)  with
215predicted  moderate  effect  size.  By  genotyping  only  a  subset of SNPs  in the replication  sample 
variants  with  lower  effect  size  may  have  been  missed  and  functional  variants  which  were  not 
represented well by the initially genotyped set of SNPs may have also been missed. Additionally, 
some variants are known to have population-specific effects, as is illustrated by the association of 
the  VEGF gene  promoter polymorphisms and  ALS.  These polymorphisms have been  positively 
associated  with  disease  in  three  studies  (Sweden,  Belgium,  Birmingham)  which  has  not  been 
replicated in another four (London, Sheffield, The Netherlands, North America) (Brockington et al, 
2005; Chen et al, 2006; Lambrechts et al, 2003; Van Vught et al, 2005). Therefore, the genes of 
the dynein-dynactin complex may be associated with disease in additional populations.
8.2.2  Are association studies the right approach for complex neurodegenerative 
diseases?
The application of association studies to complex diseases has had mixed success. Non-replication 
of association findings is common for complex diseases however, few association studies have been 
found to be consistently replicable (Table 8.1). The success of an association study is dependent on 
several factors including:  sample size and sample homogeneity (phenotypic and therefore genetic 
homogeneity and population homogeneity);  genotyping accuracy;  statistical analyses (corrections 
for multiple candidate genes or genome-wide analyses) and study design /genetic architecture to 
name a few (Abou-Sleiman et al, 2004; Hattersley et al, 2005; Healy, 2006).
Disease Gene Polymorphism Associated allele 
~Freq  -OR Reference
Thrombophilia F5 Leiden Arg506Gln 003 4 (Bertina et al.,  1994)
Crohn's disease CARD15 3 SNPs 006 4-6 (Hugot et al., 2001)
(Corder et al.,  1993; Farrer et al., 1997;
Alzheimer's APOE e2/3/4 0-15 3-3 Rubinsztein et al., 1999; Saunders et 
al.. 19931
Osteoporotic
fractures
COL1A1 Sp1  restriction site 0-19 1*3 (Mann et al., 2001; Mann et al., 2003)
Age-related (Edwards et al., 2005; Hageman et al.,
macular HF1/CFH Tyr402His 0-30 2*5 2005; Haines et al., 2005; Klein et al.,
deoeneration 2005: ZareDarsi et al.. 20051
Type 2 diabetes KCNJ11 Glu23Lys 0-36 1-23 (Gloyn et al., 2003)
Type 1 diabetes CTLA4 Thr17Ala 0-36 1-27 (Marron et al., 1997; Ueda et al., 2003)
Graves' disease CTLA4 Thr17Ala 0-36 1-6 (Chistiakov etal., 2003)
Type 1  diabetes INS Variable 5" tandem 
repeats
0-67 1-2 (Bennett et al., 1996)
Bladder cancer GSTM1 Null (gene deletion) 0-70 1-28 (Engel etal., 2002)
Type 2 diabetes PPARG Pro 12Ala 085 1-23 (Altshuler et al., 2000)
Table 8.1  C onsistent a sso cia tio n s with com p lex d isea se
Approximate disease associated polymorphism or haplotype frequency shown (~Freq) and odds ratio (~OR) 
shown
2168.2.2.1  Sample size
Sample size is of particular concern in neurodegenerative disease and is often a limiting factor in 
association studies of these diseases including the DYNCIHI study described in this thesis. Sample 
size  is  a  direct  determinant  of study  power  and  therefore  the  study  outcome.  However,  many 
neurodegenerative diseases have low disease prevalence with short survival times, which restricts 
the  development  of  the  large  sample  collections  required  to  detect  associated  variants  with 
moderate-to-low effect size or of low population frequency. As our understanding of the importance 
of sample size continues to develop, more multicentre and international collaborations have been 
undertaken.  For  example,  the  recent  genome-wide  association  study  in  ALS  undertaken  by 
Kasperavi£iute and colleagues was comprised of over 800 samples from collections across the UK 
and  resultantly,  their  study  had  sufficient  power  to  detect  a  causal  variant  with  OR  of  1.47 
(Kasperaviciute et al., 2007), In addition, WGA of these study samples was undertaken to increase 
DNA  stock  300-fold  and  ensure  that  these  limited  resources  were  not  depleted  without  any 
detrimental impact to genotyping quality or efficiency.
8.2.2.2  Statistical analyses
The availability of cheaper and more efficient genotyping platforms has recently made genome- 
wide association studies of complex diseases a reality. Several different platforms are now available 
which either employ fixed marker sets, such as the Affymetrix GeneChip arrays, or custom marker 
sets, such as the GoldenGate assays (reviewed in Syvanen, 2005) and these sets can also comprise 
HapMap tSNPs. However, the multiple testing of 100,000 or more SNPs increases the type I error 
rate  and  therefore  the  significance  threshold  must  be  corrected  to  reflect  this.  Several  different 
methods of achieving an appropriate genome wide significance threshold exist but they all mean 
that low P-values (cx-value) are required to achieve significance. This in turn affects the sample size 
required to detect an association at various susceptibility allele frequencies (Table 8.2). Genome- 
wide studies of rare neurodegenerative diseases may therefore require unfeasibly large sample sizes.
a
Susceptibility allele frequency in controls
1%  5%  10% 20% 30% 40%
005 13 599 2866 1533 886 694 623
001 19 258 4058 2171 1255 982 883
0001 27 055 5702 3051 1763 1380 1240
5*10'® 36 869 7770 4157 2403 1881 1690
5*10~* 58 678 12 366 6617 3825 2994 2690
Table 8.2  Effect of differing statistical significance levels on sample size
Numbers indicate sample size needed to detect significant association (power=90%) for different values of a, 
assuming allelic odds ratio of 1 -3, given differing allele frequencies for predisposing allele or haplotype. (From 
Hattersley et al., 2005)
2178.2.2.3  Rare diseases
Both  the  frequency  and  penetrance  of causal  alleles  affect  the  statistical  power  to  detect  these 
alleles; power increases with increasing frequency and increasing penetrance. The power to detect 
an allele therefore depends on what is ultimately the most relevant measure of a genetic variant’s 
contribution:  the  proportion  of the phenotypic  variance  in  the population  that  is  explained by a 
particular variant. This means that rare variants with modest effects will be difficult to detect by any 
method because they explain only a small fraction of the variance in a trait.
Rare alleles might  also be more difficult to detect by association  for other reasons.  Even  if rare 
alleles have strong effects, they might be difficult to detect by association methods because they are 
less well represented in SNP databases and because tag SNP approaches are currently designed to 
tag  common  SNPs  (usually  with  frequencies  >5%).However,  population-genetic  considerations 
indicate that  most  rare alleles with  frequencies <5% are  likely to  have arisen relatively recently 
(because old alleles tend to either disappear or become common), so there will have been less time 
for  recombination  and  mutation  to  disrupt  the  haplotype  on  which  they  arose.  Therefore,  rare 
variants are expected to be on single, long haplotypes, as has been observed (Kamatani et al., 2004).
However,  as  previously  discussed,  new  techniques  such  as  the  exhaustive  searching  of  all 
haplotypes employed in the EATDT approach could greatly increase power to detect rare variants 
(de Bakker et al., 2005; Lin et al., 2004). In addition, Vermeire and colleagues have shown that the 
alleles of CARDI5 with MAF<5% that contributes to IBD could have been detected indirectly with 
haplotypes composed of common variants (Vermeire et al., 2002) and a rare (<3%) haplotype in the 
11/3-hydroxysteroid dehydrogenase type 1  gene (HSD11  /31) has been shown to be associated with a 
6-fold increase in risk for sporadic AD
8.3  Identifying kuru susceptibility loci
Several different aims were investigated in the first kuru results chapter:
(i)  to perform a comprehensive analysis of PRNP codon 129 genotype data
HWE analysis of 147 kuru samples corroborated the correlation of homozygosity at codon 129 with 
earlier kuru onset and conversely, the protective effect of heterozygosity at codon  129.  Although 
only age of onset was available as a comparable phenotype, it is more likely that codon  129 status 
affected  kuru  incubation  time  of these  cases,  however,  without  knowing  approximately  when 
transmission occurred and at what dose, incubation time would be impossible to estimate. However, 
a recent study of long incubation time kuru deaths (deaths post-1960) by Collinge and colleagues 
identified a significant excess of codon 129 heterozygotes, suggesting that heterozygosity at codon 
129 is associated with long incubation times (Collinge et al., 2006). The protective effect of codon
218129 was illustrated by analysis of 125 elderly Fore women who despite being exposed repeatedly to 
kuru at multiple mortuary feasts, did not succumb to disease. The codon 129 genotype in this cohort 
was highly enriched for heterozygotes and found to be extremely significant when compared to the 
genotype proportions expected under HWE.
(ii) to identify signatures of selection at codon 129 as a paradigm for other candidate loci
Several different tests of selection were undertaken at codon  129 and across the PRNP locus. The 
co-variation of these signatures of selection with the intensity of the selective force (i.e. kuru) was 
examined. HWE and heterozygosity analyses based on linguistic groups identified deviations from 
HWE in those groups known to have the highest exposure to kuru but not in those with moderate 
exposure to kuru. In addition, despite a world-wide cline in codon  129 valine allele frequency, no 
cline within the Eastern Highlands was seen. The establishment of an exposure index to account for 
the exposure of each individual  village within a linguistic group consolidated the HWE data and 
identified a significant valine frequency cline between the highly exposed and unexposed Highland 
populations and non-Highland populations.
(iii) to develop a PNG sample panel as a resource to test candidate genes
The refinement of the PNG samples according to kuru exposure has provided a powerful resource 
for testing candidate genes against. The significant variation of valine allele frequency from non- 
Highland  to  Highland  samples  and  within  the  Highlands  from  kuru-unexposed  to  kuru-exposed 
samples  illustrates  how  potential  susceptibility  loci  may  be  identified.  Such  clines  in  allele 
frequency or magnitude of other measures such as deviation from HWE or FSt  at candidate loci 
may be indicative of a susceptibility allele.
(iv) to assess the feasibility of genome-wide genotyping on archived kuru samples
The analysis of 7  kuru samples which had undergone WGA and 7 multiple exposure samples on 
Affymetrix  NspI  GeneChip  arrays  permitted  several  observations  to  be  made.  Despite  the  PCR 
banding patterns obtained  following amplification of the WGA kuru  DNA,  fragmentation of the 
samples appeared relatively normal. The optimum rank score threshold  for analysis of the WGA 
samples, compared to a baseline analysis at P=0.1, was found to be P=0.19. At this threshold, the 
greatest gain in SNP calls was seen with a minimal increase in discordance of calls. The analysis of 
pairwise LD identified that LD was insensitive to the rank score threshold used to analyse the data, 
possibly  because  the  discordance  seen  at  lower  stringencies  comprised  a  small  fraction  of the 
overall pairwise comparisons. The inflation of pairwise LD in a small sample size was seen to affect 
long-range LD to a greater extent compared to smaller pairwise intervals (230% inflation for lOOkb 
comparisons compared to  113% inflation for 5kb comparisons). LD decay over distance for the 7
219WGA kuru samples was markedly different to that of 7 UK and 7 multiple exposure samples, which 
probably reflected the failure of the WGA DNA samples to genotype accurately. Interestingly, the 
decay of LD in the 7 multiple exposure samples was 1.25-fold greater than that of the UK samples, 
with  a  similar  distribution  implying  that  LD  is  extends  over  a  greater  distance  in  these  PNG 
samples.
8.3.1  Signatures of selection at PRNP
8.3.1.1  Evolutionary studies require good epidemiological evidence
All  tests  conducted  for  signatures  of  selection  and  for  the  influence  of  codon  129  on  kuru 
incubation/onset  have  relied on good epidemiological data.  For example,  the protective effect of 
heterozygosity at codon  129 in women aged >50 years in 2000 required the documentation of the 
date of sample collection, age data and knowledge of the approximate cessation of the practice of 
endocannibalism.  Together,  these  data  allowed  a  powerful  analysis  of those  women  who  lived 
during the peak of the kuru epidemic but  who had not succumbed to  kuru.  Similarly, the  HWE 
analysis  of the  surviving  Eastern  Highland  population  required  knowledge  of these  data  and 
appreciation of the selection model (i.e. sex specific balancing selection). These data permitted the 
stratification  of data  to  provide  a  clearer  signal  of selection  and  resultantly,  the  HWE  analysis 
recapitulated the known epidemiology of the disease.
The importance of precise epidemiological data was also highlighted in the investigation of a valine 
allele  cline across  the  Eastern Highlands.  Analysis of a valine  allele cline,  covarying with  kuru 
exposure was  undertaken  within  linguistic  groups.  This  led to the  observation of an equilibrium 
frequency for valine alleles across the Eastern Highlands. However, on application of the exposure 
index  for each village within a linguistic group, a significant cline in valine allele frequency was 
seen.
2208.3.1.2  Was evidence for selection seen at PRNP?
There were 3 key pieces of evidence that supported the role of selection at PRNP:
(i)  a highly significant increase in codon 129 heterozygosity was seen in those exposed to 
kuru but not succumbing to disease.
(ii)  a significant cline in valine allele frequency was seen with the highest value seen in the 
kuru exposed group suggesting that kuru may have been responsible for the increase.
(iii)  although  the  microsatellite  data  did  not  yield  any  useful  information  regarding 
differences in LD between exposed and unexposed groups, marginal significance was 
seen with microsatellite FS t on the valine chromosome, implying that a sudden increase 
in the valine haplotype may have resulted in a selective sweep of surrounding alleles.
8.3.1.3  PRNP selection study caveats
There are several caveats to the work carried out to identify selection at PRNP.
A necessarily limited amount of polymorphism data was analysed. Although it would have been 
preferable  to have  sequenced the PRNP ORF  and  flanking  sequences to test  for selection using 
measures based on the five main signatures of selection described by Sabeti and colleagues (Sabeti 
et al..  2006)and  summarised  in  Chapter  1,  financial  and  time constraints  dictated  that  available 
codon 129 data and microsatellite data was used. This restricted the analysis largely to single locus 
tests which omits data from surrounding polymorphisms.
The cline in valine frequency may be a demographic effect. The increase in valine  frequency 
from costal PNG populations to within the Eastern Highlands could reflect the stochastic effects of 
genetic drift through migration and population bottlenecks. Unlinked loci should have been typed to 
ascertain if the increase in valine allele frequency was due to demography rather than selection, as 
following  a  population  bottleneck  a  reduction  in  diversity  will  be  seen  across  the  genome  at 
unlinked loci. Whereas following selection, only the genetic diversity related to the selected locus 
will be affected. Unlinked markers were not typed in this study as a whole-genome study in these 
samples was anticipated.
A population bottleneck cannot explain however, the significant difference seen in valine frequency 
between the Highland exposed and unexposed populations. Analysis by linguistic groups indicates 
that  both  of these  cohorts  have  an  equilibrium  frequency  however  when  grouped  according  to 
exposure index, a significant difference is seen.
221Are the assumptions of Hardy-Weinberg equilibrium violated? Several of the tests applied to 
the  PRNP  data  in  this  thesis  and  other  published  work  have  interrogated  codon  129  data  for 
departures from HWE and have attributed departures to a violation of the assumption of an absence 
of selection. However, as there is no written history in the Eastern Highlands, we cannot be clear 
about  how the populations of the  Eastern  Highlands are  structured,  if migration occurs amongst 
them and  if mating  is truly random - at  least  prior to oral  history being obtained by  interview. 
Violation of these assumptions should be stated as a caveat to these data.
8.3.2  G127V is an additional PRNP susceptibility factor
The novel G127V polymorphism was  found to be highly geographically restricted to the Purosa 
Valley, where it was a common variant occurring at ~7%. Analysis of the multiple exposure women 
and exposed men against the kuru samples illustrated that the polymorphism confers resistance to 
kuru in the heterozygous state. The mechanism of protection associated with this polymorphism is 
unclear:  it may result steric hinderance from the addition of a bulky amino-acid side-chain which 
resultantly impedes beta-sheet formation and protect against prion formation.
The possibility that, rather than protecting against kuru, the 127V polymorphism might have instead 
triggered the epidemic cannot be completely excluded. Given that life expectancy in the kuru region 
is 42 years, it is possible that 127V is associated with a late-onset and low penetrant inherited prion 
disease  which  might  have  triggered  the  kuru  epidemic.  There  are  few  examples  of mutations 
causative of autosomal dominant neurodegenerative disease that achieve the polymorphic frequency 
observed  in  the  Purosa  Valley  (Wexler  et  al.,  2004).  A  wealth  of  data  indicates  that  prion 
transmission is generally more efficient where there is complementarity between the primary PrP 
sequence of donor and host, implying that if 127V was pathogenic it would be expected to confer 
susceptibility  to  the  corresponding  acquired  prion  disease  (Collinge,  2001).  Additionally,  the 
glycoform type of PrP^ in kuru, although restricted to a small number of autopsy samples, closely 
resembles sCJD rather than point mutation inherited prion disease (Parchi, 2000). Finally, if 127V 
had triggered kuru, the localization to the southeastern part of the Fore linguistic group would be 
inconsistent  with oral  history that  the  first  kuru patient  was  observed  in  the  Keiagana  linguistic 
group located to the northwest of the Fore. Future work should included the modelling of the  127 
mutation  in  transgenic  mouse  lines  and  in  cell-models  to  identify  how  this  change  may protect 
against disease.
2228.3.3  Is selection a valid method for mapping loci in all neurodegenerative 
diseases?
The use of identifying a signature of selection for identifying loci involved in the pathogenesis of 
complex disease is an interesting concept but one that is not yet supported by concrete examples.
There  are  several  reasons  why  signatures  of  selection  may  not  be  applicable  to  all  complex 
neurodegenerative diseases. Perhaps the most significant is that pointed out by J.B.S. Haldane who 
recognised that late-onset genetic diseases in humans, such as Huntington’s disease, encounter only 
weak  selection  (Haldane,  1941).  Haldane’s  observation  recognises  that  the  principle  driver  of 
evolution is differential fitness or fecundity, meaning that an organism’s ability to reproduce must 
be affected by mutation. However, the majority of cases of complex neurodegenerative diseases are 
late-onset,  presenting  after reproduction  is  completed  and  therefore  are  likely  to  be  under  little 
selection pressure.
For  Mendelian  diseases,  which  are  usually  caused  by  rare  strongly  deleterious  mutations,  a 
mutation-selection-balance  model  can  be  evoked,  in  which  disease  alleles  are  continuously 
generated by mutation and eliminated by purifying selection before reproduction.  This model  of 
purifying selection can also be extended to common late-onset diseases, by assuming that although 
onset  occurs  after  reproduction  is  complete,  the  susceptibility  genotypes  still  have  weakly 
deleterious effects on  fitness  (Pritchard,  2001;  Reich et al,  2001b).  Weak purifying selection is 
actually a pervasive mechanism underpinning patterns of variation in human populations, as non- 
synonymous  variants  occurring  at  evolutionarily  conserved  positions,  tend  to  occur  at  lower 
frequencies compared with synonymous polymorphisms (Hughes et al, 2003). Empirical data have 
also corroborated this model.  In analysing nucleotide sequences of genes known to be mutated in 
Mendelian diseases and replicated genes  in complex disease, Thomas and Kejariwal  identified a 
preponderance  for  Mendelian  disease-associated  non-synonymous  SNPs  to  occur  at  highly 
conserved  positions  in  proteins  compared  to  their complex  disease  counterparts  (Thomas  et al, 
2004).  This  result  strongly  suggests  that,  on  average,  the  molecular effects  of non-synonymous 
SNPs in complex diseases will be more subtle than the severe functional changes associated with 
most  non-synonymous  SNPs  in  Mendelian  disease.  In  addition,  under  this  mutation-selection- 
balance model multiple rare new alleles increasing risk are predicted to be found at trait loci. This 
has been observed at loci such as the ABCA1 gene responsible for low HDL cholesterol (Cohen et 
al, 2004).
223In contrast, some mutations may have pleiotropic effects, which are beneficial in youth, but yield a 
greater subsequent risk of neurodegenerative disease. These mutations would then be incorporated 
into the population by selection, which will act more strongly on the early, beneficial effect. This 
can be considered an extension of James Neel’s “thrifty gene” hypothesis which attempts to explain 
a  tendency  of certain  populations  towards  obesity  and  diabetes  (Neel,  1962).  The  hypothesis 
postulates that certain human genes have evolved to maximize metabolic efficiency which would 
thereby confer a survival advantage in times of food shortages. However, in times of abundance, the 
thrifty genotype no longer confers a survival advantage,  instead predisposing carriers to diseases 
caused by excess nutritional intake, such as obesity and diabetes. This hypothesis has been used to 
explain ethnic variation in AD prevalence (Farrer et al.,  1997) linked to variation in the APOE e4 
allele frequency (Reviewed in Laws et al.,  2003).  Briefly, APOE e4 is associated with increased 
levels of dietary cholesterol and hypercholesterolaemia may play a role in the mechanism by which 
APOE e4  increases the risk  for AD.  Therefore,  a change in dietary environment  for populations 
possessing this “thrifty gene”  may  lead to an increased risk of AD,  This phenomenon has been 
suggested to explain why Africans in Nigerian and East Africa show no association of APOE e4 
with AD whereas in African-Americans an association has been reported (Reviewed in Laws et al., 
2003).
A  very  strong  signature  of  selection  was  found  in  the  Fore,  related  to  kuru.  Perhaps  those 
neurodegenerative diseases where signatures of selection may be of most use are diseases similar to 
kuru - epidemics with high mortality rates and high selection coefficients. ALS with Parkinsonism 
and  dementia  seen  in  Guam  and  a  similar  disease  in  the  Kii  peninsula  of Japan  of ALS  with 
dementia are at first glance, good candidates, However despite having a historical prevalence ~400 
per 100,000 population (Galasko et al., 2000) and ~194 per 100,000 population (Yase et al., 2001) 
respectively, onset and death occur after reproductive age is reached: mean age of onset is 55 years 
(Galasko et al., 2000) in the Guamanian disease and 56.5 years in the Kii form of ALS (Yoshida et 
al.,  1998).  The  unique  feature  of prion  disease -  it’s  transmissibility -  makes  kuru  exceptional 
amongst  neurodegenerative diseases.  K may be our best example of a neurodegenerative disease 
affected by selection and provide the first clues to novel susceptibility loci but it remains to be seen 
if evolutionary analyses will have utility in other neurodegenerative diseases.
8.4  Future directions for complex genetic analyses of neurodegenerative disease
It is likely that future studies of complex diseases will not be based solely on association studies or 
studies to identify evolutionary selection. A paper published within the last few weeks by David 
Reich  and  his  group  has  illustrated the  statistical  power available  to  detect  disease  variants  by 
combining these two approaches (Ayodo et al., 2007). Reich and colleagues observed that power to
224detect  risk  variants  for  malaria  was  increased  by  several  orders  of magnitude  if case-control 
association studies were conducted with variants showing allele frequency differentiation between 
differently  exposed  populations,  The  applicability  of  this  type  of  test  to  the  majority  of 
neurodegenerative diseases remains to be seen, however, kuru, which has been shown in this thesis 
to have caused codon  129 allele frequency differentiation in differently exposed populations, may 
be a good place to begin.
In conclusion, the work presented in this thesis aimed to investigate two complex neurodegenerative 
diseases by means of two very different methods - a candidate gene case-control association study 
and analyses based on  the  signatures of selection.  The work presented in this thesis reflects the 
methods and study designs accepted and widely used at the time and therefore, this work is very 
much “of it’s time”.  No association of DYNCIHI  with FALS  or SALS was seen,  In the human 
prion disease kuru, strong balancing selection imposed by the disease was witnessed at codon 129 
of PRNP and a new protective polymorphism was identified. And finally, the role of PRNP copy 
number polymorphisms was investigated as a potential pathogenic mechanism, in kuru and sCJD. 
From the data collected, it is likely that PRNP CNPs could account for a small minority of disease 
cases.
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26610  Appendices
Alleles
Minor
allele
1 rs2180511 27670 A/T 535 14 2 0 6.0%
2 rs1678034 30289 A/C 566 14 2 0 6.3%
3 rs2180513 61497 C/T 622 16 0 0 0%
4 rs1956297 74179 err 453 16 0 0 0%
5 rs2474677 75613 err 16 0 0 0%
6 rs2474678 75617 A/G
O O U
16 0 0 0%
7 rs2448241 76261 CfT 16 0 0 0%
8 rs2093025 76319 CfT 500 16 0 0 0%
9 rs2474679 76323 C/T 16 0 0 0%
10 rs1044838 76846 A/C 16 0 0 0%
11 rs2281539 76858 CfT
510
16 0 0 0%
12 rs2273434 76920 C/G 16 0 0 0%
13 rs2273435 77049 A/G 15 1 0 3.1%
14 rs2448240 77419 C/G 360 16 0 0 0%
15 rs2448239 79006 A/G 520 16 0 0 0%
16 rs1741151 81081 C/T 320 14 2 0 6.3%
17 rs2403015 89054 A/G 591 16 0 0 0%
18 rs1622886 89874 A/G /on 16 0 0 0%
19 rs1741155 89892 A/G 12 3 1 15.6%
20 rs2749911 90216 C/T 16 0 0 0%
21 rs2720193 90225 A/G 460 12 4 0 12.5%
22 rs2720194 90295 A/G 12 4 0 12.5%
23 rs2448242 91338 A/G 440 16 0 0 0%
24 rs2273438 107101 C/T 390 12 4 0 12.5%
25 rs2273439 107195 C/T 380 16 0 0 0%
26 rs2720218 109449 A/C 190 16 0 0 0%
27 rs2749890 114824 A/G 200 12 4 0 12.5%
28 rs2749894 119522 A/C 211 16 0 0 0%
29 rs2720206 119787 CfT 260 16 0 0 0%
30 rs2720213 126498 C/G 160 15 1 0 3.1%
31 rs2251644 129341 A/G 280 12 4 0 12.5%
32 rs2749896 132256 A/G 16 0 0 0%
33 rs2749897 138855 A/G 380 16 0 0 0%
34 rs2720197 139455 A/G 16 0 0 0%
35 rs3742426*f 147536 A/G Ann 12 4 0 12.5%
36 rs2180510 147694 A/G
D U U
12 4 0 12.5%
37 rs2749899 150639 A/G 453 16 0 0 0%
38 rs2749900 151540 C/G 365 16 0 0 0%
39 rs2720198 151863 A/C 440 16 0 0 0%
40 rs2403016 153341 C/T 359 16 0 0 0%
41 rs2295445 157537 C/G 367 16 0 0 0%
42 rs754598 160726 A/G 498 16 0 0 0%
43 rs941632 163482 A/G 275 16 0 0 0%
44 rs2093024 167571 A/C 530 16 0 0 0%
45 rs941793 168955 C/T 260 12 4 1 17.6%
46 rs1190605 171447 C/G 420 16 0 0 0%
47 rs1043455 172220 C/T 327 16 0 0 0%
48 rs13749 175721 C/T 12 4 0 12.5%
49 rs2273656 175929 A/C
H O U 16 0 0 0%
50 rs941792* 176207 C/T 12 3 1 15.6%
51 rs1127284 176475 C/T 380 16 0 0 0%
52 rs1004903 176509 A/G 12 3 1 15.6%
53 rs10135238* 180364 C/T con 12 4 1 17.6%
54 rs1190610 180468 A/G
OvU 12 3 1 15.6%
55 rs1190613 183028 CfT AAn 12 4 1 17.6%
56 bp183293** 183293 A/T 15 1 0 3.1%
57 rs1190614 185042 A/T c7n 13 3 0 9.4%
58 rs11849604* 185073 ATT
Of u 13 3 0 9.4%
59 rs1203482 193407 CfT ocn 16 0 0 0%
60 rs1190618* 193460 C/G
oou 12 4 1 17.6%
Appendix 1.  Full genotypes for 60 SNPs across DYNC1H1
* SNPs previously absent from the SNP databases which have since been added 
f rs3742426 was merged with rs12895291  in May 2006 
*no information available for this SNP in SNP databases
267Primer name Forward sequence Reverse sequence
rs1741155
rs2720193
rs2720194
rs2273438
rs2749890
rs2251644
rs3742426
rs2180510
rs941793
rs13749
rs941792
rs 1004903
rs10135238
rs1190610
rs1190613
rs1190618
rs2251644CBDay
aaag
ttgta
icttgaa
icttgaa
igatcg
tea
aagt
>agt
etc
etc
aa
latg
agac
ctt
ctt
ace
3SL
eta.
ctg_
atgtc
jgetc
catgcL
Tm(°C)
60
60
60
60
60
60
60
60
60
60
60
60
60
60
63
60
60
Amplicon 
size (bp)
604
752
752
444
767
401
589
589
503
633
850
850
677
677
562
458
392
DYNC1H1  Exon 8 ttaaagccttcgtttggtcag agctcgctattacagtgctt 60 1190
DYNC1H1  Exon  13 and 14 gtggtgaaagacatgaaccttc ctggccgtgtgtctactgagtg 60 655
A ppendix 2.  DYNC1H1 inform ative prim ers
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Genetic Analysis of the Cytoplasmic Dynein 
Subunit Families
K. Kevin Pfister*,  Paresh  R. Shah,  Holger Hummerich, Andreas  Russ, James Cotton, Azlina Ahmad Annuar,
Stephen M. King,  Elizabeth  M. C.  Fisher
ABSTRACT
C
ytoplasmic dyneins,  the principal microtubule 
minus-end-directed motor proteins of the cell, are 
involved  in  many essential cellular processes. The 
major form of this enzyme is a complex of at least six protein 
subunits, and  in  mammals all but one of the subunits are 
encoded by at least two genes.  Here we review current 
knowledge concerning the subunits, their interactions, and 
their functional  roles as derived from biochemical and 
genetic analyses.  We also carried out extensive database 
searches to look for new genes and to clarify anomalies in the 
databases. Our analysis documents evolutionary relationships 
among the dynein subunits of mammals and other model 
organisms, and sheds new  light on  the  role of this diverse 
group of proteins, highlighting the existence of two 
cytoplasmic dynein complexes with distinct cellular roles.
Introduction
Dyneins are large  multi-subunit  protein complexes that 
undertake a wide range of roles within  the cell. They are 
adenosine triphosphate (ATP)-driven,  microtubule minus- 
end-directed molecular motors that can be divided, based on 
function, into two classes: axonemal and cytoplasmic dyneins 
[1-7] (reviewed in  [8,9]). Axonemal dyneins are responsible 
for the movement of cilia and flagella. Two cytoplasmic 
dynein complexes have been identified. The most abundant 
cytoplasmic dynein complex, cytoplasmic dynein  1, is 
involved  in functions as diverse as spindle-pole organization 
and  nuclear migration during mitosis, the positioning and 
functioning of the endoplasmic  reticulum, the Golgi 
apparatus, and  the nucleus, and also the minus-end-directed 
transport of vesicles,  including endosomes and lysosomes, 
along microtubules and  retrograde axonal  transport in 
neurons.  A second cytoplasmic dynein complex, cytoplasmic 
dynein 2, has a role in intraflagellar transport (IFT), a process 
required for ciliary/flagellar assembly (reviewed in  [10]).
The core of the cytoplasmic dynein  1  complex is a 
homodimer of two heavy chain polypeptides and associated 
intermediate, light intermediate, and light chain polypeptides, 
which are defined and named by their molecular mass and 
mobility in SDS-PAGE gels (Figure  1A). The protein subunits 
are encoded by families of at least two genes, and the 
expression patterns of the individual family members are 
different in various cell types. At least one of the light chains, 
DYNLL1  (LC8), has multiple cellular roles independent of its 
participation in a dynein complex. Cytoplasmic dynein  1  
interacts with various other proteins including a second 
multimer, dynactin, to form the dynein-dynactin complex. 
Dynactin is comprised of at least seven different proteins,
which together act as an adaptor that connects the cytoplasmic 
dynein motor to a range of cargoes (for review, see [11]). 
Interaction with dynactin also increases dynein motor 
processivity [12]. Furthermore, dynactin functions 
independently of dynein, anchoring microtubules at the 
centrosome [13]. Current evidence suggests that the second 
cytoplasmic dynein complex, cytoplasmic dynein 2, is also a 
homodimer of a distinct heavy chain, DYNC2H1, with 
associated light intermediate chain, DYNC2LI1 (Figure IB). No 
other subunits have yet been identified for this complex, and it 
does not appear to interact with the dynactin complex [14-16].
The cytoplasmic dynein proteins are fundamental to the 
functioning of all cells, and have recently been shown  to be 
causally mutated in forms of neurodegeneration  [17-19]. 
They are  thus of great interest for mammalian genetic, and 
other, studies. We  therefore sought to examine the role of 
cytoplasmic dynein subunits from a genetic perspective. 
During this analysis, we noted considerable confusion  in  the 
human and mouse gene and protein  names and mapping 
positions. Therefore, we reexamined the mapping locations 
for the subunit genes and clarified and updated entries in the 
various sequence databases. In doing so, we utilized the 
revised consensus nomenclature developed for the 
cytoplasmic dynein subunits and their genes (Table  1). We 
also defined, as far as possible with current data, homologous 
genes in model organisms, including Drosophila,  Caenorhabditis
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Figure 1. The Mammalian Cytoplasmic Dynein Complexes
(A) Cytoplasmic dynein. (Left panel) Polypeptides of immunoaffinity-purified rat brain cytoplasmic dynein. Polypeptide mass (in kDa) is indicated on the 
right side of the gel, and the consensus family names are indicated on the left. (Right panel) Structural model for the association of the cytoplasmic 
dynein complex subunits. The core of the cytoplasmic dynein complex is made of two DYNC1 HI  heavy chains which homodimerize via regions in their 
N-termini. The motor domains are at the C-termini of the heavy chains, the large globular heads of ~350 kDa that are composed of a ring of seven 
densities surrounding a central cavity; six of the densities are AAA domains (numbered  1-6). AAA domain  1   is the site of ATP hydrolysis. The 
microtubule-binding domain is a projection found on the opposite side of the ring between AAA domains 4 and 5. C is the C-terminus of the heavy 
chain that would form the 7th density. Two DYNC1I intermediate chains (IC74) and DYNC1LI light intermediate chains bind at overlapping regions of 
the N-terminus of the heavy chain, overlapping with the heavy chain dimerization domains. Dimers of the three light chain families; DYNLT, the Tctexl 
light chains; DYNLRB, the Roadblock light chains; and DYNLL, the LC8 light chains, bind to the intermediate chain dimers.
(B) Cytoplasmic dynein 2 complex, structural model for subunit association. This dynein complex has a unique role in IFT and is sometimes known as IFT 
dynein. Structural predictions indicate that the heavy chain, DYNC2H1, is similar to the cytoplasmic and axonemal dyneins. The only known subunit of 
this complex is a 33- to 47-kDa polypeptide, DYNC2LI1, which is related to the cytoplasmic dynein light intermediate chains. No intermediate chain or 
light chains have yet been identified [16].
elegans,  Chlamydomonas, and yeast. To further our 
understanding of the function of cytoplasmic dynein 
subunits, we also briefly examined mutations in this group of 
proteins in a variety of model organisms. We do not discuss 
dynein-binding proteins such as dynactin, LIS1, or various 
kinases, which while important for dynein function, have not 
yet been shown to be stoichiometric components of the 
cytoplasmic dynein complex.
Human  and mouse cytoplasmic dynein subunit genes. The 
subunits of the cytoplasmic dynein complexes are resolved 
into subunit polypeptides of ~530 kDa (heavy chains),  ~74 
kDa (intermediate chains), ~33-59 kDa (light intermediate 
chains), and —10— 14  kDa (light chains) in SDS-PAGE gels 
(Figure  1A). Research on the cytoplasmic dynein subunits has 
been undertaken  in a wide range of organisms from yeast to 
humans. The nomenclature of the mammalian genes 
encoding these proteins has drawn on homologs in other 
organisms and, consequently, a number of aliases have been 
found for any given human or mouse cytoplasmic dynein 
subunit. Much of the early research  into dynein genetics was 
conducted in the biflagellate green alga Chlamydomonas on the 
dyneins found in  the flagellar axoneme, and therefore some 
cytoplasmic dynein nomenclature derives from these studies. 
For example, mammalian  members of the cytoplasmic  light 
chain families DYNLRB and DYNLL have commonly been 
referred to as LC7 and LC8, respectively, which are the names 
of homologous Chlamydomonas axonemal dynein subunits.
PLoS Genetics | www.plosgenetics.org
Nomenclature. The revised classification system for 
mammalian cytoplasmic dynein (Table  1) recognizes the two 
distinct dynein complexes, cytoplasmic dynein  1   and 
cytoplasmic dynein 2, and the fact that cytoplasmic dynein 
light chains are shared with some axonemal dyneins. 
Cytoplasmic dynein subunits are also classified  into 
polypeptide families according to sequence similarity within 
groups of similarly sized proteins; thus there is sequence 
similarity within the dynein gene families (and when 
cytoplasmic and axonemal  members of the same gene 
families are compared) but  not among them.
This nomenclature has been approved by the Human 
Genome Organization Nomenclature Committee [20] and the 
International Committee on Standardized Nomenclature for 
Mice. In accordance with their policy, the designation of each 
unique cytoplasmic dynein subunit starts with  DYNC for 
dynein, cytoplasmic, followed by the specific dynein complex 
subtype  I  or 2; for example, cytoplasmic dynein 2 is 
designated DYNC2. The shared light chains start with DYN. 
Each subunit is designated with a letter(s) for the size of the 
polypeptides, H for the heavy chain, I for the intermediate 
chain, LI for the light intermediate chain, and L for the light 
chain. Additional letters (T, RB, and L) are used to distinguish 
the three distinct light chain families as described in the text. 
Individual members of the gene families are assigned 
numbers. Standard human and mouse gene nomenclature is 
used: italicized upper case for human gene symbols (for
January 2006 | Volume 2 | Issue 1   | el 0012Table  1. Human and Mouse Cytoplasmic Dynein Genes and Map Positions
Cytoplasmic Official or Proposed  Aliases Location: Human Entrez Gene IDd mRNA (NCBI Protein (NCBI/
Dynein Gene Gene Name (Hsa) NCBIb/Mouse  (Human and Mouse)/  RefSeq Accession SwissProt*
Family HUGO* (Human) (Mmu) MGf MGI ID (Mouse) Numbers) Accession Numbers)
Cytoplasm ic  dynein Hum an DYNC1H1 DNCHC1  [1771;  DNECl  [178],  H p22  (43);  pM 7  [98];  R k3-8  (98); H sa14q32 1778 N M .001376 N P_001367/Q  14204
1  heavy chain DHC1  [23];  DHC1a  [61];  MAP1C  [3];  DNCL  (201;  HL-3  [98];  KIAA0325 
[21];  AB002323  [179];  D yhl  [180];  cDHC  [44];  DYHC_HUMANf
M ouse D ynclhl D nchcl  [98];  cDHC  [44];  Loa  [181];  Rk9-32  [98]; 
D necl  [20];  DNCL  [182];  MAP1C  [41]; 
mKIAA0325  [183,184];  DYHC.MOUSE*
Mmu 12  (55cM) 13424/103147 N M .030238 N P_08451A/Q9JHU4
Cytoplasm ic  dynein Hum an DYNC2H1 DHC2  [23,74];  DH CIb  [74];  DLP4  [69];  DYH1B  [8]; H sa11q21-q22.1 79659 XM .370652® XP_370652® /000432
2  heavy chain Dyh2  [180];  h d h c ll  [1851  F U 11756  [186]
M ouse Dync2h1 Dnchc2  [187];  M dhcl 1  [185] M m u9  (1cM) 110350/107736 X M .358380 XP_358380/O 08822
C ytoplasm ic  dynein Hum an DYNC1I1 IC1  [79];  IC74  [76];  IC74-1  [40];  D1  IC74  [141; H sa7q21.3-q22.1 1780 N M _004411 N P _004402/014576
1  interm ediate  chain DH  IC-1  [188];  DNCI1  [94];  DYI1_HUMANf
M ouse Dynclil D n cid   (1871;  D n d l  [941;  DYII.MOUSE' M m u6  (4cM) 13426/107743 N M .010063 N P_034193/088485
Hum an DYNC1I2 IC2  [791;  IC74-2  [40L  DH  IC-2  [189];  DYI2.HUMAN' Hsa2q31.1 1781 N M .001378 N P_001369/Q 13409
M ouse Dync1i2 Dncic2  [187];  Dnci2  [94];  DYI2.MOUSE' M m u2  [41 cM) 13427/107750 NM _010064 N P_03419 4 /0 8 8 4 8 7
Cytoplasm ic  dynein  1 Hum an DYNC1U1 Light  chain  A  [190];  D1LIC  [14];  U C 57/59  [102]; H sa3p223 51143 NM _016141 N P_057225
light  interm ediate  chain UC-1  [102];  DYJ1.HUMAN'
M ouse Dyncllil D n dicl  [187];  M GC32416  [191] M m u9  F3 235661/2135610 NM _146229 NP_666341
Hum an DYNC1U2 U C 53/55  [102];  UC-2  [102];  DYJ2_HUMAN* Hsa16q22.1 1783 NM .006141 N P_00613 2 /0 4 3 2 3 7
M ouse Dync1li2 Dnclic2  [187] M m u8  (50cM) 110801
(and see 234663)/107738
XM _134573® XP_134573®
C ytoplasm ic dynein  2 Hum an DYNC2U1 D2UC  [14];  UC3  [15]; CGI-60  [15,192]; H sa2p25.1-p24.1 51626 NM _016008  (isoform   1)/ N P_057092  (isofotm   1)/
light  interm ediate  chain DKFZP564A033  [192] NM _015522  (isoform  2) N P_056337  (isoform   2)
M ouse Dync2li1 493340401 IRik  [193];  D2UC  [193];  m D2UC  [193]; 
MGC7211  [193];  M GC40646  [193]
M m u17  E4 213575/1913996 NM _172256 N P_758460
Cytoplasm ic  dynein Hum an DYNLT1 TCTEL1  [194]; T ctexl  [114,116];  Protein  CW-1  [195]; H sa6q25.3 6993 NM _006519 N P_006510/Q 15763
T ctexl  light  chain d y lx. h u m a n '
M ouse Dynltl Tctexl  [116]; Tcd1  [114,116];  DYLX_MOUSEf M m u17  (4cM) 21648/98643 NM _009342 N P_033368/P51807
Hum an DYNLT3 TCTE1L  [126];  rp3  [126]; TCTEX1-L  [126]; TCTL_HUMANf HsaXp21 6990 NM _006520 N P_006511 /P 5 1808
M ouse Dynlt3 T ctell  [187];  2310075M 16Rik  [196];  TCTL_MOUSEf MmuX  A1.1 67117/1914367 NM _025975 N P_080251/P56387
Cytoplasm ic  dynein Hum an DYNLRB1 M GC15113  [197];  DNCL2A  [142]  (bithoraxoid-like  protein) H sa20q 11.21 83658 NM _014183  (isoform   a)/ NP_054902/Q 9N P97  (isoform   a)/
light  chain  Roadblock [135,198);  BITH  [199];  hkm 23/m LC7-1  [144];  Robll  [143]; 
Roadblock(robl)/LC7  [135];  HSPC162  [200,201];  DL2A_HUMANf
NM _177953  (isofbrm  b)/ 
NM _177954  (isoform  c)
NP_808852  (isoform   b)/ 
NP_808853  (isoform   c)
M ouse Dynlrbl D nd2a  [187];  Dndc2A;  km 23/m LC7-1  [144];
2010012N15Rik  [196];  2010320M 17Rik  [196];  DL2A_MOUSEf
M m u2  HI 67068/1914318 NM _025947 N P_080223/O 88567
Hum an DYNLRB2 DNCL2B  [142]  (bithoraxoid-like  protein)  [135,198];  Robl2  [143]; 
LC74ike  [142];  mLC7-2  [144];  DL2B_HUMAN<
H sa16q233 83657 NM _130897 NP_570967/Q 8TF09
M ouse Dynlrb2 D nd2b  [187];  DL2B_MOUSEf M m u8  El 75465/1922715 NM _029297 NP_083573/Q 9DAJ5/AAH 48623
Cytoplasm ic  dynein Hum an DYNLL1 DCL1  [149];  DNLC1;  DNCL1  [202];  Mr  8000  LC  [104]; Hsa12q24.31 8655 NM _003746 N P_003737/Q 15701
light  chain  LC8 M, 8000  DLC  [147];  DLC8  [152];  LC8  [72];  LC8a  [148]; 
PIN  [153];  hdlcl  [162];  Dk-1  [203];  DYL1_HUMAN'
M ouse Dyrtlll D n ck l  [187] M m u5  F 56455/1861457 NM _019682 N P_062656/Q 9D6F6
Hum an DYNLL2 DLC2  [149];  LC8b  [148];  M GC17810  [204] H sa17q23.2 140735 N M .080677 N P_542408
M ouse Dynll2 Dlc2  [187];  1700064A15Rik  [205];  6720463E02Rik  [205] M m u ll  C 68097/1915347 NM _026556 N P.080832
"MGC" prefixes are from the NIH Mammalian  ene Collection (MOQ as pan of an Initiative to identify and sequence cDNA clones containing a full-length open reading frame for human, mouse, and rat [206], "CGI" prefixes are assigned by the Comparative gene Identification study, which uses the C elegans proteome as an 
alignment template to assist m novel human gene identification from human EST nucleotide databases [207). "Rik" suffixes are gene aliases assigned by the Riken Genomic Sciences Center (http://genome.gsc.riken.jp). Source: Pfister et al 12101.
*HUGO: http7/www.ger>e.ud.ac.uk/nomenclature. Accessed 25 November 2005. 
bNCBfc http://www.ncbi.nlm.nih.gov. Accessed 25 November 2005.
'MGt http://www.informatics4ax.org. Accessed 25  November 2005. Mapping position shown in cM or cytogenetic band.
“NCBI Entret Gene: http7/www.ncbi.nih.gov/entrez/queryicgi?db=gene. Accessed 25 November 2005.
•SwissProt: httpy/ca.expasy.org/sprot. Accessed 25 November 2005.
'Name as given by SwissProt
•Human DYNC2H1  sequences XM_370652 and XP_370652 are predicted by analysis of genomic sequence <NT_0338W) using the NCBI gene-prediction method GNOMON, supported by mRNA and EST evidence. Mouse Dynllil sequences XMJ34573 and XP_134573 are predicted by analysis of genomic sequence 
(NT_033899) using the NCBI gene-prediction method GNOMON, supported by mRNA and EST evidence.
OOt 10.1371/joumalpgen.0020001 .tOOlexample, DYNC1H1), italicized initial  upper case and  then 
lower-case letters for mouse  (Dynclhl),  and for proteins of 
both species,  the same symbols  in  upper case, upright 
(DYNC1H1).  In accordance  with  the  International  Union  of 
Pure and Applied Chemistry standards,  isoforms of the 
intermediate chain gene products are referred to with letters.
This nomenclature system can be expanded to other subunits 
as appropriate.  We refer to mapping positions using the 
prefixes  Hsa (Homo sapiens) for human  and  Mmu  (Mus 
musculus)  for mouse,  followed  by  the chromosomal 
localization e.g.  Hsa2qll,  M mull.
Table  1   lists  the aliases,  map  position,  and  protein/DNA- 
sequence accession data for each known  mouse  and human 
cytoplasmic dynein gene. The greatest  number of aliases was 
observed for the cytoplasmic  dynein  1   heavy chain  1  
(DYNC1H1) for which we identified  15 different names. Some 
alternative cytoplasmic dynein gene  names have come  from 
large-scale gene  and  transcript  identification  efforts such  as 
the partial DYNC1H1 clone KIAA0325 and its mouse homolog 
“mKIA00325,” generated by the Kazusa cDNA project [21]. A 
small  number of gene names have been derived from  the 
names of DNA markers and cDNA clones used to identify the 
genes,  for example, cytoplasmic  dynein  2  light  intermediate 
chain  1, DYNC2L11, was named DKFZp564A033 after the 
cDNA sequence and clone of the same name. The heavy chain 
gene DYNCIH1  has also been  referred  to by  the  name of a 
marker, Hp22, generated from  its human cDNA sequence, as 
well  as  the  rat-derived marker Rk3-8 and a cDNA clone 
named  HL-3.
Cytoplasmic Dynein Heavy Chain Gene Family 
(DYNC1H1,  DYNC2H1)
Figure 2A shows  the  phylogenetic  relationships amongst 
the dynein heavy chain  protein sequences from  various 
organisms. The heavy chain sequences fall  into  two distinct 
clades,  and  the  relationships within  each clade are generally 
consistent with  known evolutionary distances between the 
organisms shown. We  note that our phylogeny fits well with 
and extends  previous  phylogenetic  analyses of the heavy 
chain proteins [22,23]. This analysis indicates that the partial 
human sequence DNAH12, (AAB09729) [23],  is unlikely to be 
a cytoplasmic  dynein.
Cytoplasmic dynein heavy chain  1, DYNC1H1.  DYNC1H1, 
cytoplasmic dynein  I  heavy chain  1, is the largest cytoplasmic 
dynein subunit, having ~4,600 residues and a molecular weight 
of >530 kDa. First identified in rat spinal cord and brain and 
termed Microtubule Associated Protein  1C (MAP 1C) [24], 
DYNC1H1  is a distant member of the AAA family of ATPases 
and is the cytoplasmic counterpart to axonemal dynein heavy 
chains [3,25]. DYNC1H1  associates as a homodimer within the 
cytoplasmic dynein complex and effects the contact and 
translocation of the dynein complex along microtubules via its 
large motor domain [8,26] (Figure  IB).
The C-terminal  region of DYNC1H1  is the  motor domain 
of the dynein complex and is conserved in all cytoplasmic and 
axonemal dynein  heavy chains. This  region  is arranged as a 
heptameric ring with six AAA domains and a seventh domain, 
the identity  of which  remains a matter of discussion  (Figure 
IB)  [12,25,27,28],  AAA domains are  regions of ATP binding 
and hydrolysis,  and  thus they generate the energy  required 
for translocation  [29-31],  While the first AAA domain  is
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essential for motor activity [32], reviewed in [30], the first four 
AAA domains are  potentially capable of binding and 
hydrolysing ATP  [33-35].  Contact of the heavy chain with a 
microtubule  is established via an  ~15-nm  projection that 
extends between  the fourth and fifth AAA domains [28,36]. 
The  N-terminal  region  of DYNC1H1  is known as the stem, 
and force production, and therefore translocation, is thought 
to be achieved through  the contact and shift of a  10-nm fold 
of the stem  closest  to  the first  AAA domain  [37]. DYNC1H1 
dimerization  also occurs  in  the stem, and the intermediate 
chains and  light  intermediate chains  bind  in  this region as 
well  [38,39],  The  three  light chains  bind  to  the intermediate 
chains  [40]. Collectively  the  five smaller dynein subunits that 
bind to  the N-terminus of DYNC1H1  make up the cargo- 
binding portion  of the  dynein  complex.
The sequence of full-length  mammalian  DYNC1H1  was 
first obtained in rat and mouse [41,42]. Human DYNC1HI was 
identified by screening an  adenocarcinoma library with a 
partial human cDNA [23,43].  As yet,  the only mutations 
reported in mammalian heavy chains have been in the mouse: 
the Loa and Cral  strains  have allelic  point  mutations in 
Dynclhl  that cause late-onset  motor neuron degeneration in 
heterozygotes and  neuronal  apoptosis  in  homozygotes [17]. 
The loss of both copies of Dynclhl has been shown to be lethal 
during early embryonic development, with disorganization of 
the Golgi complex,  improper distribution  of endosomes and 
lysosomes, and defects in cell proliferation; no phenotype has 
yet been  reported  for heterozygote knock-out mice [44].
In Drosophila,  the dynein  heavy chain gene, Dhc64Q 
functions  in oogenesis  [45,46], oocyte differentiation  [47], 
centrosome attachment during mitosis [48], eye development, 
cell development  in  thorax, abdomen,  and wing [45], and 
axonal transport [49], Homozygous mutations induced by the 
mutagen  ethyl  methane sulfonate  in Dhc64C are larval/pupal 
lethal, whilst heterozygotes have defects  in bristle formation, 
eye development, and fertility [45]. In C elegans, dynein heavy 
chain  (dhc-1) is an essential gene, also known as let-354 
(LEThal) [50],  Extensive  mutational  analysis has been 
conducted on dhc-1  to  produce  a  range of variants from 
recessive/dominant lethals to temperature-sensitive  mutants. 
The  resultant  phenotypes  invariably include embryonic 
lethality, spindle orientation defects,  polar body 
abnormalities, and excessive blebbing in  the early embryo 
[51-54],
In  the yeast Saccharomyces cerevisiae,  heavy chain function 
ensures the alignment and orientation  of mitotic  spindles. 
Mutation of the S. cerevisiae heavy chain gene dynl, which has 
50%  similarity  (28%  identity)  to  DYNC1H1  over 80%  of the 
protein’s length, has been shown  to disrupt spindle 
orientation and  reduce  the fidelity of nuclear segregation 
during mitosis [55,56].  Despite  this phenotype, dynl  mutants 
remain viable, although dynl  and kinesin double mutants are 
lethal  [57], This observation  suggests some functional 
redundancy for dynein by kinesin  motors  in yeast. No 
cytoplasmic dynein  1   heavy chain  1   homolog has 
unambiguously been identified in Chlamydomonas, and neither 
have dyneins been  found  in either the Arabidopsis or rice 
genomes  [58,59]  (reviewed  in  [60]). There are  many dynein 
heavy chains in the Chlamydomonas genome. However, with the 
exception of DYNC2H1, they appear to be components of the 
axonemal dyneins.
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Figure 2.  P a n e l  S h o w in g   th e   P r o te in -B a se d   P h y to g e n ie s   o f   t h e   C y to p la s m ic   D y n e in   S u b u n it  F a m ilies
S p e c ie s   n a m e s   a r e   s h o w n   w ith   N C B I/G en B a n k   g e n e /p r o te in   n a m e s .  N C B I/G en B a n k   p r o te in -s e q u e n c e   a c c e s s io n   n u m b e r s  a re  g iv e n   in  T a b le   S I. 
O r th o lo g o u s   h u m a n ,  m o u s e ,  a n d   rat  g e n e   n a m e s   u s e   t h e   r e v ise d   s y s te m a tiz e d   c o n s e n s u s   n o m e n c la tu r e   (e .g .  D Y N C 1H 1  in  h u m a n s,  m o u s e ,  a n d   rat). 
R e la tio n sh ip s  a m o n g s t  d y n e in   s e q u e n c e s   o f  d iffe r e n t  s p e c ie s   d o   n o t n e c e s s a r ily   r e fle c t  th e   e v o lu tio n a r y   re la tio n sh ip s  a m o n g s t  s p e c ie s ;  s e e   [2 0 8 ]  a n d  
[2 0 9 ] fo r  fu rth e r d e ta ils .  N a m e d   c la d e s  a re  in d ic a te d   in  th e   rig h t  m a r g in s.  B a y esia n   a n d   m a x im u m -lik e lih o o d   b o o ts tr a p  v a lu e s  a re s h o w n   a s   p e r c e n ta g e s  
(to p   a n d   b o tto m ,  r e s p e c tiv e ly ),  a d ja c e n t  to   b r a n c h   p o in ts .  A ste risk s  d e n o t e   b o o ts tr a p s   b e lo w   50% .  F illed   cir cles  d e n o t e   b o o ts tr a p s   a t  100% .  S ca le-b a r 
r e p r e s e n ts   e v o lu tio n a r y   d is ta n c e   (e s tim a te d   n u m b e r s   o f  a m in o -a c id   s u b s titu tio n s   p e r   site).
(A )  C y to p la sm ic   d y n e in   h e a v y   c h a in   fa m ily .  C h lam ydom onas o u te r   a rm   h e a v y   c h a in   (ODA11)  is  u s e d   a s   t h e   o u tg r o u p .  D N A H 1 2 fra g   is  th e   partial 
a x o n e m a l  h e a v y   c h a in   fr a g m e n t  ta k e n   fr o m   [2 3 ].  F or  m o u s e   D Y N C 2H 1,  X P _ 3 5 8 3 0 ,  o n ly   p artial  p r o te in   s e q u e n c e   (3 3 6 a a )  w a s   a v a ila b le   in  th e   G en B a n k  
d a ta b a se .  A d d in g   th is   p a rtia l  s e q u e n c e  t o   o u r  a n a ly sis  r e s u lte d   in  s p u r io u s   c lu s te r in g , th e r e fo r e   w e   o b ta in e d   a n   e x te n d e d ,  p u ta tiv e   s e q u e n c e   b y   u sin g  
BLAST  (TBLASTN)  a g a in s t  th e   m o u s e   g e n o m e   (B u ild   3 2 )  w ith   h u m a n   a n d   rat  s e q u e n c e s   X P _ 3 7 0 6 5 2   a n d   N P _ 0 7 5 4 1 3 ,  r e sp e c tiv e ly .  I n c o m p le te   m o u s e  
g e n o m ic   a s s e m b ly   a t  th e   DYNC2H1  lo c u s   y ie ld e d   a  tr u n c a te d   s e q u e n c e   3 4 5 5   a m in o   a c id s  in  le n g th ,  8 5 %   th e   le n g th   o f   h u m a n   D Y N C 2H 1.
(B)  C y to p la s m ic   d y n e in   in te r m e d ia te   c h a in   fa m ily .  T h e   C h lam ydo m o na s  IC2  (ODA6)  is  u s e d   a s   th e   o u tg r o u p .
(C)  C y to p la s m ic   d y n e in   lig h t  in te r m e d ia te   c h a in   fa m ily . T h e re  d o e s   n o t  a p p e a r  t o   b e  a   su ffic ie n tly  d is ta n t  h o m o lo g   in C hlam ydom onas to   b e   u s e d   a s a n  
o u tg r o u p   in  th is   a n a ly sis,  th e r e fo r e   O D A 1 1  (Q 3 9 6 1 0 ,  a  h e a v y   c h a in   p r o te in )  w a s   c h o s e n   a s   th e   o u tg r o u p   fo r  th is  tr e e .
(D )  C y to p la s m ic   d y n e in   lig h t  c h a in   T c te x l  fa m ily .  T h e   C h lam ydo m o na s  LC2  lig h t  c h a in   is  u s e d   a s   t h e   o u tg r o u p .
(E)  C y to p la s m ic   d y n e in   lig h t  c h a in   R o a d b lo c k   fa m ily .  T h e   C h lam ydo m o na s o u te r   a rm   d y n e in   L C7a,  is  u s e d   a s  th e   o u tg r o u p .
(F)  C y to p la s m ic   d y n e in   lig h t  c h a in   LC8  fa m ily .  T h e   C h lam ydom onas Q 3 9 5 7 9   s e q u e n c e   is  u s e d   a s   a n   o u tg r o u p .  T his  p h y lo g e n y   is  p o o r ly   r e so lv e d ,  w ith  
lo w   b o o ts tr a p   s u p p o r t v a lu e s  a n d   p o s te r io r  c la d e   p r o b a b ilitie s,  m o s t  lik ely d u e  to  th e r e   b e in g   little v a ria tio n   a m o n g s t th e  in g r o u p   s e q u e n c e s . W e fo u n d  
g o o d   s u p p o r t  fo r  t h e   LC8  lig h t  c h a in   1  c la d e ,  a n d   s o m e   s u p p o r t  fo r   th e   LC8  lig h t  c h a in   2   c la d e ,  o f  fo u r  v e r te b r a te   s e q u e n c e s . T h e   r e la tio n sh ip s  o f  th e  
tw o   s e q u e n c e s ,  C.  e le g a n s   a n d   Takifugu w e r e   p o o r ly   r e s o lv e d ,  a n d   th e r e fo r e   w e   h a v e   n o t  in c lu d e d   t h e s e   in  th e   LC8  lig h t  c h a in   2   c la d e .
Cytoplasmic dynein 2 heavy chain  1, DYNC2H1. The
cytoplasmic dynein  2 heavy chain,  DYNC2H1, was originally 
identified  in  sea urchin embryos by Gibbons and colleagues 
and was  termed DYHlb [61]. It is much less abundant than 
DYNC1H1  and does not appear to heterodimerize with 
DYNC1H1; biochemical analyses suggest that DYNC2H1  is a 
homodimer [16]. DYNC2H1 contains regions characteristic of 
cytoplasmic dyneins, for example, human DYNC1H1  and 
DYNC2H1  sequences are similar within both  the motor
PLoS Genetics | www.plosgenetics.org
region and around the light intermediate chain-binding site 
[15].  However, the expression of its mRNA increases during 
embryonic reciliation, a property typical of axonemal 
dyneins, suggesting a flagellar role for an otherwise 
cytoplasmic-like dynein heavy chain. The flagellar properties 
of DYNC2H1  were clarified with its  identification as the 
motor responsible for retrograde (tip to base) IFT,  in 
Chlamydomonas,  a process required for assembly and 
maintenance of the eukaryotic cilium/flagellum  [6,22].
0015  January 2006 | Volume 2 | Issue 1   | e1DYNC2H1  is also  important in  modified ciliary structures 
such as  nematode mechanosensory  neurons  [62]  and 
vertebrate photoreceptors [63,64]. In C. elegans, the DYNC2H1 
homolog, che-3,  is expressed  in ciliated sensory neurons 
which are thought to be involved in odorant chemotaxis [65]. 
Mutations of che-3 affect  IFT,  the establishment and 
maintenance  of sensory cilia, which  are stunted and  swollen 
in  the  mutants,  [62,66], chemotactic  behavior [67], and 
formation of the  third  larval  stage, dauer formation  [68],
The first mammalian DYNC2H1  gene was described in  rat, 
designated  DLP4  [69], and full-length  sequence has been 
obtained  [15].  Genetic  and biochemical  studies suggest  that 
DYNC2H1  associates with a member of the light intermediate 
chain family, DYNC2LI1  (Figure  IB, and see discussion of the 
light  intermediate chain  family below) [14,16,70-73]  and 
possibly also with  DYNLL 1   (LC8) light chain  [72].  In  mice 
Dync2hl,  mRNA  is abundant  in  the olfactory epithelium  and 
the ependymal  layer of the  neural  tube; antibodies against 
DYNC2H1  and DYNC2LI1  strongly stain  these  tissues and 
connecting cilia in the  retina as well as primary cilia of non­
neuronal cultured cells  [15]. The co-localization  of 
DYNC2H1,  DYNC2LI1, and homologs of the  IFT pathway  in 
mammalian  ciliated  tissues  supports  a specific  role for 
DYNC2H1  in the generation and maintenance of mammalian 
cilia  [14,16]. Other antibody studies suggest that  DYNC2H1 
localizes  to  the cytoplasm of apical  regions of ciliated  rat 
tracheal epithelial cells, but not in the cilia themselves [74]. In 
non-ciliated human  COS cells, antibodies against  DYNC2H1 
show Golgi  localization and induce Golgi dispersion, 
suggesting a cytoplasmic  role for DYNC2H1  [23].
Cytoplasmic Dynein Intermediate Chain Gene 
Family (DYNC1I1, DYNC1I2)
Intermediate chains are present in axonemal  and/or 
cytoplasmic  dyneins from yeast  to mammals (Figure  2B). 
Protein-sequence data demonstrate evolutionary distant 
relationships between axonemal  and cytoplasmic dynein 
intermediate chains; for example,  rat DYNC1I1  has 48% 
similarity  to the Chlamydomonas IC2 axonemal outer arm 
dynein  intermediate chain encoded by the ODA6 locus 
[75,76].  Figure 2B shows  the dynein  intermediate chain 
protein  phylogeny. The intermediate chain sequences fall 
into  two distinct clades,  intermediate chains  1   and 2, 
comprised of vertebrate species only. An alternative 
placement of a  Takifugu sequence,  as a member of the 
intermediate chain  1   clade, is almost as well supported by the 
data as  the  placement shown  in  Figure 2B  (49%  bootstrap 
support  against  51%  support).  In view of this and with all 
non-vertebrate species  falling outside  these clades,  the data 
suggest a recent evolutionary origin  for the split  into 
intermediate chain gene  1   and  intermediate chain  gene 2, 
perhaps  as  part of a “2R” event of genome duplication  (see 
[77]  for review). The absence of an  amphibian  (Xenopus) 
intermediate chain  1   protein  may be due to  the current 
paucity of X.  laevis sequences in  the GenBank sequence 
database  (http://www.ncbi.nlm.nih.gov/Genbank).
The cytoplasmic  dynein  1   intermediate chains have a 
molecular weight of ~74 kDa  [5]  and associate  in  the 
cytoplasmic  dynein complex with  a stoichiometry of two 
intermediate chains per complex  [40,78],  DYNC1I1  and 
DYNC1I2  proteins are thought  to help assemble  the 
cytoplasmic dynein complex and to bind various cargoes. The
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intermediate chains  interact with  the dynein  activator, 
dynactin, via their conserved N-termini  [79]. The DYNC1I C- 
termini contain  a WD repeat domain  [76,80,81]  that  is 
conserved between  cytoplasmic  and axonemal  intermediate 
chains and  is important for intermediate chain-binding to 
the heavy chains [76,82]. The dynein  light chains,  DYNLL1 
(LC8) and  DYNLT1  (Tctexl),  bind near the N-termini  of the 
intermediate chains  [83-85],  and  the  DYNLRB (Roadblock) 
light chains bind just upstream of the WD repeat region  [40], 
The DYNC1I are phosphorylated, and phosphorylation at one 
site  regulates DYNC1I2  interaction  with  the  p i50 subunit of 
dynactin  [86,87],
The Chlamydomonas  IC2 axonemal  intermediate chain  was 
localized  to  the base of the dynein heavy chain dimer by 
immunoelectron  microscopy  [88].  Steffen  and colleagues 
identified  a similar location  for the cytoplasmic dynein 
intermediate chain  and found  that antibodies  to  it block 
dynein binding to membrane-bound organelles [89,90]. These 
data  indicate a role  for DYNC1I  in  targeting the dynein 
complex to various cargoes,  including membranous 
organelles and kinetochores  [76,79,89],  In Drosophila, 
mutations  in dynein  intermediate chain, Cdic  (also referred 
to as cDic and Die), lead to larval lethality, demonstrating that 
this  intermediate chain  provides  an essential  function.  Cdic 
mutations dominantly enhance  the  rough-eye  phenotype of 
Glued,  a dominant  mutation  in  the p i50 subunit of dynactin 
[91]. Shortwing (sw) is an allele of the dynein  intermediate 
chain gene but, unlike other Cdic alleles, sw is homozygous 
viable and gives  rise to a recessive, temperature-sensitive 
defect  in eye and wing development  [91].
We  note  that in Drosophila,  the Cdic gene  lies  in  the  19DE 
region of the X chromosome, adjacent to several  dynein 
intermediate chain-like sequences. These sequences are 
derived from a 7-kb duplication/deletion event involving Cdic 
and its proximal gene annexin X, which encodes a cell- 
surface-adhesion  protein  [92]. The duplication/deletion  of 
this 7-kb region resulted in the formation of a de novo coding 
sequence, under the control of a testes-specific  promoter, 
called sperm-specific dynein  intermediate chain gene  (Sdic) 
[93]. The de novo region has undergone at least  10-fold 
tandem duplication, which has given  rise  to a multi-gene 
family comprising at least four classes of Sdic gene, of which 
more  than one class is functional  [93].
Cytoplasmic dynein  I  intermediate chain  1, DYNC1I1. 
Multiple  DYNC1I1  isoforms exist  in  mammals. They are  the 
products of alternative splicing of the N-terminal region of a 
single DYNClll  gene and  phosphorylation  [76,79,86].  In 
humans, alternate splicing may arise from cryptic splice- 
acceptor sites located within exon 4 of this  17-exon gene [94], 
Two DYNClll  isoforms were found  in  rat brain  and 
DYNClll  mRNA, and protein isoform expression is regulated 
during rat brain development, and a single DYNClll  isoform 
is found  in  testis.  DYNClll  expression  is also cell-specific: 
cultured  rat  neurons express at least  two  DYNClll 
alternative splicing variants and  their phosphorylated 
isoforms, while cultured glial astrocytes do  not express any 
DYNClll  gene products  [95-97],  In  the mouse, expression of 
Dynclil  has been shown  to be  restricted primarily  to the 
brain, with weak expression  in testis  [94], further supporting 
possible neuronal specificity for Dynclil. As with  the other 
dynein  subunits,  the isoform diversity of the intermediate 
chain  is thought to result in  specific  populations of dynein
January 2006 | Volume 2 | Issue  1   | el 0016molecules  that have specific  functions; for example, both 
DYNClll  isoforms are components of cytoplasmic  dynein 
found in the slow component of axonal transport in the optic 
nerves [95].  Multiple  isoforms of the Drosophila intermediate 
chains are also produced by alternative splicing of the single 
gene [92].
Cytoplasmic dynein  1  intermediate chain 2, DYNC1I2.
Vaughan  and Vallee used a partial human cDNA sequence 
with identity to the already known DYNClll gene as a probe 
to  isolate a  rat Dyncli2 cDNA;  predicted human and rat 
DYNC1I2 sequences are 94%  identical [79], and the existence 
of two genes was supported by  mapping data that  placed 
Dynclil and Dyncli2 at distinct loci within the mouse genome 
[98]. Like Dynclil, Dyncli2 produces different splice isoforms: 
alternative splice sites lie at  two  positions within  the N- 
terminal  region. The expression  of Dyncli2 isoforms  is 
ubiquitous with  the  rat  DYNC1I2C isoform being expressed 
in all  tissues and cells examined  [79,94,96,97].  During rat 
brain development, DYNC1I2C is the only isoform found 
before E14 (embryonic day 14) and it is often the only isoform 
observed in cultured cells [96,99]. During nerve growth-factor 
stimulation  of PC12 cell differentiation and neurite 
extension, there is a change in relative expression levels of the 
DYNC1I2  isoforms  [100].  In  the rat  optic  nerve, it has been 
shown that the DYNC1I2C isoform  is the only intermediate 
chain involved  in  the fast component of anterograde 
transport to the axon  tip [95,99].
The strong expression of Dyncli2 in the mouse developing 
limb bud led to the suggestion that DYNC1I2 may play a role 
in limb development  and digit patterning and/or in 
establishing cell polarity [94]; dynein may not do this directly, 
but  may  mediate these  processes by orientating intracellular 
components correctly [101].
Cytoplasmic  Dynein  Light  Intermediate Chain  Gene 
Family (DYNC1LI1, DYNC1U2, DYNC2LI1)
Figure 2C shows  the phylogenetic  relationships amongst 
the dynein light intermediate chain  protein sequences from 
various organisms. The light intermediate chains can be 
separated into three distinct groups:  the two light 
intermediate chains that are components of cytoplasmic 
dynein  1, DYNC1LI1 and DYNC1LI2, are more closely related 
to each other than  to  the cytoplasmic dynein 2 light 
intermediate chain, DYNC2LI1.  Hughes and colleagues first 
proposed the  name light  intermediate chains for these 
subunits [102], although these polypeptides were also referred 
to as light chains  [103] prior to the discovery of the smaller 
light chains [104]. The mammalian cytoplasmic dynein 
complex contains four species with  molecular masses of 50- 
60 kDa  that resolve into  numerous  isoforms on  2D gels 
[86,102]. The multiple  isoforms observed in  ID and  2D gels 
are thought to be the  result of post-translational 
phosphorylation, although the possibility of alternate splicing 
has not been  eliminated  [86,102,103]. A third gene, 
DYNC2LI1, has  recently been  described which encodes a 
protein  that appears  to exclusively associate with  DYNC2H1 
in the cytoplasmic dynein  2 complex  [14-16,71].  Unlike  the 
other subunits of cytoplasmic dynein, homologs of the 
DYNClLIs have  not yet been  identified  in the axonemal 
dyneins [105]. The function of the DYNClLIs has yet to be 
determined, although it has been  suggested that  they may
regulate the interactions of dynein with dynactin, or with 
sub-cellular cargoes of dynein-mediated motility. DYNCILU 
and DYNC1LI2 form only homo-oligomers, and their 
mutually exclusive binding to the N-terminal base of the 
dynein heavy chain is consistent with a role in cargo binding 
[38],
C. elegans appears to have one light intermediate chain (dli- 
1) for cytoplasmic dynein  (DYNC1H1-based complexes), and 
one (xbx-1) for cytoplasmic dynein  2 (DYNC2H1-based 
complexes) [73]. (Hi-1  is required for dynein function during 
mitosis,  pronuclear migration, centrosome separation, and 
centrosome association with the male pronuclear envelope 
[106], as well as retrograde axonal transport. Mutations in dli- 
1   lead to an accumulation of cargo at axonal  terminals [52]. 
Disruption of xbx-1  results in ciliary defects and causes 
behavioral abnormalities  that are observed in other cilia 
mutants [14]. Binding of dli-1  to ZYG-12 is thought to be the 
mechanism for dynein binding to the nuclear envelope [107],
Cytoplasmic dynein  1  light intermediate chain  1, 
DYNCILIL DYNCILII was cloned from rat [38] and found to 
have a P-loop  motif, which is one of the major conserved 
motifs making up the nucleotide-binding domain found in 
numerous proteins, including ATPases and kinases [108], 
DYNCILII, however, lacks other essential  motifs associated 
with ATPase activity, which itself has not been assayed. Tynan 
showed that pericentrin, a known dynein cargo, binds 
DYNCILII  and not DYNC1LI2 [38].  DYNC 1  LI and its 
phospho-isoform are exclusively found with dynein  in  the 
slow component of axonal  transport in rat optic nerves [95]. 
In  HeLa cells, DYNCILII  localizes to the microtubule 
organizing centre and mitotic spindle, co-localizing with the 
GTPase Rab4a (which  interacts with  the central domain of 
DYNCILII  [109]); thus DYNCILII  may be implicated in the 
regulation of membrane-receptor recycling. Phosphorylation 
of the Xenopus DYNC I LI has been implicated in regulation of 
dynein binding to membrane-bound organelles [110].  It is 
thought that Xenopus  melanosomes contain a distinct dynein 
light intermediate chain  protein, possibly a version of 
DYNCILII  [111], In the chicken (Gallus gallus) DYNCILII  has 
been called DLC-A, as  part of the DLC-A group of light 
chains [103].
Cytoplasmic dynein  1  light intermediate chain 2, 
DYNC1LI2.  DYNC1LI2 is paralogous to DYNCILII and is also 
thought to be post-translationally modified by 
phosphorylation [86,102,103]. DYNC1LI2 is found in both the 
fast and slow components of axonal transport in rat optic 
nerves, although its phospho-isoforms are found only in the 
slow component of axonal transport. During nerve growth- 
factor stimulation of PC 12 cell differentiation and neurite 
extension, DYNC1LI2 gene expression is up-regulated [112], 
and phosphorylation of both DYNCILII  and DYNC1LI2 is 
increased [100]. Like DYNCILII, the chicken (G. gallus) 
DYNC1LI2 has also been termed DLC-A, as part of the DLC-A 
group of light chains [103].
Cytoplasmic dynein 2 light intermediate chain  1, 
DYNC2LIL DYNC2L11  is a light intermediate chain  that was 
identified  in  mammals by two groups and was originally 
designated D2LIC  [14]  and LIC3 [15].  DYNC2LI1  is  the light 
intermediate chain  that associates with DYNC2H1  in  the 
cytoplasmic dynein 2 complex: Grissom and colleagues 
observed that DYNC2LI1  co-immunoprecipitated specifically 
with DYNC2H1  and co-localized with DYNC2H1  at the Golgi
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acid LIC3  polypeptide  (AAD34055) had a 24%  similarity  to 
rat DYNC1LI2 but failed to observe Golgi  localization. 
DYNC2LI1  has been identified in mouse, C. elegans, Drosophila, 
and Chlamydomonas  [14,16].  A targeted deletion  of Dync2lil  in 
mouse affects development,  in  particular ventral  cell  fates 
and axis establishment  in  the early embryo  [113].  In 
Chlamydomonas,  DYNC2LI1  (DlbLIC) is essential  for 
retrograde IFT [71]. As mentioned above, DYNC2LI1  appears 
to bind exclusively with  DYNC2H1;  in agreement with  this, 
we find DYNC2LI1  homologs in species that have DYNC2H1.
The exclusive association  of DYNC2H1  and  DYNC2LI1  with 
one another, and  not  with  any of the other cytoplasmic 
dynein subunits, emphasizes  the distinct cellular identities 
and roles of these separate DYNC1H1  and DYNC2H1  dynein 
complexes.
Cytoplasmic Dynein Light Chain Gene Families
There are three known  dynein  light chain gene families 
that are components of cytoplasmic dynein  1:  (1) the /- 
complex-associated family (DYNLT1, DYNLT3),  (2)  the 
Roadblock  family (DYNLRB 1, DYNLRB2),  and (3) the LC8 
family (DYNLL1, DYNLL2). The gene families are  named 
according to  their original discovery,  through  the effect of 
mutations  in  mouse  (/-complex associated, Tctexl) and 
Drosophila (Roadblock), or according to the size of the protein 
in Chlamydomonas  (LC8) as discussed below. We present each 
family by molecular weight, starting with  the largest  light 
chain  protein gene family,  the  /-complex-associated family 
(—113 amino acids),  through  to  the Roadblock family  (—96 
amino acids) and  the smallest  light chain  proteins,  the LC8 
family  (—89 amino acids). As described below, some  of the 
light chains have cellular functions  that are  independent  of 
their role  in  the cytoplasmic  dynein  1   complex.
Cytoplasmic Dynein Light Chain Tctexl Gene Family 
(DYNLT1, DYNLT3)
Figure 2D shows the  phylogenetic  relationships amongst 
the dynein light chain Tctexl-family protein sequences from 
various organisms. Our phylogeny shows distinct clades for 
DYNLTl-like  and DYNLT3-like sequences.  Tctex2-like 
sequences  lie closer to  the outgroup than  they do  to  the 
DYNLT 1   and DYNLT3 clades  (not shown).
Cytoplasmic dynein light chain Tctexl, DYNLT1.  Tctexl  (/- 
complex /estis-expressed) gene was originally identified within 
the mouse t-complex (a 30-  to 40-Mb region  of Mmu 17) as a 
candidate for one of the “distorter” products responsible for 
the non-Mendelian transmission of variant / haplotypes [114]. 
Lader et al.  [114] and O’Neill and Artzt  [115] found evidence 
of four copies of Dynltl  (Tctexl) in  the  mouse genome; we 
found that the current genomic sequence databases appear to 
contain only one such locus that maps to Mmu  17, although a 
processed  pseudogene has also been described on  Mmu6. 
Subsequently,  DYNLT 1   was found  to be an  integral 
component of cytoplasmic dynein  [116], and has since also 
been identified within axonemal inner and outer arm dyneins 
[117,118].  DYNLT1  binds to the N-terminus of the 
intermediate chain  DYNC1I  [85],  Many studies have 
identified DYNLT1  as a binding partner for various cellular 
proteins, and it has been suggested that it may attach specific 
proteins or cellular components to cytoplasmic dynein; for
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example, DYNLT 1, but not its homolog DYNLT3 (see below), 
binds to the C-terminal domain of rhodopsin and is required 
for the  trafficking of this visual  pigment within 
photoreceptors  [119]. The two  DYNLT1  polypeptides  in  the 
cytoplasmic dynein complex dimerize,  and  their dimer 
structure  is similar to  that of the  DYNLL 1,  LC8, dimer 
[116,120-122]. The evidence  suggests  that the same Dynltl 
gene product  is a component of both axonemal  and 
cytoplasmic dyneins  in  mouse  [117]. The binding site on 
DYNCII  for DYNLT 1   has been  mapped  to a  19-amino  acid 
region  at  the N-terminus  [85].
The Schizosaccharomyces pombe DYNLT-like gene 
SPAC 1805.08 (also referred  to as  Die 1) is  involved  in 
movement of nuclear material  during meiotic  prophase and 
is expressed  in  astral  microtubules and microtubule- 
anchoring sites on  the cell  cortex. The Dlcl  localization 
pattern  is similar to  that of cytoplasmic  dynein heavy chain 
Dhcl  [123].  Dlcl  null  mutants are viable but have  irregular 
nuclear movement during meiosis and defects in sporulation, 
recombination,  and karyogamy  [123]. Genetic  analyses  in 
Drosophila,  which appears  to have only one  member of the 
DYNLT family, suggest  that DYNLT 1   is  not essential  for 
cytoplasmic dynein function, as  the  null  mutation  is  not 
lethal.  However, the mutants do have sperm-motility defects, 
suggesting they do have an essential  role in axonemal dynein 
[124,125]. In Chlamydomonas, Tctexl  is an axonemal inner arm 
dynein component  [117], and  recently a variant form has 
been  identified in axonemal outer arm dynein (DiBella et al., 
in  press).
Cytoplasmic dynein light chain, DYNLT3. Closely  related 
to DYNLT1  is DYNLT3, also known  as rp3 because it was 
initially a candidate for causing X-linked retinitis pigmentosa 
type 3 [126]. However, the actual gene that is defective in this 
disease was later identified as a guanine nucleotide exchange 
factor that is unrelated to DYNLT3 [127]. Subsequently, King 
and colleagues  found that DYNLT3  is a cytoplasmic dynein 
light chain that is differentially expressed in a cell- and tissue- 
specific  manner [78,116].  Interestingly,  while  many proteins 
have been  identified as binding partners for DYNLT 1,  none 
have been identified as binding exclusively to DYNLT3, 
though  recently the Herpes simplex virus capsid protein VP26 
has been shown  to bind both DYNLT1  and DYNLT3  [128]. 
There  is  no evidence  that  DYNLT3 is a component of 
axonemal dyneins.
Axonemal dynein light chain, Tctex2. To avoid confusion 
with Tctex2, an axonemal dynein subunit,  the  DYNLT2 
designation  is  not used:  a third human  /-complex  testis- 
cxpressed gene,  originally characterized by Rappold and 
colleagues  [129,130], was given  the  name  Tctex2, and  is also 
known as  LC2,  TCTE3,  and Tcd3.  Patel-King and colleagues 
demonstrated  that  it has 35%  identity to  the  19,000-Mr 
(relative  mobility) axonemal  outer arm dynein  light chain 
(LC2) of Chlamydomonas [131], and that it is distantly related to 
cytoplasmic light chains  DYNLT1  and DYNLT3 [116,120]. 
LC2 is essential for outer arm dynein assembly [132]. There is 
evidence that Tctex2 may interact substoichiometrically with 
cytoplasmic dynein,  but  there has not yet been  a definitive 
demonstration  that it is a cytoplasmic dynein  subunit.
In  mice, expression of Tctex2 is testis-specific,  particularly 
in later spermatogenic stages, and isoforms are thought to be 
generated by alternative splicing [130]. As yet, isoforms of the 
human homolog have not been  identified, and its expression
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Mutations in  Tctex2 have been  implicated in  the autosomal 
recessive disorder primary ciliary dyskinesia, which results in 
the impairment of ciliary and flagellar function, although 
these mutations are thought not to be the primary cause of 
the disorder [133].
Mouse Tctex2 lies within the Mmu 17 /-complex in a central 
region containing the distorter/sterility locus  Tcd3 [134]. 
Human  Tctex2 maps to the long arm of Chromosome 6 [129] 
and, interestingly, is a neighbor of the  two genes,  TCP1  and 
TCP10, which are also homologs of mouse /-complex loci 
found adjacent  to mouse  Tctex2. This conservation of gene 
order suggests that the region of Chromosome 6q containing 
these genes  is syntenic  to the homologous central  region of 
mouse Chromosome  17.  In contrast, DYNLT1  and DYNLT3 
are located on human Chromosome 6p and show synteny  to 
the distal portion of the mouse /-complex, suggesting that the 
middle and distal portions of the mouse /-complex are 
syntenic to the long and short arms of human Chromosome 6, 
respectively [129].
Cytoplasmic  Dynein  Light Chain  Roadblock Gene 
Family (DYNLRB1, DYNLRB2)
The first  Roadblock gene was  identified in Drosophila 
through mutational analyses, and from biochemical and 
sequence comparisons with the Chlamydomonas outer arm 
dynein LC7a light chain  [135,136]. Drosophila has at least six 
Roadblock homologs,  including bithoraxoid, which has been 
implicated in thoracic and abdominal  parasegment 
development. These proteins belong to an ancient family that 
has been  implicated in NTPase regulation  in bacteria [137]. 
Mutations in the Roadblock genes result in the accumulation 
of axonal cargoes, mitotic defects, female sterility, and either 
larval or pupal  lethality  [135].  Roadblock mutations also 
affect  neuroblast proliferation and  result in  reduced 
dendritic complexity, as well as in defects in axonal transport 
[138].  Mutational analysis in Chlamydomonas suggests  that 
DYNLRB (LC7a) is involved in axonemal outer arm dynein 
assembly, and a related protein  (LC7b) is associated with 
dynein  regulatory elements  [136,139].
Figure 2E shows the phylogenetic  relationships amongst 
the dynein  light chain Roadblock-family  protein  sequences 
from various organisms. The Roadblock sequences are 
remarkably well conserved between different organisms, with 
96%  of pair-wise sequence comparisons amongst all 
sequences shown  in Figure 2E demonstrating an identity 
greater than 50%  (data not shown). The high conservation of 
Roadblock-family sequences presumably arises from 
functional constraints on the proteins. We note that genes in 
mammals and in other species incorporate conserved and 
complete Roadblock sequences (known as Roadblock 
domains) within  their coding regions [135,137].  However, 
these genes are not thought  to be cytoplasmic dyneins; for 
example, MAPBPIP in human and mouse appears to function 
mainly  in  the endosome/lysosome pathway  [140].  Both 
DYNLRB polypeptides are found in  mammalian cytoplasmic 
dynein, but it is not yet known if  just one, or both, are utilized 
in mammalian axonemal dyneins.
Cytoplasmic dynein light chain Roadblock 1, DYNLRB 1. 
Database searches [135,141] (Figure 2E) revealed there are 
two Roadblock-related proteins in  mammals, DYNLRB 1   and
DYNLRB2 (also termed DYNLC2A and DYNLC2B)  [142]. 
Biochemical studies suggest that in mammals both 
Roadblocks exist as homo- and heterodimers that associate 
with cytoplasmic dynein  [143]  through specific binding sites 
on  the intermediate chains, distinct from those for the 
DYNLL (LC8) and DYNLT (Tctexl) light chains [40]. 
Expression studies in humans have identified tissue-specific 
differences in  the expression of the two human Roadblock­
like genes, with strong expression of DYNLRB1 in heart, liver, 
and brain, and up-regulation in hepatocellular carcinoma 
tissues [142]. In a role  that  may be independent of its 
association with cytoplasmic dynein, TGFb phosphorylation 
of human DYNLRB 1   (termed mLC7-l/km23 by Tang and 
colleagues [144]) results in the human DYNLRB 1   binding to 
the TGFb receptor that mediates TGFb responses including 
JNK activation, c-JUN  phosphorylation, and growth 
inhibition.
Cytoplasmic dynein light chain Roadblock 2, DYNLRB2.
DYNLRB2 was identified by EST database searches for 
sequences homologous to Chlamydomonas LC7a [135,141]; 
human DYNLRB2 was cloned in 2001  [142] and was found to 
be differentially expressed in various tissues, including 
hepatocellular carcinomas.
Cytoplasmic  Dynein  Light Chain  LC8 Gene  Family 
(DYNLL1, DYNLL2)
Cytoplasmic dynein light chain LC8  1, DYNLL1.  DYNLL 
(the light chain that has been known as LC8, as well as LC8a 
and PIN) is a component of many enzyme systems, and it has a 
long and somewhat confusing history. This protein was 
originally identified, using biochemical methods, as a light 
chain of the Chlamydomonas axonemal outer arm dynein 
[145,146]. The term LC8 derives from the observation that this 
component migrates at ~ 8 kDa in SDS-PAGE gels, and it is 
also the smallest of the eight light chains then known within 
this Chlamydomonas axonemal dynein. It was first cloned from 
Chlamydomonas, and closely related sequences were identified 
in mouse and nematode along with more distantly related 
proteins in higher plants [147,148]. Using biochemical and 
immunochemical methods, DYNLL was also identified as an 
integral component of brain cytoplasmic dynein [104]. Only 
recently, it has been realized that mammals have two closely 
related DYNLL genes, and that the protein products of both 
genes are components of cytoplasmic dynein [148,149]. Thus, 
most of the studies on the cellular roles of DYNLL do not 
distinguish between the two DYNLL polypeptides.
Another factor complicating efforts to elucidate the role of 
the DYNLL polypeptides in dynein function was the 
realization that large amounts of DYNLL1  in brain, and 
presumably cells in general, are not associated with  the 
dynein complex  [104].  In fact, the DYNLL polypeptides have 
other important functions unrelated to their role in 
axonemal and cytoplasmic dyneins.  DYNLL 1   is a subunit of 
the flagellar radial spokes which are involved  in control of 
axonemal dynein  motor function  [150],  DYNLL 1  is also a 
substrate of a p21-activating kinase, and its interaction with 
the kinase may be important for cell survival  [151]. A DYNLL 
is an integral component of the actin-based motor myosin V 
[152].  Immunostaining shows  that a DYNLL is concentrated 
in dendritic spines and growth cones, and it is proposed that 
this is due to its association with the actin-based motor
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nitric  oxide synthase  (nNOS)  [14] and  named “PIN” for 
“protein  inhibitor of nNOS”  [153].  However,  it  is unclear 
whether it  is actually an  inhibitor of nNOS or is  merely a 
component of the nNOS complex, as DYNLL 1   appears to be 
required for the stability of various  multimeric  enzyme 
complexes.  DYNLL 1   has been  found to  interact with  a wide 
variety of other cytoplasmic  components,  including the  pro- 
apoptotic  factor Bim  [154], Drosophila swallow  [155,156], and 
rabies virus  P protein  [157], and it may act to attach  them to 
the dynein  and/or myosin-V  molecular motors.  In addition, 
there are many other DYNLL-interacting proteins not 
mentioned here  that have been  identified  using yeast  two- 
hybrid  screens and other methods.
There are two copies of DYNLL in the cytoplasmic dynein 
complex, and the crystal and NMR structures of the DYNLL 
dimer with bound peptide are known [104,158-160]. Both 
monomers contribute to the formation of two symmetrical 
grooves in the dimer that are the binding sites for two DYNCII 
polypeptides reviewed in [161]. Adding DYNLL to an N- 
terminal polypeptide of DYNC II in vitro increases the 
structural order of DYNC II, suggesting that DYNLL is 
important for the assembly of a functional dynein complex [84],
Figure 2F shows the phylogenetic relationships amongst the 
dynein  light chain  LC8-family  protein  sequences from 
various organisms. Our phylogeny shows that the mammalian 
LC8 light chain family falls into two distinct clades containing 
DYNLL 1- and  DYNLL2-like genes.  DYNLL is highly 
conserved from alga and humans, and homologs are required 
for sensory axon  projection  and other developmental events 
in Drosophila [162,163],  nuclear migration  in Aspergillus  [164], 
and  retrograde  IFT in  Chlamydomonas  [72]. The  phenotype of 
partial  loss-of-function  mutants  in Drosophila revealed a wide 
array of pleiomorphic developmental defects; the  total  loss- 
of-function  mutation was embryonic  lethal  [162].  The 
Drosophila dynein  light chain  1   (Cdlcl, also known  as ddlcl 
and “cut-up” [ctpj) is ubiquitously expressed during 
development and  in  adult tissue,  and  is  required for proper 
embryogenesis and cellular differentiation.  Mutations in  this 
gene  result  in  female sterility, which  may be due  to  the 
severely disordered cytoskeletons of ovarian and embryonic 
cells  [162].  A high degree of sequence similarity  (92%) exists 
between Drosophila Cdlcl  and  the  8-kDa flagellar outer arm 
dynein  light chain from Chlamydomonas,  and with human  and 
C. elegans light chain  1   (91%), suggesting this gene has been 
under strong selective  pressure  [162]. S. pombe has a single 
known  DYNLL homolog, SPAC926.07c  (also referred  to as 
Dlc2); it is transcribed during the vegetative phase, induced at 
low level  in  the sexual  phase,  and  is enriched at  the  nuclear 
periphery [123]. A  Dlc2  null  mutant  has been described with 
marginally  reduced recombination  in  meiosis, but no other 
reported  phenotype  [123].
During the course of homology searches for this paper, we 
noted that DYNLLl has related sequences in several locations 
in the human genome (data not shown); none of these appear 
to be associated with expressed sequences and thus  may be 
pseudogenes. There was also a discrepancy  in  the likely 
mapping position of DYNLLl, and therefore we carried out a 
sequence analysis of DYNLLl-related genomic  loci and show 
that the cognate human  locus lies on  Hsal2q24.31  (data not 
shown), which agrees with the mouse mapping result of Dynlll 
on Mmu5.
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Cytoplasmic dynein light chain LC8 2, DYNLL2.  DYNLL2, 
also known as DYNLL2 and LC8b, is the second member of this 
light chain family. It was identified by micro-sequencing of 
polypeptides from purified brain cytoplasmic dynein [148] and 
a yeast two-hybrid screen [149]. Mammalian DYNLL1  and 
DYNLL2 have 93%  identity, differing by only six amino acids 
out of 89. Indicative of the extraordinary conservation of these 
proteins, the amino acid sequences of both DYNLL1  and 
DYNLL2 from human, mouse, rat, pig, and cow are identical 
[148], Human DYNLL2 was identified in a yeast two-hybrid 
screen using the guanylate kinase-associated protein (GKAP) 
as bait and may mediate the interaction between GKAP and 
actin- and microtubule-based motors, allowing GKAP and its 
associated proteins to be translocated as a cargo, although 
DYNLL1  also binds to GKAP [149], DYNLL2 binds the pro- 
apoptotic factor Bmf, which binds Bcl2, neutralizing its 
antiapoptotic activity, a role comparable to that reported for 
the binding of Bim to DYNLL1 [165], However, it has also been 
observed that Bim and Bmf have identical binding affinities for 
both DYNLL 1   and DYNLL2 [166].
It has  further been  proposed that  DYNLL1  binds 
specifically to  the dynein  intermediate chain  DYNCII,  while 
DYNLL2 binds  to  the  myosin-V heavy chain.  However, 
DYNLL2 co-purifies with cytoplasmic dynein from various rat 
tissues  [148], and DYNLLl- and  DYNLL2-GST are equally 
effective  in  binding myosin V  [149].  Furthermore,  DYNLL 1  
and DYNLL2 bind with equal affinity to DYNC II in pair-wise 
yeast  two-hybrid studies (K. W.  Lo and  K.  K.  Pfister, 
unpublished data).  It is not yet known  if one, or both, of the 
DYNLL polypeptides are associated  with axonemal  dyneins; 
however, DYNLL 1   is enriched in testes and lung—tissues that 
have large  numbers of cilia or flagella [148],
Human and Mouse Cytoplasmic Dyneins: 
Nomenclature, Map Positions, and Sequences
To create Table  1, we cataloged, by literature searches, all 
known gene and protein  names for the cytoplasmic  dyneins 
in mouse and human. In addition, aliases were recorded from 
the single-query interface LocusLink (http://www.ncbi.nlm. 
nih.gov/LocusLink) and the Mouse Genome  Informatics 
(MGI) website (http://www.informatics.jax.org).  We also 
included aliases previously approved by the HUGO Gene 
Nomenclature Committee (http://www.gene.ucl.ac.uk/ 
nomenclature) as well as aliases referenced  in sequence 
submissions to  the GenBank  (http://www.ncbi.nlm.nih.gov/ 
Genbank) and Entrez (http://www.ncbi.nlm.nih.gov/entrez) 
sequence databases  [167].
Human and mouse orthologs in Table  1   are taken from the 
literature and databases.  Human and mouse chromosomal 
locations were obtained from  the literature and from  the 
MGI and LocusLink databases. The OMIM numbers given for 
gene and disease loci  in humans refers  to the unique 
accession  numbers  in  the On-line  Mendelian  Inheritance  in 
Man database (http://www.ncbi.nlm.nih.gov/entrez/query. 
fcgi?db=OMIM). Nucleotide and protein  sequences  (prefix
NM  and NP  ,  respectively) are National Center for
Biotechnology Information  (NCBI) Reference Sequence 
(RefSeq, http://www.ncbi.nlm.nih.gov/RefSeq) and Swiss-Prot 
accession  numbers (http://www.ebi.ac.uk/swissprot), 
respectively  [167], The NCBI RefSeq  project provides a  non- 
redundant and comprehensive collection of nucleotide and
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database GenBank. RefSeq collates and summarizes primary- 
sequence data to give a minimal  tiling path for individual 
transcripts, using available cDNA and genomic sequence 
whilst removing mutations, sequencing errors, and cloning 
artifacts. Sequences are validated in silico by NCBI’s Genome 
Annotation  project to confirm  that any genomic sequence 
incorporated into a RefSeq cDNA  matches primary cDNA 
sequences in GenBank, and that the coding region really can 
be translated  into  the corresponding protein sequence.
Accession  numbers beginning with  the prefix XM  (mRNA)
and XP  (protein) are RefSeq  sequences of transcripts and
proteins that are annotated on NCBI genomic contigs; these 
may have incomplete cDNA-tiling-sequence data or contig 
sequences [168]. For dyneins with known isoforms,  isoform- 
sequence accession  numbers available within  nucleotide and 
protein databases are given.
Included in  the heavy chains that we found were “Cell 
Division Cycle 23, yeast homolog” (CDC23) and “Cell Division 
Cycle 22, yeast homolog” (CDC22), which are GenBank aliases 
for human and mouse dynein heavy chain  1, respectively. We 
found no evidence in  the literature to support the “CDC” 
designation of these genes and their products  in  terms of 
either “Cell Division Cycle” or “Cytoplasmic Dynein Chain”.
We compared mouse and human heavy chain  1   cDNA and 
protein sequences with mouse, human, and yeast CDC23 and 
CDC22 sequences and found no similarity to support  this 
designation  (data not shown). We concluded that the 
synonym CDC had  most likely been attributed in error, and 
we contacted NCBI who, in agreement with our findings, 
removed the CDC designation  from the sequences involved.
Human/Mouse  Homology Searches
Homology searches of human cytoplasmic dynein subunit 
genes were conducted using position-specific iterative BLAST 
(PSI-BLAST) [169] at NCBI (http://www.ncbi.nlm.nih.gov/
BLAST; Table 2). The PSI-BLAST program identifies families 
of related proteins using an iterative BLAST procedure [170].
In an initial search, a position-specific scoring matrix is 
constructed from a multiple sequence alignment of the highest 
scoring hits. Subsequent iterations using the position-specific 
scoring matrix are performed in a new BLAST query to refine 
the profile and find additional related sequences. We used 
nucleotide and protein sequences from each known human 
dynein gene to query the human and mouse non-redundant 
sequence databases at GenBank, using default parameters and 
the BLOSUM-62 substitution matrix, which has been shown to 
be the most effective substitution matrix to identify new 
members of a protein family [171]. Where dynein isoforms were 
present, the longest sequence was used to search the databases.
Phylogenetic Analysis
To establish gene family groupings, we investigated the 
phylogenetic relationships between dynein protein homologs 
in various organisms.  Homologous sequences were identified 
by searching the GenBank  non-redundant protein database, 
with the human  protein using PSI-BLAST with default 
parameters and the BLOSUM-62 substitution matrix.
Searches of pufferfish sequence Takifugu rubripes (commonly 
known as Fugu rubripes), for which little transcribed sequence 
exists although a usable genome assembly is present, were
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performed using the BLAST (TBLASTN) feature at the 
Ensembl Fugu Genome Browser (version 2.0; http:// 
www.ensembl.org/Fugu_rubripes), searching with human 
protein sequence against a translated nucleotide database.
Protein sequences were aligned for comparison across their 
full  lengths  using the multiple sequence alignment program 
CLUSTALW [172]  (http://www.ebi.ac.uk/clustalw) and 
applying the GONNET250 matrix as default. The 
GONNET250 is a widely used matrix for performing protein- 
sequence alignments, allowing 250 accepted point mutations 
per  100 amino acids, using scoring tables based on  the 
PAM250 matrix [173].
Two different phylogenetic  methods were used to analyse 
the dynein gene family alignments. Maximum-likelihood trees 
were inferred under the Jones, Taylor, and Thornton (JTT) 
empirical model of amino-acid substitution using PHYML 
version 2.4.3 [174], as was non-parametric bootstrapping 
using  100 resampled alignments for each gene family. 
Bayesian analyses were performed using MrBayes version 
3.0B4 [175], using the default Bayesian priors on  tree 
topologies and branch lengths. Two different sets of analyses 
were performed for each gene family, the first allowing the 
Markov-chain  Monte-Carlo algorithm to move between the 
11  different amino-acid substitution models available in 
MrBayes, and another specifying the JTT model. The first 
analysis allows the chain to take into account uncertainty in 
the substitution process. For all analyses performed here, the 
posterior probability of the JTT model was at least 99%, 
confirming that this model best describes the evolution of the 
dynein sequences—so only results from the fixed-JTT model 
analyses are shown here.
For each analysis, three chains of 1,000,000 generations each 
were run, sampling parameters every 100 generations and 
discarding the first 100,000 generations as a burn-in period. 
Running these multiple independent chains allowed visual 
confirmation that the chains had reached a stationary state by 
ensuring that all three chains were moving around a region of 
similar likelihood. For one of the gene families (cytoplasmic 
dynein heavy chain), the three chains had reached different 
likelihood values after 1,000.000 generations, suggesting failure 
to converge. Running another three independent chains 
resulted in five out of six chains agreeing on the likelihood 
values, suggesting that only one chain had not converged 
properly. In all cases, the phylogeny presented is the majority- 
rule consensus of the posterior sample of tree topologies from 
all three Markov chains, drawn using TreeView [176] with 
posterior clade probabilities and maximum-likelihood 
bootstrap values shown for each clade on these trees.
Searching for Function  and  Mutant  Phenotypes
As well  as literature searches, information on  protein 
function was taken from  the Gene Ontology database (http:// 
www.geneontology.org), which provides data on function and 
processes associated with  a search  protein.  Mutant- 
phenotype data were obtained from the literature and the 
following sources: Online Mendelian Inheritance in Man  at 
NCBI for human  (http://www.ncbi.nlm.nih.gov/entrez/ 
query.fcgi?db=OMIM); MGI for mouse (http://www. 
informatics.jax.org); FlyBase for Drosophila (http://www.flybase. 
org); and WormBase for C. elegans (http://www.wormbase.org).
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In  this paper,  we have  provided an  overview of the  two 
cytoplasmic  dynein complexes, cytoplasmic dynein  1   and 
cytoplasmic  dynein  2, from a genetic  perspective.  We have 
highlighted the unique subunit compositions and cellular 
functions of the  two cytoplasmic  dyneins, and we have 
emphasized  the unique  role of cytoplasmic dynein  2  in  IFT. 
We have described  the different mammalian  dynein  gene 
families, and have shown  the  phylogenetic  and functional 
relationships between  members of individual  families.  We 
carried out  initial  database searches and clarified and 
corrected anomalous data.  We  have also discussed known 
functions and  mutations  of these  proteins, and we  have 
highlighted  both  their fundamental  importance  to  the cell 
and the fact that much  research remains to be carried out to 
define  the  roles of individual proteins.
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Figures 2A-F
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Accession Numbers
The Entrez Gene database (http://www.ncbi.nlm.nih.gov/entrez) 
accession  numbers for the proteins discussed in this paper arc Cdic 
(also referred to as cDic and Die) (44160); che-3 (DYNC2H1  homolog) 
(172593); DYNClll  (1780); DYNC 112 (1781); DYNCILII  (51143); 
DYNC1LI2, (1783); DYNC2H1, (79659); DYNC2LI1  (51626); DYNLL 1  
(LC8) (8655); DYNLL2 (also known as DYNLL2 and LC8b) (140735); 
DYNLRB 1   (also termed DYNLC2A) (83658); DYNLRB2 (also termed 
DYNLC2B) (83657); DYNLT 1   (Tctexl) (6993); MAPBPIP (28956); 
SPAC 1805.08 (also referred to as Dlcl) (3361491).
The Entrez Gene database (http://www.ncbi.nlm.nih.gov/entrez) 
accession numbers for the genes discussed in this paper are Dhc64C 
(38580); dli-1  (178260); dynl  (853928); Dynclhl  (13424); DYNC1H1 
(1778) ; Dynclil  (13426); Dynclil (13427); DyncHil  (213575); Dynltl 
(Tctexl) in  the mouse genome (21648); DYNLT3 (6990); human  Tctex2 
(also known as LC2, TCTE3, and Tcd3) (6991); mouse Tctex2 (21647); 
xbx-1  (184080).
The Entrez Protein database (http://www.ncbi.nlm.nih.gov/entrez/ 
query.fcgi?db=protein&cmd=search&ternv=) accession numbers for 
the proteins discussed in this paper are C. elegans LC8 sequence 
(49822); C. elegans light chain  1   (498422); Cdlcl  (525075); 
Chlamydomonas  19,000-Mr axonemal outer arm dynein light chain 
(LC2) (AAB58383); rat DYNClll  (062107); rat DYNC1LI2 (112288).
The OMIM (http://www.ncbi.nlm.nih.gov/entrez/query. 
fcgi?db=OMIM) accession numbers for the proteins discussed in this 
paper are autosomal recessive disorder primary ciliary dyskinesia 
(242650); Bim (603827); Bmf (606266); X-linked retinitis pigmentosa 
type 3 (300389).
The Ensembl (http://www.ensembl.org/Fugu  rubripes/textview)
accession  number for the  Takifugu LC8 sequence is 
SINFRUP0000015498.
The SwissProt  (http://ca.cxpasy.org/sprot/) accession  numbers for 
the Chlamydomonas 8-kDa flagellar outer arm dynein light chain and 
the Chlamydomonas LC2 light chain used as the outgroup in  Figure 2 
arc Q39580 and T08216,  respectively.  ■
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